GenCore version 5.1.6

OM protein - protein search, using sw model

Run on: March 5, 2004, 16:09:43 ; Search time 33 Seconds
(without alignments)
19.196 Million cell updates/sec

Title: US-09-998-491-9
Perfect score: 15
Sequence: 1 RER 3

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 809742 seqs, 211153259 residues

Total number of hits satisfying chosen parameters: 441

Minimum DB seq length: 0
Maximum DB seq length: 20

Post-processing: Minimum Match 100%
Maximum Match 100%
Listing first 1000 summaries

Database : Published_Applications_AA:*
1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep:*
2: /cgn2_6/ptodata/1/pubpaa/PCT_NEW_PUB.pep:*
3: /cgn2_6/ptodata/1/pubpaa/US06_NEW_PUB.pep:*
4: /cgn2_6/ptodata/1/pubpaa/US06_PUBCOMB.pep:*
5: /cgn2_6/ptodata/1/pubpaa/US07_NEW_PUB.pep:*
6: /cgn2_6/ptodata/1/pubpaa/PCTUS_PUBCOMB.pep:*
7: /cgn2_6/ptodata/1/pubpaa/US08_NEW_PUB.pep:*
8: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep:*
9: /cgn2_6/ptodata/1/pubpaa/US09A_PUBCOMB.pep:*
10: /cgn2_6/ptodata/1/pubpaa/US09B_PUBCOMB.pep:*
11: /cgn2_6/ptodata/1/pubpaa/US09C_PUBCOMB.pep:*
12: /cgn2_6/ptodata/1/pubpaa/US09_NEW_PUB.pep:*
13: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pep:*
14: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pep:*
15: /cgn2_6/ptodata/1/pubpaa/US10C_PUBCOMB.pep:*
16: /cgn2_6/ptodata/1/pubpaa/US10_NEW_PUB.pep:*
17: /cgn2_6/ptodata/1/pubpaa/US60_NEW_PUB.pep:*
18: /cgn2_6/ptodata/1/pubpaa/US60_PUBCOMB.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	15	100.0	3	10	US-09-998-491-9	Sequence 9, Appli
2	15	100.0	4	10	US-09-998-491-10	Sequence 10, Appl
3	15	100.0	4	10	US-09-998-491-11	Sequence 11, Appl
4	15	100.0	4	14	US-10-357-467-29	Sequence 29, Appl
5	15	100.0	5	9	US-09-096-749A-59	Sequence 59, Appl
6	15	100.0	5	10	US-09-903-412-59	Sequence 59, Appl
7	15	100.0	5	10	US-09-998-491-3	Sequence 3, Appli
8	15	100.0	5	10	US-09-998-491-4	Sequence 4, Appli
9	15	100.0	5	14	US-10-174-717A-59	Sequence 59, Appl
10	15	100.0	5	14	US-10-165-155-59	Sequence 59, Appl
11	15	100.0	5	14	US-10-190-162-59	Sequence 59, Appl
12	15	100.0	6	14	US-10-082-747A-60	Sequence 60, Appl
13	15	100.0	6	14	US-10-315-964A-462	Sequence 462, App
14	15	100.0	6	14	US-10-315-964A-524	Sequence 524, App
15	15	100.0	6	14	US-10-315-964A-525	Sequence 525, App
16	15	100.0	6	14	US-10-317-251A-462	Sequence 462, App
17	15	100.0	6	14	US-10-317-251A-524	Sequence 524, App
18	15	100.0	6	14	US-10-317-251A-525	Sequence 525, App
19	15	100.0	6	14	US-10-317-252A-462	Sequence 462, App
20	15	100.0	6	14	US-10-317-252A-524	Sequence 524, App
21	15	100.0	6	14	US-10-317-252A-525	Sequence 525, App
22	15	100.0	6	14	US-10-232-544-21	Sequence 21, Appl
23	15	100.0	7	9	US-09-970-088-2	Sequence 2, Appli
24	15	100.0	7	10	US-09-876-904A-495	Sequence 495, App
25	15	100.0	7	10	US-09-876-904A-508	Sequence 508, App
26	15	100.0	7	10	US-09-972-656-17	Sequence 17, Appl
27	15	100.0	7	14	US-10-232-544-49	Sequence 49, Appl
28	15	100.0	8	10	US-09-876-904A-455	Sequence 455, App
29	15	100.0	8	10	US-09-876-904A-503	Sequence 503, App
30	15	100.0	8	10	US-09-876-904A-506	Sequence 506, App
31	15	100.0	8	10	US-09-876-904A-519	Sequence 519, App
32	15	100.0	8	10	US-09-833-039-39	Sequence 39, Appl
33	15	100.0	8	10	US-09-833-039-64	Sequence 64, Appl
34	15	100.0	8	10	US-09-833-039-91	Sequence 91, Appl
35	15	100.0	8	10	US-09-833-039-111	Sequence 111, App
36	15	100.0	8	13	US-10-014-485A-54	Sequence 54, Appl
37	15	100.0	8	14	US-10-174-105A-54	Sequence 54, Appl
38	15	100.0	8	14	US-10-224-999A-2180	Sequence 2180, Ap
39	15	100.0	8	14	US-10-224-999A-2181	Sequence 2181, Ap
40	15	100.0	8	14	US-10-177-277-39	Sequence 39, Appl
41	15	100.0	8	14	US-10-177-277-64	Sequence 64, Appl
42	15	100.0	8	14	US-10-177-277-91	Sequence 91, Appl
43	15	100.0	8	14	US-10-177-277-111	Sequence 111, App
44	15	100.0	8	15	US-10-376-121A-79	Sequence 79, Appl
45	15	100.0	8	15	US-10-376-121A-80	Sequence 80, Appl
46	15	100.0	9	10	US-09-809-638-516	Sequence 516, App
47	15	100.0	9	10	US-09-809-638-621	Sequence 621, App
48	15	100.0	9	10	US-09-876-904A-379	Sequence 379, App
49	15	100.0	9	10	US-09-932-165-1036	Sequence 1036, Ap
50	15	100.0	9	10	US-09-833-039-41	Sequence 41, Appl
51	15	100.0	9	10	US-09-833-039-68	Sequence 68, Appl
52	15	100.0	9	10	US-09-833-039-75	Sequence 75, Appl
53	15	100.0	9	10	US-09-833-039-94	Sequence 94, Appl
54	15	100.0	9	10	US-09-833-039-112	Sequence 112, App
55	15	100.0	9	14	US-10-062-710-103	Sequence 103, App
56	15	100.0	9	14	US-10-211-088-187	Sequence 187, App
57	15	100.0	9	14	US-10-197-954-5	Sequence 5, Appli
58	15	100.0	9	14	US-10-301-644-15	Sequence 15, Appl
59	15	100.0	9	14	US-10-224-999A-2185	Sequence 2185, Ap
60	15	100.0	9	14	US-10-224-999A-2186	Sequence 2186, Ap
61	15	100.0	9	14	US-10-224-999A-2187	Sequence 2187, Ap
62	15	100.0	9	14	US-10-239-313A-6	Sequence 6, Appli
63	15	100.0	9	14	US-10-239-313A-429	Sequence 429, App
64	15	100.0	9	14	US-10-283-741-31	Sequence 31, Appl
65	15	100.0	9	14	US-10-177-277-41	Sequence 41, Appl
66	15	100.0	9	14	US-10-177-277-68	Sequence 68, Appl
67	15	100.0	9	14	US-10-177-277-75	Sequence 75, Appl
68	15	100.0	9	14	US-10-177-277-94	Sequence 94, Appl
69	15	100.0	9	14	US-10-177-277-112	Sequence 112, App
70	15	100.0	9	14	US-10-031-874A-127	Sequence 127, App
71	15	100.0	9	15	US-10-107-532-150	Sequence 150, App
72	15	100.0	9	15	US-10-107-532-199	Sequence 199, App
73	15	100.0	9	15	US-10-107-532-696	Sequence 696, App
74	15	100.0	9	15	US-10-107-532-1224	Sequence 1224, Ap
75	15	100.0	9	15	US-10-107-532-1231	Sequence 1231, Ap
76	15	100.0	9	15	US-10-107-532-1264	Sequence 1264, Ap
77	15	100.0	9	15	US-10-107-532-1734	Sequence 1734, Ap
78	15	100.0	9	15	US-10-107-532-1742	Sequence 1742, Ap
79	15	100.0	9	15	US-10-107-532-1746	Sequence 1746, Ap
80	15	100.0	9	15	US-10-107-532-1789	Sequence 1789, Ap
81	15	100.0	9	15	US-10-107-532-2342	Sequence 2342, Ap
82	15	100.0	9	15	US-10-107-532-2818	Sequence 2818, Ap
83	15	100.0	9	15	US-10-107-532-2836	Sequence 2836, Ap
84	15	100.0	9	15	US-10-107-532-2864	Sequence 2864, Ap
85	15	100.0	9	15	US-10-107-532-2870	Sequence 2870, Ap
86	15	100.0	9	15	US-10-107-532-3369	Sequence 3369, Ap
87	15	100.0	9	15	US-10-107-532-3427	Sequence 3427, Ap
88	15	100.0	9	15	US-10-107-532-3432	Sequence 3432, Ap

89	15	100.0	9	15	US-10-107-532-4399	Sequence 4399, Ap
90	15	100.0	9	15	US-10-107-532-4451	Sequence 4451, Ap
91	15	100.0	9	15	US-10-107-532-4469	Sequence 4469, Ap
92	15	100.0	9	15	US-10-107-532-4530	Sequence 4530, Ap
93	15	100.0	9	15	US-10-107-532-4568	Sequence 4568, Ap
94	15	100.0	9	15	US-10-107-532-4573	Sequence 4573, Ap
95	15	100.0	9	15	US-10-107-532-4587	Sequence 4587, Ap
96	15	100.0	9	15	US-10-107-532-4626	Sequence 4626, Ap
97	15	100.0	9	15	US-10-107-532-4642	Sequence 4642, Ap
98	15	100.0	10	9	US-09-731-221-7	Sequence 7, Appli
99	15	100.0	10	10	US-09-983-802-388	Sequence 388, App
100	15	100.0	10	10	US-09-894-912A-21	Sequence 21, Appl
101	15	100.0	10	10	US-09-809-638-208	Sequence 208, App
102	15	100.0	10	10	US-09-809-638-394	Sequence 394, App
103	15	100.0	10	10	US-09-809-638-471	Sequence 471, App
104	15	100.0	10	10	US-09-809-638-566	Sequence 566, App
105	15	100.0	10	10	US-09-809-638-671	Sequence 671, App
106	15	100.0	10	10	US-09-876-904A-231	Sequence 231, App
107	15	100.0	10	10	US-09-876-904A-238	Sequence 238, App
108	15	100.0	10	10	US-09-572-404B-214	Sequence 214, App
109	15	100.0	10	10	US-09-572-404B-216	Sequence 216, App
110	15	100.0	10	10	US-09-572-404B-1630	Sequence 1630, Ap
111	15	100.0	10	10	US-09-572-404B-1801	Sequence 1801, Ap
112	15	100.0	10	10	US-09-572-404B-1809	Sequence 1809, Ap
113	15	100.0	10	10	US-09-572-404B-1811	Sequence 1811, Ap
114	15	100.0	10	10	US-09-572-404B-1823	Sequence 1823, Ap
115	15	100.0	10	10	US-09-572-404B-1825	Sequence 1825, Ap
116	15	100.0	10	10	US-09-572-404B-2048	Sequence 2048, Ap
117	15	100.0	10	10	US-09-572-404B-3142	Sequence 3142, Ap
118	15	100.0	10	10	US-09-572-270A-26	Sequence 26, Appl
119	15	100.0	10	10	US-09-572-270A-120	Sequence 120, App
120	15	100.0	10	10	US-09-572-270A-467	Sequence 467, App
121	15	100.0	10	10	US-09-572-270A-654	Sequence 654, App
122	15	100.0	10	11	US-09-933-780C-36	Sequence 36, Appl
123	15	100.0	10	14	US-10-228-806-13	Sequence 13, Appl
124	15	100.0	10	14	US-10-228-806-61	Sequence 61, Appl
125	15	100.0	10	14	US-10-228-806-62	Sequence 62, Appl
126	15	100.0	10	14	US-10-228-806-63	Sequence 63, Appl
127	15	100.0	10	14	US-10-228-806-64	Sequence 64, Appl
128	15	100.0	10	14	US-10-228-806-65	Sequence 65, Appl
129	15	100.0	10	14	US-10-190-082-339	Sequence 339, App
130	15	100.0	10	14	US-10-167-831-32	Sequence 32, Appl
131	15	100.0	10	14	US-10-167-831-44	Sequence 44, Appl
132	15	100.0	10	14	US-10-224-999A-2191	Sequence 2191, Ap
133	15	100.0	10	14	US-10-224-999A-2192	Sequence 2192, Ap
134	15	100.0	10	14	US-10-224-999A-2193	Sequence 2193, Ap
135	15	100.0	10	14	US-10-224-999A-2194	Sequence 2194, Ap
136	15	100.0	10	14	US-10-155-693-28	Sequence 28, Appl
137	15	100.0	10	14	US-10-200-708-104	Sequence 104, App
138	15	100.0	10	14	US-10-200-708-260	Sequence 260, App
139	15	100.0	10	15	US-10-100-303A-15	Sequence 15, Appl
140	15	100.0	10	15	US-10-100-303A-48	Sequence 48, Appl
141	15	100.0	10	15	US-10-100-303A-49	Sequence 49, Appl
142	15	100.0	10	15	US-10-100-303A-50	Sequence 50, Appl
143	15	100.0	10	15	US-10-100-303A-51	Sequence 51, Appl
144	15	100.0	10	15	US-10-100-303A-52	Sequence 52, Appl
145	15	100.0	10	15	US-10-107-532-422	Sequence 422, App
146	15	100.0	10	15	US-10-107-532-434	Sequence 434, App
147	15	100.0	10	15	US-10-107-532-456	Sequence 456, App
148	15	100.0	10	15	US-10-107-532-461	Sequence 461, App
149	15	100.0	10	15	US-10-107-532-480	Sequence 480, App
150	15	100.0	10	15	US-10-107-532-966	Sequence 966, App
151	15	100.0	10	15	US-10-107-532-1480	Sequence 1480, Ap
152	15	100.0	10	15	US-10-107-532-1490	Sequence 1490, Ap
153	15	100.0	10	15	US-10-107-532-1524	Sequence 1524, Ap
154	15	100.0	10	15	US-10-107-532-1533	Sequence 1533, Ap
155	15	100.0	10	15	US-10-107-532-1552	Sequence 1552, Ap
156	15	100.0	10	15	US-10-107-532-1999	Sequence 1999, Ap
157	15	100.0	10	15	US-10-107-532-2004	Sequence 2004, Ap
158	15	100.0	10	15	US-10-107-532-2025	Sequence 2025, Ap
159	15	100.0	10	15	US-10-107-532-2049	Sequence 2049, Ap
160	15	100.0	10	15	US-10-107-532-2065	Sequence 2065, Ap
161	15	100.0	10	15	US-10-107-532-2603	Sequence 2603, Ap
162	15	100.0	10	15	US-10-107-532-3096	Sequence 3096, Ap
163	15	100.0	10	15	US-10-107-532-3115	Sequence 3115, Ap
164	15	100.0	10	15	US-10-107-532-3131	Sequence 3131, Ap
165	15	100.0	10	15	US-10-107-532-3138	Sequence 3138, Ap
166	15	100.0	10	15	US-10-107-532-3139	Sequence 3139, Ap
167	15	100.0	10	15	US-10-107-532-3153	Sequence 3153, Ap
168	15	100.0	10	15	US-10-107-532-3163	Sequence 3163, Ap
169	15	100.0	10	15	US-10-107-532-3614	Sequence 3614, Ap
170	15	100.0	10	15	US-10-107-532-3629	Sequence 3629, Ap
171	15	100.0	10	15	US-10-107-532-3689	Sequence 3689, Ap
172	15	100.0	10	15	US-10-107-532-5311	Sequence 5311, Ap
173	15	100.0	10	15	US-10-107-532-5398	Sequence 5398, Ap
174	15	100.0	10	15	US-10-107-532-5404	Sequence 5404, Ap
175	15	100.0	10	15	US-10-107-532-5450	Sequence 5450, Ap
176	15	100.0	10	15	US-10-452-510-65	Sequence 65, Appl
177	15	100.0	11	9	US-09-966-871-3	Sequence 3, Appli
178	15	100.0	11	10	US-09-876-904A-239	Sequence 239, App
179	15	100.0	11	10	US-09-940-316B-57	Sequence 57, Appl
180	15	100.0	11	13	US-10-039-645-3	Sequence 3, Appli
181	15	100.0	11	14	US-10-062-710-165	Sequence 165, App
182	15	100.0	11	14	US-10-062-710-166	Sequence 166, App
183	15	100.0	11	14	US-10-139-084-3	Sequence 3, Appli
184	15	100.0	11	14	US-10-224-999A-2198	Sequence 2198, Ap
185	15	100.0	11	14	US-10-224-999A-2199	Sequence 2199, Ap
186	15	100.0	11	14	US-10-224-999A-2200	Sequence 2200, Ap
187	15	100.0	11	14	US-10-224-999A-2201	Sequence 2201, Ap
188	15	100.0	11	14	US-10-224-999A-2202	Sequence 2202, Ap
189	15	100.0	11	15	US-10-411-869A-30	Sequence 30, Appl
190	15	100.0	12	8	US-08-666-340-4	Sequence 4, Appli
191	15	100.0	12	9	US-09-096-749A-118	Sequence 118, App
192	15	100.0	12	10	US-09-903-412-118	Sequence 118, App
193	15	100.0	12	14	US-10-174-717A-118	Sequence 118, App
194	15	100.0	12	14	US-10-165-155-118	Sequence 118, App
195	15	100.0	12	14	US-10-286-457-204	Sequence 204, App
196	15	100.0	12	14	US-10-190-162-118	Sequence 118, App
197	15	100.0	12	14	US-10-224-999A-2206	Sequence 2206, Ap
198	15	100.0	12	14	US-10-224-999A-2207	Sequence 2207, Ap
199	15	100.0	12	14	US-10-224-999A-2208	Sequence 2208, Ap
200	15	100.0	12	14	US-10-224-999A-2209	Sequence 2209, Ap
201	15	100.0	12	14	US-10-224-999A-2210	Sequence 2210, Ap
202	15	100.0	12	14	US-10-224-999A-2211	Sequence 2211, Ap
203	15	100.0	12	15	US-10-452-510-63	Sequence 63, Appl
204	15	100.0	12	15	US-10-452-510-64	Sequence 64, Appl
205	15	100.0	13	10	US-09-999-220B-21	Sequence 21, Appl
206	15	100.0	13	10	US-09-999-220B-47	Sequence 47, Appl
207	15	100.0	13	10	US-09-999-220B-73	Sequence 73, Appl
208	15	100.0	13	14	US-10-014-162-63	Sequence 63, Appl
209	15	100.0	13	14	US-10-120-604-36	Sequence 36, Appl
210	15	100.0	13	14	US-10-120-604-64	Sequence 64, Appl
211	15	100.0	13	14	US-10-224-999A-2215	Sequence 2215, Ap
212	15	100.0	13	14	US-10-224-999A-2216	Sequence 2216, Ap
213	15	100.0	13	14	US-10-224-999A-2217	Sequence 2217, Ap
214	15	100.0	13	14	US-10-224-999A-2218	Sequence 2218, Ap
215	15	100.0	13	14	US-10-224-999A-2219	Sequence 2219, Ap
216	15	100.0	13	14	US-10-224-999A-2220	Sequence 2220, Ap
217	15	100.0	13	14	US-10-224-999A-2221	Sequence 2221, Ap
218	15	100.0	13	14	US-10-193-477-60	Sequence 60, Appl
219	15	100.0	13	14	US-10-193-477-61	Sequence 61, Appl
220	15	100.0	14	9	US-09-096-749A-1	Sequence 1, Appli
221	15	100.0	14	9	US-09-876-187-23	Sequence 23, Appl
222	15	100.0	14	9	US-09-900-530A-19	Sequence 19, Appl
223	15	100.0	14	10	US-09-903-412-1	Sequence 1, Appli
224	15	100.0	14	10	US-09-992-665-3	Sequence 3, Appli
225	15	100.0	14	13	US-10-078-547-27	Sequence 27, Appl
226	15	100.0	14	14	US-10-014-162-62	Sequence 62, Appl
227	15	100.0	14	14	US-10-012-456A-42	Sequence 42, Appl
228	15	100.0	14	14	US-10-174-717A-1	Sequence 1, Appli
229	15	100.0	14	14	US-10-165-155-1	Sequence 1, Appli
230	15	100.0	14	14	US-10-190-162-1	Sequence 1, Appli
231	15	100.0	14	14	US-10-224-999A-2225	Sequence 2225, Ap
232	15	100.0	14	14	US-10-224-999A-2226	Sequence 2226, Ap
233	15	100.0	14	14	US-10-224-999A-2227	Sequence 2227, Ap
234	15	100.0	14	14	US-10-224-999A-2228	Sequence 2228, Ap

235	15	100.0	14	14	US-10-224-999A-2229	Sequence 2229, Ap
236	15	100.0	14	14	US-10-224-999A-2230	Sequence 2230, Ap
237	15	100.0	14	14	US-10-224-999A-2231	Sequence 2231, Ap
238	15	100.0	14	14	US-10-224-999A-2232	Sequence 2232, Ap
239	15	100.0	14	15	US-10-436-715-227	Sequence 227, App
240	15	100.0	14	15	US-10-436-715-257	Sequence 257, App
241	15	100.0	15	9	US-09-827-948-29	Sequence 29, Appl
242	15	100.0	15	10	US-09-992-665-22	Sequence 22, Appl
243	15	100.0	15	14	US-10-014-162-61	Sequence 61, Appl
244	15	100.0	15	14	US-10-174-105A-94	Sequence 94, Appl
245	15	100.0	15	14	US-10-174-105A-95	Sequence 95, Appl
246	15	100.0	15	14	US-10-215-168-2	Sequence 2, Appli
247	15	100.0	15	14	US-10-211-088-196	Sequence 196, App
248	15	100.0	15	14	US-10-225-567A-941	Sequence 941, App
249	15	100.0	15	14	US-10-225-567A-1577	Sequence 1577, Ap
250	15	100.0	15	14	US-10-264-303-8	Sequence 8, Appli
251	15	100.0	15	14	US-10-264-303-9	Sequence 9, Appli
252	15	100.0	15	14	US-10-245-618-33	Sequence 33, Appl
253	15	100.0	15	14	US-10-224-999A-2236	Sequence 2236, Ap
254	15	100.0	15	14	US-10-224-999A-2237	Sequence 2237, Ap
255	15	100.0	15	14	US-10-224-999A-2238	Sequence 2238, Ap
256	15	100.0	15	14	US-10-224-999A-2239	Sequence 2239, Ap
257	15	100.0	15	14	US-10-224-999A-2240	Sequence 2240, Ap
258	15	100.0	15	14	US-10-224-999A-2241	Sequence 2241, Ap
259	15	100.0	15	14	US-10-224-999A-2242	Sequence 2242, Ap
260	15	100.0	15	14	US-10-224-999A-2243	Sequence 2243, Ap
261	15	100.0	15	14	US-10-224-999A-2244	Sequence 2244, Ap
262	15	100.0	15	14	US-10-176-071-29	Sequence 29, Appl
263	15	100.0	15	15	US-10-368-280-35	Sequence 35, Appl
264	15	100.0	15	15	US-10-374-035-35	Sequence 35, Appl
265	15	100.0	15	15	US-10-107-532-5904	Sequence 5904, Ap
266	15	100.0	15	15	US-10-107-532-5932	Sequence 5932, Ap
267	15	100.0	15	15	US-10-107-532-5982	Sequence 5982, Ap
268	15	100.0	15	15	US-10-107-532-5992	Sequence 5992, Ap
269	15	100.0	15	15	US-10-107-532-6012	Sequence 6012, Ap
270	15	100.0	15	15	US-10-107-532-6029	Sequence 6029, Ap
271	15	100.0	15	15	US-10-107-532-6056	Sequence 6056, Ap
272	15	100.0	15	15	US-10-107-532-6067	Sequence 6067, Ap
273	15	100.0	15	15	US-10-107-532-6097	Sequence 6097, Ap
274	15	100.0	15	15	US-10-107-532-6110	Sequence 6110, Ap
275	15	100.0	15	15	US-10-107-532-6120	Sequence 6120, Ap
276	15	100.0	15	15	US-10-107-532-6126	Sequence 6126, Ap
277	15	100.0	16	10	US-09-876-904A-115	Sequence 115, App
278	15	100.0	16	11	US-09-730-559B-115	Sequence 115, App
279	15	100.0	16	11	US-09-933-780C-37	Sequence 37, Appl
280	15	100.0	16	13	US-10-061-395-45	Sequence 45, Appl
281	15	100.0	16	14	US-10-014-162-60	Sequence 60, Appl
282	15	100.0	16	14	US-10-014-162-74	Sequence 74, Appl
283	15	100.0	16	14	US-10-014-162-75	Sequence 75, Appl
284	15	100.0	16	14	US-10-014-162-76	Sequence 76, Appl
285	15	100.0	16	14	US-10-014-162-77	Sequence 77, Appl
286	15	100.0	16	14	US-10-012-542-523	Sequence 523, App
287	15	100.0	16	14	US-10-052-942-51	Sequence 51, Appl
288	15	100.0	16	14	US-10-169-223-26	Sequence 26, Appl
289	15	100.0	16	14	US-10-224-999A-2248	Sequence 2248, Ap
290	15	100.0	16	14	US-10-224-999A-2249	Sequence 2249, Ap
291	15	100.0	16	14	US-10-224-999A-2250	Sequence 2250, Ap
292	15	100.0	16	14	US-10-224-999A-2251	Sequence 2251, Ap
293	15	100.0	16	14	US-10-224-999A-2252	Sequence 2252, Ap
294	15	100.0	16	14	US-10-224-999A-2253	Sequence 2253, Ap
295	15	100.0	16	14	US-10-224-999A-2254	Sequence 2254, Ap
296	15	100.0	16	14	US-10-224-999A-2255	Sequence 2255, Ap
297	15	100.0	16	14	US-10-224-999A-2256	Sequence 2256, Ap
298	15	100.0	16	14	US-10-224-999A-2257	Sequence 2257, Ap
299	15	100.0	16	14	US-10-224-999A-2671	Sequence 2671, Ap
300	15	100.0	16	15	US-10-368-280-1	Sequence 1, Appli
301	15	100.0	16	15	US-10-374-035-1	Sequence 1, Appli
302	15	100.0	16	15	US-10-444-575-19	Sequence 19, Appl
303	15	100.0	17	9	US-09-864-761-45943	Sequence 45943, A
304	15	100.0	17	9	US-09-864-761-46718	Sequence 46718, A
305	15	100.0	17	9	US-09-789-836-15	Sequence 15, Appl
306	15	100.0	17	9	US-09-789-836-16	Sequence 16, Appl
307	15	100.0	17	10	US-09-983-802-349	Sequence 349, App
308	15	100.0	17	10	US-09-876-904A-116	Sequence 116, App
309	15	100.0	17	10	US-09-965-876A-6	Sequence 6, Appli
310	15	100.0	17	10	US-09-998-491-6	Sequence 6, Appli
311	15	100.0	17	10	US-09-998-491-7	Sequence 7, Appli
312	15	100.0	17	10	US-09-789-831-20	Sequence 20, Appl
313	15	100.0	17	14	US-10-014-162-59	Sequence 59, Appl
314	15	100.0	17	14	US-10-097-065-268	Sequence 268, App
315	15	100.0	17	14	US-10-097-065-549	Sequence 549, App
316	15	100.0	17	14	US-10-211-088-219	Sequence 219, App
317	15	100.0	17	14	US-10-211-088-310	Sequence 310, App
318	15	100.0	17	14	US-10-225-567A-741	Sequence 741, App
319	15	100.0	17	14	US-10-225-567A-1290	Sequence 1290, Ap
320	15	100.0	17	14	US-10-231-894-39	Sequence 39, Appl
321	15	100.0	17	14	US-10-279-130-22	Sequence 22, Appl
322	15	100.0	17	14	US-10-224-999A-2261	Sequence 2261, Ap
323	15	100.0	17	14	US-10-224-999A-2262	Sequence 2262, Ap
324	15	100.0	17	14	US-10-224-999A-2263	Sequence 2263, Ap
325	15	100.0	17	14	US-10-224-999A-2264	Sequence 2264, Ap
326	15	100.0	17	14	US-10-224-999A-2265	Sequence 2265, Ap
327	15	100.0	17	14	US-10-224-999A-2266	Sequence 2266, Ap
328	15	100.0	17	14	US-10-224-999A-2267	Sequence 2267, Ap
329	15	100.0	17	14	US-10-224-999A-2268	Sequence 2268, Ap
330	15	100.0	17	14	US-10-224-999A-2269	Sequence 2269, Ap
331	15	100.0	17	14	US-10-224-999A-2270	Sequence 2270, Ap
332	15	100.0	17	14	US-10-224-999A-2271	Sequence 2271, Ap
333	15	100.0	17	14	US-10-224-999A-2684	Sequence 2684, Ap
334	15	100.0	17	14	US-10-224-999A-2685	Sequence 2685, Ap
335	15	100.0	17	14	US-10-231-889-39	Sequence 39, Appl
336	15	100.0	17	15	US-10-349-397-2	Sequence 2, Appli
337	15	100.0	18	9	US-09-864-761-42961	Sequence 42961, A
338	15	100.0	18	9	US-09-864-761-46460	Sequence 46460, A
339	15	100.0	18	9	US-09-864-866-1	Sequence 1, Appli
340	15	100.0	18	10	US-09-876-904A-442	Sequence 442, App
341	15	100.0	18	11	US-09-933-780C-28	Sequence 28, Appl
342	15	100.0	18	11	US-09-933-780C-31	Sequence 31, Appl
343	15	100.0	18	11	US-09-833-245-389	Sequence 389, App
344	15	100.0	18	14	US-10-014-162-58	Sequence 58, Appl
345	15	100.0	18	14	US-10-225-567A-1883	Sequence 1883, Ap
346	15	100.0	18	14	US-10-061-607A-7	Sequence 7, Appli
347	15	100.0	18	14	US-10-224-999A-2275	Sequence 2275, Ap
348	15	100.0	18	14	US-10-224-999A-2276	Sequence 2276, Ap
349	15	100.0	18	14	US-10-224-999A-2277	Sequence 2277, Ap
350	15	100.0	18	14	US-10-224-999A-2278	Sequence 2278, Ap
351	15	100.0	18	14	US-10-224-999A-2279	Sequence 2279, Ap
352	15	100.0	18	14	US-10-224-999A-2280	Sequence 2280, Ap
353	15	100.0	18	14	US-10-224-999A-2281	Sequence 2281, Ap
354	15	100.0	18	14	US-10-224-999A-2282	Sequence 2282, Ap
355	15	100.0	18	14	US-10-224-999A-2283	Sequence 2283, Ap
356	15	100.0	18	14	US-10-224-999A-2284	Sequence 2284, Ap
357	15	100.0	18	14	US-10-224-999A-2285	Sequence 2285, Ap
358	15	100.0	18	14	US-10-224-999A-2286	Sequence 2286, Ap
359	15	100.0	18	14	US-10-224-999A-2698	Sequence 2698, Ap
360	15	100.0	18	14	US-10-224-999A-2699	Sequence 2699, Ap
361	15	100.0	18	14	US-10-224-999A-2700	Sequence 2700, Ap
362	15	100.0	18	14	US-10-224-999A-3140	Sequence 3140, Ap
363	15	100.0	19	9	US-09-864-761-33440	Sequence 33440, A
364	15	100.0	19	10	US-09-931-325A-138	Sequence 138, App
365	15	100.0	19	10	US-09-876-904A-575	Sequence 575, App
366	15	100.0	19	10	US-09-965-876A-8	Sequence 8, Appli
367	15	100.0	19	10	US-09-965-876A-33	Sequence 33, Appl
368	15	100.0	19	10	US-09-965-876A-39	Sequence 39, Appl
369	15	100.0	19	10	US-09-930-915A-179	Sequence 179, App
370	15	100.0	19	13	US-10-001-887-110	Sequence 110, App
371	15	100.0	19	13	US-10-038-612-13	Sequence 13, Appl
372	15	100.0	19	14	US-10-014-162-57	Sequence 57, Appl
373	15	100.0	19	14	US-10-062-710-150	Sequence 150, App
374	15	100.0	19	14	US-10-211-088-311	Sequence 311, App
375	15	100.0	19	14	US-10-224-999A-2290	Sequence 2290, Ap
376	15	100.0	19	14	US-10-224-999A-2291	Sequence 2291, Ap
377	15	100.0	19	14	US-10-224-999A-2292	Sequence 2292, Ap
378	15	100.0	19	14	US-10-224-999A-2293	Sequence 2293, Ap
379	15	100.0	19	14	US-10-224-999A-2294	Sequence 2294, Ap
380	15	100.0	19	14	US-10-224-999A-2295	Sequence 2295, Ap

381	15	100.0	19	14	US-10-224-999A-2296	Sequence 2296, Ap
382	15	100.0	19	14	US-10-224-999A-2297	Sequence 2297, Ap
383	15	100.0	19	14	US-10-224-999A-2298	Sequence 2298, Ap
384	15	100.0	19	14	US-10-224-999A-2299	Sequence 2299, Ap
385	15	100.0	19	14	US-10-224-999A-2300	Sequence 2300, Ap
386	15	100.0	19	14	US-10-224-999A-2301	Sequence 2301, Ap
387	15	100.0	19	14	US-10-224-999A-2302	Sequence 2302, Ap
388	15	100.0	19	14	US-10-224-999A-2713	Sequence 2713, Ap
389	15	100.0	19	14	US-10-224-999A-2714	Sequence 2714, Ap
390	15	100.0	19	14	US-10-224-999A-2715	Sequence 2715, Ap
391	15	100.0	19	14	US-10-224-999A-2716	Sequence 2716, Ap
392	15	100.0	19	14	US-10-224-999A-3155	Sequence 3155, Ap
393	15	100.0	19	14	US-10-224-999A-3156	Sequence 3156, Ap
394	15	100.0	19	14	US-10-029-386-27935	Sequence 27935, A
395	15	100.0	19	14	US-10-121-909-1	Sequence 1, Appli
396	15	100.0	20	10	US-09-978-178-3	Sequence 3, Appli
397	15	100.0	20	10	US-09-965-876A-34	Sequence 34, Appl
398	15	100.0	20	10	US-09-965-876A-40	Sequence 40, Appl
399	15	100.0	20	10	US-09-974-026-64	Sequence 64, Appl
400	15	100.0	20	13	US-10-038-612-95	Sequence 95, Appl
401	15	100.0	20	14	US-10-014-162-56	Sequence 56, Appl
402	15	100.0	20	14	US-10-098-093-58	Sequence 58, Appl
403	15	100.0	20	14	US-10-225-567A-774	Sequence 774, App
404	15	100.0	20	14	US-10-225-567A-873	Sequence 873, App
405	15	100.0	20	14	US-10-225-567A-1301	Sequence 1301, Ap
406	15	100.0	20	14	US-10-225-567A-1763	Sequence 1763, Ap
407	15	100.0	20	14	US-10-225-567A-1858	Sequence 1858, Ap
408	15	100.0	20	14	US-10-225-567A-1927	Sequence 1927, Ap
409	15	100.0	20	14	US-10-225-567A-2012	Sequence 2012, Ap
410	15	100.0	20	14	US-10-267-730-5	Sequence 5, Appli
411	15	100.0	20	14	US-10-224-999A-2306	Sequence 2306, Ap
412	15	100.0	20	14	US-10-224-999A-2307	Sequence 2307, Ap
413	15	100.0	20	14	US-10-224-999A-2308	Sequence 2308, Ap
414	15	100.0	20	14	US-10-224-999A-2309	Sequence 2309, Ap
415	15	100.0	20	14	US-10-224-999A-2310	Sequence 2310, Ap
416	15	100.0	20	14	US-10-224-999A-2311	Sequence 2311, Ap
417	15	100.0	20	14	US-10-224-999A-2312	Sequence 2312, Ap
418	15	100.0	20	14	US-10-224-999A-2313	Sequence 2313, Ap
419	15	100.0	20	14	US-10-224-999A-2314	Sequence 2314, Ap
420	15	100.0	20	14	US-10-224-999A-2315	Sequence 2315, Ap
421	15	100.0	20	14	US-10-224-999A-2316	Sequence 2316, Ap
422	15	100.0	20	14	US-10-224-999A-2317	Sequence 2317, Ap
423	15	100.0	20	14	US-10-224-999A-2318	Sequence 2318, Ap
424	15	100.0	20	14	US-10-224-999A-2319	Sequence 2319, Ap
425	15	100.0	20	14	US-10-224-999A-2729	Sequence 2729, Ap
426	15	100.0	20	14	US-10-224-999A-2730	Sequence 2730, Ap
427	15	100.0	20	14	US-10-224-999A-2731	Sequence 2731, Ap
428	15	100.0	20	14	US-10-224-999A-2732	Sequence 2732, Ap
429	15	100.0	20	14	US-10-224-999A-2733	Sequence 2733, Ap
430	15	100.0	20	14	US-10-224-999A-3171	Sequence 3171, Ap
431	15	100.0	20	14	US-10-224-999A-3172	Sequence 3172, Ap
432	15	100.0	20	14	US-10-224-999A-3173	Sequence 3173, Ap
433	15	100.0	20	14	US-10-280-066-100	Sequence 100, App
434	15	100.0	20	14	US-10-280-066-259	Sequence 259, App
435	15	100.0	20	14	US-10-103-256-1	Sequence 1, Appli
436	15	100.0	20	14	US-10-103-256-2	Sequence 2, Appli
437	15	100.0	20	14	US-10-103-256-3	Sequence 3, Appli
438	15	100.0	20	14	US-10-103-256-4	Sequence 4, Appli
439	15	100.0	20	14	US-10-103-256-5	Sequence 5, Appli
440	15	100.0	20	14	US-10-206-677-5	Sequence 5, Appli
441	15	100.0	20	15	US-10-255-551-3	Sequence 3, Appli

ALIGNMENTS

```
RESULT 1
US-09-998-491-9
; Sequence 9, Application US/09998491
; Publication No. US20030166529A1
; GENERAL INFORMATION:
;  APPLICANT: Mileusnic, Radmilla
;  APPLICANT:  Rose, Stephen Peter Russell
;  TITLE OF INVENTION: Polypeptides and their Uses
;  FILE REFERENCE: 3578-120
;  CURRENT APPLICATION NUMBER: US/09/998,491
;  CURRENT FILING DATE:  2001-11-30
;  PRIOR APPLICATION NUMBER: GB 0109558.7
;  PRIOR FILING DATE: 2001-04-18
;  PRIOR APPLICATION NUMBER: GB 0120084
;  PRIOR FILING DATE: 2001-08-07
;  NUMBER OF SEQ ID NOS: 11
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 9
;   LENGTH: 3
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: 3-mer polypeptide
US-09-998-491-9

  Query Match             100.0%;  Score 15;  DB 10;  Length 3;
  Best Local Similarity   100.0%;  Pred. No. 7.1e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          1 RER 3


RESULT 2
US-09-998-491-10
; Sequence 10, Application US/09998491
; Publication No. US20030166529A1
; GENERAL INFORMATION:
;  APPLICANT: Mileusnic, Radmilla
;  APPLICANT:  Rose, Stephen Peter Russell
;  TITLE OF INVENTION: Polypeptides and their Uses
;  FILE REFERENCE: 3578-120
;  CURRENT APPLICATION NUMBER: US/09/998,491
;  CURRENT FILING DATE:  2001-11-30
;  PRIOR APPLICATION NUMBER: GB 0109558.7
;  PRIOR FILING DATE: 2001-04-18
;  PRIOR APPLICATION NUMBER: GB 0120084
;  PRIOR FILING DATE: 2001-08-07
;  NUMBER OF SEQ ID NOS: 11
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 10
;   LENGTH: 4
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: 4-mer polypeptide
US-09-998-491-10

  Query Match             100.0%;  Score 15;  DB 10;  Length 4;
  Best Local Similarity   100.0%;  Pred. No. 7.1e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          1 RER 3


RESULT 3
US-09-998-491-11
; Sequence 11, Application US/09998491
; Publication No. US20030166529A1
; GENERAL INFORMATION:
;  APPLICANT: Mileusnic, Radmilla
;  APPLICANT:  Rose, Stephen Peter Russell
;  TITLE OF INVENTION: Polypeptides and their Uses
;  FILE REFERENCE: 3578-120
;  CURRENT APPLICATION NUMBER: US/09/998,491
;  CURRENT FILING DATE:  2001-11-30
;  PRIOR APPLICATION NUMBER: GB 0109558.7
```

```
;  PRIOR FILING DATE: 2001-04-18
;  PRIOR APPLICATION NUMBER: GB 0120084
;  PRIOR FILING DATE: 2001-08-07
;  NUMBER OF SEQ ID NOS: 11
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 11
;   LENGTH: 4
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: 4-mer polypeptide
US-09-998-491-11

  Query Match             100.0%;  Score 15;  DB 10;  Length 4;
  Best Local Similarity   100.0%;  Pred. No. 7.1e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          2 RER 4


RESULT 4
US-10-357-467-29
; Sequence 29, Application US/10357467
; Publication No. US20030194729A1
;   GENERAL INFORMATION:
;        APPLICANT: Abogadie, Fe C.
;                   Cruz, Lourdes J.
;                   Olivera, Baldomero M.
;                   Walker, Craig
;                   Colledge, Clark
;                   Hillyard, David R.
;                   Jimenez, Elsie
;        TITLE OF INVENTION: Conantokins
;        NUMBER OF SEQUENCES: 71
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Rothwell, Figg, Ernst & Manbeck, p.c.
;             STREET: 1425 K Street, N.W., Suite 800
;             CITY: Washington
;             STATE: D.C.
;             COUNTRY: USA
;             ZIP: 20005
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/10/357,467
;             FILING DATE: 04-Feb-2003
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US 09/142,080
;             FILING DATE: 15-MAY-2000
;             APPLICATION NUMBER: WO US97/12618
;             FILING DATE: 21-JUL-1997
;             APPLICATION NUMBER: US 08/684,742
;             FILING DATE: 22-JUL-1996
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Ihnen, Jeffrey L.
;             REGISTRATION NUMBER: 28,957
;             REFERENCE/DOCKET NUMBER: 2314-256.A
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: 202-783-6040
;             TELEFAX: 202-783-6031
;   INFORMATION FOR SEQ ID NO: 29:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 4 amino acids
;             TYPE: amino acid
;             STRANDEDNESS: <Unknown>
;             TOPOLOGY: linear
;        MOLECULE TYPE: peptide
;        FRAGMENT TYPE: internal
;        FEATURE:
;             NAME/KEY:  Modified-site
;             LOCATION:  4
;             OTHER INFORMATION:  /note= "Xaa is
;             gamma-carboxyglutamic acid"
;        SEQUENCE DESCRIPTION: SEQ ID NO: 29:
US-10-357-467-29

  Query Match             100.0%;  Score 15;  DB 14;  Length 4;
  Best Local Similarity   100.0%;  Pred. No. 7.1e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          1 RER 3


RESULT 5
US-09-096-749A-59
; Sequence 59, Application US/09096749A
; Patent No. US20020019517A1
;  GENERAL INFORMATION:
;    APPLICANT:  Koieda, Shohei
;    TITLE OF INVENTION:  ARTIFICIAL ANTIBODY POLYPEPTIDES
;    NUMBER OF SEQUENCES:  118
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Schwegman, Lundberg, Woessner & Kluth P.A.
;      STREET:  121 South Eighth Street, Ste. 1600
;      CITY:  Minneapolis
;      STATE:  MN
;      COUNTRY:  USA
;      ZIP:  55402
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  DOS
;      SOFTWARE:  FastSEQ Version 2.0b
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/096,749A
;      FILING DATE:  June 12, 1998
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Ann S. Viksnins
;      REGISTRATION NUMBER:  37,748
;      REFERENCE/DOCKET NUMBER:  109.034US1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (612) 373-6900
;      TELEFAX:  (612) 339-3061
;  INFORMATION FOR SEQ ID NO:  59:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  5 amino acids
;      TYPE:  amino acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
;    FRAGMENT TYPE:  internal
;    ORIGINAL SOURCE:
US-09-096-749A-59

  Query Match             100.0%;  Score 15;  DB 9;  Length 5;
  Best Local Similarity   100.0%;  Pred. No. 7.1e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          3 RER 5


RESULT 6
```

```
US-09-903-412-59
; Sequence 59, Application US/09903412
; Publication No. US20030027319A1
; GENERAL INFORMATION:
;  APPLICANT: Koide, Shohei
;  TITLE OF INVENTION: ARTIFICIAL ANTIBODY POLYPEPTIDES
;  FILE REFERENCE: 109.050US1
;  CURRENT APPLICATION NUMBER: US/09/903,412
;  CURRENT FILING DATE:  2001-07-11
;  PRIOR APPLICATION NUMBER: US 60/217,474
;  PRIOR FILING DATE: 2000-07-11
;  NUMBER OF SEQ ID NOS: 121
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 59
;   LENGTH: 5
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: The sequence of the BC loop of clone pLB24.6.
US-09-903-412-59

  Query Match            100.0%;  Score 15;  DB 10;  Length 5;
  Best Local Similarity  100.0%;  Pred. No. 7.1e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
               |||
Db          3 RER 5


RESULT 7
US-09-998-491-3
; Sequence 3, Application US/09998491
; Publication No. US20030166529A1
; GENERAL INFORMATION:
;  APPLICANT: Mileusnic, Radmilla
;  APPLICANT:  Rose, Stephen Peter Russell
;  TITLE OF INVENTION: Polypeptides and their Uses
;  FILE REFERENCE: 3578-120
;  CURRENT APPLICATION NUMBER: US/09/998,491
;  CURRENT FILING DATE:  2001-11-30
;  PRIOR APPLICATION NUMBER: GB 0109558.7
;  PRIOR FILING DATE: 2001-04-18
;  PRIOR APPLICATION NUMBER: GB 0120084
;  PRIOR FILING DATE: 2001-08-07
;  NUMBER OF SEQ ID NOS: 11
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 3
;   LENGTH: 5
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: 5-mer polypeptide
US-09-998-491-3

  Query Match            100.0%;  Score 15;  DB 10;  Length 5;
  Best Local Similarity  100.0%;  Pred. No. 7.1e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
               |||
Db          1 RER 3


RESULT 8
US-09-998-491-4
; Sequence 4, Application US/09998491
; Publication No. US20030166529A1
; GENERAL INFORMATION:
;  APPLICANT: Mileusnic, Radmilla
;  APPLICANT:  Rose, Stephen Peter Russell
;  TITLE OF INVENTION: Polypeptides and their Uses
;  FILE REFERENCE: 3578-120
;  CURRENT APPLICATION NUMBER: US/09/998,491
;  CURRENT FILING DATE:  2001-11-30
;  PRIOR APPLICATION NUMBER: GB 0109558.7
;  PRIOR FILING DATE: 2001-04-18
;  PRIOR APPLICATION NUMBER: GB 0120084
;  PRIOR FILING DATE: 2001-08-07
;  NUMBER OF SEQ ID NOS: 11
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 4
;   LENGTH: 5
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: 5-mer polypeptide
US-09-998-491-4

  Query Match            100.0%;  Score 15;  DB 10;  Length 5;
  Best Local Similarity  100.0%;  Pred. No. 7.1e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
               |||
Db          3 RER 5


RESULT 9
US-10-174-717A-59
; Sequence 59, Application US/10174717A
; Publication No. US20030108948A1
;        APPLICANT: Koide, Shohei
;        TITLE OF INVENTION: ARTIFICIAL ANTIBODY POLYPEPTIDES
;        NUMBER OF SEQUENCES: 118
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Schwegman, Lundberg, Woessner & Kluth P.A.
;             STREET: 121 South Eighth Street, St. 1600
;             CITY: Minneapolis
;             STATE: MN
;             COUNTRY: USA
;             ZIP: 55402
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Diskette
;             COMPUTER: IBM Compatible
;             OPERATING SYSTEM: WINDOWS
;             SOFTWARE: FastSEQ Version 2.0b
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/10/174,717A
;             FILING DATE: 18-Jun-2002
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 09/096,749
;             FILING DATE: June 12, 1998
;             APPLICATION NUMBER: 60/049,410
;             FILING DATE: June 12, 1997
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Ann S. Viksnins
;             REGISTRATION NUMBER: 37,748
;             REFERENCE/DOCKET NUMBER: 109.034US4
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (612) 373-6900
;             TELEFAX: (612) 339-3061
;   INFORMATION FOR SEQ ID NO: 59:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 5 amino acids
;             TYPE: amino acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: peptide
;        HYPOTHETICAL: NO
;        ANTI-SENSE: NO
;        FRAGMENT TYPE: internal
;        ORIGINAL SOURCE:
;        SEQUENCE DESCRIPTION: SEQ ID NO: 59:
US-10-174-717A-59
```

```
  Query Match             100.0%;  Score 15;  DB 14;  Length 5;
  Best Local Similarity   100.0%;  Pred. No. 7.1e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          3 RER 5


RESULT 10
US-10-165-155-59
; Sequence 59, Application US/10165155
; Publication No. US20030134386A1
;   GENERAL INFORMATION:
;        APPLICANT: Koieda, Shohei
;        TITLE OF INVENTION: ARTIFICIAL ANTIBODY POLYPEPTIDES
;        NUMBER OF SEQUENCES: 118
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Schwegman, Lundberg, Woessner & Kluth P.A.
;             STREET: 121 South Eighth Street, Ste. 1600
;             CITY: Minneapolis
;             STATE: MN
;             COUNTRY: USA
;             ZIP: 55402
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Diskette
;             COMPUTER: IBM Compatible
;             OPERATING SYSTEM: DOS
;             SOFTWARE: FastSEQ Version 2.0b
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/10/165,155
;             FILING DATE: 06-Jun-2002
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US/09/096,749
;             FILING DATE: June 12, 1998
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Ann S. Viksnins
;             REGISTRATION NUMBER: 37,748
;             REFERENCE/DOCKET NUMBER: 109.034US1
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (612) 373-6900
;             TELEFAX: (612) 339-3061
;   INFORMATION FOR SEQ ID NO: 59:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 5 amino acids
;             TYPE: amino acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: peptide
;        HYPOTHETICAL: NO
;        ANTI-SENSE: NO
;        FRAGMENT TYPE: internal
;        ORIGINAL SOURCE:
;        SEQUENCE DESCRIPTION: SEQ ID NO: 59:
US-10-165-155-59

  Query Match             100.0%;  Score 15;  DB 14;  Length 5;
  Best Local Similarity   100.0%;  Pred. No. 7.1e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          3 RER 5


RESULT 11
US-10-190-162-59
; Sequence 59, Application US/10190162
; Publication No. US20030170753A1
;   GENERAL INFORMATION:
;        APPLICANT: Koieda, Shohei
;        TITLE OF INVENTION: ARTIFICIAL ANTIBODY POLYPEPTIDES
;        NUMBER OF SEQUENCES: 118
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Schwegman, Lundberg, Woessner & Kluth P.A.
;             STREET: 121 South Eighth Street, Ste. 1600
;             CITY: Minneapolis
;             STATE: MN
;             COUNTRY: USA
;             ZIP: 55402
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Diskette
;             COMPUTER: IBM Compatible
;             OPERATING SYSTEM: DOS
;             SOFTWARE: FastSEQ Version 2.0b
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/10/190,162
;             FILING DATE: 03-Jul-2002
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US/09/096,749
;             FILING DATE: June 12, 1998
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Ann S. Viksnins
;             REGISTRATION NUMBER: 37,748
;             REFERENCE/DOCKET NUMBER: 109.034US1
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (612) 373-6900
;             TELEFAX: (612) 339-3061
;   INFORMATION FOR SEQ ID NO: 59:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 5 amino acids
;             TYPE: amino acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: peptide
;        HYPOTHETICAL: NO
;        ANTI-SENSE: NO
;        FRAGMENT TYPE: internal
;        ORIGINAL SOURCE:
;        SEQUENCE DESCRIPTION: SEQ ID NO: 59:
US-10-190-162-59

  Query Match             100.0%;  Score 15;  DB 14;  Length 5;
  Best Local Similarity   100.0%;  Pred. No. 7.1e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          3 RER 5


RESULT 12
US-10-082-747A-60
; Sequence 60, Application US/10082747A
; Publication No. US20030129688A1
; GENERAL INFORMATION:
;  APPLICANT: Genentech, Inc.
;  APPLICANT:  Ballinger, Marcus D.
;  APPLICANT:  Jones, Jennifer T.
;  APPLICANT:  Fairbrother, Wayne J.
;  APPLICANT:  Sliwkowski, Mark X.
;  APPLICANT:  Wells, James A.
;  TITLE OF INVENTION: HEREGULIN VARIANTS
;  FILE REFERENCE: 402E-476112US
;  CURRENT APPLICATION NUMBER: US/10/082,747A
;  CURRENT FILING DATE:  2002-09-16
;  PRIOR APPLICATION NUMBER: US 09/101,544
;  PRIOR FILING DATE: 1998-07-17
;  PRIOR APPLICATION NUMBER: PCT/US/98/01579
;  PRIOR FILING DATE: 1998-02-10
;  PRIOR APPLICATION NUMBER: US 08/799,054
;  PRIOR FILING DATE: 1997-02-10
;  NUMBER OF SEQ ID NOS: 116
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 60
;   LENGTH: 6
```

```
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Variant sequence at human heregulin-beta1
;   OTHER INFORMATION: residues 183-188
US-10-082-747A-60

  Query Match             100.0%;  Score 15;  DB 14;  Length 6;
  Best Local Similarity   100.0%;  Pred. No. 7.1e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          2 RER 4


RESULT 13
US-10-315-964A-462
; Sequence 462, Application US/10315964A
; Publication No. US20030148956A1
; GENERAL INFORMATION:
;  APPLICANT: The Procter & Gamble Company
;  APPLICANT:  Isfort, Robert J
;  APPLICANT:  Mazur, Wieslaw A
;  TITLE OF INVENTION: Cortcotropin Releasing Factor 2 Receptor Agonists
;  FILE REFERENCE: 8847M3
;  CURRENT APPLICATION NUMBER: US/10/315,964A
;  CURRENT FILING DATE:  2003-04-01
;  PRIOR APPLICATION NUMBER: US 60/349,117
;  PRIOR FILING DATE: 2002-01-16
;  PRIOR APPLICATION NUMBER: US 60/376,337
;  PRIOR FILING DATE: 2002-04-29
;  PRIOR APPLICATION NUMBER: US 60/388,895
;  PRIOR FILING DATE: 2002-06-14
;  PRIOR APPLICATION NUMBER: US 60/411,988
;  PRIOR FILING DATE: 2002-09-19
;  NUMBER OF SEQ ID NOS: 530
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 462
;   LENGTH: 6
;   TYPE: PRT
;   ORGANISM: artificial
;   FEATURE:
;   OTHER INFORMATION: Chemically synthesized artificial peptide
US-10-315-964A-462

  Query Match             100.0%;  Score 15;  DB 14;  Length 6;
  Best Local Similarity   100.0%;  Pred. No. 7.1e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          3 RER 5


RESULT 14
US-10-315-964A-524
; Sequence 524, Application US/10315964A
; Publication No. US20030148956A1
; GENERAL INFORMATION:
;  APPLICANT: The Procter & Gamble Company
;  APPLICANT:  Isfort, Robert J
;  APPLICANT:  Mazur, Wieslaw A
;  TITLE OF INVENTION: Cortcotropin Releasing Factor 2 Receptor Agonists
;  FILE REFERENCE: 8847M3
;  CURRENT APPLICATION NUMBER: US/10/315,964A
;  CURRENT FILING DATE:  2003-04-01
;  PRIOR APPLICATION NUMBER: US 60/349,117
;  PRIOR FILING DATE: 2002-01-16
;  PRIOR APPLICATION NUMBER: US 60/376,337
;  PRIOR FILING DATE: 2002-04-29
;  PRIOR APPLICATION NUMBER: US 60/388,895
;  PRIOR FILING DATE: 2002-06-14
;  PRIOR APPLICATION NUMBER: US 60/411,988
;  PRIOR FILING DATE: 2002-09-19
;  NUMBER OF SEQ ID NOS: 530
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 524
;   LENGTH: 6
;   TYPE: PRT
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: Chemically synthesized artificial peptide
US-10-315-964A-524

  Query Match             100.0%;  Score 15;  DB 14;  Length 6;
  Best Local Similarity   100.0%;  Pred. No. 7.1e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          3 RER 5


RESULT 15
US-10-315-964A-525
; Sequence 525, Application US/10315964A
; Publication No. US20030148956A1
; GENERAL INFORMATION:
;  APPLICANT: The Procter & Gamble Company
;  APPLICANT:  Isfort, Robert J
;  APPLICANT:  Mazur, Wieslaw A
;  TITLE OF INVENTION: Cortcotropin Releasing Factor 2 Receptor Agonists
;  FILE REFERENCE: 8847M3
;  CURRENT APPLICATION NUMBER: US/10/315,964A
;  CURRENT FILING DATE:  2003-04-01
;  PRIOR APPLICATION NUMBER: US 60/349,117
;  PRIOR FILING DATE: 2002-01-16
;  PRIOR APPLICATION NUMBER: US 60/376,337
;  PRIOR FILING DATE: 2002-04-29
;  PRIOR APPLICATION NUMBER: US 60/388,895
;  PRIOR FILING DATE: 2002-06-14
;  PRIOR APPLICATION NUMBER: US 60/411,988
;  PRIOR FILING DATE: 2002-09-19
;  NUMBER OF SEQ ID NOS: 530
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 525
;   LENGTH: 6
;   TYPE: PRT
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: Chemically synthesized artificial peptide
US-10-315-964A-525

  Query Match             100.0%;  Score 15;  DB 14;  Length 6;
  Best Local Similarity   100.0%;  Pred. No. 7.1e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          3 RER 5


RESULT 16
US-10-317-251A-462
; Sequence 462, Application US/10317251A
; Publication No. US20030148957A1
; GENERAL INFORMATION:
;  APPLICANT: The Procter & Gamble Company
;  APPLICANT:  Isfort, Robert J
;  APPLICANT:  Mazur, Wieslaw A
;  TITLE OF INVENTION: Cortcotropin Releasing Factor 2 Receptor Agonists
;  FILE REFERENCE: 8847M2
;  CURRENT APPLICATION NUMBER: US/10/317,251A
;  CURRENT FILING DATE:  2002-12-11
;  PRIOR APPLICATION NUMBER: US 60/349,117
```

; PRIOR FILING DATE: 2002-01-16
; PRIOR APPLICATION NUMBER: US 60/376,337
; PRIOR FILING DATE: 2002-04-29
; PRIOR APPLICATION NUMBER: US 60/388,895
; PRIOR FILING DATE: 2002-06-14
; PRIOR APPLICATION NUMBER: US 60/411,988
; PRIOR FILING DATE: 2002-09-19
; NUMBER OF SEQ ID NOS: 530
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 462
; LENGTH: 6
; TYPE: PRT
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Chemically synthesized artificial peptide
US-10-317-251A-462

Query Match 100.0%; Score 15; DB 14; Length 6;
Best Local Similarity 100.0%; Pred. No. 7.1e+05;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
|||
Db 3 RER 5

RESULT 17
US-10-317-251A-524
; Sequence 524, Application US/10317251A
; Publication No. US20030148957A1
; GENERAL INFORMATION:
; APPLICANT: The Procter & Gamble Company
; APPLICANT: Isfort, Robert J
; APPLICANT: Mazur, Wieslaw A
; TITLE OF INVENTION: Cortcotropin Releasing Factor 2 Receptor Agonists
; FILE REFERENCE: 8847M2
; CURRENT APPLICATION NUMBER: US/10/317,251A
; CURRENT FILING DATE: 2002-12-11
; PRIOR APPLICATION NUMBER: US 60/349,117
; PRIOR FILING DATE: 2002-01-16
; PRIOR APPLICATION NUMBER: US 60/376,337
; PRIOR FILING DATE: 2002-04-29
; PRIOR APPLICATION NUMBER: US 60/388,895
; PRIOR FILING DATE: 2002-06-14
; PRIOR APPLICATION NUMBER: US 60/411,988
; PRIOR FILING DATE: 2002-09-19
; NUMBER OF SEQ ID NOS: 530
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 524
; LENGTH: 6
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Chemically synthesized artificial peptide
US-10-317-251A-524

Query Match 100.0%; Score 15; DB 14; Length 6;
Best Local Similarity 100.0%; Pred. No. 7.1e+05;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
|||
Db 3 RER 5

RESULT 18
US-10-317-251A-525
; Sequence 525, Application US/10317251A
; Publication No. US20030148957A1
; GENERAL INFORMATION:
; APPLICANT: The Procter & Gamble Company
; APPLICANT: Isfort, Robert J
; APPLICANT: Mazur, Wieslaw A
; TITLE OF INVENTION: Cortcotropin Releasing Factor 2 Receptor Agonists
; FILE REFERENCE: 8847M2
; CURRENT APPLICATION NUMBER: US/10/317,251A
; CURRENT FILING DATE: 2002-12-11
; PRIOR APPLICATION NUMBER: US 60/349,117
; PRIOR FILING DATE: 2002-01-16
; PRIOR APPLICATION NUMBER: US 60/376,337
; PRIOR FILING DATE: 2002-04-29
; PRIOR APPLICATION NUMBER: US 60/388,895
; PRIOR FILING DATE: 2002-06-14
; PRIOR APPLICATION NUMBER: US 60/411,988
; PRIOR FILING DATE: 2002-09-19
; NUMBER OF SEQ ID NOS: 530
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 525
; LENGTH: 6
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Chemically synthesized artificial peptide
US-10-317-251A-525

Query Match 100.0%; Score 15; DB 14; Length 6;
Best Local Similarity 100.0%; Pred. No. 7.1e+05;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
|||
Db 3 RER 5

RESULT 19
US-10-317-252A-462
; Sequence 462, Application US/10317252A
; Publication No. US20030148958A1
; GENERAL INFORMATION:
; APPLICANT: The Procter & Gamble Company
; APPLICANT: Isfort, Robert J
; APPLICANT: Mazur, Wieslaw A
; TITLE OF INVENTION: Cortcotropin Releasing Factor 2 Receptor Agonists
; FILE REFERENCE: 8847M
; CURRENT APPLICATION NUMBER: US/10/317,252A
; CURRENT FILING DATE: 2003-03-31
; PRIOR APPLICATION NUMBER: US 60/349,117
; PRIOR FILING DATE: 2002-01-16
; PRIOR APPLICATION NUMBER: US 60/376,337
; PRIOR FILING DATE: 2002-04-29
; PRIOR APPLICATION NUMBER: US 60/388,895
; PRIOR FILING DATE: 2002-06-14
; PRIOR APPLICATION NUMBER: US 60/411,988
; PRIOR FILING DATE: 2002-09-19
; NUMBER OF SEQ ID NOS: 530
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 462
; LENGTH: 6
; TYPE: PRT
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Chemically synthesized artificial peptide
US-10-317-252A-462

Query Match 100.0%; Score 15; DB 14; Length 6;
Best Local Similarity 100.0%; Pred. No. 7.1e+05;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
|||
Db 3 RER 5

RESULT 20
US-10-317-252A-524
; Sequence 524, Application US/10317252A

; Publication No. US20030148958A1
; GENERAL INFORMATION:
; APPLICANT: The Procter & Gamble Company
; APPLICANT: Isfort, Robert J
; APPLICANT: Mazur, Wieslaw A
; TITLE OF INVENTION: Cortcotropin Releasing Factor 2 Receptor Agonists
; FILE REFERENCE: 8847M
; CURRENT APPLICATION NUMBER: US/10/317,252A
; CURRENT FILING DATE: 2003-03-31
; PRIOR APPLICATION NUMBER: US 60/349,117
; PRIOR FILING DATE: 2002-01-16
; PRIOR APPLICATION NUMBER: US 60/376,337
; PRIOR FILING DATE: 2002-04-29
; PRIOR APPLICATION NUMBER: US 60/388,895
; PRIOR FILING DATE: 2002-06-14
; PRIOR APPLICATION NUMBER: US 60/411,988
; PRIOR FILING DATE: 2002-09-19
; NUMBER OF SEQ ID NOS: 530
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 524
; LENGTH: 6
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Chemically synthesized artificial peptide
US-10-317-252A-524

Query Match 100.0%; Score 15; DB 14; Length 6;
Best Local Similarity 100.0%; Pred. No. 7.1e+05;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
|||
Db 3 RER 5

RESULT 21
US-10-317-252A-525
; Sequence 525, Application US/10317252A
; Publication No. US20030148958A1
; GENERAL INFORMATION:
; APPLICANT: The Procter & Gamble Company
; APPLICANT: Isfort, Robert J
; APPLICANT: Mazur, Wieslaw A
; TITLE OF INVENTION: Cortcotropin Releasing Factor 2 Receptor Agonists
; FILE REFERENCE: 8847M
; CURRENT APPLICATION NUMBER: US/10/317,252A
; CURRENT FILING DATE: 2003-03-31
; PRIOR APPLICATION NUMBER: US 60/349,117
; PRIOR FILING DATE: 2002-01-16
; PRIOR APPLICATION NUMBER: US 60/376,337
; PRIOR FILING DATE: 2002-04-29
; PRIOR APPLICATION NUMBER: US 60/388,895
; PRIOR FILING DATE: 2002-06-14
; PRIOR APPLICATION NUMBER: US 60/411,988
; PRIOR FILING DATE: 2002-09-19
; NUMBER OF SEQ ID NOS: 530
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 525
; LENGTH: 6
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Chemically synthesized artificial peptide
US-10-317-252A-525

Query Match 100.0%; Score 15; DB 14; Length 6;
Best Local Similarity 100.0%; Pred. No. 7.1e+05;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
|||
Db 3 RER 5

RESULT 22
US-10-232-544-21
; Sequence 21, Application US/10232544
; Publication No. US20030199069A1
; GENERAL INFORMATION:
; APPLICANT: Fuglsang, Claus
; APPLICANT: Okkels, Jens
; APPLICANT: Petersen, Dorte
; APPLICANT: Patkar, Shamkant
; APPLICANT: Thellersen, Marianne
; APPLICANT: Svenden, Allan
; APPLICANT: Borch, Kim
; APPLICANT: Royer, John
; APPLICANT: Kretzschmar, Titus
; APPLICANT: Halkier, Torben
; APPLICANT: Vind, Jesper
; APPLICANT: Jorgensen, Steen
; TITLE OF INVENTION: No. US20030199069A1el Lipolytic Enzymes
; FILE REFERENCE: 4455.404-US
; CURRENT APPLICATION NUMBER: US/10/232,544
; CURRENT FILING DATE: 2002-08-30
; PRIOR APPLICATION NUMBER: US/09/007,288
; PRIOR FILING DATE: 2000-01-14
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 21
; LENGTH: 6
; TYPE: PRT
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Peptide addition
US-10-232-544-21

Query Match 100.0%; Score 15; DB 14; Length 6;
Best Local Similarity 100.0%; Pred. No. 7.1e+05;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
|||
Db 4 RER 6

RESULT 23
US-09-970-088-2
; Sequence 2, Application US/09970088
; Patent No. US20020151489A1
; GENERAL INFORMATION:
; APPLICANT: GRAVEREAUX, EDWIN C.
; APPLICANT: SILVER, MARCY
; APPLICANT: ISNER, JEFFREY M.
; APPLICANT: YOON, YOUNG-SUP
; TITLE OF INVENTION: USE OF LYMPHANGIOGENIC AGENTS TO TREAT LYMPHATIC
; TITLE OF INVENTION: DISORDERS
; FILE REFERENCE: 71417/55062
; CURRENT APPLICATION NUMBER: US/09/970,088
; CURRENT FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: 60/237,171
; PRIOR FILING DATE: 2000-10-02
; NUMBER OF SEQ ID NOS: 14
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 7
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Illustrative
; OTHER INFORMATION: peptide
US-09-970-088-2

Query Match 100.0%; Score 15; DB 9; Length 7;
Best Local Similarity 100.0%; Pred. No. 7.1e+05;

Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 RER 3
              |||
Db          5 RER 7
```

RESULT 24
US-09-876-904A-495
; Sequence 495, Application US/09876904A
; Publication No. US20030072794A1
; GENERAL INFORMATION:
; APPLICANT: BOULIKAS, TENI
; TITLE OF INVENTION: ENCAPSULATION OF PLASMID DNA (LIPOGENES TM) AND THERAPEUTIC
; TITLE OF INVENTION: AGENTS WITH NUCLEAR LOCALIZATION SIGNAL/FUSOGENIC PEPTIDE
; TITLE OF INVENTION: CONJUGATES INTO TARGETED LIPOSOME COMPLEXES
; FILE REFERENCE: TB-2002.00
; CURRENT APPLICATION NUMBER: US/09/876,904A
; CURRENT FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/210,925
; PRIOR FILING DATE: 2000-06-09
; NUMBER OF SEQ ID NOS: 629
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 495
; LENGTH: 7
; TYPE: PRT
; ORGANISM: Rattus sp.
; FEATURE:
; OTHER INFORMATION: Rat AT-BP1.
US-09-876-904A-495

Query Match 100.0%; Score 15; DB 10; Length 7;
Best Local Similarity 100.0%; Pred. No. 7.1e+05;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 RER 3
              |||
Db          3 RER 5
```

RESULT 25
US-09-876-904A-508
; Sequence 508, Application US/09876904A
; Publication No. US20030072794A1
; GENERAL INFORMATION:
; APPLICANT: BOULIKAS, TENI
; TITLE OF INVENTION: ENCAPSULATION OF PLASMID DNA (LIPOGENES TM) AND THERAPEUTIC
; TITLE OF INVENTION: AGENTS WITH NUCLEAR LOCALIZATION SIGNAL/FUSOGENIC PEPTIDE
; TITLE OF INVENTION: CONJUGATES INTO TARGETED LIPOSOME COMPLEXES
; FILE REFERENCE: TB-2002.00
; CURRENT APPLICATION NUMBER: US/09/876,904A
; CURRENT FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/210,925
; PRIOR FILING DATE: 2000-06-09
; NUMBER OF SEQ ID NOS: 629
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 508
; LENGTH: 7
; TYPE: PRT
; ORGANISM: Unknown Organism
; FEATURE:
; OTHER INFORMATION: Description of Unknown Organism: Ig/EBP-1 (immunoglobulin
; OTHER INFORMATION: gene enhancer-binding protein).
US-09-876-904A-508

Query Match 100.0%; Score 15; DB 10; Length 7;
Best Local Similarity 100.0%; Pred. No. 7.1e+05;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 RER 3
              |||
Db          5 RER 7
```

RESULT 26
US-09-972-656-17
; Sequence 17, Application US/09972656
; Publication No. US20030099647A1
; GENERAL INFORMATION:
; APPLICANT: Deshpande, Rajendra
; APPLICANT: Tsai, Mei-Mei
; TITLE OF INVENTION: Fully Human Antibody Fab Fragments with Human Interferon-Gamma
; TITLE OF INVENTION: Neutralizing Activity
; FILE REFERENCE: A-799
; CURRENT APPLICATION NUMBER: US/09/972,656
; CURRENT FILING DATE: 2001-10-05
; NUMBER OF SEQ ID NOS: 135
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 17
; LENGTH: 7
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-972-656-17

Query Match 100.0%; Score 15; DB 10; Length 7;
Best Local Similarity 100.0%; Pred. No. 7.1e+05;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 RER 3
              |||
Db          3 RER 5
```

RESULT 27
US-10-232-544-49
; Sequence 49, Application US/10232544
; Publication No. US20030199069A1
; GENERAL INFORMATION:
; APPLICANT: Fuglsang, Claus
; APPLICANT: Okkels, Jens
; APPLICANT: Petersen, Dorte
; APPLICANT: Patkar, Shamkant
; APPLICANT: Thellersen, Marianne
; APPLICANT: Svenden, Allan
; APPLICANT: Borch, Kim
; APPLICANT: Royer, John
; APPLICANT: Kretzschmar, Titus
; APPLICANT: Halkier, Torben
; APPLICANT: Vind, Jesper
; APPLICANT: Jorgensen, Steen
; TITLE OF INVENTION: No. US20030199069A1el Lipolytic Enzymes
; FILE REFERENCE: 4455.404-US
; CURRENT APPLICATION NUMBER: US/10/232,544
; CURRENT FILING DATE: 2002-08-30
; PRIOR APPLICATION NUMBER: US/09/007,288
; PRIOR FILING DATE: 2000-01-14
; NUMBER OF SEQ ID NOS: 162
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 49
; LENGTH: 7
; TYPE: PRT
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Peptide addition
US-10-232-544-49

Query Match 100.0%; Score 15; DB 14; Length 7;
Best Local Similarity 100.0%; Pred. No. 7.1e+05;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 RER 3
              |||
Db          4 RER 6
```

RESULT 28

US-09-876-904A-455
; Sequence 455, Application US/09876904A
; Publication No. US20030072794A1
; GENERAL INFORMATION:
; APPLICANT: BOULIKAS, TENI
; TITLE OF INVENTION: ENCAPSULATION OF PLASMID DNA (LIPOGENES TM) AND THERAPEUTIC
; TITLE OF INVENTION: AGENTS WITH NUCLEAR LOCALIZATION SIGNAL/FUSOGENIC PEPTIDE
; TITLE OF INVENTION: CONJUGATES INTO TARGETED LIPOSOME COMPLEXES
; FILE REFERENCE: TB-2002.00
; CURRENT APPLICATION NUMBER: US/09/876,904A
; CURRENT FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/210,925
; PRIOR FILING DATE: 2000-06-09
; NUMBER OF SEQ ID NOS: 629
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 455
; LENGTH: 8
; TYPE: PRT
; ORGANISM: Unknown Organism
; FEATURE:
; OTHER INFORMATION: Description of Unknown Organism: C/EBP (CCAAT/enhancer
; OTHER INFORMATION: binding protein).
US-09-876-904A-455

Query Match 100.0%; Score 15; DB 10; Length 8;
Best Local Similarity 100.0%; Pred. No. 7.1e+05;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
|||
Db 5 RER 7

RESULT 29
US-09-876-904A-503
; Sequence 503, Application US/09876904A
; Publication No. US20030072794A1
; GENERAL INFORMATION:
; APPLICANT: BOULIKAS, TENI
; TITLE OF INVENTION: ENCAPSULATION OF PLASMID DNA (LIPOGENES TM) AND THERAPEUTIC
; TITLE OF INVENTION: AGENTS WITH NUCLEAR LOCALIZATION SIGNAL/FUSOGENIC PEPTIDE
; TITLE OF INVENTION: CONJUGATES INTO TARGETED LIPOSOME COMPLEXES
; FILE REFERENCE: TB-2002.00
; CURRENT APPLICATION NUMBER: US/09/876,904A
; CURRENT FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/210,925
; PRIOR FILING DATE: 2000-06-09
; NUMBER OF SEQ ID NOS: 629
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 503
; LENGTH: 8
; TYPE: PRT
; ORGANISM: Mus sp.
; FEATURE:
; OTHER INFORMATION: Mouse AGP/EBP.
US-09-876-904A-503

Query Match 100.0%; Score 15; DB 10; Length 8;
Best Local Similarity 100.0%; Pred. No. 7.1e+05;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
|||
Db 5 RER 7

RESULT 30
US-09-876-904A-506
; Sequence 506, Application US/09876904A
; Publication No. US20030072794A1
; GENERAL INFORMATION:
; APPLICANT: BOULIKAS, TENI
; TITLE OF INVENTION: ENCAPSULATION OF PLASMID DNA (LIPOGENES TM) AND THERAPEUTIC
; TITLE OF INVENTION: AGENTS WITH NUCLEAR LOCALIZATION SIGNAL/FUSOGENIC PEPTIDE
; TITLE OF INVENTION: CONJUGATES INTO TARGETED LIPOSOME COMPLEXES
; FILE REFERENCE: TB-2002.00
; CURRENT APPLICATION NUMBER: US/09/876,904A
; CURRENT FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/210,925
; PRIOR FILING DATE: 2000-06-09
; NUMBER OF SEQ ID NOS: 629
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 506
; LENGTH: 8
; TYPE: PRT
; ORGANISM: Rattus sp.
; FEATURE:
; OTHER INFORMATION: Rat LAP, a 32-kD liver enriched transcriptional
; OTHER INFORMATION: activator, also present in lung, with 71% sequence
; OTHER INFORMATION: similarity to C/EBP.
US-09-876-904A-506

Query Match 100.0%; Score 15; DB 10; Length 8;
Best Local Similarity 100.0%; Pred. No. 7.1e+05;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
|||
Db 5 RER 7

RESULT 31
US-09-876-904A-519
; Sequence 519, Application US/09876904A
; Publication No. US20030072794A1
; GENERAL INFORMATION:
; APPLICANT: BOULIKAS, TENI
; TITLE OF INVENTION: ENCAPSULATION OF PLASMID DNA (LIPOGENES TM) AND THERAPEUTIC
; TITLE OF INVENTION: AGENTS WITH NUCLEAR LOCALIZATION SIGNAL/FUSOGENIC PEPTIDE
; TITLE OF INVENTION: CONJUGATES INTO TARGETED LIPOSOME COMPLEXES
; FILE REFERENCE: TB-2002.00
; CURRENT APPLICATION NUMBER: US/09/876,904A
; CURRENT FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/210,925
; PRIOR FILING DATE: 2000-06-09
; NUMBER OF SEQ ID NOS: 629
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 519
; LENGTH: 8
; TYPE: PRT
; ORGANISM: Saccharomyces cerevisiae
; FEATURE:
; OTHER INFORMATION: Human NF-IL6 (345 aa).
US-09-876-904A-519

Query Match 100.0%; Score 15; DB 10; Length 8;
Best Local Similarity 100.0%; Pred. No. 7.1e+05;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
|||
Db 5 RER 7

RESULT 32
US-09-833-039-39
; Sequence 39, Application US/09833039
; Publication No. US20030175960A1
; GENERAL INFORMATION:
; APPLICANT: Tureci, Ozlem
; APPLICANT: Sahin, Ugur
; APPLICANT: Pfreundschuh, Michael
; TITLE OF INVENTION: Tumor Associated Peptide and Uses Thereof
; FILE REFERENCE: LUD 5622.1
; CURRENT APPLICATION NUMBER: US/09/833,039
; CURRENT FILING DATE: 2001-04-12

; PRIOR APPLICATION NUMBER: US 09/409,455
; PRIOR FILING DATE: 1999-09-30
; PRIOR APPLICATION NUMBER: US 09/344,040
; PRIOR FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: US 09/105,839
; PRIOR FILING DATE: 1998-06-26
; PRIOR APPLICATION NUMBER: US 08/851,130
; PRIOR FILING DATE: 1997-05-05
; NUMBER OF SEQ ID NOS: 129
; SEQ ID NO 39
; LENGTH: 8
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-833-039-39

Query Match 100.0%; Score 15; DB 10; Length 8;
Best Local Similarity 100.0%; Pred. No. 7.1e+05;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
|||
Db 3 RER 5

RESULT 33
US-09-833-039-64
; Sequence 64, Application US/09833039
; Publication No. US20030175960A1
; GENERAL INFORMATION:
; APPLICANT: Tureci, Ozlem
; APPLICANT: Sahin, Ugur
; APPLICANT: Pfreundschuh, Michael
; TITLE OF INVENTION: Tumor Associated Peptide and Uses Thereof
; FILE REFERENCE: LUD 5622.1
; CURRENT APPLICATION NUMBER: US/09/833,039
; CURRENT FILING DATE: 2001-04-12
; PRIOR APPLICATION NUMBER: US 09/409,455
; PRIOR FILING DATE: 1999-09-30
; PRIOR APPLICATION NUMBER: US 09/344,040
; PRIOR FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: US 09/105,839
; PRIOR FILING DATE: 1998-06-26
; PRIOR APPLICATION NUMBER: US 08/851,130
; PRIOR FILING DATE: 1997-05-05
; NUMBER OF SEQ ID NOS: 129
; SEQ ID NO 64
; LENGTH: 8
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-833-039-64

Query Match 100.0%; Score 15; DB 10; Length 8;
Best Local Similarity 100.0%; Pred. No. 7.1e+05;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
|||
Db 3 RER 5

RESULT 34
US-09-833-039-91
; Sequence 91, Application US/09833039
; Publication No. US20030175960A1
; GENERAL INFORMATION:
; APPLICANT: Tureci, Ozlem
; APPLICANT: Sahin, Ugur
; APPLICANT: Pfreundschuh, Michael
; TITLE OF INVENTION: Tumor Associated Peptide and Uses Thereof
; FILE REFERENCE: LUD 5622.1
; CURRENT APPLICATION NUMBER: US/09/833,039
; CURRENT FILING DATE: 2001-04-12
; PRIOR APPLICATION NUMBER: US 09/409,455
; PRIOR FILING DATE: 1999-09-30
; PRIOR APPLICATION NUMBER: US 09/344,040
; PRIOR FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: US 09/105,839
; PRIOR FILING DATE: 1998-06-26
; PRIOR APPLICATION NUMBER: US 08/851,130
; PRIOR FILING DATE: 1997-05-05
; NUMBER OF SEQ ID NOS: 129
; SEQ ID NO 91
; LENGTH: 8
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-833-039-91

Query Match 100.0%; Score 15; DB 10; Length 8;
Best Local Similarity 100.0%; Pred. No. 7.1e+05;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
|||
Db 3 RER 5

RESULT 35
US-09-833-039-111
; Sequence 111, Application US/09833039
; Publication No. US20030175960A1
; GENERAL INFORMATION:
; APPLICANT: Tureci, Ozlem
; APPLICANT: Sahin, Ugur
; APPLICANT: Pfreundschuh, Michael
; TITLE OF INVENTION: Tumor Associated Peptide and Uses Thereof
; FILE REFERENCE: LUD 5622.1
; CURRENT APPLICATION NUMBER: US/09/833,039
; CURRENT FILING DATE: 2001-04-12
; PRIOR APPLICATION NUMBER: US 09/409,455
; PRIOR FILING DATE: 1999-09-30
; PRIOR APPLICATION NUMBER: US 09/344,040
; PRIOR FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: US 09/105,839
; PRIOR FILING DATE: 1998-06-26
; PRIOR APPLICATION NUMBER: US 08/851,130
; PRIOR FILING DATE: 1997-05-05
; NUMBER OF SEQ ID NOS: 129
; SEQ ID NO 111
; LENGTH: 8
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-833-039-111

Query Match 100.0%; Score 15; DB 10; Length 8;
Best Local Similarity 100.0%; Pred. No. 7.1e+05;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
|||
Db 3 RER 5

RESULT 36
US-10-014-485A-54
; Sequence 54, Application US/10014485A
; Publication No. US20020168684A1
; GENERAL INFORMATION:
; APPLICANT: Cell Signaling Technology, Inc.
; APPLICANT: COMB, Michael J.
; APPLICANT: ZHANG, Hui
; APPLICANT: TAN, Yi
; TITLE OF INVENTION: PRODUCTION OF MOTIF-SPECIFIC AND CONTEXT-INDEPENDENT ANTIBODIES US
; TITLE OF INVENTION: PEPTIDE LIBRARIES AS ANTIGENS
; FILE REFERENCE: CST-138 CIP2
; CURRENT APPLICATION NUMBER: US/10/014,485A
; CURRENT FILING DATE: 2002-03-18

; PRIOR APPLICATION NUMBER: US 09/148,712
; PRIOR FILING DATE: 1998-09-04
; PRIOR APPLICATION NUMBER: US 09/535,364
; PRIOR FILING DATE: 2000-03-24
; NUMBER OF SEQ ID NOS: 145
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 54
; LENGTH: 8
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: MOD_RES
; LOCATION: (6)..(6)
; OTHER INFORMATION: PHOSPHORYLATION; threonine at position 6 is phosphorylated
US-10-014-485A-54

Query Match 100.0%; Score 15; DB 13; Length 8;
Best Local Similarity 100.0%; Pred. No. 7.1e+05;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
|||
Db 1 RER 3

RESULT 37
US-10-174-105A-54
; Sequence 54, Application US/10174105A
; Publication No. US20030068652A1
; GENERAL INFORMATION:
; APPLICANT: Cell Signaling Technology, Inc.
; APPLICANT: ZHANG, Hui
; APPLICANT: COMB, Michael J.
; APPLICANT: TAN, Yi
; TITLE OF INVENTION: POSITIVE IDENTIFICATION OF PHOSPHO-PROTEINS USING MOTIF-SPECIFIC,
; TITLE OF INVENTION: CONTEXT-INDEPENDENT ANTIBODIES COUPLED WITH DATABASE SEARCHING
; FILE REFERENCE: CST-138 CIP3
; CURRENT APPLICATION NUMBER: US/10/174,105A
; CURRENT FILING DATE: 2002-06-18
; PRIOR APPLICATION NUMBER: US 09/148,712
; PRIOR FILING DATE: 1998-09-04
; PRIOR APPLICATION NUMBER: US 09/535,364
; PRIOR FILING DATE: 2000-03-24
; NUMBER OF SEQ ID NOS: 193
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 54
; LENGTH: 8
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Peptide
; FEATURE:
; NAME/KEY: MOD_RES
; LOCATION: (6)..(6)
; OTHER INFORMATION: PHOSPHORYLATION; threonine at position 6 is phosphorylated
US-10-174-105A-54

Query Match 100.0%; Score 15; DB 14; Length 8;
Best Local Similarity 100.0%; Pred. No. 7.1e+05;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
|||
Db 1 RER 3

RESULT 38
US-10-224-999A-2180
; Sequence 2180, Application US/10224999A
; Publication No. US20030171318A1
; GENERAL INFORMATION:
; APPLICANT: Myriad Genetics, Inc.
; APPLICANT: Morham, Scott
; APPLICANT: Zavitz, Kenton
; APPLICANT: Hobden, Adrian
; TITLE OF INVENTION: Composition and Method for Treating Viral Infection
; FILE REFERENCE: 5004.01
; CURRENT APPLICATION NUMBER: US/10/224,999A
; CURRENT FILING DATE: 2003-03-03
; PRIOR APPLICATION NUMBER: US 60/313,695
; PRIOR FILING DATE: 2001-08-20
; NUMBER OF SEQ ID NOS: 3484
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2180
; LENGTH: 8
; TYPE: PRT
; ORGANISM: Rubella virus
US-10-224-999A-2180

Query Match 100.0%; Score 15; DB 14; Length 8;
Best Local Similarity 100.0%; Pred. No. 7.1e+05;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
|||
Db 2 RER 4

RESULT 39
US-10-224-999A-2181
; Sequence 2181, Application US/10224999A
; Publication No. US20030171318A1
; GENERAL INFORMATION:
; APPLICANT: Myriad Genetics, Inc.
; APPLICANT: Morham, Scott
; APPLICANT: Zavitz, Kenton
; APPLICANT: Hobden, Adrian
; TITLE OF INVENTION: Composition and Method for Treating Viral Infection
; FILE REFERENCE: 5004.01
; CURRENT APPLICATION NUMBER: US/10/224,999A
; CURRENT FILING DATE: 2003-03-03
; PRIOR APPLICATION NUMBER: US 60/313,695
; PRIOR FILING DATE: 2001-08-20
; NUMBER OF SEQ ID NOS: 3484
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2181
; LENGTH: 8
; TYPE: PRT
; ORGANISM: Rubella virus
US-10-224-999A-2181

Query Match 100.0%; Score 15; DB 14; Length 8;
Best Local Similarity 100.0%; Pred. No. 7.1e+05;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
|||
Db 1 RER 3

RESULT 40
US-10-177-277-39
; Sequence 39, Application US/10177277
; Publication No. US20030185844A1
; GENERAL INFORMATION:
; APPLICANT: Tureci, Ozlem
; APPLICANT: Sahin, Ugur
; APPLICANT: Pfreundschuh, Michael
; APPLICANT: Ramensee, Hans Georg
; APPLICANT: Stevanovic, Stefan
; TITLE OF INVENTION: Method for Determining Presence of Cancer In a Sample By Determini
; TITLE OF INVENTION: Expression of an SSX Gene, Peptides Derived From Said SSX Gene ar
; TITLE OF INVENTION: Gene, and Uses Thereof
; FILE REFERENCE: LUD 5556.1
; CURRENT APPLICATION NUMBER: US/10/177,277
; CURRENT FILING DATE: 2002-06-21

; PRIOR APPLICATION NUMBER: US/09/344,040
; PRIOR FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: US 09/105,839
; PRIOR FILING DATE: 1998-06-26
; PRIOR APPLICATION NUMBER: US 08/851,130
; PRIOR FILING DATE: 1997-05-05
; NUMBER OF SEQ ID NOS: 132
; SEQ ID NO 39
; LENGTH: 8
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-177-277-39

Query Match 100.0%; Score 15; DB 14; Length 8;
Best Local Similarity 100.0%; Pred. No. 7.1e+05;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
|||
Db 3 RER 5

RESULT 41
US-10-177-277-64
; Sequence 64, Application US/10177277
; Publication No. US20030185844A1
; GENERAL INFORMATION:
; APPLICANT: Tureci, Ozlem
; APPLICANT: Sahin, Ugur
; APPLICANT: Pfreundschuh, Michael
; APPLICANT: Ramensee, Hans Georg
; APPLICANT: Stevanovic, Stefan
; TITLE OF INVENTION: Method for Determining Presence of Cancer In a Sample By Determin
; TITLE OF INVENTION: Expression of an SSX Gene, Peptides Derived From Said SSX Gene a
; TITLE OF INVENTION: Gene, and Uses Thereof
; FILE REFERENCE: LUD 5556.1
; CURRENT APPLICATION NUMBER: US/10/177,277
; CURRENT FILING DATE: 2002-06-21
; PRIOR APPLICATION NUMBER: US/09/344,040
; PRIOR FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: US 09/105,839
; PRIOR FILING DATE: 1998-06-26
; PRIOR APPLICATION NUMBER: US 08/851,130
; PRIOR FILING DATE: 1997-05-05
; NUMBER OF SEQ ID NOS: 132
; SEQ ID NO 64
; LENGTH: 8
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-177-277-64

Query Match 100.0%; Score 15; DB 14; Length 8;
Best Local Similarity 100.0%; Pred. No. 7.1e+05;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
|||
Db 3 RER 5

RESULT 42
US-10-177-277-91
; Sequence 91, Application US/10177277
; Publication No. US20030185844A1
; GENERAL INFORMATION:
; APPLICANT: Tureci, Ozlem
; APPLICANT: Sahin, Ugur
; APPLICANT: Pfreundschuh, Michael
; APPLICANT: Ramensee, Hans Georg
; APPLICANT: Stevanovic, Stefan
; TITLE OF INVENTION: Method for Determining Presence of Cancer In a Sample By Determin
; TITLE OF INVENTION: Expression of an SSX Gene, Peptides Derived From Said SSX Gene a
; TITLE OF INVENTION: Gene, and Uses Thereof
; FILE REFERENCE: LUD 5556.1
; CURRENT APPLICATION NUMBER: US/10/177,277
; CURRENT FILING DATE: 2002-06-21
; PRIOR APPLICATION NUMBER: US/09/344,040
; PRIOR FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: US 09/105,839
; PRIOR FILING DATE: 1998-06-26
; PRIOR APPLICATION NUMBER: US 08/851,130
; PRIOR FILING DATE: 1997-05-05
; NUMBER OF SEQ ID NOS: 132
; SEQ ID NO 91
; LENGTH: 8
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-177-277-91

Query Match 100.0%; Score 15; DB 14; Length 8;
Best Local Similarity 100.0%; Pred. No. 7.1e+05;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
|||
Db 3 RER 5

RESULT 43
US-10-177-277-111
; Sequence 111, Application US/10177277
; Publication No. US20030185844A1
; GENERAL INFORMATION:
; APPLICANT: Tureci, Ozlem
; APPLICANT: Sahin, Ugur
; APPLICANT: Pfreundschuh, Michael
; APPLICANT: Ramensee, Hans Georg
; APPLICANT: Stevanovic, Stefan
; TITLE OF INVENTION: Method for Determining Presence of Cancer In a Sample By Determini
; TITLE OF INVENTION: Expression of an SSX Gene, Peptides Derived From Said SSX Gene ar
; TITLE OF INVENTION: Gene, and Uses Thereof
; FILE REFERENCE: LUD 5556.1
; CURRENT APPLICATION NUMBER: US/10/177,277
; CURRENT FILING DATE: 2002-06-21
; PRIOR APPLICATION NUMBER: US/09/344,040
; PRIOR FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: US 09/105,839
; PRIOR FILING DATE: 1998-06-26
; PRIOR APPLICATION NUMBER: US 08/851,130
; PRIOR FILING DATE: 1997-05-05
; NUMBER OF SEQ ID NOS: 132
; SEQ ID NO 111
; LENGTH: 8
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-177-277-111

Query Match 100.0%; Score 15; DB 14; Length 8;
Best Local Similarity 100.0%; Pred. No. 7.1e+05;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
|||
Db 3 RER 5

RESULT 44
US-10-376-121A-79
; Sequence 79, Application US/10376121A
; Publication No. US20030216544A1
; GENERAL INFORMATION:
; APPLICANT: Harley, John
; TITLE OF INVENTION: METHODS AND REAGENTS FOR DIAGNOSIS OF
; AUTOANTIBODIES
; NUMBER OF SEQUENCES: 218
; CORRESPONDENCE ADDRESS:

```
;             ADDRESSEE: Patrea L. Pabst
;             STREET: Suite 2000, 1201 West Peachtree Street, N.E.
;             CITY: Atlanta
;             STATE: GA
;             COUNTRY: USA
;             ZIP: 30309-3400
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.25
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/10/376,121A
;             FILING DATE: 27-Mar-2003
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 07/867,819
;             FILING DATE: April 13, 1992
;             APPLICATION NUMBER: 07/648,205
;             FILING DATE: January 31, 1991
;             APPLICATION NUMBER: 07/472,947
;             FILING DATE: January 31, 1990
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Pabst, Patrea L.
;             REGISTRATION NUMBER: 31,284
;             REFERENCE/DOCKET NUMBER: OMRF114CIP(2)DIV(2)
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (404)-817-8473
;             TELEFAX: (404)-817-8588
;    INFORMATION FOR SEQ ID NO: 79:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 8 amino acids
;             TYPE: amino acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: peptide
;        FEATURE:
;             NAME/KEY:  Binding-site
;             LOCATION:  1..8
;        SEQUENCE DESCRIPTION: SEQ ID NO: 79:
US-10-376-121A-79

  Query Match             100.0%;  Score 15;  DB 15;  Length 8;
  Best Local Similarity   100.0%;  Pred. No. 7.1e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          5 RER 7


RESULT 45
US-10-376-121A-80
; Sequence 80, Application US/10376121A
; Publication No. US20030216544A1
;   GENERAL INFORMATION:
;        APPLICANT: Harley, John
;        TITLE OF INVENTION: METHODS AND REAGENTS FOR DIAGNOSIS OF
;                            AUTOANTIBODIES
;        NUMBER OF SEQUENCES: 218
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Patrea L. Pabst
;             STREET: Suite 2000, 1201 West Peachtree Street, N.E.
;             CITY: Atlanta
;             STATE: GA
;             COUNTRY: USA
;             ZIP: 30309-3400
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.25
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/10/376,121A
;             FILING DATE: 27-Mar-2003
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 07/867,819
;             FILING DATE: April 13, 1992
;             APPLICATION NUMBER: 07/648,205
;             FILING DATE: January 31, 1991
;             APPLICATION NUMBER: 07/472,947
;             FILING DATE: January 31, 1990
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Pabst, Patrea L.
;             REGISTRATION NUMBER: 31,284
;             REFERENCE/DOCKET NUMBER: OMRF114CIP(2)DIV(2)
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (404)-817-8473
;             TELEFAX: (404)-817-8588
;    INFORMATION FOR SEQ ID NO: 80:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 8 amino acids
;             TYPE: amino acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: peptide
;        FEATURE:
;             NAME/KEY:  Binding-site
;             LOCATION:  1..8
;        SEQUENCE DESCRIPTION: SEQ ID NO: 80:
US-10-376-121A-80

  Query Match             100.0%;  Score 15;  DB 15;  Length 8;
  Best Local Similarity   100.0%;  Pred. No. 7.1e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          2 RER 4


RESULT 46
US-09-809-638-516
; Sequence 516, Application US/09809638
; Publication No. US20030059895A1
; GENERAL INFORMATION:
;  APPLICANT: Mary Faris
;  APPLICANT:  Pia M. Challita-Eid
;  APPLICANT:  Steve Chappell Mitchell
;  APPLICANT:  Daniel E.H. Afar
;  APPLICANT:  Arthur B. Raitano
;  APPLICANT:  Aya Jakobovits
;  TITLE OF INVENTION: 125P5C8:  A TISSUE SPECIFIC PROTEIN
;  TITLE OF INVENTION:  HIGHLY EXPRESSED IN VARIOUS CANCERS
;  FILE REFERENCE: 129.35US01
;  CURRENT APPLICATION NUMBER: US/09/809,638
;  CURRENT FILING DATE:  2001-03-14
;  NUMBER OF SEQ ID NOS: 746
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 516
;   LENGTH: 9
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-09-809-638-516

  Query Match             100.0%;  Score 15;  DB 10;  Length 9;
  Best Local Similarity   100.0%;  Pred. No. 7.1e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          3 RER 5


RESULT 47
```

```
US-09-809-638-621
; Sequence 621, Application US/09809638
; Publication No. US20030059895A1
; GENERAL INFORMATION:
;  APPLICANT: Mary Faris
;  APPLICANT:  Pia M. Challita-Eid
;  APPLICANT:  Steve Chappell Mitchell
;  APPLICANT:  Daniel E.H. Afar
;  APPLICANT:  Arthur B. Raitano
;  APPLICANT:  Aya Jakobovits
;  TITLE OF INVENTION: 125P5C8:  A TISSUE SPECIFIC PROTEIN
;  TITLE OF INVENTION:  HIGHLY EXPRESSED IN VARIOUS CANCERS
;  FILE REFERENCE: 129.35US01
;  CURRENT APPLICATION NUMBER: US/09/809,638
;  CURRENT FILING DATE:  2001-03-14
;  NUMBER OF SEQ ID NOS: 746
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 621
;   LENGTH: 9
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-09-809-638-621

  Query Match            100.0%;  Score 15;  DB 10;  Length 9;
  Best Local Similarity  100.0%;  Pred. No. 7.1e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          3 RER 5


RESULT 48
US-09-876-904A-379
; Sequence 379, Application US/09876904A
; Publication No. US20030072794A1
; GENERAL INFORMATION:
;  APPLICANT: BOULIKAS, TENI
;  TITLE OF INVENTION: ENCAPSULATION OF PLASMID DNA (LIPOGENES TM) AND THERAPEUTIC
;  TITLE OF INVENTION:  AGENTS WITH NUCLEAR LOCALIZATION SIGNAL/FUSOGENIC PEPTIDE
;  TITLE OF INVENTION:  CONJUGATES INTO TARGETED LIPOSOME COMPLEXES
;  FILE REFERENCE: TB-2002.00
;  CURRENT APPLICATION NUMBER: US/09/876,904A
;  CURRENT FILING DATE:  2001-06-08
;  PRIOR APPLICATION NUMBER: US 60/210,925
;  PRIOR FILING DATE: 2000-06-09
;  NUMBER OF SEQ ID NOS: 629
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 379
;   LENGTH: 9
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: Human thyroid hormone receptor alpha (c-erbA-1
;   OTHER INFORMATION: gene).
US-09-876-904A-379

  Query Match            100.0%;  Score 15;  DB 10;  Length 9;
  Best Local Similarity  100.0%;  Pred. No. 7.1e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          2 RER 4


RESULT 49
US-09-932-165-1036
; Sequence 1036, Application US/09932165
; Publication No. US20030134784A1
; GENERAL INFORMATION:
;  APPLICANT: RAITANO, ARTHUR
;  APPLICANT:  CHALLITA-EID, PIA M.
;  APPLICANT:  FARIS, MARY
;  APPLICANT:  SAFFRAN, DOUGLAS
;  APPLICANT:  AFAR, DANIEL
;  APPLICANT:  LEVIN, ELANA
;  APPLICANT:  HUBERT, RENE
;  APPLICANT:  GE, WANGMAO
;  APPLICANT:  JAKOBOVITS, AYA
;  TITLE OF INVENTION: NUCLEIC ACIDS AND CORRESPONDING PROTEINS ENTITLED
;  TITLE OF INVENTION:  83P2H3 AND CaTrF2E11 USEFUL IN TREATMENT AND
;  TITLE OF INVENTION:  DETECTION OF CANCER
;  FILE REFERENCE: 51158-20014.00
;  CURRENT APPLICATION NUMBER: US/09/932,165
;  CURRENT FILING DATE:  2001-08-17
;  PRIOR APPLICATION NUMBER: 60/226,329
;  PRIOR FILING DATE: 2000-08-17
;  NUMBER OF SEQ ID NOS: 1508
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1036
;   LENGTH: 9
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Peptide motif
US-09-932-165-1036

  Query Match            100.0%;  Score 15;  DB 10;  Length 9;
  Best Local Similarity  100.0%;  Pred. No. 7.1e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          3 RER 5


RESULT 50
US-09-833-039-41
; Sequence 41, Application US/09833039
; Publication No. US20030175960A1
; GENERAL INFORMATION:
;  APPLICANT: Tureci, Ozlem
;  APPLICANT:  Sahin, Ugur
;  APPLICANT:  Pfreundschuh, Michael
;  TITLE OF INVENTION: Tumor Associated Peptide and Uses Thereof
;  FILE REFERENCE: LUD 5622.1
;  CURRENT APPLICATION NUMBER: US/09/833,039
;  CURRENT FILING DATE:  2001-04-12
;  PRIOR APPLICATION NUMBER: US 09/409,455
;  PRIOR FILING DATE: 1999-09-30
;  PRIOR APPLICATION NUMBER: US 09/344,040
;  PRIOR FILING DATE: 1999-06-25
;  PRIOR APPLICATION NUMBER: US 09/105,839
;  PRIOR FILING DATE: 1998-06-26
;  PRIOR APPLICATION NUMBER: US 08/851,130
;  PRIOR FILING DATE: 1997-05-05
;  NUMBER OF SEQ ID NOS: 129
; SEQ ID NO 41
;   LENGTH: 9
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-09-833-039-41

  Query Match            100.0%;  Score 15;  DB 10;  Length 9;
  Best Local Similarity  100.0%;  Pred. No. 7.1e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          1 RER 3


Search completed: March  5, 2004, 16:12:26
Job time : 33 secs
```

GenCore version 5.1.6

OM protein - protein search, using sw model

Run on: March 5, 2004, 16:06:22 ; Search time 21 Seconds
(without alignments)
13.742 Million cell updates/sec

Title: US-09-998-491-9
Perfect score: 15
Sequence: 1 RER 3

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283366 seqs, 96191526 residues

Total number of hits satisfying chosen parameters: 5

Minimum DB seq length: 0
Maximum DB seq length: 20

Post-processing: Minimum Match 100%
Maximum Match 100%
Listing first 1000 summaries

Database : PIR_78:*
1: pir1:*
2: pir2:*
3: pir3:*
4: pir4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	15	100.0	12	2	T44420	hypothetical prote
2	15	100.0	13	2	PH1595	Ig H chain V-D-J r
3	15	100.0	15	2	S57584	T cell receptor V-
4	15	100.0	16	2	PH1475	T-cell receptor be
5	15	100.0	18	2	S54270	GATA-2 protein - A

ALIGNMENTS

RESULT 1
T44420
hypothetical protein [imported] - Bacillus stearothermophilus (fragment)
C;Species: Bacillus stearothermophilus
C;Date: 21-Jan-2000 #sequence_revision 21-Jan-2000 #text_change 21-Jan-2000
C;Accession: T44420
R;Vlaskova, H.; Krasny, L.; Fucik, V.; Jonak, J.
submitted to the EMBL Data Library, September 1997
A;Description: The pyrAb gene coding for the large subunit of carbamoylphosphate synthet
A;Reference number: Z22760
A;Accession: T44420
A;Status: preliminary; translated from GB/EMBL/DDBJ
A;Molecule type: DNA
A;Residues: 1-12 <VLA>
A;Cross-references: EMBL:AJ001805; PIDN:CAA05021.1
A;Experimental source: strain CCM 2184
C;Genetics:
A;Note: ORF2

Query Match 100.0%; Score 15; DB 2; Length 12;
Best Local Similarity 100.0%; Pred. No. 3e+02;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 RER 3
              |||
Db          4 RER 6
```

RESULT 2
PH1595
Ig H chain V-D-J region (wild-type clone 150) - mouse (fragment)
C;Species: Mus musculus (house mouse)
C;Date: 02-Jun-1994 #sequence_revision 02-Jun-1994 #text_change 17-Mar-1999
C;Accession: PH1595
R;Levinson, D.A.; Campos-Torres, J.; Leder, P.
J. Exp. Med. 178, 317-329, 1993
A;Title: Molecular characterization of transgene-induced immunodeficiency in B-less mice
A;Reference number: PH1580; MUID:93301609; PMID:8315387
A;Accession: PH1595
A;Molecule type: DNA
A;Residues: 1-13 <LEV>
A;Experimental source: bone marrow pre-B lymphocyte
C;Keywords: immunoglobulin

Query Match 100.0%; Score 15; DB 2; Length 13;
Best Local Similarity 100.0%; Pred. No. 3.2e+02;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 RER 3
              |||
Db          3 RER 5
```

RESULT 3
S57584
T cell receptor V-D-J junctional alpha chain region - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 19-Oct-1995 #sequence_revision 17-Nov-1995 #text_change 05-Nov-1999
C;Accession: S57584
R;Burrows, S.R.; Silins, S.L.; Moss, D.J.; Khanna, R.; Misko, I.S.; Argaet, V.P.
submitted to the EMBL Data Library, June 1995
A;Description: T cell receptor repertoire for a viral epitope in humans is diversified by
A;Reference number: S57494
A;Accession: S57584
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-15 <BUR>
A;Cross-references: EMBL:Z49956; NID:g887466; PIDN:CAA90227.1; PID:g887467
C;Keywords: T-cell receptor

Query Match 100.0%; Score 15; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 RER 3
              |||
Db          6 RER 8
```

RESULT 4
PH1475
T-cell receptor beta chain (clone 223/5) - mouse (fragment)
C;Species: Mus musculus (house mouse)
C;Date: 10-Mar-1994 #sequence_revision 10-Mar-1994 #text_change 11-Apr-1995
C;Accession: PH1475
R;Casanova, J.L.; Martinon, F.; Gournier, H.; Barra, C.; Pannetier, C.; Regnault, A.; Kou
J. Exp. Med. 177, 811-820, 1993
A;Title: T cell receptor selection by and recognition of two class I major histocompatibi
A;Reference number: PH1430; MUID:93171821; PMID:8436911
A;Accession: PH1475
A;Molecule type: mRNA
A;Residues: 1-16 <CAS>

A;Experimental source: cytolytic T-lymphocyte
C;Superfamily: immunoglobulin homology
C;Keywords: receptor; T-cell

Query Match 100.0%; Score 15; DB 2; Length 16;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
||||
Db 10 RER 12

RESULT 5
S54270
GATA-2 protein - African clawed frog
C;Species: Xenopus laevis (African clawed frog)
C;Date: 27-Oct-1995 #sequence_revision 03-Nov-1995 #text_change 03-Nov-1995
C;Accession: S54270
R;Brewer, A.C.; Guille, M.J.; Fear, D.J.; Partington, G.A.; Patient, R.K.
EMBO J. 14, 757-766, 1995
A;Title: Nuclear translocation of a maternal CCAAT factor at the start of gastrulation a
A;Reference number: S54270; MUID:95188880; PMID:7882979
A;Accession: S54270
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-18 <BRE>

Query Match 100.0%; Score 15; DB 2; Length 18;
Best Local Similarity 100.0%; Pred. No. 4.4e+02;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
||||
Db 9 RER 11

Search completed: March 5, 2004, 16:11:05
Job time : 22 secs

GenCore version 5.1.6

OM protein - protein search, using sw model

Run on: March 5, 2004, 16:04:07 ; Search time 11 Seconds
(without alignments)
14.201 Million cell updates/sec

Title: US-09-998-491-9
Perfect score: 15
Sequence: 1 RER 3

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 141681 seqs, 52070155 residues

Total number of hits satisfying chosen parameters: 0

Minimum DB seq length: 0
Maximum DB seq length: 20

Post-processing: Minimum Match 100%
Maximum Match 100%
Listing first 1000 summaries

Database : SwissProt_42:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description

No matches found

Search completed: March 5, 2004, 16:09:40
Job time : 11 secs

GenCore version 5.1.6

OM protein - protein search, using sw model

Run on: March 5, 2004, 16:05:07 ; Search time 38 Seconds
(without alignments)
24.909 Million cell updates/sec

Title: US-09-998-491-9
Perfect score: 15
Sequence: 1 RER 3

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1017041 seqs, 315518202 residues

Total number of hits satisfying chosen parameters: 9

Minimum DB seq length: 0
Maximum DB seq length: 20

Post-processing: Minimum Match 100%
Maximum Match 100%
Listing first 1000 summaries

Database : SPTREMBL_25:*
1: sp_archea:*
2: sp_bacteria:*
3: sp_fungi:*
4: sp_human:*
5: sp_invertebrate:*
6: sp_mammal:*
7: sp_mhc:*
8: sp_organelle:*
9: sp_phage:*
10: sp_plant:*
11: sp_rodent:*
12: sp_virus:*
13: sp_vertebrate:*
14: sp_unclassified:*
15: sp_rvirus:*
16: sp_bacteriap:*
17: sp_archeap:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	15	100.0	11	10	Q9S8X4	Q9s8x4 glycine max
2	15	100.0	12	2	O50303	O50303 bacillus st
3	15	100.0	15	11	O35411	O35411 mus musculu
4	15	100.0	16	4	Q9UD21	Q9ud21 homo sapien
5	15	100.0	16	8	Q9T2R8	Q9t2r8 solanum tub
6	15	100.0	17	15	Q9QEX8	Q9qex8 human immun
7	15	100.0	17	15	Q9QEX9	Q9qex9 human immun
8	15	100.0	18	6	Q9GMH1	Q9gmh1 macaca mula
9	15	100.0	20	4	Q8NEE1	Q8nee1 homo sapien

ALIGNMENTS

RESULT 1
Q9S8X4
ID Q9S8X4 PRELIMINARY; PRT; 11 AA.
AC Q9S8X4;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-JUN-2002 (TrEMBLrel. 21, Last annotation update)
DE Vegetative storage protein 94 peptide 3, VSP94=LIPOXYGENASE
DE (Fragment).
OS Glycine max (Soybean).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids;
OC eurosids I; Fabales; Fabaceae; Papilionoideae; Phaseoleae; Glycine.
OX NCBI_TaxID=3847;
RN [1]
RP SEQUENCE.
RX MEDLINE=92361246; PubMed=1822994;
RA Tranbarger T.J., Franceschi V.R., Hildebrand D.F., Grimes H.D.;
RT "The soybean 94-kilodalton vegetative storage protein is a
RT lipoxygenase that is localized in paraveinal mesophyll cell
RT vacuoles.";
RL Plant Cell 3:973-987(1991).
FT NON_TER 1 1
FT NON_TER 11 11
SQ SEQUENCE 11 AA; 1366 MW; 9B337C3C0DD9CB1A CRC64;

Query Match 100.0%; Score 15; DB 10; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.5e+03;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
|||
Db 8 RER 10

RESULT 2
O50303
ID O50303 PRELIMINARY; PRT; 12 AA.
AC O50303;
DT 01-JUN-1998 (TrEMBLrel. 06, Created)
DT 01-JUN-1998 (TrEMBLrel. 06, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Hypothetical protein (Fragment).
OS Bacillus stearothermophilus.
OC Bacteria; Firmicutes; Bacillales; Bacillaceae; Geobacillus.
OX NCBI_TaxID=1422;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=CCM 2184;
RX MEDLINE=20194845; PubMed=10732707;
RA Vlaskova H., Krasny L., Fucik V., Jonak J.;
RT "The pyrAb Gene Coding for the Large Subunit of Carbamoylphosphate
RT Synthetase from Bacillus stearothermophilus: Molecular cloning and
RT Functional Characterization.";
RL Folia Biol. (Praha) 44:163-172(1998).
DR EMBL; AJ001805; CAA05021.1; -.
DR PIR; T44420; T44420.
KW Hypothetical protein.
FT NON_TER 12 12
SQ SEQUENCE 12 AA; 1379 MW; 70087CB0E8A6840B CRC64;

Query Match 100.0%; Score 15; DB 2; Length 12;
Best Local Similarity 100.0%; Pred. No. 1.6e+03;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
|||
Db 4 RER 6

RESULT 3
O35411
ID O35411 PRELIMINARY; PRT; 15 AA.
AC O35411;
DT 01-JAN-1998 (TrEMBLrel. 05, Created)

```
DT   01-JAN-1998 (TrEMBLrel. 05, Last sequence update)
DT   01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
DE   Beta III spectrin (Fragment).
GN   SPNB3.
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   SEQUENCE FROM N.A.
RC   STRAIN=C57BL/6J; TISSUE=Embryo;
RX   MEDLINE=99045654; PubMed=9826670;
RA   Stankewich M.C., Tse W.T., Peters L.L., Ch'ng Y., John K.M.,
RA   Stabach P.R., Devarajan P., Morrow J.S., Lux S.E.;
RT   "A widely expressed betaIII spectrin associated with Golgi and
RT   cytoplasmic vesicles.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:14158-14163(1998).
DR   EMBL; AF026489; AAC79505.1; -.
DR   MGD; MGI:1313261; Spnb3.
FT   NON_TER       1      1
SQ   SEQUENCE   15 AA;  2029 MW;  CAF6B165F69F1AA8 CRC64;

  Query Match             100.0%;  Score 15;  DB 11;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 2e+03;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          2 RER 4


RESULT 4
Q9UD21
ID   Q9UD21      PRELIMINARY;      PRT;    16 AA.
AC   Q9UD21;
DT   01-MAY-2000 (TrEMBLrel. 13, Created)
DT   01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT   01-JUN-2000 (TrEMBLrel. 14, Last annotation update)
DE   Cyclin E-L (Fragment).
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   SEQUENCE FROM N.A.
RX   MEDLINE=95257942; PubMed=7739542;
RA   Ohtsubo M., Theodoras A.M., Schumacher J., Roberts J.M., Pagano M.;
RT   "Human cyclin E, a nuclear protein essential for the G1-to-S phase
RT   transition.";
RL   Mol. Cell. Biol. 15:2612-2624(1995).
SQ   SEQUENCE   16 AA;  2089 MW;  777EFC69C445E29C CRC64;

  Query Match             100.0%;  Score 15;  DB 4;  Length 16;
  Best Local Similarity   100.0%;  Pred. No. 2.1e+03;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          3 RER 5


RESULT 5
Q9T2R8
ID   Q9T2R8      PRELIMINARY;      PRT;    16 AA.
AC   Q9T2R8;
DT   01-MAY-2000 (TrEMBLrel. 13, Created)
DT   01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT   01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE   Cytochrome-C reductase 53 kDa subunit (EC 1.10.2.2) (Fragment).
OS   Solanum tuberosum (Potato).
OG   Mitochondrion.
OC   Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC   Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; asterids;
OC   lamiids; Solanales; Solanaceae; Solanum.
OX   NCBI_TaxID=4113;
RN   [1]
RP   SEQUENCE.
RX   MEDLINE=94198758; PubMed=7764624;
RA   Braun H.P., Kruft V., Schmitz U.K.;
RL   Planta 193:99-106(1994).
DR   GO; GO:0008121; F:ubiquinol-cytochrome-c reductase activity; IEA.
SQ   SEQUENCE   16 AA;  2116 MW;  915C55A205F04C82 CRC64;

  Query Match             100.0%;  Score 15;  DB 8;  Length 16;
  Best Local Similarity   100.0%;  Pred. No. 2.1e+03;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          9 RER 11


RESULT 6
Q9QEX8
ID   Q9QEX8      PRELIMINARY;      PRT;    17 AA.
AC   Q9QEX8;
DT   01-MAY-2000 (TrEMBLrel. 13, Created)
DT   01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT   01-OCT-2002 (TrEMBLrel. 22, Last annotation update)
DE   Nef protein (Fragment).
GN   NEF.
OS   Human immunodeficiency virus 1.
OC   Viruses; Retroid viruses; Retroviridae; Lentivirus.
OX   NCBI_TaxID=11676;
RN   [1]
RP   SEQUENCE FROM N.A.
RX   MEDLINE=21103026; PubMed=11170057;
RA   Lin H.J., Siwak E.B., Lauder I.J., Hollinger F.B.;
RT   "Long-term culture of human immunodeficiency virus type 1 resulting in
RT   loss of glycosylation sites.";
RL   J. Med. Virol. 63:197-202(2001).
DR   EMBL; AF178662; AAF04368.1; -.
FT   NON_TER       1      1
FT   NON_TER      17     17
SQ   SEQUENCE   17 AA;  2032 MW;  919FC3C6F3515653 CRC64;

  Query Match             100.0%;  Score 15;  DB 15;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 2.2e+03;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db         14 RER 16


RESULT 7
Q9QEX9
ID   Q9QEX9      PRELIMINARY;      PRT;    17 AA.
AC   Q9QEX9;
DT   01-MAY-2000 (TrEMBLrel. 13, Created)
DT   01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT   01-OCT-2002 (TrEMBLrel. 22, Last annotation update)
DE   Nef protein (Fragment).
GN   NEF.
OS   Human immunodeficiency virus 1.
OC   Viruses; Retroid viruses; Retroviridae; Lentivirus.
OX   NCBI_TaxID=11676;
RN   [1]
RP   SEQUENCE FROM N.A.
RX   MEDLINE=21103026; PubMed=11170057;
RA   Lin H.J., Siwak E.B., Lauder I.J., Hollinger F.B.;
RT   "Long-term culture of human immunodeficiency virus type 1 resulting in
RT   loss of glycosylation sites.";
RL   J. Med. Virol. 63:197-202(2001).
DR   EMBL; AF178661; AAF04367.1; -.
FT   NON_TER       1      1
```

```
FT   NON_TER      17     17
SQ   SEQUENCE   17 AA;  1960 MW;  9315C3C6F3515653 CRC64;

  Query Match            100.0%;  Score 15;  DB 15;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 2.2e+03;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db         14 RER 16


RESULT 8
Q9GMH1
ID   Q9GMH1      PRELIMINARY;      PRT;    18 AA.
AC   Q9GMH1;
DT   01-MAR-2001 (TrEMBLrel. 16, Created)
DT   01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
DT   01-MAR-2001 (TrEMBLrel. 16, Last annotation update)
DE   Matrix Gla protein (Fragment).
GN   MGP.
OS   Macaca mulatta (Rhesus macaque).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Primates; Catarrhini; Cercopithecidae;
OC   Cercopithecinae; Macaca.
OX   NCBI_TaxID=9544;
RN   [1]
RP   SEQUENCE FROM N.A.
RC   TISSUE=Carotid artery;
RA   Wu K.-J., Yee A., Zhu N.L., Gordon E.M., Hall F.L.;
RT   "Characterization of differential gene expression in monkey arterial
RT   neointima following balloon catheter injury.";
RL   Submitted (JUN-1999) to the EMBL/GenBank/DDBJ databases.
DR   EMBL; AF162477; AAF98709.1; -.
FT   NON_TER       1      1
SQ   SEQUENCE   18 AA;  2255 MW;  FB4F252C395E5DB1 CRC64;

  Query Match            100.0%;  Score 15;  DB 6;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+03;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db         12 RER 14


RESULT 9
Q8NEE1
ID   Q8NEE1      PRELIMINARY;      PRT;    20 AA.
AC   Q8NEE1;
DT   01-OCT-2002 (TrEMBLrel. 22, Created)
DT   01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT   01-OCT-2002 (TrEMBLrel. 22, Last annotation update)
DE   Hypothetical protein (Fragment).
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   SEQUENCE FROM N.A.
RC   TISSUE=Testis;
RA   Strausberg R.;
RL   Submitted (JUN-2002) to the EMBL/GenBank/DDBJ databases.
DR   EMBL; BC031872; AAH31872.1; -.
KW   Hypothetical protein.
FT   NON_TER       1      1
SQ   SEQUENCE   20 AA;  2218 MW;  8C8A0AD4BF387987 CRC64;

  Query Match            100.0%;  Score 15;  DB 4;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.6e+03;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          1 RER 3


Search completed: March  5, 2004, 16:10:32
Job time : 39 secs
```

OM protein - protein search, using sw model

Run on: March 5, 2004, 16:01:37 ; Search time 53 Seconds
(without alignments)
15.993 Million cell updates/sec

Title: US-09-998-491-9
Perfect score: 15
Sequence: 1 RER 3

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1586107 seqs, 282547505 residues

Total number of hits satisfying chosen parameters: 1006

Minimum DB seq length: 0
Maximum DB seq length: 20

Post-processing: Minimum Match 100%
Maximum Match 100%
Listing first 1000 summaries

Database : A_Geneseq_29Jan04:*
1: geneseqp1980s:*
2: geneseqp1990s:*
3: geneseqp2000s:*
4: geneseqp2001s:*
5: geneseqp2002s:*
6: geneseqp2003as:*
7: geneseqp2003bs:*
8: geneseqp2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	15	100.0	3	2	AAW56176	Aaw56176 Anti-infl
2	15	100.0	4	2	AAW48192	Aaw48192 Conantoki
3	15	100.0	4	2	AAW49974	Aaw49974 Conantoki
4	15	100.0	4	2	AAB24196	Aab24196 Dual pept
5	15	100.0	4	3	AAY71269	Aay71269 Bovine ch
6	15	100.0	4	4	AAG79029	Aag79029 Amino aci
7	15	100.0	4	5	AAE16624	Aae16624 Peptide o
8	15	100.0	4	6	ABB99613	Abb99613 Peptide d
9	15	100.0	4	6	ABB99614	Abb99614 Peptide d
10	15	100.0	5	2	AAR62114	Aar62114 Hydrophil
11	15	100.0	5	2	AAR62113	Aar62113 Hydrophil
12	15	100.0	5	2	AAR62154	Aar62154 Basic/aci
13	15	100.0	5	2	AAR54661	Aar54661 Native se
14	15	100.0	5	2	AAR77510	Aar77510 NeuroD ba
15	15	100.0	5	2	AAW22449	Aaw22449 NeuroD1 N
16	15	100.0	5	2	AAW12517	Aaw12517 Interleuk
17	15	100.0	5	2	AAW71013	Aaw71013 Motif of
18	15	100.0	5	2	AAW94160	Aaw94160 BC loop s
19	15	100.0	5	4	AAB91809	Aab91809 Amyloid b
20	15	100.0	5	4	AAB91776	Aab91776 Amyloid b
21	15	100.0	5	4	AAU01260	Aau01260 B. subtil
22	15	100.0	5	5	ABB94415	Abb94415 Ubiquitin
23	15	100.0	5	6	ABG71799	Abg71799 bHLH fami
24	15	100.0	5	6	ABB99606	Abb99606 Peptide d
25	15	100.0	5	6	ABB99607	Abb99607 Peptide d
26	15	100.0	5	6	ABU62548	Abu62548 Human sec
27	15	100.0	6	2	AAR62104	Aar62104 Hydrophil
28	15	100.0	6	2	AAR62189	Aar62189 U1 snRNP
29	15	100.0	6	2	AAW21203	Aaw21203 Farnesyl
30	15	100.0	6	2	AAW21037	Aaw21037 Lipolytic
31	15	100.0	6	2	AAW23160	Aaw23160 Terminal
32	15	100.0	6	2	AAY55251	Aay55251 ATCC HB 1
33	15	100.0	6	3	AAY86997	Aay86997 Human hae
34	15	100.0	6	3	AAB36760	Aab36760 HRG-beta1
35	15	100.0	6	3	AAY94683	Aay94683 Human zsi
36	15	100.0	6	4	AAB97624	Aab97624 Neuropept
37	15	100.0	6	4	AAB82171	Aab82171 Peptide #
38	15	100.0	6	6	ABB99622	Abb99622 Peptide d
39	15	100.0	6	7	ADE65222	Ade65222 Corticotr
40	15	100.0	6	7	ADE65221	Ade65221 Corticotr
41	15	100.0	6	7	ADE65159	Ade65159 Corticotr
42	15	100.0	6	7	ADE51507	Ade51507 CRF2 non-
43	15	100.0	6	7	ADE51445	Ade51445 CRF2 non-
44	15	100.0	6	7	ADE51508	Ade51508 CRF2 non-
45	15	100.0	7	2	AAR24590	Aar24590 Immunomod
46	15	100.0	7	2	AAW21423	Aaw21423 Alzheimer
47	15	100.0	7	2	AAR77509	Aar77509 Basic reg
48	15	100.0	7	2	AAR77508	Aar77508 Basic reg
49	15	100.0	7	2	AAW22454	Aaw22454 NARERR mo
50	15	100.0	7	2	AAW22453	Aaw22453 NARERR mo
51	15	100.0	7	2	AAW23188	Aaw23188 Terminal
52	15	100.0	7	2	AAW30427	Aaw30427 HRE-I aff
53	15	100.0	7	2	AAW71011	Aaw71011 Motif fou
54	15	100.0	7	2	AAW71012	Aaw71012 Motif fou
55	15	100.0	7	2	AAY20383	Aay20383 Human mic
56	15	100.0	7	3	AAY51553	Aay51553 Neuropept
57	15	100.0	7	3	AAY51554	Aay51554 Neuropept
58	15	100.0	7	4	AAB97625	Aab97625 Neuropept
59	15	100.0	7	5	ABB74731	Abb74731 Transcrip
60	15	100.0	7	5	ABB74744	Abb74744 Transcrip
61	15	100.0	7	5	ABG77696	Abg77696 Targettin
62	15	100.0	7	5	AAU79989	Aau79989 Conserved
63	15	100.0	7	6	ABG71798	Abg71798 Fruit fly
64	15	100.0	7	6	ABG71797	Abg71797 Fruit fly
65	15	100.0	8	2	AAR61427	Aar61427 PF4-relat
66	15	100.0	8	2	AAW58625	Aaw58625 Platelet
67	15	100.0	8	2	AAW54949	Aaw54949 Mouse neu
68	15	100.0	8	2	AAY39803	Aay39803 Beta-amyl
69	15	100.0	8	2	AAY10269	Aay10269 T cell ep
70	15	100.0	8	3	AAY76744	Aay76744 SSX-1 HLA
71	15	100.0	8	3	AAY76732	Aay76732 SSX-2 HLA
72	15	100.0	8	3	AAY79697	Aay79697 SSX-4 der
73	15	100.0	8	3	AAY79724	Aay79724 SSX-2 der
74	15	100.0	8	3	AAY79744	Aay79744 SSX-1 der
75	15	100.0	8	3	AAY78489	Aay78489 SSX-5 der
76	15	100.0	8	4	AAU69064	Aau69064 Bacterial
77	15	100.0	8	4	AAB82155	Aab82155 Peptide #
78	15	100.0	8	4	ABP22272	Abp22272 HIV A03 m
79	15	100.0	8	4	ABP22267	Abp22267 HIV A03 m
80	15	100.0	8	4	ABP17494	Abp17494 HIV B27 s
81	15	100.0	8	4	ABP15111	Abp15111 HIV A03 s
82	15	100.0	8	4	ABP24031	Abp24031 HIV A11 m
83	15	100.0	8	5	ABB74691	Abb74691 Transcrip
84	15	100.0	8	5	ABB74739	Abb74739 Transcrip
85	15	100.0	8	5	ABB74742	Abb74742 Transcrip
86	15	100.0	8	5	ABB74755	Abb74755 Transcrip
87	15	100.0	8	5	ABG69774	Abg69774 Polypepti
88	15	100.0	8	5	ABU57487	Abu57487 HIV cytot
89	15	100.0	8	5	AAM50915	Aam50915 Beta amyl
90	15	100.0	8	5	ABG79951	Abg79951 MHC class
91	15	100.0	8	6	ABR57049	Abr57049 Furin-rec
92	15	100.0	8	6	ABU64629	Abu64629 Motif-spe
93	15	100.0	9	2	AAR24671	Aar24671 Immunomod
94	15	100.0	9	2	AAR61697	Aar61697 HLA-A2.1
95	15	100.0	9	2	AAR61019	Aar61019 Dynorphin
96	15	100.0	9	2	AAW21554	Aaw21554 Corticotr
97	15	100.0	9	2	AAW12599	Aaw12599 SH2 bindi
98	15	100.0	9	2	AAW09450	Aaw09450 Melanoma

99	15	100.0	9	2	AAY20470	Aay20470 Human mic
100	15	100.0	9	2	AAW41588	Aaw41588 Melanoma
101	15	100.0	9	2	AAY01011	Aay01011 Bacterial
102	15	100.0	9	3	AAY76726	Aay76726 SSX-2 HLA
103	15	100.0	9	3	AAY76745	Aay76745 SSX-1 HLA
104	15	100.0	9	3	AAY76735	Aay76735 SSX-2 HLA
105	15	100.0	9	3	AAY78491	Aay78491 SSX-5 der
106	15	100.0	9	3	AAY79727	Aay79727 SSX-2 der
107	15	100.0	9	3	AAY79701	Aay79701 SSX-4 der
108	15	100.0	9	3	AAY79708	Aay79708 SSX-2 der
109	15	100.0	9	3	AAY79745	Aay79745 SSX-1 der
110	15	100.0	9	4	AAM99326	Aam99326 Vaccine r
111	15	100.0	9	4	AAM98903	Aam98903 Vaccine r
112	15	100.0	9	4	ABP15116	Abp15116 HIV A03 s
113	15	100.0	9	4	ABP20861	Abp20861 HIV A03 m
114	15	100.0	9	4	ABP22956	Abp22956 HIV A11 m
115	15	100.0	9	4	ABP16400	Abp16400 HIV A24 s
116	15	100.0	9	4	ABP22268	Abp22268 HIV A03 m
117	15	100.0	9	4	ABP14244	Abp14244 HIV A02 s
118	15	100.0	9	4	ABP24326	Abp24326 HIV A24 m
119	15	100.0	9	4	ABP22259	Abp22259 HIV A03 m
120	15	100.0	9	4	ABP24024	Abp24024 HIV A11 m
121	15	100.0	9	5	AAM49825	Aam49825 Human D40
122	15	100.0	9	5	ABB74615	Abb74615 Transcrip
123	15	100.0	9	5	AAE18744	Aae18744 Human leu
124	15	100.0	9	5	AAE18750	Aae18750 Human leu
125	15	100.0	9	5	AAE18747	Aae18747 Human leu
126	15	100.0	9	5	ABJ12791	Abj12791 Human 125
127	15	100.0	9	5	ABJ12828	Abj12828 Human 125
128	15	100.0	9	5	ABJ13140	Abj13140 Human 125
129	15	100.0	9	5	ABJ12773	Abj12773 Human 125
130	15	100.0	9	5	ABJ13011	Abj13011 Human 125
131	15	100.0	9	5	ABJ12002	Abj12002 Human 125
132	15	100.0	9	5	ABJ12107	Abj12107 Human 125
133	15	100.0	9	5	ABJ12580	Abj12580 Human 125
134	15	100.0	9	5	ABJ12673	Abj12673 Human 125
135	15	100.0	9	5	ABJ12709	Abj12709 Human 125
136	15	100.0	9	5	ABJ13033	Abj13033 Human 125
137	15	100.0	9	5	ABJ13221	Abj13221 Human 125
138	15	100.0	9	5	ABJ12655	Abj12655 Human 125
139	15	100.0	9	5	ABJ13244	Abj13244 Human 125
140	15	100.0	9	5	ABJ12278	Abj12278 Human 125
141	15	100.0	9	5	AAU82561	Aau82561 Llama CDR
142	15	100.0	9	5	AAE17429	Aae17429 Bacteriop
143	15	100.0	9	5	AAU95053	Aau95053 Human nov
144	15	100.0	9	5	AAU79913	Aau79913 Corynebac
145	15	100.0	9	6	ABU73981	Abu73981 Novel pro
146	15	100.0	9	6	ABU77115	Abu77115 Novel pro
147	15	100.0	9	6	ABU72915	Abu72915 Novel pro
148	15	100.0	9	6	ABU73412	Abu73412 Novel pro
149	15	100.0	9	6	ABU73941	Abu73941 Novel pro
150	15	100.0	9	6	ABU75534	Abu75534 Novel pro
151	15	100.0	9	6	ABU75580	Abu75580 Novel pro
152	15	100.0	9	6	ABU77167	Abu77167 Novel pro
153	15	100.0	9	6	ABU77303	Abu77303 Novel pro
154	15	100.0	9	6	ABU76085	Abu76085 Novel pro
155	15	100.0	9	6	ABU74451	Abu74451 Novel pro
156	15	100.0	9	6	ABU76143	Abu76143 Novel pro
157	15	100.0	9	6	ABU77342	Abu77342 Novel pro
158	15	100.0	9	6	ABU74459	Abu74459 Novel pro
159	15	100.0	9	6	ABU75854	Abu75854 Novel pro
160	15	100.0	9	6	ABU77185	Abu77185 Novel pro
161	15	100.0	9	6	ABU77284	Abu77284 Novel pro
162	15	100.0	9	6	ABU73948	Abu73948 Novel pro
163	15	100.0	9	6	ABU77358	Abu77358 Novel pro
164	15	100.0	9	6	ABU75552	Abu75552 Novel pro
165	15	100.0	9	6	ABU75586	Abu75586 Novel pro
166	15	100.0	9	6	ABU72866	Abu72866 Novel pro
167	15	100.0	9	6	ABU75058	Abu75058 Novel pro
168	15	100.0	9	6	ABU77289	Abu77289 Novel pro
169	15	100.0	9	6	ABU74463	Abu74463 Novel pro
170	15	100.0	9	6	ABU74506	Abu74506 Novel pro
171	15	100.0	9	6	ABU76148	Abu76148 Novel pro
172	15	100.0	9	6	ABU77246	Abu77246 Novel pro
173	15	100.0	9	6	ABJ38075	Abj38075 Human cyt
174	15	100.0	9	6	ABJ20567	Abj20567 162P1E6 c
175	15	100.0	9	6	ABJ20602	Abj20602 162P1E6 c
176	15	100.0	9	6	ABJ21965	Abj21965 162P1E6 c
177	15	100.0	9	6	ABJ21994	Abj21994 162P1E6 c
178	15	100.0	9	6	ABJ24087	Abj24087 162P1E6 c
179	15	100.0	9	6	ABJ24088	Abj24088 162P1E6 c
180	15	100.0	9	6	ABJ20598	Abj20598 162P1E6 c
181	15	100.0	9	6	ABJ21980	Abj21980 162P1E6 c
182	15	100.0	9	6	ABJ22659	Abj22659 162P1E6 c
183	15	100.0	9	6	ABJ24748	Abj24748 162P1E6 c
184	15	100.0	9	6	ABJ24763	Abj24763 162P1E6 c
185	15	100.0	9	6	ABJ22691	Abj22691 162P1E6 c
186	15	100.0	9	6	ABJ23377	Abj23377 162P1E6 c
187	15	100.0	9	6	ABJ21271	Abj21271 162P1E6 c
188	15	100.0	9	6	ABJ21985	Abj21985 162P1E6 c
189	15	100.0	9	6	ABJ23386	Abj23386 162P1E6 c
190	15	100.0	9	6	ABJ20591	Abj20591 162P1E6 c
191	15	100.0	9	6	ABJ21265	Abj21265 162P1E6 c
192	15	100.0	9	6	ABJ23369	Abj23369 162P1E6 c
193	15	100.0	9	6	ABJ24785	Abj24785 162P1E6 c
194	15	100.0	9	6	ABJ24749	Abj24749 162P1E6 c
195	15	100.0	9	6	ABJ24754	Abj24754 162P1E6 c
196	15	100.0	9	6	ABJ24784	Abj24784 162P1E6 c
197	15	100.0	9	6	ABJ20592	Abj20592 162P1E6 c
198	15	100.0	9	6	ABJ21266	Abj21266 162P1E6 c
199	15	100.0	9	6	ABJ21286	Abj21286 162P1E6 c
200	15	100.0	9	6	ABJ22678	Abj22678 162P1E6 c
201	15	100.0	9	6	ABJ23354	Abj23354 162P1E6 c
202	15	100.0	9	6	ABJ20593	Abj20593 162P1E6 c
203	15	100.0	9	6	ABJ22677	Abj22677 162P1E6 c
204	15	100.0	9	6	ABJ23367	Abj23367 162P1E6 c
205	15	100.0	9	6	ABJ21285	Abj21285 162P1E6 c
206	15	100.0	9	6	ABJ21964	Abj21964 162P1E6 c
207	15	100.0	9	6	ABJ21997	Abj21997 162P1E6 c
208	15	100.0	9	6	ABJ22694	Abj22694 162P1E6 c
209	15	100.0	9	6	ABJ24051	Abj24051 162P1E6 c
210	15	100.0	9	6	ABJ24052	Abj24052 162P1E6 c
211	15	100.0	9	6	ABJ21986	Abj21986 162P1E6 c
212	15	100.0	9	6	ABJ22661	Abj22661 162P1E6 c
213	15	100.0	9	6	ABJ22685	Abj22685 162P1E6 c
214	15	100.0	9	6	ABJ24054	Abj24054 162P1E6 c
215	15	100.0	9	6	ABJ24063	Abj24063 162P1E6 c
216	15	100.0	9	6	ABJ24064	Abj24064 162P1E6 c
217	15	100.0	9	6	ABJ24773	Abj24773 162P1E6 c
218	15	100.0	9	6	ABJ23362	Abj23362 162P1E6 c
219	15	100.0	9	6	ABJ20596	Abj20596 162P1E6 c
220	15	100.0	9	6	ABJ21300	Abj21300 162P1E6 c
221	15	100.0	9	6	ABJ21299	Abj21299 162P1E6 c
222	15	100.0	9	6	ABJ23391	Abj23391 162P1E6 c
223	15	100.0	9	6	ABR16032	Abr16032 Human can
224	15	100.0	9	6	ABR16580	Abr16580 Human can
225	15	100.0	9	6	ABR16053	Abr16053 Human can
226	15	100.0	9	6	ABR16237	Abr16237 Human can
227	15	100.0	9	6	ABR16392	Abr16392 Human can
228	15	100.0	9	6	ABR16767	Abr16767 Human can
229	15	100.0	9	6	ABR17008	Abr17008 Human can
230	15	100.0	9	6	ABR18242	Abr18242 Human can
231	15	100.0	9	6	ABR16662	Abr16662 Human can
232	15	100.0	9	6	ABR17603	Abr17603 Human can
233	15	100.0	9	6	ABR18040	Abr18040 Human can
234	15	100.0	9	6	ABR16574	Abr16574 Human can
235	15	100.0	9	6	ABR17981	Abr17981 Human can
236	15	100.0	9	6	ABR16596	Abr16596 Human can
237	15	100.0	9	6	ABR16791	Abr16791 Human can
238	15	100.0	9	6	ABR16973	Abr16973 Human can
239	15	100.0	9	6	ABR17185	Abr17185 Human can
240	15	100.0	9	6	ABR16369	Abr16369 Human can
241	15	100.0	9	6	ABR16398	Abr16398 Human can
242	15	100.0	9	6	ABR18461	Abr18461 Human can
243	15	100.0	9	6	ABR18644	Abr18644 Human can
244	15	100.0	9	6	ABR16209	Abr16209 Human can

245	15	100.0	9	6	ABR16244	Abr16244 Human can
246	15	100.0	9	6	ABJ60991	Abj60991 184P1E2-r
247	15	100.0	9	6	ABJ61120	Abj61120 184P1E2-r
248	15	100.0	9	6	ABJ63446	Abj63446 184P1E2-r
249	15	100.0	9	6	ABJ64742	Abj64742 184P1E2-r
250	15	100.0	9	6	ABJ65479	Abj65479 184P1E2-r
251	15	100.0	9	6	ABJ61164	Abj61164 184P1E2-r
252	15	100.0	9	6	ABJ61228	Abj61228 184P1E2-r
253	15	100.0	9	6	ABJ61593	Abj61593 184P1E2-r
254	15	100.0	9	6	ABJ63538	Abj63538 184P1E2-r
255	15	100.0	9	6	ABJ64032	Abj64032 184P1E2-r
256	15	100.0	9	6	ABJ60239	Abj60239 184P1E2-r
257	15	100.0	9	6	ABJ61226	Abj61226 184P1E2-r
258	15	100.0	9	6	ABJ61227	Abj61227 184P1E2-r
259	15	100.0	9	6	ABJ61520	Abj61520 184P1E2-r
260	15	100.0	9	6	ABJ65480	Abj65480 184P1E2-r
261	15	100.0	9	6	ABJ58783	Abj58783 184P1E2-r
262	15	100.0	9	6	ABJ59836	Abj59836 184P1E2-r
263	15	100.0	9	6	ABJ60280	Abj60280 184P1E2-r
264	15	100.0	9	6	ABJ61119	Abj61119 184P1E2-r
265	15	100.0	9	6	ABJ61731	Abj61731 184P1E2-r
266	15	100.0	9	6	ABJ61805	Abj61805 184P1E2-r
267	15	100.0	9	6	ABJ65478	Abj65478 184P1E2-r
268	15	100.0	9	6	ABJ59488	Abj59488 184P1E2-r
269	15	100.0	9	6	ABJ61594	Abj61594 184P1E2-r
270	15	100.0	9	6	ABJ61662	Abj61662 184P1E2-r
271	15	100.0	9	6	ABJ61933	Abj61933 184P1E2-r
272	15	100.0	9	6	ABJ61996	Abj61996 184P1E2-r
273	15	100.0	9	6	ABJ62392	Abj62392 184P1E2-r
274	15	100.0	9	6	ABJ62688	Abj62688 184P1E2-r
275	15	100.0	9	6	ABJ62690	Abj62690 184P1E2-r
276	15	100.0	9	6	ABJ63295	Abj63295 184P1E2-r
277	15	100.0	9	6	ABJ63699	Abj63699 184P1E2-r
278	15	100.0	9	6	ABJ64741	Abj64741 184P1E2-r
279	15	100.0	9	6	ABJ59837	Abj59837 184P1E2-r
280	15	100.0	9	6	ABJ61941	Abj61941 184P1E2-r
281	15	100.0	9	6	ABJ62687	Abj62687 184P1E2-r
282	15	100.0	9	6	ABJ63821	Abj63821 184P1E2-r
283	15	100.0	9	6	ABJ65557	Abj65557 184P1E2-r
284	15	100.0	9	6	ABJ59879	Abj59879 184P1E2-r
285	15	100.0	9	6	ABJ60214	Abj60214 184P1E2-r
286	15	100.0	9	6	ABJ61405	Abj61405 184P1E2-r
287	15	100.0	9	6	ABJ62308	Abj62308 184P1E2-r
288	15	100.0	9	6	ABJ62656	Abj62656 184P1E2-r
289	15	100.0	9	6	ABJ62689	Abj62689 184P1E2-r
290	15	100.0	9	6	ABJ63165	Abj63165 184P1E2-r
291	15	100.0	9	6	ABJ64957	Abj64957 184P1E2-r
292	15	100.0	9	6	ABJ57614	Abj57614 184P1E2-r
293	15	100.0	9	6	ABJ65556	Abj65556 184P1E2-r
294	15	100.0	9	6	ABJ59228	Abj59228 184P1E2-r
295	15	100.0	9	6	ABJ63294	Abj63294 184P1E2-r
296	15	100.0	9	6	ABJ59227	Abj59227 184P1E2-r
297	15	100.0	9	6	ABJ62866	Abj62866 184P1E2-r
298	15	100.0	9	6	ABJ64040	Abj64040 184P1E2-r
299	15	100.0	9	6	ABJ60003	Abj60003 184P1E2-r
300	15	100.0	9	6	ABJ60322	Abj60322 184P1E2-r
301	15	100.0	9	6	ABJ63927	Abj63927 184P1E2-r
302	15	100.0	9	6	ABJ64669	Abj64669 184P1E2-r
303	15	100.0	9	6	ABJ64740	Abj64740 184P1E2-r
304	15	100.0	9	6	ABJ65177	Abj65177 184P1E2-r
305	15	100.0	9	6	ABJ57872	Abj57872 184P1E2-r
306	15	100.0	9	6	ABJ58840	Abj58840 184P1E2-r
307	15	100.0	9	6	ABJ59229	Abj59229 184P1E2-r
308	15	100.0	9	6	ABJ59797	Abj59797 184P1E2-r
309	15	100.0	9	6	ABJ62865	Abj62865 184P1E2-r
310	15	100.0	9	6	ABJ63131	Abj63131 184P1E2-r
311	15	100.0	9	6	ABJ64261	Abj64261 184P1E2-r
312	15	100.0	9	6	ABJ60373	Abj60373 184P1E2-r
313	15	100.0	9	6	ABJ59878	Abj59878 184P1E2-r
314	15	100.0	9	6	ABJ64411	Abj64411 184P1E2-r
315	15	100.0	9	6	ABJ57870	Abj57870 184P1E2-r
316	15	100.0	9	6	ABJ60279	Abj60279 184P1E2-r
317	15	100.0	9	6	ABJ62180	Abj62180 184P1E2-r
318	15	100.0	9	6	ABJ64392	Abj64392 184P1E2-r
319	15	100.0	9	7	ADC22338	Adc22338 Nuclear l
320	15	100.0	9	7	ADC53179	Adc53179 Human Cyt
321	15	100.0	9	7	ADD22354	Add22354 HLA-B46 c
322	15	100.0	9	7	ADD22353	Add22353 HLA-B46 c
323	15	100.0	10	2	AAR25219	Aar25219 Residues
324	15	100.0	10	2	AAR25224	Aar25224 Residues
325	15	100.0	10	2	AAR28136	Aar28136 Cell-to-c
326	15	100.0	10	2	AAR74985	Aar74985 N-termina
327	15	100.0	10	2	AAW12571	Aaw12571 SH2 bindi
328	15	100.0	10	2	AAW12566	Aaw12566 SH2 bindi
329	15	100.0	10	2	AAW24171	Aaw24171 Peanut al
330	15	100.0	10	2	AAW35338	Aaw35338 Rat GDNF
331	15	100.0	10	2	AAY30682	Aay30682 Apo-B100
332	15	100.0	10	2	AAY15253	Aay15253 Peanut al
333	15	100.0	10	2	AAY06987	Aay06987 HLA bindi
334	15	100.0	10	2	AAY07157	Aay07157 HLA bindi
335	15	100.0	10	2	AAW84177	Aaw84177 Rat GDNFR
336	15	100.0	10	2	AAY40921	Aay40921 Ara h 1 a
337	15	100.0	10	3	AAY78309	Aay78309 NRD somat
338	15	100.0	10	3	AAB38098	Aab38098 Human ABC
339	15	100.0	10	3	AAB32161	Aab32161 Peptide m
340	15	100.0	10	3	AAB27522	Aab27522 Ara h 1 l
341	15	100.0	10	3	AAB27521	Aab27521 Ara h 1 l
342	15	100.0	10	3	AAB27525	Aab27525 Ara h 1 l
343	15	100.0	10	3	AAB27457	Aab27457 Ara h 1 a
344	15	100.0	10	3	AAB27524	Aab27524 Ara h 1 l
345	15	100.0	10	3	AAB27523	Aab27523 Ara h 1 l
346	15	100.0	10	3	AAB30357	Aab30357 C. elegan
347	15	100.0	10	3	AAB33505	Aab33505 Human imm
348	15	100.0	10	3	AAB23056	Aab23056 Peanut Ar
349	15	100.0	10	4	AAM98322	Aam98322 Human pep
350	15	100.0	10	4	AAG83827	Aag83827 Arabidops
351	15	100.0	10	4	AAG84014	Aag84014 Arabidops
352	15	100.0	10	4	AAG83386	Aag83386 Arabidops
353	15	100.0	10	4	AAG83480	Aag83480 Arabidops
354	15	100.0	10	4	AAB83788	Aab83788 Amino aci
355	15	100.0	10	4	AAB83776	Aab83776 Amino aci
356	15	100.0	10	4	AAB83785	Aab83785 Amino aci
357	15	100.0	10	4	AAU04718	Aau04718 IgE bindi
358	15	100.0	10	4	AAG95854	Aag95854 Human com
359	15	100.0	10	4	AAG95629	Aag95629 Human com
360	15	100.0	10	4	AAG94020	Aag94020 Human com
361	15	100.0	10	4	AAG95615	Aag95615 Human com
362	15	100.0	10	4	AAG94022	Aag94022 Human com
363	15	100.0	10	4	AAG95607	Aag95607 Human com
364	15	100.0	10	4	AAG96948	Aag96948 Human com
365	15	100.0	10	4	AAG95631	Aag95631 Human com
366	15	100.0	10	4	AAG95436	Aag95436 Human com
367	15	100.0	10	4	AAG95617	Aag95617 Human com
368	15	100.0	10	4	AAE13158	Aae13158 Human SCR
369	15	100.0	10	4	AAG85897	Aag85897 Saccharom
370	15	100.0	10	4	AAG86163	Aag86163 Saccharom
371	15	100.0	10	4	AAG86255	Aag86255 Saccharom
372	15	100.0	10	4	AAU05043	Aau05043 Human IgE
373	15	100.0	10	4	ABP23713	Abp23713 HIV A11 m
374	15	100.0	10	4	ABP17504	Abp17504 HIV B27 s
375	15	100.0	10	5	ABB74467	Abb74467 DNA repai
376	15	100.0	10	5	ABB74474	Abb74474 DNA repai
377	15	100.0	10	5	ABJ14005	Abj14005 Human 125
378	15	100.0	10	5	ABJ13480	Abj13480 Human 125
379	15	100.0	10	5	ABJ13523	Abj13523 Human 125
380	15	100.0	10	5	ABJ12157	Abj12157 Human 125
381	15	100.0	10	5	ABJ11957	Abj11957 Human 125
382	15	100.0	10	5	ABJ13600	Abj13600 Human 125
383	15	100.0	10	5	ABJ14168	Abj14168 Human 125
384	15	100.0	10	5	ABJ11880	Abj11880 Human 125
385	15	100.0	10	5	ABJ11694	Abj11694 Human 125
386	15	100.0	10	5	ABJ14169	Abj14169 Human 125
387	15	100.0	10	5	ABJ12052	Abj12052 Human 125
388	15	100.0	10	5	ABJ13809	Abj13809 Human 125
389	15	100.0	10	5	ABJ14170	Abj14170 Human 125
390	15	100.0	10	5	ABJ13965	Abj13965 Human 125

391	15	100.0	10	5	ABJ13978	Abj13978 Human 125
392	15	100.0	10	5	ABJ05634	Abj05634 Peptide m
393	15	100.0	10	5	AAU78947	Aau78947 cAMP depe
394	15	100.0	10	5	AAU93333	Aau93333 Granulocy
395	15	100.0	10	5	AAU93331	Aau93331 Granulocy
396	15	100.0	10	5	AAU93332	Aau93332 Granulocy
397	15	100.0	10	5	ABG68970	Abg68970 Signature
398	15	100.0	10	5	ABG68958	Abg68958 Signature
399	15	100.0	10	6	ABU73150	Abu73150 Novel pro
400	15	100.0	10	6	ABU73172	Abu73172 Novel pro
401	15	100.0	10	6	ABU75869	Abu75869 Novel pro
402	15	100.0	10	6	ABU74207	Abu74207 Novel pro
403	15	100.0	10	6	ABU75831	Abu75831 Novel pro
404	15	100.0	10	6	ABU76345	Abu76345 Novel pro
405	15	100.0	10	6	ABU73177	Abu73177 Novel pro
406	15	100.0	10	6	ABU74781	Abu74781 Novel pro
407	15	100.0	10	6	ABU78027	Abu78027 Novel pro
408	15	100.0	10	6	ABU73138	Abu73138 Novel pro
409	15	100.0	10	6	ABU74241	Abu74241 Novel pro
410	15	100.0	10	6	ABU74716	Abu74716 Novel pro
411	15	100.0	10	6	ABU75812	Abu75812 Novel pro
412	15	100.0	10	6	ABU73682	Abu73682 Novel pro
413	15	100.0	10	6	ABU74197	Abu74197 Novel pro
414	15	100.0	10	6	ABU76330	Abu76330 Novel pro
415	15	100.0	10	6	ABU78114	Abu78114 Novel pro
416	15	100.0	10	6	ABU75879	Abu75879 Novel pro
417	15	100.0	10	6	ABU74741	Abu74741 Novel pro
418	15	100.0	10	6	ABU75855	Abu75855 Novel pro
419	15	100.0	10	6	ABU76405	Abu76405 Novel pro
420	15	100.0	10	6	ABU74269	Abu74269 Novel pro
421	15	100.0	10	6	ABU78166	Abu78166 Novel pro
422	15	100.0	10	6	ABU74250	Abu74250 Novel pro
423	15	100.0	10	6	ABU78120	Abu78120 Novel pro
424	15	100.0	10	6	ABU74721	Abu74721 Novel pro
425	15	100.0	10	6	ABU74765	Abu74765 Novel pro
426	15	100.0	10	6	ABU75319	Abu75319 Novel pro
427	15	100.0	10	6	ABU73196	Abu73196 Novel pro
428	15	100.0	10	6	ABU75847	Abu75847 Novel pro
429	15	100.0	10	6	ABU90789	Abu90789 Peptide #
430	15	100.0	10	6	ABJ23037	Abj23037 162P1E6 c
431	15	100.0	10	6	ABJ23732	Abj23732 162P1E6 c
432	15	100.0	10	6	ABJ24426	Abj24426 162P1E6 c
433	15	100.0	10	6	ABJ24428	Abj24428 162P1E6 c
434	15	100.0	10	6	ABJ20921	Abj20921 162P1E6 c
435	15	100.0	10	6	ABJ20949	Abj20949 162P1E6 c
436	15	100.0	10	6	ABJ20951	Abj20951 162P1E6 c
437	15	100.0	10	6	ABJ21610	Abj21610 162P1E6 c
438	15	100.0	10	6	ABJ21636	Abj21636 162P1E6 c
439	15	100.0	10	6	ABJ24403	Abj24403 162P1E6 c
440	15	100.0	10	6	ABJ24407	Abj24407 162P1E6 c
441	15	100.0	10	6	ABJ25102	Abj25102 162P1E6 c
442	15	100.0	10	6	ABJ25126	Abj25126 162P1E6 c
443	15	100.0	10	6	ABJ22315	Abj22315 162P1E6 c
444	15	100.0	10	6	ABJ23006	Abj23006 162P1E6 c
445	15	100.0	10	6	ABJ23706	Abj23706 162P1E6 c
446	15	100.0	10	6	ABJ23722	Abj23722 162P1E6 c
447	15	100.0	10	6	ABJ23723	Abj23723 162P1E6 c
448	15	100.0	10	6	ABJ20934	Abj20934 162P1E6 c
449	15	100.0	10	6	ABJ20942	Abj20942 162P1E6 c
450	15	100.0	10	6	ABJ22329	Abj22329 162P1E6 c
451	15	100.0	10	6	ABJ23017	Abj23017 162P1E6 c
452	15	100.0	10	6	ABJ23042	Abj23042 162P1E6 c
453	15	100.0	10	6	ABJ20915	Abj20915 162P1E6 c
454	15	100.0	10	6	ABJ22313	Abj22313 162P1E6 c
455	15	100.0	10	6	ABJ23710	Abj23710 162P1E6 c
456	15	100.0	10	6	ABJ25105	Abj25105 162P1E6 c
457	15	100.0	10	6	ABJ25121	Abj25121 162P1E6 c
458	15	100.0	10	6	ABJ22334	Abj22334 162P1E6 c
459	15	100.0	10	6	ABJ25099	Abj25099 162P1E6 c
460	15	100.0	10	6	ABJ22325	Abj22325 162P1E6 c
461	15	100.0	10	6	ABJ23727	Abj23727 162P1E6 c
462	15	100.0	10	6	ABJ24421	Abj24421 162P1E6 c
463	15	100.0	10	6	ABJ20918	Abj20918 162P1E6 c
464	15	100.0	10	6	ABJ20948	Abj20948 162P1E6 c
465	15	100.0	10	6	ABJ21623	Abj21623 162P1E6 c
466	15	100.0	10	6	ABJ21638	Abj21638 162P1E6 c
467	15	100.0	10	6	ABJ21641	Abj21641 162P1E6 c
468	15	100.0	10	6	ABJ23023	Abj23023 162P1E6 c
469	15	100.0	10	6	ABJ23716	Abj23716 162P1E6 c
470	15	100.0	10	6	ABJ22335	Abj22335 162P1E6 c
471	15	100.0	10	6	ABJ23007	Abj23007 162P1E6 c
472	15	100.0	10	6	ABJ22310	Abj22310 162P1E6 c
473	15	100.0	10	6	ABJ22345	Abj22345 162P1E6 c
474	15	100.0	10	6	ABJ23009	Abj23009 162P1E6 c
475	15	100.0	10	6	ABJ23720	Abj23720 162P1E6 c
476	15	100.0	10	6	ABJ21633	Abj21633 162P1E6 c
477	15	100.0	10	6	ABJ21634	Abj21634 162P1E6 c
478	15	100.0	10	6	ABJ21644	Abj21644 162P1E6 c
479	15	100.0	10	6	ABJ24422	Abj24422 162P1E6 c
480	15	100.0	10	6	ABJ25104	Abj25104 162P1E6 c
481	15	100.0	10	6	ABJ24406	Abj24406 162P1E6 c
482	15	100.0	10	6	ABJ25124	Abj25124 162P1E6 c
483	15	100.0	10	6	ABJ23032	Abj23032 162P1E6 c
484	15	100.0	10	6	ABJ24400	Abj24400 162P1E6 c
485	15	100.0	10	6	ABJ25128	Abj25128 162P1E6 c
486	15	100.0	10	6	ABR16891	Abr16891 Human can
487	15	100.0	10	6	ABR17557	Abr17557 Human can
488	15	100.0	10	6	ABR17883	Abr17883 Human can
489	15	100.0	10	6	ABR18129	Abr18129 Human can
490	15	100.0	10	6	ABR16480	Abr16480 Human can
491	15	100.0	10	6	ABR16095	Abr16095 Human can
492	15	100.0	10	6	ABR18470	Abr18470 Human can
493	15	100.0	10	6	ABR16144	Abr16144 Human can
494	15	100.0	10	6	ABR17078	Abr17078 Human can
495	15	100.0	10	6	ABR16270	Abr16270 Human can
496	15	100.0	10	6	ABR16901	Abr16901 Human can
497	15	100.0	10	6	ABR17124	Abr17124 Human can
498	15	100.0	10	6	ABR17880	Abr17880 Human can
499	15	100.0	10	6	ABR18069	Abr18069 Human can
500	15	100.0	10	6	ABR18289	Abr18289 Human can
501	15	100.0	10	6	ABR16689	Abr16689 Human can
502	15	100.0	10	6	ABR16715	Abr16715 Human can
503	15	100.0	10	6	ABR17308	Abr17308 Human can
504	15	100.0	10	6	ABR17760	Abr17760 Human can
505	15	100.0	10	6	ABR16328	Abr16328 Human can
506	15	100.0	10	6	ABR16523	Abr16523 Human can
507	15	100.0	10	6	ABR16910	Abr16910 Human can
508	15	100.0	10	6	ABR17324	Abr17324 Human can
509	15	100.0	10	6	ABR18328	Abr18328 Human can
510	15	100.0	10	6	ABR18493	Abr18493 Human can
511	15	100.0	10	6	ABR16492	Abr16492 Human can
512	15	100.0	10	6	ABR16545	Abr16545 Human can
513	15	100.0	10	6	ABR16705	Abr16705 Human can
514	15	100.0	10	6	ABR16733	Abr16733 Human can
515	15	100.0	10	6	ABR16764	Abr16764 Human can
516	15	100.0	10	6	ABR18164	Abr18164 Human can
517	15	100.0	10	6	ABR18730	Abr18730 Human can
518	15	100.0	10	6	ABR17145	Abr17145 Human can
519	15	100.0	10	6	ABR16964	Abr16964 Human can
520	15	100.0	10	6	ABR16267	Abr16267 Human can
521	15	100.0	10	6	ABR18094	Abr18094 Human can
522	15	100.0	10	6	ABR17337	Abr17337 Human can
523	15	100.0	10	6	ABR18674	Abr18674 Human can
524	15	100.0	10	6	ABR17102	Abr17102 Human can
525	15	100.0	10	6	ABU52457	Abu52457 Peanut Ar
526	15	100.0	10	6	ABU52454	Abu52454 Peanut Ar
527	15	100.0	10	6	ABU52456	Abu52456 Peanut Ar
528	15	100.0	10	6	ABU52420	Abu52420 Peanut Ar
529	15	100.0	10	6	ABU52453	Abu52453 Peanut Ar
530	15	100.0	10	6	ABU52455	Abu52455 Peanut Ar
531	15	100.0	10	6	ABU69942	Abu69942 Human imm
532	15	100.0	10	6	ABU69786	Abu69786 Human imm
533	15	100.0	10	6	ABJ57989	Abj57989 184P1E2-r
534	15	100.0	10	6	ABJ66010	Abj66010 184P1E2-r
535	15	100.0	10	6	ABJ66088	Abj66088 184P1E2-r
536	15	100.0	10	6	ABJ68260	Abj68260 184P1E2-r

537	15	100.0	10	6	ABJ68383	Abj68383 184P1E2-r
538	15	100.0	10	6	ABJ65782	Abj65782 184P1E2-r
539	15	100.0	10	6	ABJ66828	Abj66828 184P1E2-r
540	15	100.0	10	6	ABJ68261	Abj68261 184P1E2-r
541	15	100.0	10	6	ABJ68647	Abj68647 184P1E2-r
542	15	100.0	10	6	ABJ66681	Abj66681 184P1E2-r
543	15	100.0	10	6	ABJ68504	Abj68504 184P1E2-r
544	15	100.0	10	6	ABJ66532	Abj66532 184P1E2-r
545	15	100.0	10	6	ABJ68262	Abj68262 184P1E2-r
546	15	100.0	10	6	ABJ67149	Abj67149 184P1E2-r
547	15	100.0	10	6	ABJ68084	Abj68084 184P1E2-r
548	15	100.0	10	6	ABJ68170	Abj68170 184P1E2-r
549	15	100.0	10	6	ABJ66970	Abj66970 184P1E2-r
550	15	100.0	10	6	ABJ67129	Abj67129 184P1E2-r
551	15	100.0	10	6	ABJ67613	Abj67613 184P1E2-r
552	15	100.0	10	6	ABJ69398	Abj69398 184P1E2-r
553	15	100.0	10	6	ABJ66637	Abj66637 184P1E2-r
554	15	100.0	10	6	ABJ68438	Abj68438 184P1E2-r
555	15	100.0	10	6	ABJ66089	Abj66089 184P1E2-r
556	15	100.0	10	6	ABJ65781	Abj65781 184P1E2-r
557	15	100.0	10	6	ABJ66531	Abj66531 184P1E2-r
558	15	100.0	10	6	ABJ67173	Abj67173 184P1E2-r
559	15	100.0	10	6	ABJ66772	Abj66772 184P1E2-r
560	15	100.0	10	6	ABJ67322	Abj67322 184P1E2-r
561	15	100.0	10	6	ABJ69062	Abj69062 184P1E2-r
562	15	100.0	10	6	ABJ69399	Abj69399 184P1E2-r
563	15	100.0	10	6	ABJ68842	Abj68842 184P1E2-r
564	15	100.0	10	6	ABJ69015	Abj69015 184P1E2-r
565	15	100.0	10	6	ABJ65964	Abj65964 184P1E2-r
566	15	100.0	10	6	ABJ67567	Abj67567 184P1E2-r
567	15	100.0	10	6	ABJ68623	Abj68623 184P1E2-r
568	15	100.0	10	6	ABJ69166	Abj69166 184P1E2-r
569	15	100.0	10	6	ABJ66996	Abj66996 184P1E2-r
570	15	100.0	10	6	ABJ67292	Abj67292 184P1E2-r
571	15	100.0	10	6	ABJ67504	Abj67504 184P1E2-r
572	15	100.0	10	6	ABJ68169	Abj68169 184P1E2-r
573	15	100.0	10	6	ABJ68171	Abj68171 184P1E2-r
574	15	100.0	10	6	ABJ68762	Abj68762 184P1E2-r
575	15	100.0	10	6	ABJ68841	Abj68841 184P1E2-r
576	15	100.0	10	6	ABJ69167	Abj69167 184P1E2-r
577	15	100.0	10	6	ABJ67024	Abj67024 184P1E2-r
578	15	100.0	10	6	ABJ69061	Abj69061 184P1E2-r
579	15	100.0	10	6	ABB99621	Abb99621 Peptide d
580	15	100.0	10	6	ABO44422	Abo44422 Human HMG
581	15	100.0	10	7	ADA07567	Ada07567 Human sec
582	15	100.0	10	7	ADC53180	Adc53180 Human Cyt
583	15	100.0	10	7	ADD96475	Add96475 HIV-1 cro
584	15	100.0	10	7	ADD96319	Add96319 HIV-1 cro
585	15	100.0	11	2	AAR28089	Aar28089 Cell-to-c
586	15	100.0	11	2	AAR28128	Aar28128 Cell-to-c
587	15	100.0	11	2	AAR28130	Aar28130 Cell-to-c
588	15	100.0	11	2	AAR28132	Aar28132 Cell-to-c
589	15	100.0	11	2	AAW12602	Aaw12602 SH2 bindi
590	15	100.0	11	2	AAW15675	Aaw15675 Platelet
591	15	100.0	11	2	AAW16616	Aaw16616 Phosphoin
592	15	100.0	11	3	AAY88542	Aay88542 NCAM Ig1
593	15	100.0	11	3	AAY94681	Aay94681 Human zsi
594	15	100.0	11	4	AAB72846	Aab72846 Human p53
595	15	100.0	11	4	ABP17507	Abp17507 HIV B27 s
596	15	100.0	11	5	ABB74475	Abb74475 DNA repai
597	15	100.0	11	5	ABG69342	Abg69342 Human neu
598	15	100.0	11	5	ABP54083	Abp54083 Transport
599	15	100.0	11	5	ABP61370	Abp61370 Anti-thro
600	15	100.0	11	5	AAU96240	Aau96240 Class I G
601	15	100.0	11	6	AAE34290	Aae34290 Human 5-h
602	15	100.0	11	6	AAE34216	Aae34216 Human 5-h
603	15	100.0	11	6	ABB99619	Abb99619 Peptide d
604	15	100.0	11	6	ABB99620	Abb99620 Peptide d
605	15	100.0	11	7	ADC19828	Adc19828 Fluoresce
606	15	100.0	12	1	AAP82895	Aap82895 immunosup
607	15	100.0	12	1	AAP82369	Aap82369 immunosup
608	15	100.0	12	2	AAR12501	Aar12501 Peptide I
609	15	100.0	12	2	AAR62102	Aar62102 Hydrophil
610	15	100.0	12	2	AAW21260	Aaw21260 Hydroxyme
611	15	100.0	12	2	AAR66777	Aar66777 Cell adhe
612	15	100.0	12	2	AAW63620	Aaw63620 Human HDC
613	15	100.0	12	2	AAY39461	Aay39461 CD147 bin
614	15	100.0	12	2	AAY14377	Aay14377 Peptide #
615	15	100.0	12	2	AAY14378	Aay14378 Peptide #
616	15	100.0	12	2	AAY15792	Aay15792 Antigenic
617	15	100.0	12	2	AAY15794	Aay15794 Antigenic
618	15	100.0	12	3	AAB38096	Aab38096 Human ABC
619	15	100.0	12	3	AAB38097	Aab38097 Mouse ABC
620	15	100.0	12	3	AAB08233	Aab08233 Amino aci
621	15	100.0	12	4	AAE12454	Aae12454 Dodecamer
622	15	100.0	12	4	AAE12455	Aae12455 Dodecamer
623	15	100.0	12	4	AAE07435	Aae07435 Synthetic
624	15	100.0	12	4	AAE07434	Aae07434 Synthetic
625	15	100.0	12	5	AAE15770	Aae15770 Synthetic
626	15	100.0	12	5	AAE15769	Aae15769 Synthetic
627	15	100.0	12	5	ABB94464	Abb94464 Ubiquitin
628	15	100.0	12	5	ABB81991	Abb81991 Human iPF
629	15	100.0	12	5	AAU76778	Aau76778 6A peptid
630	15	100.0	12	5	AAU76779	Aau76779 6B peptid
631	15	100.0	12	5	ABG70964	Abg70964 Human col
632	15	100.0	12	5	AAO22420	Aao22420 Protease
633	15	100.0	12	6	ABB99618	Abb99618 Peptide d
634	15	100.0	12	7	ADC44476	Adc44476 Endotheli
635	15	100.0	12	7	ADC13997	Adc13997 Rheumatoi
636	15	100.0	12	7	ADC13887	Adc13887 Rheumatoi
637	15	100.0	12	7	ADC89504	Adc89504 Human nat
638	15	100.0	13	2	AAR78694	Aar78694 HIV-1 Nef
639	15	100.0	13	2	AAR67683	Aar67683 Mouse del
640	15	100.0	13	2	AAY21047	Aay21047 Human gli
641	15	100.0	13	2	AAW53679	Aaw53679 Enteric n
642	15	100.0	13	4	AAB80501	Aab80501 PTH2 rece
643	15	100.0	13	5	ABG79232	Abg79232 Human K+a
644	15	100.0	13	5	ABG79276	Abg79276 Human K+a
645	15	100.0	13	5	ABG79250	Abg79250 Human K+a
646	15	100.0	13	5	AAE23214	Aae23214 HIV-1 tat
647	15	100.0	13	6	ABJ38758	Abj38758 Human G-p
648	15	100.0	13	6	ABJ38712	Abj38712 Human G-p
649	15	100.0	13	7	ADE03475	Ade03475 BGS-3 PKC
650	15	100.0	13	7	ADE03476	Ade03476 BGS-3 PKC
651	15	100.0	14	2	AAR15705	Aar15705 Rev HIV-1
652	15	100.0	14	2	AAR96587	Aar96587 Feline le
653	15	100.0	14	2	AAW10314	Aaw10314 Murine ga
654	15	100.0	14	2	AAW59114	Aaw59114 FMDV non-
655	15	100.0	14	2	AAW68346	Aaw68346 MHC bindi
656	15	100.0	14	2	AAW63082	Aaw63082 Human imm
657	15	100.0	14	2	AAY29728	Aay29728 Feline le
658	15	100.0	14	2	AAW87572	Aaw87572 Anti-hen
659	15	100.0	14	3	AAY68223	Aay68223 Altered M
660	15	100.0	14	3	AAY98906	Aay98906 HLA class
661	15	100.0	14	3	AAY99015	Aay99015 HLA class
662	15	100.0	14	3	AAY52877	Aay52877 Altered M
663	15	100.0	14	4	AAM96942	Aam96942 Human pep
664	15	100.0	14	4	AAM97114	Aam97114 Human pep
665	15	100.0	14	4	AAM97000	Aam97000 Human pep
666	15	100.0	14	4	AAM96943	Aam96943 Human pep
667	15	100.0	14	4	AAM96994	Aam96994 Human pep
668	15	100.0	14	4	AAM98733	Aam98733 Human pep
669	15	100.0	14	4	AAM97547	Aam97547 Human pep
670	15	100.0	14	4	AAB91022	Aab91022 Somatosta
671	15	100.0	14	4	AAM00284	Aam00284 Human pro
672	15	100.0	14	4	AAM00283	Aam00283 Human pro
673	15	100.0	14	4	AAB58638	Aab58638 Altered M
674	15	100.0	14	4	ABB56576	Abb56576 Human SNP
675	15	100.0	14	4	ABB56871	Abb56871 Human SNP
676	15	100.0	14	4	AAG67322	Aag67322 Peptide e
677	15	100.0	14	4	AAG67304	Aag67304 Peptide e
678	15	100.0	14	4	AABB0502	Aab80502 PTH2 rece
679	15	100.0	14	5	ABB94375	Abb94375 Anti-hen
680	15	100.0	14	5	AAE19420	Aae19420 Human myo
681	15	100.0	14	5	ABJ01158	Abj01158 Human neu
682	15	100.0	14	6	ABB99617	Abb99617 Peptide d

683	15	100.0	14	6	ABP71392	Abp71392 Cadherin
684	15	100.0	14	6	ADA24278	Ada24278 WIP pepti
685	15	100.0	14	7	ADE31935	Ade31935 AKt inhib
686	15	100.0	15	1	AAP30057	Aap30057 Somatosta
687	15	100.0	15	1	AAP50754	Aap50754 Sequence
688	15	100.0	15	2	AAR33100	Aar33100 Human cyt
689	15	100.0	15	2	AAW13662	Aaw13662 Hepatocyt
690	15	100.0	15	2	AAY20661	Aay20661 Human neu
691	15	100.0	15	2	AAW56700	Aaw56700 Modified
692	15	100.0	15	3	AAY79270	Aay79270 PHELIX pe
693	15	100.0	15	3	AAB63143	Aab63143 Human sec
694	15	100.0	15	4	AAG67078	Aag67078 Human NF-
695	15	100.0	15	4	AAU05231	Aau05231 HIV RNA b
696	15	100.0	15	4	ABB99027	Abb99027 Human cal
697	15	100.0	15	4	ABP24629	Abp24629 HIV DR su
698	15	100.0	15	4	ABG18409	Abg18409 Novel hum
699	15	100.0	15	4	AAG89744	Aag89744 p53 DR3 b
700	15	100.0	15	4	AAG89441	Aag89441 p53 DR su
701	15	100.0	15	4	AAG89514	Aag89514 p53 DR 3b
702	15	100.0	15	4	AAG89727	Aag89727 p53 DR su
703	15	100.0	15	4	AAB80503	Aab80503 PTH2 rece
704	15	100.0	15	5	AAE27041	Aae27041 Mouse TCR
705	15	100.0	15	5	AAO19143	Aao19143 Truncated
706	15	100.0	15	5	ABJ14411	Abj14411 Human 125
707	15	100.0	15	5	ABJ14622	Abj14622 Human 125
708	15	100.0	15	5	ABJ14258	Abj14258 Human 125
709	15	100.0	15	5	ABJ14529	Abj14529 Human 125
710	15	100.0	15	5	ABJ14828	Abj14828 Human 125
711	15	100.0	15	5	ABJ14655	Abj14655 Human 125
712	15	100.0	15	5	ABJ14497	Abj14497 Human 125
713	15	100.0	15	5	ABJ14242	Abj14242 Human 125
714	15	100.0	15	5	ABJ15002	Abj15002 Human 125
715	15	100.0	15	5	ABJ14952	Abj14952 Human 125
716	15	100.0	15	5	ABJ14410	Abj14410 Human 125
717	15	100.0	15	5	AAE17366	Aae17366 Bacteriop
718	15	100.0	15	5	ABJ01177	Abj01177 Human Ptx
719	15	100.0	15	5	AAU78971	Aau78971 Cyclin-L
720	15	100.0	15	5	ABB75634	Abb75634 Mitochond
721	15	100.0	15	6	ABU78648	Abu78648 Novel pro
722	15	100.0	15	6	ABU78708	Abu78708 Novel pro
723	15	100.0	15	6	ABU78728	Abu78728 Novel pro
724	15	100.0	15	6	ABU78620	Abu78620 Novel pro
725	15	100.0	15	6	ABU78813	Abu78813 Novel pro
726	15	100.0	15	6	ABU78772	Abu78772 Novel pro
727	15	100.0	15	6	ABU78826	Abu78826 Novel pro
728	15	100.0	15	6	ABU78745	Abu78745 Novel pro
729	15	100.0	15	6	ABU78842	Abu78842 Novel pro
730	15	100.0	15	6	ABU78783	Abu78783 Novel pro
731	15	100.0	15	6	ABU78836	Abu78836 Novel pro
732	15	100.0	15	6	ABU78698	Abu78698 Novel pro
733	15	100.0	15	6	ABJ25259	Abj25259 162P1E6 c
734	15	100.0	15	6	ABJ25265	Abj25265 162P1E6 c
735	15	100.0	15	6	ABJ25264	Abj25264 162P1E6 c
736	15	100.0	15	6	ABJ25260	Abj25260 162P1E6 c
737	15	100.0	15	6	ABR34512	Abr34512 Human can
738	15	100.0	15	6	ABR34297	Abr34297 Human can
739	15	100.0	15	6	ABR34549	Abr34549 Human can
740	15	100.0	15	6	ABR34559	Abr34559 Human can
741	15	100.0	15	6	ABR34329	Abr34329 Human can
742	15	100.0	15	6	ABR34413	Abr34413 Human can
743	15	100.0	15	6	ABP82904	Abp82904 G protein
744	15	100.0	15	6	ABP82268	Abp82268 G protein
745	15	100.0	15	6	ABP71667	Abp71667 MUC7 prot
746	15	100.0	15	6	ABJ70291	Abj70291 184P1E2-r
747	15	100.0	15	6	ABJ70749	Abj70749 184P1E2-r
748	15	100.0	15	6	ABJ71203	Abj71203 184P1E2-r
749	15	100.0	15	6	ABJ71505	Abj71505 184P1E2-r
750	15	100.0	15	6	ABJ71693	Abj71693 184P1E2-r
751	15	100.0	15	6	ABJ70330	Abj70330 184P1E2-r
752	15	100.0	15	6	ABJ70675	Abj70675 184P1E2-r
753	15	100.0	15	6	ABJ71527	Abj71527 184P1E2-r
754	15	100.0	15	6	ABJ71958	Abj71958 184P1E2-r
755	15	100.0	15	6	ABJ71918	Abj71918 184P1E2-r
756	15	100.0	15	6	ABJ71189	Abj71189 184P1E2-r
757	15	100.0	15	6	ABJ71738	Abj71738 184P1E2-r
758	15	100.0	15	6	ABJ70163	Abj70163 184P1E2-r
759	15	100.0	15	6	ABJ69950	Abj69950 184P1E2-r
760	15	100.0	15	6	ABJ71066	Abj71066 184P1E2-r
761	15	100.0	15	6	ABJ71229	Abj71229 184P1E2-r
762	15	100.0	15	6	ABJ69912	Abj69912 184P1E2-r
763	15	100.0	15	6	ABJ71657	Abj71657 184P1E2-r
764	15	100.0	15	6	ABJ69887	Abj69887 184P1E2-r
765	15	100.0	15	6	ABJ70133	Abj70133 184P1E2-r
766	15	100.0	15	6	ABJ71202	Abj71202 184P1E2-r
767	15	100.0	15	6	ABJ71247	Abj71247 184P1E2-r
768	15	100.0	15	6	ABJ69886	Abj69886 184P1E2-r
769	15	100.0	15	6	ABJ70023	Abj70023 184P1E2-r
770	15	100.0	15	6	ABJ70552	Abj70552 184P1E2-r
771	15	100.0	15	6	ABJ71228	Abj71228 184P1E2-r
772	15	100.0	15	6	ABJ69951	Abj69951 184P1E2-r
773	15	100.0	15	6	ABJ70581	Abj70581 184P1E2-r
774	15	100.0	15	6	ABJ70022	Abj70022 184P1E2-r
775	15	100.0	15	6	ABJ70132	Abj70132 184P1E2-r
776	15	100.0	15	6	ABJ70290	Abj70290 184P1E2-r
777	15	100.0	15	6	ABJ70674	Abj70674 184P1E2-r
778	15	100.0	15	6	ABJ71067	Abj71067 184P1E2-r
779	15	100.0	15	6	ABJ71429	Abj71429 184P1E2-r
780	15	100.0	15	6	ABJ70086	Abj70086 184P1E2-r
781	15	100.0	15	6	ABJ71250	Abj71250 184P1E2-r
782	15	100.0	15	6	ABJ71428	Abj71428 184P1E2-r
783	15	100.0	15	6	ABJ71737	Abj71737 184P1E2-r
784	15	100.0	15	6	ABJ70085	Abj70085 184P1E2-r
785	15	100.0	15	6	ABJ71249	Abj71249 184P1E2-r
786	15	100.0	15	6	ABJ71677	Abj71677 184P1E2-r
787	15	100.0	15	6	ABJ71957	Abj71957 184P1E2-r
788	15	100.0	15	6	ABJ70289	Abj70289 184P1E2-r
789	15	100.0	15	6	ABJ70509	Abj70509 184P1E2-r
790	15	100.0	15	6	ABJ71248	Abj71248 184P1E2-r
791	15	100.0	15	6	ABJ71900	Abj71900 184P1E2-r
792	15	100.0	15	6	ABJ70134	Abj70134 184P1E2-r
793	15	100.0	15	6	ABJ71526	Abj71526 184P1E2-r
794	15	100.0	15	6	ABB99616	Abb99616 Peptide d
795	15	100.0	15	6	ABR82589	Abr82589 Protein k
796	15	100.0	15	6	ABR82584	Abr82584 Protein k
797	15	100.0	15	7	AAO27209	Aao27209 Polypepti
798	15	100.0	15	7	ADC22347	Adc22347 Nuclear l
799	15	100.0	15	8	ADE80941	Ade80941 Cashew nu
800	15	100.0	15	8	ADE80942	Ade80942 Cashew nu
801	15	100.0	16	2	AAR12502	Aar12502 Peptide I
802	15	100.0	16	2	AAR48257	Aar48257 Nucleolar
803	15	100.0	16	2	AAR95577	Aar95577 HIV rev p
804	15	100.0	16	2	AAR67635	Aar67635 Epitope o
805	15	100.0	16	2	AAW34425	Aaw34425 Fixed lib
806	15	100.0	16	2	AAW35989	Aaw35989 Library w
807	15	100.0	16	2	AAW96355	Aaw96355 Nucleolar
808	15	100.0	16	2	AAY23681	Aay23681 RNA-bindi
809	15	100.0	16	3	AAB22837	Aab22837 HIV rev n
810	15	100.0	16	3	AAW90745	Aaw90745 Human IgA
811	15	100.0	16	3	AAB36539	Aab36539 Human ser
812	15	100.0	16	3	AAY86576	Aay86576 Human gen
813	15	100.0	16	3	AAY82235	Aay82235 HIV rev s
814	15	100.0	16	3	AAY78329	Aay78329 HIV-1 rev
815	15	100.0	16	3	AAB36546	Aab36546 Human ser
816	15	100.0	16	3	AAB15703	Aab15703 HIV rev n
817	15	100.0	16	4	AAG64274	Aag64274 Human lym
818	15	100.0	16	4	AAB80504	Aab80504 PTH2 rece
819	15	100.0	16	5	ABB74351	Abb74351 Nuclear l
820	15	100.0	16	5	AAE20154	Aae20154 Human imm
821	15	100.0	16	5	ABG62592	Abg62592 Eubacteri
822	15	100.0	16	5	AAM47310	Aam47310 GMT-JMT f
823	15	100.0	16	5	AAE23166	Aae23166 Human imm
824	15	100.0	16	5	AAU78948	Aau78948 Cyclin L
825	15	100.0	16	5	AAU93632	Aau93632 Granulocy
826	15	100.0	16	5	ABG92990	Abg92990 Nucleolar
827	15	100.0	16	6	ABP56585	Abp56585 Nucleus s
828	15	100.0	16	6	ABB99615	Abb99615 Peptide d

829	15	100.0	16	6	ABO53747	Abo53747	Novel hum
830	15	100.0	17	1	AAP90644	Aap90644	Signal pe
831	15	100.0	17	2	AAR38622	Aar38622	Sequence
832	15	100.0	17	2	AAR33096	Aar33096	Human cyt
833	15	100.0	17	2	AAR33101	Aar33101	Human cyt
834	15	100.0	17	2	AAR57339	Aar57339	Peptide f
835	15	100.0	17	2	AAR75822	Aar75822	Antimicro
836	15	100.0	17	2	AAR67707	Aar67707	HIV-1 Rev
837	15	100.0	17	2	AAR93664	Aar93664	HIV princ
838	15	100.0	17	2	AAW68955	Aaw68955	Cytotoxic
839	15	100.0	17	2	AAY24901	Aay24901	Peptide N
840	15	100.0	17	2	AAY02812	Aay02812	Fragment
841	15	100.0	17	2	AAY36571	Aay36571	Fragment
842	15	100.0	17	2	AAY36476	Aay36476	Fragment
843	15	100.0	17	4	AAM98330	Aam98330	Human pep
844	15	100.0	17	4	AAG67730	Aag67730	Peptide H
845	15	100.0	17	4	AAM52220	Aam52220	HIV-1 Rev
846	15	100.0	17	4	AAB91810	Aab91810	Amyloid b
847	15	100.0	17	4	AAB91777	Aab91777	Amyloid b
848	15	100.0	17	4	ABB43353	Abb43353	Peptide #
849	15	100.0	17	4	AAM37207	Aam37207	Peptide #
850	15	100.0	17	4	AAU97010	Aau97010	Human C/E
851	15	100.0	17	4	AAE11953	Aae11953	Nuclear l
852	15	100.0	17	4	AAM77086	Aam77086	Human bon
853	15	100.0	17	4	AAM64265	Aam64265	Human bra
854	15	100.0	17	4	ABG52037	Abg52037	Human liv
855	15	100.0	17	4	AAB80505	Aab80505	PTH2 rece
856	15	100.0	17	5	AAU09993	Aau09993	Human M t
857	15	100.0	17	5	ABB74352	Abb74352	Nuclear l
858	15	100.0	17	5	AAU78969	Aau78969	Thyroid a
859	15	100.0	17	5	AAU78973	Aau78973	C-fos pep
860	15	100.0	17	5	AAG80776	Aag80776	Heptadeca
861	15	100.0	17	5	AAE23689	Aae23689	Fluoresce
862	15	100.0	17	6	ABP59497	Abp59497	Human hep
863	15	100.0	17	6	ABJ38986	Abj38986	Linear Ga
864	15	100.0	17	6	ABJ38987	Abj38987	Linear Ga
865	15	100.0	17	6	ABP82068	Abp82068	G protein
866	15	100.0	17	6	ABP82617	Abp82617	G protein
867	15	100.0	17	6	ABU09879	Abu09879	HIV-1 Rev
868	15	100.0	17	6	ABB99610	Abb99610	Peptide d
869	15	100.0	17	6	ABB99609	Abb99609	Peptide d
870	15	100.0	17	6	ABB82916	Abb82916	HIV-1 rev
871	15	100.0	17	6	ADA11740	Ada11740	Human nov
872	15	100.0	17	6	ADA12021	Ada12021	Human nov
873	15	100.0	17	7	ADA07528	Ada07528	Human sec
874	15	100.0	17	7	ADC22461	Adc22461	RNA bindi
875	15	100.0	17	7	ADC22370	Adc22370	Nuclear l
876	15	100.0	17	7	ADE11588	Ade11588	HIV-1 Rev
877	15	100.0	17	8	ADD32095	Add32095	HIV-1 Rev
878	15	100.0	18	1	AAP81125	Aap81125	c-fos-rel
879	15	100.0	18	2	AAR15706	Aar15706	Rev HIV-1
880	15	100.0	18	2	AAR57845	Aar57845	VnRbeta3-
881	15	100.0	18	2	AAR86963	Aar86963	Plant nuc
882	15	100.0	18	2	AAW05768	Aaw05768	Presenili
883	15	100.0	18	2	AAW19796	Aaw19796	Plant nuc
884	15	100.0	18	2	AAW72735	Aaw72735	Nuclear t
885	15	100.0	18	2	AAW66646	Aaw66646	HSV-2 gly
886	15	100.0	18	2	AAY24900	Aay24900	Peptide R
887	15	100.0	18	2	AAY23683	Aay23683	RNA-bindi
888	15	100.0	18	3	AAY85064	Aay85064	Immunogen
889	15	100.0	18	3	AAY85063	Aay85063	Immunogen
890	15	100.0	18	3	AAB06400	Aab06400	Randomise
891	15	100.0	18	3	AAY69731	Aay69731	Labelled-
892	15	100.0	18	3	AAY92059	Aay92059	CHUK/IKK-
893	15	100.0	18	3	AAY82237	Aay82237	Lambda N
894	15	100.0	18	3	AAY97251	Aay97251	M68 TNFR-
895	15	100.0	18	4	AAM22114	Aam22114	Peptide #
896	15	100.0	18	4	AAU27366	Aau27366	Novel bon
897	15	100.0	18	4	AAE03084	Aae03084	Human gen
898	15	100.0	18	4	ABB36122	Abb36122	Peptide #
899	15	100.0	18	4	ABB44520	Abb44520	Peptide #
900	15	100.0	18	4	AAM29613	Aam29613	Peptide #
901	15	100.0	18	4	AAM38567	Aam38567	Peptide #
902	15	100.0	18	4	ABB30933	Abb30933	Peptide #
903	15	100.0	18	4	AAM78321	Aam78321	Human bon
904	15	100.0	18	4	AAM69293	Aam69293	Human bon
905	15	100.0	18	4	AAM65705	Aam65705	Human bra
906	15	100.0	18	4	AAM56905	Aam56905	Human bra
907	15	100.0	18	4	ABG50969	Abg50969	Human liv
908	15	100.0	18	4	ABG59929	Abg59929	Human liv
909	15	100.0	18	4	AAB80506	Aab80506	PTH2 rece
910	15	100.0	18	5	ABB74678	Abb74678	Transcrip
911	15	100.0	18	5	ABG47346	Abg47346	Human pep
912	15	100.0	18	5	ABG38907	Abg38907	Human pep
913	15	100.0	18	5	ABG32405	Abg32405	Peptide #
914	15	100.0	18	5	ABG32403	Abg32403	Peptide #
915	15	100.0	18	5	ABG32402	Abg32402	Peptide #
916	15	100.0	18	5	ABG32404	Abg32404	Peptide #
917	15	100.0	18	5	ABG71092	Abg71092	Escherich
918	15	100.0	18	5	AAE15901	Aae15901	Mitochond
919	15	100.0	18	5	ABG63642	Abg63642	Human alb
920	15	100.0	18	5	AAU78941	Aau78941	Nucleopla
921	15	100.0	18	5	AAU78938	Aau78938	Thyroid A
922	15	100.0	18	5	AAU78942	Aau78942	C-fos pep
923	15	100.0	18	5	ABG95806	Abg95806	Cell pene
924	15	100.0	18	6	AAO16674	Aao16674	HIV cell-
925	15	100.0	18	6	ABP83210	Abp83210	G protein
926	15	100.0	19	2	AAR61270	Aar61270	19-residu
927	15	100.0	19	2	AAR82623	Aar82623	70K autoa
928	15	100.0	19	2	AAW07666	Aaw07666	Bacteriop
929	15	100.0	19	2	AAW42128	Aaw42128	T-cell ep
930	15	100.0	19	2	AAW41434	Aaw41434	Mouse PS1
931	15	100.0	19	2	AAY41106	Aay41106	Human can
932	15	100.0	19	2	AAW99306	Aaw99306	Human BAI
933	15	100.0	19	3	AAY98298	Aay98298	Alpha D p
934	15	100.0	19	3	AAY79970	Aay79970	Non-typea
935	15	100.0	19	3	AAY79969	Aay79969	Non-typea
936	15	100.0	19	4	AAM13713	Aam13713	Peptide #
937	15	100.0	19	4	ABB32645	Abb32645	Peptide #
938	15	100.0	19	4	AAM26114	Aam26114	Peptide #
939	15	100.0	19	4	AAM84644	Aam84644	Human imm
940	15	100.0	19	4	ABB27493	Abb27493	Human pep
941	15	100.0	19	4	ABB18142	Abb18142	Protein #
942	15	100.0	19	4	AAM65851	Aam65851	Human bon
943	15	100.0	19	4	AAO04808	Aao04808	Human pol
944	15	100.0	19	4	AAM53473	Aam53473	Human bra
945	15	100.0	19	4	ABG47498	Abg47498	Human liv
946	15	100.0	19	4	AAM01463	Aam01463	Peptide #
947	15	100.0	19	4	AAB80507	Aab80507	PTH2 rece
948	15	100.0	19	5	AAU87767	Aau87767	Human epi
949	15	100.0	19	5	ABB74811	Abb74811	Nuclear p
950	15	100.0	19	5	ABG35486	Abg35486	Human pep
951	15	100.0	19	5	ABJ01027	Abj01027	Human bre
952	15	100.0	19	5	AAU93911	Aau93911	Human P45
953	15	100.0	19	5	AAE23714	Aae23714	Fluoresce
954	15	100.0	19	5	AAE23708	Aae23708	Fluoresce
955	15	100.0	19	5	AAE23754	Aae23754	Alternati
956	15	100.0	19	7	ADC22462	Adc22462	RNA bindi
957	15	100.0	20	1	AAP50414	Aap50414	Swine duo
958	15	100.0	20	1	AAP71704	Aap71704	Internal
959	15	100.0	20	2	AAR10787	Aar10787	S-antigen
960	15	100.0	20	2	AAR10788	Aar10788	S-antigen
961	15	100.0	20	2	AAR27708	Aar27708	PTH/PTHrP
962	15	100.0	20	2	AAR33097	Aar33097	Human cyt
963	15	100.0	20	2	AAR33098	Aar33098	Human cyt
964	15	100.0	20	2	AAR33095	Aar33095	Human cyt
965	15	100.0	20	2	AAR62800	Aar62800	Residues
966	15	100.0	20	2	AAR62799	Aar62799	Residues
967	15	100.0	20	2	AAR47507	Aar47507	Tumour su
968	15	100.0	20	2	AAR64983	Aar64983	MMLV p15E
969	15	100.0	20	2	AAR98304	Aar98304	p21WAF1 p
970	15	100.0	20	2	AAR98303	Aar98303	p21WAF1 p
971	15	100.0	20	2	AAR92279	Aar92279	PTH/PTHrP
972	15	100.0	20	2	AAW44227	Aaw44227	Human p21
973	15	100.0	20	2	AAW44218	Aaw44218	Human p21
974	15	100.0	20	2	AAW18245	Aaw18245	PSKH-1 se

975	15	100.0	20	2	AAW42129	Aaw42129 T-cell ep
976	15	100.0	20	2	AAW73318	Aaw73318 Parathyro
977	15	100.0	20	2	AAY43183	Aay43183 S. rochei
978	15	100.0	20	3	AAY78381	Aay78381 Human pap
979	15	100.0	20	3	AAY98380	Aay98380 Alpha D p
980	15	100.0	20	3	AAB17271	Aab17271 p16-mimet
981	15	100.0	20	3	AAW90840	Aaw90840 Human lym
982	15	100.0	20	3	AAW90839	Aaw90839 Human lym
983	15	100.0	20	3	AAB14194	Aab14194 Human pla
984	15	100.0	20	4	AAB80508	Aab80508 PTH2 rece
985	15	100.0	20	5	ABB79795	Abb79795 Human G-p
986	15	100.0	20	5	ABB73349	Abb73349 Exemplary
987	15	100.0	20	5	ABB81206	Abb81206 Human amy
988	15	100.0	20	5	AAE23709	Aae23709 Fluoresce
989	15	100.0	20	5	AAE23715	Aae23715 Fluoresce
990	15	100.0	20	5	ABJ15282	Abj15282 IGF relat
991	15	100.0	20	6	ABJ38089	Abj38089 Human cyt
992	15	100.0	20	6	ABP83090	Abp83090 G protein
993	15	100.0	20	6	ABP82101	Abp82101 G protein
994	15	100.0	20	6	ABP83254	Abp83254 G protein
995	15	100.0	20	6	ABP82200	Abp82200 G protein
996	15	100.0	20	6	ABP83185	Abp83185 G protein
997	15	100.0	20	6	ABP82628	Abp82628 G protein
998	15	100.0	20	6	ABP83339	Abp83339 G protein
999	15	100.0	20	7	ABR82828	Abr82828 Human hsp
1000	15	100.0	20	7	ADC99267	Adc99267 Cancer-re

ALIGNMENTS

RESULT 1
AAW56176
ID AAW56176 standard; peptide; 3 AA.
XX
AC AAW56176;
XX
DT 20-JUL-1998 (first entry)
XX
DE Anti-inflammatory tripeptide.
XX
KW Anti-inflammatory; macrophage inhibitory activity; fibronectin;
KW T-cell inhibitory activity; adherence; extracellular matrix;
KW up-regulation; fas receptor expression; inflammation.
XX
OS Synthetic.
XX
PN WO9809985-A2.
XX
PD 12-MAR-1998.
XX
PF 03-SEP-1997; 97WO-IL000295.
XX
PR 03-SEP-1996; 96US-0025376P.
PR 20-NOV-1996; 96US-00753141.
PR 28-MAY-1997; 97US-00864301.
XX
PA (YEDA) YEDA RES & DEV CO LTD.
XX
PI Eisenbachschwartz M, Beserman P, Hirschberg DL;
XX
DR WPI; 1998-193550/17.
XX
PT Anti-inflammatory peptides and derivatives - used for treating, e.g.
PT arthritis, ulcerative colitis, auto-immune disease, allergy asthma,
PT shock, HIV infection, transplant rejection or Alzheimer's disease.
XX
PS Claim 3; Page 34; 42pp; English.
XX
CC AAW56171-248 represent anti-inflammatory tripeptides of the invention.
CC They are derived from the formulae: Xaa-Glu-Arg, Arg-Glu-Xaa, Xaa-Arg-
CC Glu, or Glu-arg-Xaa, where Xaa = any amino acid residue. Cyclic
CC derivatives of the peptides also function as anti-inflammatory agents.
CC The peptides can be covalently linked to one another either directly or
CC through a spacer. The peptides and their derivatives have macrophage
CC inhibitory and T-cell inhibitory activity and thus, anti-inflammatory
CC activity. The peptides and compositions have anti-immune activity, i.e.
CC inhibitory effects against a cellular and humoral immune response,
CC including a response not associated with inflammation. The peptides also
CC inhibit the ability of macrophages and T-cells to adhere to extracellular
CC matrix components and fibronectin, as well as up-regulated fas receptor
CC expression in T-cells. They can be used to inhibit unwanted immune
CC reaction and inflammation
XX
SQ Sequence 3 AA;

Query Match 100.0%; Score 15; DB 2; Length 3;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
|||
Db 1 RER 3

RESULT 2
AAW48192
ID AAW48192 standard; peptide; 4 AA.
XX
AC AAW48192;
XX
DT 30-JUN-1998 (first entry)
XX
DE Conantokin peptide derivative.
XX
KW Conantokin; predatory cone snail; treatment; neurologic disorder;
KW psychiatric disorder; anticonvulsant; neuroprotective;
KW analgesic. HIV infection; ophthalmic indication; memory; learning defect;
KW cognitive defect.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 4
FT /note= "gamma-carboxyglutamic acid"
XX
PN WO9803541-A1.
XX
PD 29-JAN-1998.
XX
PF 21-JUL-1997; 97WO-US012618.
XX
PR 22-JUL-1996; 96US-00684742.
XX
PA (UTAH) UNIV UTAH RES FOUND.
PA (COGN-) COGNETIX INC.
XX
PI Abogadie FC, Cruz LJ, Olivera BM, Walker C, Colledge C;
PI Hillyard DR, Jimenez E, Layer RT, Zhou L, Shen GS, Mccabe RT;
PI Rivier JE;
XX
DR WPI; 1998-120694/11.
XX
PT New conantokin peptide(s) - useful for e.g. treating neurologic or
PT psychiatric disorders, or the management of pain.
XX
PS Claim 15; Page 98; 122pp; English.
XX
CC The present sequence is a conantokin peptide derivative, which can be
CC used to treat neurologic and psychiatric disorders, e.g. as an
CC anticonvulsant, neuroprotective or analgesic agent. Neurologic and
CC psychiatric disorders include epilepsy, convulsions, neurotoxic injury
CC (associated with conditions of hypoxia, anoxia or ischaemia, which
CC typically follow stroke, cerebrovascular accident, brain or spinal cord
CC trauma, myocardial infarct, physical trauma, drowning, suffocation,
CC perinatal asphyxia or hypoglycaemic events), neurodegeneration

```
CC   (associated with Alzheimer's disease, senile dementia, Amyotrophic
CC   Lateral Sclerosis, Multiple Sclerosis, Parkinson's disease, Huntington's
CC   disease, Down's Syndrome, Korsakoff's disease, schizophrenia, AIDS
CC   dementia, multi-infarct dementia, Binswanger dementia and neuronal damage
CC   associated with uncontrolled seizures), chemical toxicity (such as
CC   addiction, and morphine, opiate, opioid and barbiturate tolerance), pain
CC   (acute, chronic, migraine), anxiety, major depression, manic-depressive
CC   illness, obsessive-compulsive disorder, schizophrenia and mood disorders
CC   (such as bipolar disorder, unipolar depression, dysthymia and seasonal
CC   effective disorder) and dystonia (movement disorder), sleep disorder,
CC   muscle relaxation and urinary incontinence. The peptide can also be used
CC   to treat HIV infection, ophthalmic indication and memory, learning or
CC   cognitive defects
XX
SQ   Sequence 4 AA;

  Query Match             100.0%;  Score 15;  DB 2;  Length 4;
  Best Local Similarity   100.0%;  Pred. No. 1.4e+06;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          1 RER 3


RESULT 3
AAW49974
ID   AAW49974 standard; peptide; 4 AA.
XX
AC   AAW49974;
XX
DT   30-JUN-1998  (first entry)
XX
DE   Conantokin peptide derivative.
XX
KW   Conantokin; predatory cone snail; treatment; neurologic disorder;
KW   psychiatric disorder; anticonvulsant; neuroprotective;
KW   analgesic. HIV infection; ophthalmic indication; memory; learning defect;
KW   cognitive defect.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   Modified-site   4
FT                   /note= "gamma-carboxyglutamic acid"
XX
PN   WO9803189-A1.
XX
PD   29-JAN-1998.
XX
PF   21-JUL-1997;   97WO-US012652.
XX
PR   22-JUL-1996;   96US-00684750.
PR   06-DEC-1996;   96US-00762377.
XX
PA   (COGN-) COGNETIX INC.
XX
PI   Mccabe RT,  Zhou L,  Layer RT;
XX
DR   WPI; 1998-120469/11.
XX
PT   Use of conantokin peptide(s) - for treating disorders involving excessive
PT   excitation of nerve cells by excitatory amino acids or agonists of the N-
PT   methyl-D-aspartate receptor.
XX
PS   Example 19; Page 73; 122pp; English.
XX
CC   The present sequence is a conantokin peptide derivative, which can be
CC   used to treat neurologic and psychiatric disorders, e.g. as an
CC   anticonvulsant, neuroprotective or analgesic agent. Neurologic and
CC   psychiatric disorders include epilepsy, convulsions, neurotoxic injury
CC   (associated with conditions of hypoxia, anoxia or ischaemia, which
CC   typically follow stroke, cerebrovascular accident, brain or spinal cord
CC   trauma, myocardial infarct, physical trauma, drowning, suffocation,
CC   perinatal asphyxia or hypoglycaemic events), neurodegeneration
CC   (associated with Alzheimer's disease, senile dementia, Amyotrophic
CC   Lateral Sclerosis, Multiple Sclerosis, Parkinson's disease, Huntington's
CC   disease, Down's Syndrome, Korsakoff's disease, schizophrenia, AIDS
CC   dementia, multi-infarct dementia, Binswanger dementia and neuronal damage
CC   associated with uncontrolled seizures), chemical toxicity (such as
CC   addiction, and morphine, opiate, opioid and barbiturate tolerance), pain
CC   (acute, chronic, migraine), anxiety, major depression, manic-depressive
CC   illness, obsessive-compulsive disorder, schizophrenia and mood disorders
CC   (such as bipolar disorder, unipolar depression, dysthymia and seasonal
CC   effective disorder) and dystonia (movement disorder), sleep disorder,
CC   muscle relaxation and urinary incontinence. The peptide can also be used
CC   to treat HIV infection, ophthalmic indication and memory, learning or
CC   cognitive defects
XX
SQ   Sequence 4 AA;

  Query Match             100.0%;  Score 15;  DB 2;  Length 4;
  Best Local Similarity   100.0%;  Pred. No. 1.4e+06;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          1 RER 3


RESULT 4
AAB24196
ID   AAB24196 standard; peptide; 4 AA.
XX
AC   AAB24196;
XX
DT   02-FEB-2001  (first entry)
XX
DE   Dual peptide amino acid sequence SEQ ID NO:1.
XX
KW   Dual peptide; antirheumatic; antiarthritic; antiallergic; antiimmune;
KW   antiinflammatory; antiasthmatic; dermatological; immunosuppressive;
KW   antiarteriosclerotic; cardiant; antiulcer; hepatotropic; vulnerary;
KW   ophthalmological; antiparkinsonian; nootropic; neuroprotective;
KW   cerebroprotective; gynaecological; anticonvulsant; tranquilliser;
KW   antibacterial; cytostatic; inflammation; rheumatoid arthritis;
KW   graft rejection; transplantation; macrophage migration; immune response.
XX
OS   Synthetic.
XX
PN   US6126939-A.
XX
PD   03-OCT-2000.
XX
PF   28-MAY-1997;   97US-00864301.
XX
PR   03-SEP-1996;   96US-0025376P.
PR   20-NOV-1996;   96US-0031191P.
PR   20-NOV-1996;   96US-00753141.
XX
PA   (YEDA ) YEDA RES & DEV CO LTD.
XX
PI   Eisenbach-Schwartz M,  Hirschberg DL,  Beserman P;
XX
DR   WPI; 1998-193550/17.
XX
PT   Anti-inflammatory peptides and derivatives - used for treating, e.g.
PT   arthritis, ulcerative colitis, auto-immune disease, allergy asthma,
PT   shock, HIV infection, transplant rejection or Alzheimer's disease.
XX
PS   Disclosure; Col 9; 17pp; English.
XX
CC   The present invention describes a pure anti-inflammatory dipeptide (I)
CC   comprising the sequence of Glu-Arg. (I) can have antirheumatic,
CC   antiarthritic, antiallergic, antiinflammatory, antiimmune, antiasthmatic,
CC   dermatological, immunosuppressive, antiarteriosclerotic, cardiant,
```

CC antiulcer, hepatotropic, ophthalmological, antiparkinsonian, vulnerary,
CC nootropic, neuroprotective, cerebroprotective, gynaecological,
CC anticonvulsant, tranquilliser, antibacterial and cytostatic activities.
CC (I) can be used as inhibitors of macrophage migration and/or macrophage
CC phagocytic activity and inflammation in animals, preferably mammals,
CC including human. It is used as inhibitors of T cell adhesive activity in
CC mammals and for the inhibition of an immune response not associated with
CC inflammation. It is also used for restoration of immune privilege at
CC immune privileged sites and in the treatment of or amelioration of
CC inflammatory symptoms in any disease, condition or disorder, e.g.
CC rheumatoid arthritis. It also prevents and/or treats graft rejection in
CC cases of transplantation of natural or artificial cells, tissue, and
CC organs, e.g. cornea, bone marrow, organs, lenses, pacemakers, natural and
CC artificial skin tissue. (I) inhibits the macrophage activity and has
CC macrophage migration and/or macrophage phagocytic inhibitory activity as
CC assessed in vitro assay. It also inhibits T cells and has T cell
CC inhibitory activity. The present sequence represents a dual peptide which
CC is used in the exemplification of the present invention
XX
SQ Sequence 4 AA;

Query Match 100.0%; Score 15; DB 2; Length 4;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
||||
Db 2 RER 4

RESULT 5
AAY71269
ID AAY71269 standard; peptide; 4 AA.
XX
AC AAY71269;
XX
DT 21-SEP-2000 (first entry)
XX
DE Bovine chondromodulin (Chm)-I protein processing signal sequence, RERR.
XX
KW Chondromodulin-like protein; Zchm1; human; chromosome 11p15.4; cancer;
KW cell differentiation regulator; osteoblast proliferation stimulator;
KW cytostatic; diagnostic; therapeutic; polypeptide-toxin fusion protein;
KW class II cell surface protein; transmembrane domain; gene therapy;
KW targeted cell inhibition; bovine; chondromodulin-I; Chm-I.
XX
OS Bos sp.
XX
PN WO200029579-A1.
XX
PD 25-MAY-2000.
XX
PF 12-NOV-1999; 99WO-US026909.
XX
PR 13-NOV-1998; 98US-00191986.
XX
PA (ZYMO) ZYMOGENETICS INC.
XX
PI Lok S, Presnell SR;
XX
DR WPI; 2000-387792/33.
XX
PT Polynucleotide encoding mammalian chondromodulin-like polypeptide useful
PT for gene therapy of various disorders by regulating growth or
PT differentiation of cells especially cancer cells.
XX
PS Disclosure; Page 1; 87pp; English.
XX
CC The present sequence is the bovine chondromodulin-I (Chm-I) protein
CC processing signal sequence RERR, that precedes the mature protein
CC sequence. Bovine Chm-I has sequence homology to human chondromodulin-
CC like protein, Zchm-I. The Zchm1 locus is mapped to chromosome 11p15.4. It
CC functions as a cell differentiation regulator and osteoblast
CC proliferation stimulator. Zchm1 can be used as growth or differentiation
CC regulator for cells, especially mesenchymal, myogenic, chondrogenic or
CC endothelial cells. Zchm1 proteins or antibodies are useful for
CC identifying or treating tissues or organs expressing the anti-
CC complementary molecule, e.g., receptor or antigen. The Zchm1 polypeptides
CC conjugated to drugs, radionuclides and toxins are useful for in vivo
CC diagnostic or therapeutic applications and polypeptide-toxin fusion
CC proteins are useful for targeted cell or tissue inhibition or ablation
CC for treating various disorders, especially cancer. It is useful for gene
CC therapy of disorders associated with altered Zchm1 activity
XX
SQ Sequence 4 AA;

Query Match 100.0%; Score 15; DB 3; Length 4;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
||||
Db 1 RER 3

RESULT 6
AAG79029
ID AAG79029 standard; peptide; 4 AA.
XX
AC AAG79029;
XX
DT 10-DEC-2001 (first entry)
XX
DE Amino acid sequence of conantokin S1 domain III.
XX
KW Conantokin; cone snail; nerve cell excitation; NMDA receptor; epilepsy;
KW N-methyl-D-aspartate receptor; pain; psychiatric disorder;
KW neutrotoxic injury; hypoxia; anoxia; ischemia; neurodegeneration;
KW chemical toxicity; addiction; drug craving; psychiatric disorder;
KW anxiety; depression; obsessive compulsive disorder; schizophrenia;
KW mood disorder; ophthalmic disorder; neurological disorder; dystonia;
KW sleep disorder; muscle relaxation; urinary incontinence;
KW cognition enhancement; HIV infection.
XX
OS Conus sulcatus.
XX
FH Key Location/Qualifiers
FT Modified-site 4
FT /note= "gamma-carboxyglutamic acid"
XX
PN US6277825-B1.
XX
PD 21-AUG-2001.
XX
PF 20-JUL-1999; 99US-00357141.
XX
PR 22-JUL-1996; 96US-00684750.
PR 06-DEC-1996; 96US-00762377.
PR 21-JUL-1997; 97WO-US012652.
PR 10-FEB-1999; 99US-00142076.
PR 01-APR-1999; 99US-00283277.
XX
PA (UTAH) UNIV UTAH RES FOUND.
PA (COGN-) COGNETIX INC.
XX
PI Olivera BM, Mcintosh JM, Mccabe RT, Layer RT, Zhou L;
XX
DR WPI; 2001-601377/68.
XX
PT Use of conantokin peptide or its derivatives or a conantokin peptide
PT chimera for treating disorders e.g. migraine.
XX
PS Claim 9; Col 80; 60pp; English.
XX
CC AAG79012-43 and AAG790054-56 represent domains of conantokin peptides.
CC Conantokins differ from conotoxins, in that they contain gamma-

CC carboxyglutamic acid. The conantokins are derived from the venom of cone
CC snails. They are used for the treatment of disorders in which the
CC pathophysiology involves excessive excitation of nerve cells by
CC excitatory amino acids or agonist of N-methyl-D-aspartate (NMDA)
CC receptor. The conantokin peptides are used for the treatment of disorders
CC such as pain; neurologic or psychiatric disorders such epilepsy; for
CC reducing neutrotoxic injury associated with conditions of hypoxia, anoxia
CC or ischemia; for treating neurodegeneration; for treating chemical
CC toxicity such as addiction, drug craving, alcohol abuse, morphine, opioid
CC and barbiturate tolerance; for treating psychiatric disorders such as
CC anxiety, major depression, manic-depression illness, obsessive compulsive
CC disorder, schizophrenia or mood disorder; for treating ophthalmic
CC disorder; for treating additional neurological disorders e.g. dystonia,
CC sleep disorder, muscle relaxation and urinary incontinence; for
CC memory/cognition enhancement; for treating HIV infection
XX
SQ Sequence 4 AA;

Query Match 100.0%; Score 15; DB 4; Length 4;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
||| |
Db 1 RER 3

RESULT 7
AAE16624
ID AAE16624 standard; peptide; 4 AA.
XX
AC AAE16624;
XX
DT 09-APR-2002 (first entry)
XX
DE Peptide of human KCNQ5 S4 membrane-spanning domain.
XX
KW Human; potassium channel polypeptide; KCNQ5; pain; migraine; stroke;
KW dementia; trauma; epilepsy; seizure; amyotrophic lateral sclerosis; ALS;
KW multiple sclerosis; MS; Parkinson's disease; ataxia; depression;
KW anxiety disorder; bipolar disorder; sleep disorder; eating disorder;
KW addiction; myokymia; Alzheimer's disease; age-associated memory loss;
KW learning deficiency; cognitive disorder; motor disease; neuron disease;
KW neurophysiological disorder; neuropsychological disorder; asthma;
KW neuron cell death; brain tumour; gene therapy; antisense therapy;
KW synaptic transmission; S4 membrane-spanning domain;
KW electrical excitability.
XX
OS Homo sapiens.
XX
PN WO200192526-A1.
XX
PD 06-DEC-2001.
XX
PF 24-MAY-2001; 2001WO-US017314.
XX
PR 26-MAY-2000; 2000US-0207389P.
XX
PA (BRIM) BRISTOL-MYERS SQUIBB CO.
XX
PI Dworetzky SI, Ramanathan CS, Trojnacki JT, Boissard CG;
PI Gribkoff VK;
XX
DR WPI; 2002-122069/16.
XX
PT Novel potassium channel polypeptide, KCNQ5 and polynucleotide encoding
PT it, for diagnosing, treating and identifying modulators useful in
PT treating neurological, neurophysiological and neuropsychological
PT diseases.
XX
PS Disclosure; Page 21; 128pp; English.
XX
CC The invention relates to potassium channel polypeptides referred to as
CC KCNQ5 and nucleic acid molecules encoding such polypeptides. KCNQ5
CC polypeptides are useful for identifying compounds that modulate their
CC biological activity. The compounds identified and KCNQ5 polynucleotides
CC are useful for treating acute and chronic pain, migraine, acute stroke,
CC dementia, trauma, epilepsy, seizure, amyotrophic lateral sclerosis (ALS),
CC multiple sclerosis (MS), Parkinson's disease, ataxia, anxiety disorders,
CC depression, bipolar disorders, sleep disorders, eating disorders,
CC addiction, myokymia, Alzheimer's disease, age-associated memory loss,
CC learning deficiencies, cognitive disorders and motor neuron diseases. The
CC nucleic acid molecules of the invention are further useful for treating
CC neurophysiological, neuropsychological disorders, asthma, neuron cell
CC death and brain tumours. They are also used in gene therapy and antisense
CC therapy. KCNQ5 polypeptides modulate synaptic transmission and electrical
CC excitability in the brain and are useful for generating antibodies. They
CC are also useful to affinity purify biological effectors from biological
CC materials e.g. disease tissues or cells. The present sequence is peptide
CC of human KCNQ5 S4 membrane-spanning domain
XX
SQ Sequence 4 AA;

Query Match 100.0%; Score 15; DB 5; Length 4;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
||| |
Db 2 RER 4

RESULT 8
ABB99613
ID ABB99613 standard; peptide; 4 AA.
XX
AC ABB99613;
XX
DT 28-MAR-2003 (first entry)
XX
DE Peptide derived from human amyloid precursor protein (APP).
XX
KW Amyloid precursor protein; APP; protein derivative;
KW neurodegenerative disease; Alzheimer's disease; cognitive enhancer.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO200283729-A2.
XX
PD 24-OCT-2002.
XX
PF 17-APR-2002; 2002WO-GB001769.
XX
PR 18-APR-2001; 2001GB-00009558.
PR 17-AUG-2001; 2001GB-00020084.
PR 30-NOV-2001; 2001US-00998491.
PR 28-MAR-2002; 2002GB-00007387.
XX
PA (UYOP-) UNIV OPEN.
XX
PI Mileusnic R, Rose SPR;
XX
DR WPI; 2003-111814/10.
XX
PT Derivatives of polypeptides, useful for treating neurodegenerative
PT disease e.g. Alzheimer's disease, comprises one functional amino acid
PT residue or derivative protected by a protective group.
XX
PS Claim 74; Page 65; 85pp; English.
XX
CC The present sequence is derived from amyloid precursor protein (APP).
CC Derivatives of the invention are based on APP sequences. The
CC specification describes a derivative of a polypeptide in which at least
CC one functional group of at least one amino acid residue or derivative is
CC protected by a protective group. This derivative is of the formula given

```
CC   in ABB99625. The derivative is useful in medicine and in the preparation
CC   of a medicament for use in the treatment of a neurodegenerative disease
CC   e.g. Alzheimer's disease. It is also useful as a cognitive enhancer
XX
SQ   Sequence 4 AA;

  Query Match            100.0%;  Score 15;  DB 6;  Length 4;
  Best Local Similarity  100.0%;  Pred. No. 1.4e+06;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          1 RER 3


RESULT 9
ABB99614
ID   ABB99614 standard; peptide; 4 AA.
XX
AC   ABB99614;
XX
DT   28-MAR-2003  (first entry)
XX
DE   Peptide derived from human amyloid precursor protein (APP).
XX
KW   Amyloid precursor protein; APP; protein derivative;
KW   neurodegenerative disease; Alzheimer's disease; cognitive enhancer.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO200283729-A2.
XX
PD   24-OCT-2002.
XX
PF   17-APR-2002; 2002WO-GB001769.
XX
PR   18-APR-2001; 2001GB-00009558.
PR   17-AUG-2001; 2001GB-00020084.
PR   30-NOV-2001; 2001US-00998491.
PR   28-MAR-2002; 2002GB-00007387.
XX
PA   (UYOP-) UNIV OPEN.
XX
PI   Mileusnic R,  Rose SPR;
XX
DR   WPI; 2003-111814/10.
XX
PT   Derivatives of polypeptides, useful for treating neurodegenerative
PT   disease e.g. Alzheimer's disease, comprises one functional amino acid
PT   residue or derivative protected by a protective group.
XX
PS   Disclosure; Page 1; 85pp; English.
XX
CC   The present sequence is derived from amyloid precursor protein (APP).
CC   Derivatives of the invention are based on APP sequences. The
CC   specification describes a derivative of a polypeptide in which at least
CC   one functional group of at least one amino acid residue or derivative is
CC   protected by a protective group. This derivative is of the formula given
CC   in ABB99625. The derivative is useful in medicine and in the preparation
CC   of a medicament for use in the treatment of a neurodegenerative disease
CC   e.g. Alzheimer's disease. It is also useful as a cognitive enhancer
XX
SQ   Sequence 4 AA;

  Query Match            100.0%;  Score 15;  DB 6;  Length 4;
  Best Local Similarity  100.0%;  Pred. No. 1.4e+06;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          2 RER 4


RESULT 10
AAR62114
ID   AAR62114 standard; peptide; 5 AA.
XX
AC   AAR62114;
XX
DT   25-MAR-2003  (revised)
DT   27-APR-1995  (first entry)
XX
DE   Hydrophilic motif from U1 snRNP 70K protein.
XX
KW   Small ribonucleoprotein complex; U1 snRNP; 70K protein; epitope;
KW   autoantibody; immunoinfective cluster virus; nuclear protein antigen;
KW   systemic rheumatic disorder; human immunodeficiency virus; HIV-1.
XX
OS   Homo sapiens.
XX
PN   WO9420141-A1.
XX
PD   15-SEP-1994.
XX
PF   10-MAR-1994;   94WO-US002631.
XX
PR   11-MAR-1993;   93US-00029850.
XX
PA   (UYSC-) UNIV SOUTHERN CALIFORNIA.
XX
PI   Douvas A,  Takehana Y,  Ehresmann G;
XX
DR   WPI; 1994-302689/37.
XX
PT   Methods for treating immunoinfective cluster virus infections - utilise
PT   antibodies or fragments characteristic of auto antibodies produced by
PT   patients with rheumatic disorders.
XX
PS   Disclosure; Page 8; 106pp; English.
XX
CC   The sequence RERRR (AAR62113) is a preferred example of an alternating
CC   acidic/basic amino acid, hydrophilic epitope motif, found in the U1 snRNP
CC   70K protein. It also occurs as RRERE and EREEER (AAR62114 and AAR62115)
CC   in the 70K protein. The motif is also found in similar form in
CC   immunoinfective cluster viruses. The motif serves as an epitope for anti-
CC   viral antibodies and also for autoantibodies which occur in high titre in
CC   patients suffering from systemic rheumatic disorders. Sera from such
CC   patients could be used for treatment of immunoinfective cluster virus
CC   (e.g. HIV, EBV, rubella virus) infections. (Updated on 25-MAR-2003 to
CC   correct PN field.)
XX
SQ   Sequence 5 AA;

  Query Match            100.0%;  Score 15;  DB 2;  Length 5;
  Best Local Similarity  100.0%;  Pred. No. 1.4e+06;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          2 RER 4


RESULT 11
AAR62113
ID   AAR62113 standard; peptide; 5 AA.
XX
AC   AAR62113;
XX
DT   25-MAR-2003  (revised)
DT   27-APR-1995  (first entry)
XX
DE   Hydrophilic motif from U1 snRNP 70K protein.
XX
KW   Small ribonucleoprotein complex; U1 snRNP; 70K protein; epitope;
KW   autoantibody; immunoinfective cluster virus; nuclear protein antigen;
```

KW systemic rheumatic disorder; human immunodeficiency virus; HIV-1.
XX
OS Homo sapiens.
XX
PN WO9420141-A1.
XX
PD 15-SEP-1994.
XX
PF 10-MAR-1994; 94WO-US002631.
XX
PR 11-MAR-1993; 93US-00029850.
XX
PA (UYSC-) UNIV SOUTHERN CALIFORNIA.
XX
PI Douvas A, Takehana Y, Ehresmann G;
XX
DR WPI; 1994-302689/37.
XX
PT Methods for treating immunoinfective cluster virus infections - utilise
PT antibodies or fragments characteristic of auto antibodies produced by
PT patients with rheumatic disorders.
XX
PS Claim 13; Page 78; 106pp; English.
XX
CC The sequence RERRR (AAR62113) is a preferred example of an alternating
CC acidic/basic amino acid, hydrophilic epitope motif, found in the U1 snRNP
CC 70K protein. It also occurs as RRERE and EREEER (AAR62114 and AAR62115)
CC in the 70K protein. The motif is also found in similar form in
CC immunoinfective cluster viruses. The motif serves as an epitope for anti-
CC viral antibodies and also for autoantibodies which occur in high titre in
CC patients suffering from systemic rheumatic disorders. Sera from such
CC patients could be used for treatment of immunoinfective cluster virus
CC (e.g. HIV, EBV, rubella virus) infections. (Updated on 25-MAR-2003 to
CC correct PN field.)
XX
SQ Sequence 5 AA;

```
  Query Match             100.0%;  Score 15;  DB 2;  Length 5;
  Best Local Similarity   100.0%;  Pred. No. 1.4e+06;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          1 RER 3
```

RESULT 12
AAR62154
ID AAR62154 standard; peptide; 5 AA.
XX
AC AAR62154;
XX
DT 27-AUG-2003 (revised)
DT 25-MAR-2003 (revised)
DT 02-MAY-1995 (first entry)
XX
DE Basic/acidic motif from HIV-1 gp120/41 and U1 snRNP 70K protein.
XX
KW Small ribonucleoprotein complex; U1 snRNP; 70K protein; epitope;
KW autoantibody; immunoinfective cluster virus; nuclear protein antigen;
KW systemic rheumatic disorder; human immunodeficiency virus; HIV-1;
KW systemic lupus erythematosus; mixed connective tissue disease;
KW scleroderma; glycoprotein 120; glycoprotein 41.
XX
OS Homo sapiens.
OS Human immunodeficiency virus 1.
XX
PN WO9420141-A1.
XX
PD 15-SEP-1994.
XX
PF 10-MAR-1994; 94WO-US002631.
XX
PR 11-MAR-1993; 93US-00029850.
XX
PA (UYSC-) UNIV SOUTHERN CALIFORNIA.
XX
PI Douvas A, Takehana Y, Ehresmann G;
XX
DR WPI; 1994-302689/37.
XX
PT Methods for treating immunoinfective cluster virus infections - utilise
PT antibodies or fragments characteristic of auto antibodies produced by
PT patients with rheumatic disorders.
XX
PS Disclosure; Page 59; 106pp; English.
XX
CC The hydrophilic C-terminal regions of U1 snRNP 70K protein and HIV-1 gp41
CC share extensive homologies. These include the repeating RDRDR (AAR62153)
CC motif and a block of alternating basic and acidic residues begining at
CC positions 513 and 732 of 70K and gp41, respectively. In this block, 11 of
CC 18 of the 70K amino acids are identical to gp41, and 3 more represent
CC conservative substitutions of Glu and Asp. Configurations of alternating
CC basic and acidic amino acids (AAR62153- AAR62156) are antigenic to anti-
CC U1 antibodies. Such autoantibodies occur in the systemic rheumatoid
CC disorders of mixed connective tissue disease, scleroderma and systemic
CC lupus erythematosus and can be used to neutralise HIV-1. (Updated on 25-
CC MAR-2003 to correct PN field.) (Updated on 27-AUG-2003 to correct OS
CC field.)
XX
SQ Sequence 5 AA;

```
  Query Match             100.0%;  Score 15;  DB 2;  Length 5;
  Best Local Similarity   100.0%;  Pred. No. 1.4e+06;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          1 RER 3
```

RESULT 13
AAR54661
ID AAR54661 standard; peptide; 5 AA.
XX
AC AAR54661;
XX
DT 25-MAR-2003 (revised)
DT 29-NOV-1994 (first entry)
XX
DE Native secreted amyloid precursor protein (APP) peptide.
XX
KW Amyloid precursor protein; Alzheimer's disease; neuron growth.
XX
OS Synthetic.
XX
PN WO9409808-A1.
XX
PD 11-MAY-1994.
XX
PF 23-OCT-1992; 92WO-US009070.
XX
PR 23-OCT-1992; 92WO-US009070.
XX
PA (REGC) UNIV CALIFORNIA.
XX
PI Saitoh T;
XX
DR WPI; 1994-167118/20.
XX
PT Peptide(s) and analogues based on amyloid precursor protein - used for
PT promoting neuronal growth in conditions involving damage to neurons or in
PT treating Alzheimer's Disease etc.
XX
PS Claim 1; Page 5; 116pp; English.
XX

```
CC   This sequence corresponds to AA 328-332 of amyloid precursor protein.
CC   This peptide, which is smaller than a native APP, retains at least some
CC   neuronal growth promoting effect of APP. The peptide can be used for
CC   increasing the memory-retention ability of a mammal, for promoting the
CC   regeneration of damaged neurons in vivo in a mammal, for treating a
CC   condition associated with cerebral deposition of amyloid beta-protein in
CC   a human patient such as Alzheimer's disease, or for treating a
CC   neurological condition. This sequence is uniquely required for the growth
CC   -promoting activity of secreted APP (695 AA) on fibroblasts. (Updated on
CC   25-MAR-2003 to correct PN field.)
XX
SQ   Sequence 5 AA;

  Query Match             100.0%;  Score 15;  DB 2;  Length 5;
  Best Local Similarity   100.0%;  Pred. No. 1.4e+06;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          1 RER 3


RESULT 14
AAR77510
ID   AAR77510 standard; protein; 5 AA.
XX
AC   AAR77510;
XX
DT   27-AUG-2003  (revised)
DT   14-APR-1996  (first entry)
XX
DE   NeuroD basic region motif in bHLH proteins.
XX
KW   NeuroD; neurogenic differentiation; neuronal growth factor;
KW   basic helix-loop-helix secondary structure; neurogenesis;
KW   non-neuronal cell differentiation; antigen; drug screening;
KW   neurodegenerative disease; traumatic injury; gene therapy.
XX
OS   Metazoa.
XX
PN   WO9530693-A1.
XX
PD   16-NOV-1995.
XX
PF   08-MAY-1995;   95WO-US005741.
XX
PR   06-MAY-1994;   94US-00239228.
XX
PA   (HUTC-) HUTCHINSON CANCER RES CENT FRED.
PA   (WEIN/) WEINTRAUB N.
XX
PI   Weintraub HM,  Lee JE,  Hollenberg SM,  Tapscott SJ;
XX
DR   WPI; 1995-404081/51.
XX
PT   Nucleic acid molecule which hybridises with a neuroD HLH domain - is used
PT   in a method for inducing differentiation of a non-neuronal cell.
XX
PS   Example 3; Page 41; 50pp; English.
XX
CC   The NARER basic region motif of NeuroD is shared by other proteins with
CC   the basic helix-loop-helix secondary structure, and the Drosophila
CC   Daughterless (Da) and mammalian E proteins. NeuroD induces
CC   differentiation of a non-neuronal cell into a neuron. DNA encoding NeuroD
CC   may be used in the development of probes, in the construction of
CC   recombinant cell lines and transgenic animals, and in the construction of
CC   gene therapy vectors for the repair of neuronal defects resulting from
CC   traumatic injury and neurodegenerative diseases (Alzheimer's disease,
CC   Huntington's disease, Parkinson's disease). Transformed host cells are
CC   used (1) as a source of neuronal growth factors, (2) in transient and
CC   continuous cultures for anti-cancer drug screening, and (3) as sources of
CC   recombinant NeuroD for use as an antigen in diagnostic antibody
CC   production. (Updated on 27-AUG-2003 to correct OS field.)
XX
SQ   Sequence 5 AA;

  Query Match             100.0%;  Score 15;  DB 2;  Length 5;
  Best Local Similarity   100.0%;  Pred. No. 1.4e+06;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          3 RER 5


RESULT 15
AAW22449
ID   AAW22449 standard; peptide; 5 AA.
XX
AC   AAW22449;
XX
DT   02-OCT-1997  (first entry)
XX
DE   NeuroD1 NARER motif.
XX
KW   Neurogenic differentiation protein; neuroD1; transcriptional activator.
XX
OS   Mus musculus.
XX
PN   WO9716548-A1.
XX
PD   09-MAY-1997.
XX
PF   30-OCT-1996;   96WO-US017532.
XX
PR   02-NOV-1995;   95US-00552142.
XX
PA   (HUTC-) HUTCHINSON CANCER RES CENT FRED.
PA   (WEIN/) WEINTRAUB N.
XX
PI   Weintraub HM,  Lee JE,  Hollenberg SM,  Tapscott SJ;
XX
DR   WPI; 1997-272117/24.
XX
PT   Nucleic acid encoding neurogenic differentiation polypeptide - useful
PT   e.g. in regulating neuronal, endocrine and gastrointestinal development.
XX
PS   Example 3; Page 23; 81pp; English.
XX
CC   The NARER motif (AAW22449) of mouse neurogenic differentiation protein
CC   neuroD1 (see also AAW22436) is shared by other basic- helix-loop-helix
CC   (bHLH) proteins, and the Drosophila Daughterless and mammalian E
CC   proteins. Similar motifs (see also AAW22453 and AAW22454) have been found
CC   in Drosophila Atonal and mammalian achaete- scute homologue proteins,
CC   which are thought to be involved in neurogenesis. The basic region of
CC   bHLH proteins is important for DNA binding site recognition, and there is
CC   homology between neuroD1 and other neuroproteins in this functional
CC   region
XX
SQ   Sequence 5 AA;

  Query Match             100.0%;  Score 15;  DB 2;  Length 5;
  Best Local Similarity   100.0%;  Pred. No. 1.4e+06;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          3 RER 5


RESULT 16
AAW12517
ID   AAW12517 standard; peptide; 5 AA.
XX
AC   AAW12517;
XX
```

DT 22-APR-1997 (first entry)
XX
DE Interleukin-6 antagonist 82.
XX
KW Interleukin-6; IL-6; antagonist; inhibitor; autoimmune disease; skin;
KW intestine; systemic lupus erythematosus; chronic rheumatism.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 5
FT /note= "amidated"
XX
PN JP08311098-A.
XX
PD 26-NOV-1996.
XX
PF 22-MAY-1995; 95JP-00146742.
XX
PR 22-MAY-1995; 95JP-00146742.
XX
PA (DAIL) DAICEL CHEM IND LTD.
PA (FUJI) FUJISAWA PHARM CO LTD.
XX
DR WPI; 1997-061811/06.
XX
PT Interleukin-6 antagonistic peptide(s) comprising arginine - useful for
PT treating autoimmune, renal, skin and intestinal diseases.
XX
PS Example 82; Page 12; 20pp; Japanese.
XX
CC The present peptide is a specific example of new interleukin-6
CC antagonists of the general formula E-F-G-H-Arg-NH2, where E, F and H each
CC represent any optionally protected amino acid and where G is preferably
CC an Arg residue having an opt. protected guanidino group, but can be any
CC amino acid. The peptides are useful for treating autoimmune diseases
CC (e.g. systemic lupus erythematosus or chronic rheumatism), renal, skin
CC and intestinal diseases
XX
SQ Sequence 5 AA;

Query Match 100.0%; Score 15; DB 2; Length 5;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
|||
Db 3 RER 5

RESULT 17
AAW71013
ID AAW71013 standard; peptide; 5 AA.
XX
AC AAW71013;
XX
DT 25-MAR-2003 (revised)
DT 21-OCT-1998 (first entry)
XX
DE Motif of neuroD1 and Drosophila daughterless and mammalian E proteins.
XX
KW Basic helix-loop-helix; bHLH; neuroD; neuroectodermal tumour;
KW classification; medulloblastoma; Drosophila daughterless;
KW mammalian E protein.
XX
OS Unidentified.
XX
PN US5795723-A.
XX
PD 18-AUG-1998.
XX
PF 07-AUG-1997; 97US-00910973.
XX
PR 06-MAY-1994; 94US-00239238.
PR 02-NOV-1995; 95US-00552142.
PR 30-OCT-1996; 96WO-US017532.
XX
PA (HUTC-) HUTCHINSON CANCER RES CENT FRED.
XX
PI Tapscott SJ, Olson JM;
XX
DR WPI; 1998-466661/40.
XX
PT Classifying neuroectodermal tumours from expression pattern of basic-
PT helix-loop-helix genes - especially for identifying medulla:blastoma and
PT assessing its aggressiveness, specifically associated with expression of
PT BHLH genes neuroD 1-3.
XX
PS Example 3; Col 18; 43pp; English.
XX
CC The present sequence represents a motif found in neuroD1 and Drosophila
CC daughterless and mammalian E proteins. NeuroD is a member of the basic
CC helix-loop-helix (bHLH) protein family. The bHLH genes are a family of
CC genes associated with vertebrate neuronal, endocrinal and
CC gastrointestinal development. The observed pattern of neuroD expression
CC distinguishes subclasses of neuroectodermal tumours. The specification
CC describes a method for the classification of human neuroectodermal
CC tumours. The method comprises measuring, in a tumour sample, expression
CC of at least one basic bHLH gene and identifying the tumour subclass by
CC matching expression to predetermined expression profiles for known
CC subclasses. For classifying the tumour as a medulloblastoma, the bHLH
CC gene detected is neuroD1 and neuroD3. The method is used to classify
CC neuroectodermal tumours, and to identify medullablastoma and for
CC prognosis of this as aggressive. (Updated on 25-MAR-2003 to correct PR
CC field.)
XX
SQ Sequence 5 AA;

Query Match 100.0%; Score 15; DB 2; Length 5;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
|||
Db 3 RER 5

RESULT 18
AAW94160
ID AAW94160 standard; peptide; 5 AA.
XX
AC AAW94160;
XX
DT 14-APR-1999 (first entry)
XX
DE BC loop sequence of fluorescein-binding monobody clone pLB24.6.
XX
KW Fibronectin type III; Fn3; monobody; beta-strand domain; loop region;
KW specific binding partner; SBP; catalysis; LRS; fluorescein.
XX
OS Unidentified.
XX
PN WO9856915-A2.
XX
PD 17-DEC-1998.
XX
PF 12-JUN-1998; 98WO-US012099.
XX
PR 12-JUN-1997; 97US-0049410P.
XX
PA (RESE) RESEARCH CORP TECHNOLOGIES INC.
XX
PI Koide S;
XX
DR WPI; 1999-060331/05.
XX

PT Fibronectin type III (Fn3) polypeptide monobody (artificial mini-
PT antibodies) comprising Fn3 P-strand domain sequences that are linked to
PT loop region sequences, useful in therapeutic, diagnostic and catalytic
PT applications.
XX
PS Example 12; Page 42; 96pp; English.
XX
CC The invention relates to a synthetic fibronectin type III (Fn3)
CC polypeptide monobody that comprises Fn3 beta-strand domain sequences that
CC are linked to loop region sequences (LRSs). One or more of the loop
CC sequences in the synthetic Fn3 vary by deletion, insertion, or
CC replacement of at least 2 amino acids from the corresponding LRss in wild
CC -type Fn3. Host cells containing an expression vector comprising the
CC synthetic Fn3 nucleic acid are used for the production of the Fn3
CC monobody. The invention also provides methods of identifying the amino
CC acid sequence of a polypeptide molecule (i) capable of binding to a
CC specific binding partner (SBP) so as to form a polypeptide:SBP complex;
CC (ii) capable of catalysing a chemical reaction with a catalysed rate
CC constant, Kcat, and an uncatalysed rate constant, Kuncat, such that the
CC ratio of the Kcat/kuncat is greater than 10. Sequences AAW94155-63
CC represent BC loop sequences of fluorescein-binding monobody clones from
CC library #2
XX
SQ Sequence 5 AA;

Query Match 100.0%; Score 15; DB 2; Length 5;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
|||
Db 3 RER 5

RESULT 19
AAB91809
ID AAB91809 standard; peptide; 5 AA.
XX
AC AAB91809;
XX
DT 22-JUN-2001 (first entry)
XX
DE Amyloid beta-protein fragment peptide SEQ ID NO:985.
XX
KW Protection; endogenous therapeutic peptide; peptidase; conjugation;
KW blood component; modification; succinimidyl; maleimido group; amino;
KW hydroxyl; thiol; hormone; growth factor; neurotransmitter.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200069900-A2.
XX
PD 23-NOV-2000.
XX
PF 17-MAY-2000; 2000WO-US013576.
XX
PR 17-MAY-1999; 99US-0134406P.
PR 10-SEP-1999; 99US-0153406P.
PR 15-OCT-1999; 99US-0159783P.
XX
PA (CONJ-) CONJUCHEM INC.
XX
PI Bridon DP, Ezrin AM, Milner PG, Holmes DL, Thibaudeau K;
XX
DR WPI; 2001-112059/12.
XX
PT Modifying and attaching therapeutic peptides to albumin prevents
PT peptidase degradation, useful for increasing length of in vivo activity.
XX
PS Disclosure; Page 516; 733pp; English.
XX
CC The present invention describes a modified therapeutic peptide (I)
CC comprising a therapeutically active amino acid region (III) and a
CC reactive group (II) (e.g. succinimidyl and maleimido groups) attached to
CC a less therapeutically active amino acid region (IV), which covalently
CC bonds with amino/hydroxyl/thiol groups on blood components to form a
CC peptidase stabilised therapeutic peptide composed of 3-50 amino acids.
CC (I) are useful for modifying therapeutic peptides e.g. hormones, growth
CC factors and neurotransmitters, to protect them from peptidase activity in
CC vivo for the treatment of various disorders. Endogenous therapeutic
CC peptides are not suitable as drug candidates as they require frequent
CC administration due to rapid degradation by peptidases in the body.
CC Modifying and attaching therapeutic peptides to albumin prevents or
CC reduces the action of peptidases to increase length of activity (half
CC life) and specificity as bonding to large molecules decreases
CC intracellular uptake and interference with physiological processes.
CC AAB90829 to AAB92441 represent peptides which can be used in the
CC exemplification of the present invention
XX
SQ Sequence 5 AA;

Query Match 100.0%; Score 15; DB 4; Length 5;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
|||
Db 1 RER 3

RESULT 20
AAB91776
ID AAB91776 standard; peptide; 5 AA.
XX
AC AAB91776;
XX
DT 22-JUN-2001 (first entry)
XX
DE Amyloid beta-protein fragment peptide SEQ ID NO:952.
XX
KW Protection; endogenous therapeutic peptide; peptidase; conjugation;
KW blood component; modification; succinimidyl; maleimido group; amino;
KW hydroxyl; thiol; hormone; growth factor; neurotransmitter.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200069900-A2.
XX
PD 23-NOV-2000.
XX
PF 17-MAY-2000; 2000WO-US013576.
XX
PR 17-MAY-1999; 99US-0134406P.
PR 10-SEP-1999; 99US-0153406P.
PR 15-OCT-1999; 99US-0159783P.
XX
PA (CONJ-) CONJUCHEM INC.
XX
PI Bridon DP, Ezrin AM, Milner PG, Holmes DL, Thibaudeau K;
XX
DR WPI; 2001-112059/12.
XX
PT Modifying and attaching therapeutic peptides to albumin prevents
PT peptidase degradation, useful for increasing length of in vivo activity.
XX
PS Disclosure; Page 505; 733pp; English.
XX
CC The present invention describes a modified therapeutic peptide (I)
CC comprising a therapeutically active amino acid region (III) and a
CC reactive group (II) (e.g. succinimidyl and maleimido groups) attached to
CC a less therapeutically active amino acid region (IV), which covalently
CC bonds with amino/hydroxyl/thiol groups on blood components to form a
CC peptidase stabilised therapeutic peptide composed of 3-50 amino acids.
CC (I) are useful for modifying therapeutic peptides e.g. hormones, growth

CC factors and neurotransmitters, to protect them from peptidase activity in
CC vivo for the treatment of various disorders. Endogenous therapeutic
CC peptides are not suitable as drug candidates as they require frequent
CC administration due to rapid degradation by peptidases in the body.
CC Modifying and attaching therapeutic peptides to albumin prevents or
CC reduces the action of peptidases to increase length of activity (half
CC life) and specificity as bonding to large molecules decreases
CC intracellular uptake and interference with physiological processes.
CC AAB90829 to AAB92441 represent peptides which can be used in the
CC exemplification of the present invention
XX
SQ Sequence 5 AA;

Query Match 100.0%; Score 15; DB 4; Length 5;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
|||
Db 1 RER 3

RESULT 21
AAU01260
ID AAU01260 standard; peptide; 5 AA.
XX
AC AAU01260;
XX
DT 18-JUL-2001 (first entry)
XX
DE B. subtilis pantothenate synthetase altered C-terminus #1.
XX
KW Pantothenate synthetase; panC; pantothenate biosynthesis; NDI; NDII;
KW vitamin B5; nutritional supplement; panto-compound; pantoate; RBS;
KW ribosome binding site.
XX
OS Bacillus subtilis.
XX
PN WO200121772-A2.
XX
PD 29-MAR-2001.
XX
PF 21-SEP-2000; 2000WO-US025993.
XX
PR 21-SEP-1999; 99US-00400494.
PR 07-JUN-2000; 2000US-0210072P.
PR 28-JUL-2000; 2000US-0221836P.
PR 24-AUG-2000; 2000US-0227860P.
XX
PA (OMNI-) OMNIGENE BIOPRODUCTS.
XX
PI Yocum RR, Patterson TA, Hermann T, Pero JG;
XX
DR WPI; 2001-218644/22.
DR N-PSDB; AAS01012, AAS02311.
XX
PT New recombinant microorganism which overexpress a Bacillus subtilis
PT pantothenate biosynthetic enzyme, useful for the high yield production of
PT panto-compounds such as pantothenate and pantoate.
XX
PS Disclosure; Page 49; 292pp; English.
XX
CC The sequence is the C-terminus of B. subtilis pantothenate synthetase
CC (encoded by the panC gene, an enzyme of the pantothenate biosynthetic
CC pathway), as encoded by the artificial Ribosome binding sites NDI and
CC NDII used for panD, the next gene in the operon. Pantothenate, also known
CC as vitamin B5, is used as a nutritional supplement in mammals and humans.
CC The invention concerns methods of producing recombinant microorganisms
CC overexpressing at least one B. subtilis pantothenate biosynthetic enzyme.
CC The microorganisms and methods of producing them are useful for producing
CC a panto-compound such as pantothenate or pantoate, which is a nutritional
CC requirement for livestock and humans. The methods are also useful for the
CC identification of pantothenate kinase modulators. Panto-compounds are
CC produced at a significantly higher yield than prior art methods and can
CC be produced independent of the need to feed precursors which decreases
CC expense
XX
SQ Sequence 5 AA;

Query Match 100.0%; Score 15; DB 4; Length 5;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
|||
Db 2 RER 4

RESULT 22
ABB94415
ID ABB94415 standard; peptide; 5 AA.
XX
AC ABB94415;
XX
DT 12-JUN-2002 (first entry)
XX
DE Ubiquitin binding antibody clone pLB24-6 BC loop SEQ ID NO: 59.
XX
KW Fibronectin type 3; mutant; stabilising mutation; Fn3; antibody;
KW binding protein.
XX
OS Unidentified.
XX
PN WO200204523-A2.
XX
PD 17-JAN-2002.
XX
PF 11-JUL-2001; 2001WO-US021855.
XX
PR 11-JUL-2000; 2000US-0217474P.
XX
PA (RESE) RESEARCH CORP TECHNOLOGIES INC.
PA (KOID/) KOIDE S.
XX
PI Koide S;
XX
DR WPI; 2002-171708/22.
XX
PT New fibronectin type III molecule comprising a stabilizing mutation,
PT useful for introducing more mutations for better functions, and in a
PT wider range of applications.
XX
PS Example 12; Page 145; 164pp; English.
XX
CC The present invention relates to fibronectin type III (Fn3) molecules
CC comprising a stabilising mutation as compared to a wild-type Fn3. Fn3 can
CC be used as a scaffold to engineer artificial binding proteins.
CC Modifications of the Fn3 scaffold that increase its stability are useful
CC in that they allow the introduction of more mutations for better
CC functions, and that these make it possible to use Fn3-based engineered
CC proteins in a wider range of applications. The present sequence is a
CC peptide described in the exemplification of the invention
XX
SQ Sequence 5 AA;

Query Match 100.0%; Score 15; DB 5; Length 5;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
|||
Db 3 RER 5

RESULT 23
ABG71799

ID ABG71799 standard; peptide; 5 AA.
XX
AC ABG71799;
XX
DT 23-JAN-2003 (first entry)
XX
DE bHLH family neuroD protein basic region motif.
XX
KW Mouse; neuroD3; neuroD; basic-helix-loop-helix; bHLH; differentiation;
KW neurone; endocrine; gastrointestine; development; transgenic; embryo;
KW birth defect; spontaneous abortion; stem cell; cancer;
KW neural growth factor; tumour; diagnostic; motor; sensory;
KW traumatic neural injury; hearing; vision; brain; spinal cord;
KW malabsorption syndrome; gastrointestinal dysmotility syndrome;
KW Hirsh Prung's disease; therapeutic; DNA binding site.
XX
OS Mus musculus.
XX
PN US6444463-B1.
XX
PD 03-SEP-2002.
XX
PF 07-FEB-2000; 2000US-00499227.
XX
PR 06-MAY-1994; 94US-00239238.
PR 08-MAY-1995; 95WO-US005741.
PR 02-NOV-1995; 95US-00552142.
PR 30-OCT-1996; 96WO-US017532.
PR 07-AUG-1997; 97US-00910973.
PR 05-AUG-1998; 98WO-US016417.
XX
PA (HUTC-) HUTCHINSON CANCER RES CENT FRED.
XX
PI Tapscott SJ;
XX
DR WPI; 2003-056678/05.
XX
PT New neurogenic differentiation gene, useful in gene therapy to correct
PT traumatic neural injury that has resulted in loss of motor or sensory
PT neural function and for constructing recombinant cell lines.
XX
PS Example 3; Col 55; 43pp; English.
XX
CC The invention discloses an isolated nucleic acid molecule which encodes a
CC functionally active human neuroD3 polypeptide. NeuroD proteins represent
CC a new family within the basic-helix-loop-helix (bHLH) family which are
CC implicated in the regulation of differentiation. NeuroD proteins are
CC particularly involved in neuronal, endocrine and gastrointestinal
CC development. The nucleic acid is useful for constructing recombinant cell
CC lines, transgenic embryos and animals and for quantifying the level of
CC expression of neuroD in a cell. Birth defects and spontaneous abortions
CC may result from expression of an abnormal neuroD protein. The
CC polynucleotide sequences permit the establishment of primary cultures of
CC proliferating embryonic neuronal stem cells under conditions mimicking
CC those that are active in development and cancer. The resultant cell lines
CC find use as sources of novel neural growth factors, in assays for
CC identifying novel neuronal growth factors which can be used for screening
CC anti-cancer drugs capable of driving terminal differentiation in neural
CC tumours, for producing antibodies useful in diagnostic assays and for
CC screening for compounds capable of modulating the activity of neuroD.
CC Transformed host cells, nucleic acids and polypeptides are also useful
CC for treating sites of traumatic neural injury where motor or sensory
CC neural activity has been lost, e.g. hearing or vision loss and brain or
CC spinal cord damage. The host cells find use in the treatment of
CC malabsorption syndromes or gastrointestinal dysmotility syndromes (Hirsh
CC Prung's Disease). The cell lines also find use in screening for candidate
CC therapeutic agents capable of either substituting for neuroD or
CC correcting the cellular defect caused by a defective neuroD. The sequence
CC presented is the bHLH family neuroD protein basic region motif which is
CC similar to the basic region motif of neuroD proteins and is responsible
CC for DNA binding site recognition
XX
SQ Sequence 5 AA;

Query Match 100.0%; Score 15; DB 6; Length 5;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
|||
Db 3 RER 5

RESULT 24
ABB99606
ID ABB99606 standard; peptide; 5 AA.
XX
AC ABB99606;
XX
DT 28-MAR-2003 (first entry)
XX
DE Peptide derived from human amyloid precursor protein (APP).
XX
KW Amyloid precursor protein; APP; protein derivative;
KW neurodegenerative disease; Alzheimer's disease; cognitive enhancer.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO200283729-A2.
XX
PD 24-OCT-2002.
XX
PF 17-APR-2002; 2002WO-GB001769.
XX
PR 18-APR-2001; 2001GB-00009558.
PR 17-AUG-2001; 2001GB-00020084.
PR 30-NOV-2001; 2001US-00998491.
PR 28-MAR-2002; 2002GB-00007387.
XX
PA (UYOP-) UNIV OPEN.
XX
PI Mileusnic R, Rose SPR;
XX
DR WPI; 2003-111814/10.
XX
PT Derivatives of polypeptides, useful for treating neurodegenerative
PT disease e.g. Alzheimer's disease, comprises one functional amino acid
PT residue or derivative protected by a protective group.
XX
PS Claim 74; Page 65; 85pp; English.
XX
CC The present sequence is derived from amyloid precursor protein (APP).
CC Derivatives of the invention may be based on APP sequences. The
CC specification describes a derivative of a polypeptide in which at least
CC one functional group of at least one amino acid residue or derivative is
CC protected by a protective group. This derivative is of the formula given
CC in ABB99625. The derivative is useful in medicine and in the preparation
CC of a medicament for use in the treatment of a neurodegenerative disease
CC e.g. Alzheimer's disease. It is also useful as a cognitive enhancer
XX
SQ Sequence 5 AA;

Query Match 100.0%; Score 15; DB 6; Length 5;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
|||
Db 1 RER 3

RESULT 25
ABB99607
ID ABB99607 standard; peptide; 5 AA.
XX

AC ABB99607;
XX
DT 28-MAR-2003 (first entry)
XX
DE Peptide derived from human amyloid precursor protein (APP).
XX
KW Amyloid precursor protein; APP; protein derivative;
KW neurodegenerative disease; Alzheimer's disease; cognitive enhancer.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO200283729-A2.
XX
PD 24-OCT-2002.
XX
PF 17-APR-2002; 2002WO-GB001769.
XX
PR 18-APR-2001; 2001GB-00009558.
PR 17-AUG-2001; 2001GB-00020084.
PR 30-NOV-2001; 2001US-00998491.
PR 28-MAR-2002; 2002GB-00007387.
XX
PA (UYOP-) UNIV OPEN.
XX
PI Mileusnic R, Rose SPR;
XX
DR WPI; 2003-111814/10.
XX
PT Derivatives of polypeptides, useful for treating neurodegenerative
PT disease e.g. Alzheimer's disease, comprises one functional amino acid
PT residue or derivative protected by a protective group.
XX
PS Claim 74; Page 65; 85pp; English.
XX
CC The present sequence is derived from amyloid precursor protein (APP).
CC Derivatives of the invention may be based on APP sequences. The
CC specification describes a derivative of a polypeptide in which at least
CC one functional group of at least one amino acid residue or derivative is
CC protected by a protective group. This derivative is of the formula given
CC in ABB99625. The derivative is useful in medicine and in the preparation
CC of a medicament for use in the treatment of a neurodegenerative disease
CC e.g. Alzheimer's disease. It is also useful as a cognitive enhancer
XX
SQ Sequence 5 AA;

Query Match 100.0%; Score 15; DB 6; Length 5;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
||| |
Db 3 RER 5

RESULT 26
ABU62548
ID ABU62548 standard; peptide; 5 AA.
XX
AC ABU62548;
XX
DT 18-SEP-2003 (first entry)
XX
DE Human secreted amyloid precursor protein alpha (sAPP alpha) region.
XX
KW Human; secreted amyloid precursor protein; sAPP; sAPP alpha;
KW inflammation; ApoE3; apolipoprotein E; Alzheimer's disease; epilepsy;
KW traumatic brain injury; stroke; antiinflammatory; anticonvulsant;
KW cerebroprotective; vulnerary; tranquiliser; nootropic; neuroprotective.
XX
OS Homo sapiens.
XX
PN US2003069198-A1.
XX
PD 10-APR-2003.
XX
PF 10-JUN-2002; 2002US-00166482.
XX
PR 28-AUG-1998; 98US-00141951.
XX
PA (BARG/) BARGER S W.
XX
PI Barger SW;
XX
DR WPI; 2003-540888/51.
XX
PT Reducing inflammation caused by secreted amyloid precursor protein (sAPP)
PT in brain of a mammal, by administering a compound which inhibits amino
PT terminal region of sAPP involved in inflammatory response.
XX
PS Example 5; Page 5; 9pp; English.
XX
CC The invention relates to a method for reducing inflammation caused by
CC secreted amyloid precursor protein (sAPP) in the brain of a mammal or
CC potentiating the neuroprotective effect of sAPP alpha in a person,
CC involving administering a compound which inhibits the amino terminal
CC region of sAPP or sAPP alpha, respectively involved in the inflammatory
CC response. The method is useful for reducing inflammation caused by sAPP
CC in the brain of a mammal, preferably human, or for potentiating the
CC neuroprotective effect of sAPP alpha in a person. The method is
CC preferably useful for reducing inflammation due to reduced levels of
CC ApoE3 or inflammation caused by Alzheimer's disease or traumatic brain
CC injury. The method is useful for treating epilepsy, stroke, traumatic
CC brain injury and Alzheimer's disease. This sequence represents a peptide
CC region of human sAPP alpha
XX
SQ Sequence 5 AA;

Query Match 100.0%; Score 15; DB 6; Length 5;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
||| |
Db 1 RER 3

RESULT 27
AAR62104
ID AAR62104 standard; peptide; 6 AA.
XX
AC AAR62104;
XX
DT 25-MAR-2003 (revised)
DT 27-APR-1995 (first entry)
XX
DE Hydrophilic motif from nuclear protein antigens.
XX
KW Small ribonucleoprotein complex; U1 snRNP; 70K protein; epitope;
KW autoantibody; immunoinfective cluster virus; nuclear protein antigen;
KW systemic rheumatic disorder; human immunodeficiency virus; HIV-1;
KW centromere CENP-B; thyroglobulin-h; thyroid peroxidase; scleroderma;
KW systemic lupus erythematosus.
XX
OS Homo sapiens.
XX
PN WO9420141-A1.
XX
PD 15-SEP-1994.
XX
PF 10-MAR-1994; 94WO-US002631.
XX
PR 11-MAR-1993; 93US-00029850.
XX
PA (UYSC-) UNIV SOUTHERN CALIFORNIA.
XX

PI Douvas A, Takehana Y, Ehresmann G;
XX
DR WPI; 1994-302689/37.
XX
PT Methods for treating immunoinfective cluster virus infections - utilise
PT antibodies or fragments characteristic of auto antibodies produced by
PT patients with rheumatic disorders.
XX
PS Disclosure; Page 8; 106pp; English.
XX
CC This sequence is an example of an alternating acidic/basic amino acid,
CC hydrophilic motif possibly found in nuclear protein antigens. As well as
CC occurring in normal human proteins, the motif is found in similar form in
CC immunoinfective cluster viruses. The motif serves as an epitope for anti-
CC viral antibodies and also for autoantibodies which occur in high titre in
CC patients suffering from systemic rheumatic disorders. Sera from such
CC patients could be used for treatment of immunoinfective cluster virus
CC (e.g. HIV, EBV, rubella virus) infections. (Updated on 25-MAR-2003 to
CC correct PN field.)
XX
SQ Sequence 6 AA;

Query Match 100.0%; Score 15; DB 2; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
||||
Db 2 RER 4

RESULT 28
AAR62189
ID AAR62189 standard; protein; 6 AA.
XX
AC AAR62189;
XX
DT 25-MAR-2003 (revised)
DT 03-MAY-1995 (first entry)
XX
DE U1 snRNP 70K protein amino acids 471-476, homologous to EBV motif.
XX
KW Small ribonucleoprotein complex; U1 snRNP; 70K protein; epitope;
KW autoantibody; immunoinfective cluster virus; nuclear protein antigen;
KW systemic rheumatic disorder; Epstein-Barr virus; EBV na protein;
KW systemic lupus erythematosus; scleroderma.
XX
OS Homo sapiens.
XX
PN WO9420141-A1.
XX
PD 15-SEP-1994.
XX
PF 10-MAR-1994; 94WO-US002631.
XX
PR 11-MAR-1993; 93US-00029850.
XX
PA (UYSC-) UNIV SOUTHERN CALIFORNIA.
XX
PI Douvas A, Takehana Y, Ehresmann G;
XX
DR WPI; 1994-302689/37.
XX
PT Methods for treating immunoinfective cluster virus infections - utilise
PT antibodies or fragments characteristic of auto antibodies produced by
PT patients with rheumatic disorders.
XX
PS Disclosure; Page 69; 106pp; English.
XX
CC A comparison of the U1 snRNP 70K protein sequence with proteins from
CC immunoinfective cluster viruses revealed widespread homologies. The
CC importance of these homologous motifs is that they are epitopes for
CC autoantibodies occurring in high titres in systemic rheumatic disorders.
CC Sera from such patients could be used for treatment of immunoinfective
CC cluster virus infections. (Updated on 25-MAR-2003 to correct PN field.)
XX
SQ Sequence 6 AA;

Query Match 100.0%; Score 15; DB 2; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
||||
Db 2 RER 4

RESULT 29
AAW21203
ID AAW21203 standard; peptide; 6 AA.
XX
AC AAW21203;
XX
DT 29-JUL-1997 (first entry)
XX
DE Farnesyl synthetase derived signal oligopeptide #3.
XX
KW Hydrophilic; signal oligopeptide; hydrophilicity maxima; vaccine; SIV;
KW competitive inhibitor; feedback regulator; synthesis; gastrin precursor;
KW charge; polarity; farnesyl synthetase; plasminogen activator inhibitor 1;
KW hydroxymethylglutaryl coenzyme A reductase; glucagon precursor; rhesus;
KW gonadoliberin precursor; plasminogen activator inhibitor 2; prorenin;
KW Alzheimer amyloid A4; corticotropin releasing factor binding protein;
KW apolipoprotein E; herpes virus 1 glycoprotein B; HSV1; human; OMVVS;
KW herpes virus 2 glycoprotein B; HSV2; collagenase; apolipoprotein A;
KW Treponema pallidum membrane protein; TMPA; islet amyloid polypeptide;
KW fibroblast MMP1; schistosoma elastase precursor; schistosomin;
KW hepatitis delta antigen; rev protein; HIV; VILV; angiotensinogen.
XX
OS Homo sapiens.
XX
PN WO9519568-A1.
XX
PD 20-JUL-1995.
XX
PF 12-JAN-1995; 95WO-US000575.
XX
PR 14-JAN-1994; 94US-00182248.
XX
PA (RATH/) RATH M.
XX
PI Rath M;
XX
DR WPI; 1995-263953/34.
XX
PT Identifying signal oligopeptide(s) in protein sequence(s) - shown as
PT regions of max. hydrophilicity, used in modulating communication between
PT protein(s).
XX
PS Claim 5; Page 23; 88pp; English.
XX
CC The sequences given in AAW21201-560 represent hydrophilic signal oligo-
CC peptides. These signal oligopeptides are localised on the surface of the
CC protein and are represented by the hydrophilicity maxima of the protein.
CC These peptides are enriched in charged amino acids arranged with neutral
CC spacer amino acids. The specific signal character of these oligopeptides
CC is determined by a characteristic combination of conformation and charge
CC within the signal sequence. These oligopeptides may be used as vaccines
CC in the treatment of human disease, as competitive inhibitors to prevent
CC or reduce the metabolic action or interaction of a selected protein by
CC blocking its specific signal sequences, or as therapeutic agents to
CC function as feedback regulators to reduce synthesis rate of a selected
CC protein. These peptides may be modified by omitting one or more amino
CC acids at the N- and/or C-terminal, by substituting one or more amino
CC acids without consideration of charge and polarity, by substituting one
CC or more amino acids with amino acid residues with similar charge and/or

```
CC   polarity, by omitting one or more amino acids or a combination of these
XX
SQ   Sequence 6 AA;

  Query Match             100.0%;  Score 15;  DB 2;  Length 6;
  Best Local Similarity   100.0%;  Pred. No. 1.4e+06;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          4 RER 6


RESULT 30
AAW21037
ID   AAW21037 standard; peptide; 6 AA.
XX
AC   AAW21037;
XX
DT   19-JUN-1997  (first entry)
XX
DE   Lipolytic enzyme opt. N- or C-terminal extension peptide #5.
XX
KW   Lipolytic enzyme; detergent; lard; cotton swatch; laundry; dishwashing.
XX
OS   Synthetic.
XX
PN   WO9707202-A1.
XX
PD   27-FEB-1997.
XX
PF   12-AUG-1996;   96WO-DK000341.
XX
PR   11-AUG-1995;   95DK-00000905.
PR   29-SEP-1995;   95DK-00001096.
PR   14-FEB-1996;   96US-0011627P.
PR   01-APR-1996;   96DK-00000374.
PR   07-MAY-1996;   96US-0016754P.
XX
PA   (NOVO ) NOVO-NORDISK AS.
XX
PI   Okkels JS,  Svendsen A,  Borch K,  Thellersen M,  Patkar SA;
PI   Petersen DA,  Royer JC,  Kretzschmar T;
XX
DR   WPI; 1997-165287/15.
XX
PT   Lipolytic enzyme with high capacity to remove lard in one wash cycle -
PT   also related DNA, vectors and transformed cells, useful in laundry and
PT   dishwashing formulations.
XX
PS   Claim 17; Page 244; 274pp; English.
XX
CC   The sequences given in AAW21033-92 are peptides which may be added to the
CC   N- or C-terminal of the lipolytic enzyme of the invention. The lipolytic
CC   enzyme, when present in a specified detergent composition, is able to
CC   remove at least 15% more lard from soiled cotton swatches (9 by 9 cm)
CC   than an equiv. enzyme-free compsn. in a one-cycle wash assay. The assay
CC   uses 7 lard-stained cotton swatches in 1000 ml water (3.2 mM Ca2+/Mg2=,
CC   ratio 5:1; 5 g/l detergent; pH 10 plus 12500 LU of enzyme/l) for 20 min
CC   at 30 deg.C, in a thermostated Terg-O-to-Meter, then 15 min rinsing,
CC   drying overnight and soxhlet extn. and quantification of fatty material.
CC   The enzyme may be used in laundry and dishwashing formulations. It is are
CC   able to remove a substantial amount of lard in a single cycle under
CC   realistic washing conditions
XX
SQ   Sequence 6 AA;

  Query Match             100.0%;  Score 15;  DB 2;  Length 6;
  Best Local Similarity   100.0%;  Pred. No. 1.4e+06;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          4 RER 6


RESULT 31
AAW23160
ID   AAW23160 standard; peptide; 6 AA.
XX
AC   AAW23160;
XX
DT   28-OCT-1997  (first entry)
XX
DE   Terminal peptide extension for lipolytic enzyme.
XX
KW   Lipolytic enzyme; modification; peptide extension; detergent;
KW   washing powder; dishwashing composition; pitch removal; paper; pulp;
KW   manufacture; degreasing; hide; sheepskin; wool; catalysis;
KW   organic synthesis; transesterification; esterification; ester hydrolysis;
KW   baking; defatting.
XX
OS   Synthetic.
XX
PN   WO9704078-A1.
XX
PD   06-FEB-1997.
XX
PF   12-JUL-1996;   96WO-DK000321.
XX
PR   14-JUL-1995;   95DK-00000832.
PR   13-SEP-1995;   95DK-00001013.
PR   29-SEP-1995;   95DK-00001096.
PR   21-NOV-1995;   95DK-00001306.
PR   14-FEB-1996;   96US-0011634P.
PR   01-APR-1996;   96DK-00000372.
PR   07-MAY-1996;   96US-0020461P.
XX
PA   (NOVO ) NOVO-NORDISK AS.
XX
PI   Fuglsang CC,  Okkels JS,  Pertersen DA,  Patkar SA,  Thellersen M;
PI   Vind J,  Jorgensen ST;
XX
DR   WPI; 1997-132621/12.
XX
PT   Modified lipolytic enzymes with peptide extensions at one or both ends -
PT   esp. for use in detergent and dishwashing compsn., have improved
PT   substrate affinity, stability and wash performance.
XX
PS   Claim 12; Page 178; 197pp; English.
XX
CC   A lipolytic enzyme, modified by a peptide extension, e.g. the present
CC   sequence, of its carboxy and/or amino terminus, can be used in
CC   detergents, particularly in washing powders or dishwashing compositions.
CC   It may also be used to remove pitch in paper and pulp manufacture, to
CC   degrease hides, sheepskins and wool, to catalyse organic synthesis, e.g.
CC   (trans)esterification or ester hydrolysis, in baking and in other
CC   degreasing/defatting processes. The peptide extension(s) increases
CC   substrate affinity, confers stability and especially improves wash
CC   performance, i.e. better lipid soil removal, reducing the amount of
CC   enzyme used
XX
SQ   Sequence 6 AA;

  Query Match             100.0%;  Score 15;  DB 2;  Length 6;
  Best Local Similarity   100.0%;  Pred. No. 1.4e+06;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          4 RER 6


RESULT 32
AAY55251
ID   AAY55251 standard; peptide; 6 AA.
```

XX
AC AAY55251;
XX
DT 07-JAN-2000 (first entry)
XX
DE ATCC HB 11885 monoclonal antibody 9079 releasing peptide SEQ ID NO:145.
XX
KW Antibody releasing peptide; CD34; hybridoma; binding; antigen;
KW cell surface antigen; identification; haematopoietic stem cell; tumour;
KW cancer; immune system; therapy; displacement.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN US5968753-A.
XX
PD 19-OCT-1999.
XX
PF 07-JUN-1995; 95US-00482228.
XX
PR 14-JUN-1994; 94US-00259427.
XX
PA (NEXE-) NEXELL THERAPEUTICS INC.
XX
PI Guillermo R, Helgerson SL, Deans RJ, Tseng-Law J, Kobori JA;
PI Al-Abdaly FA;
XX
DR WPI; 1999-590399/50.
XX
PT Short peptides useful for displacing antibodies from cell surface
PT antigens.
XX
PS Example 9; Col 32; 81pp; English.
XX
CC The present invention describes peptides of 4-17 amino acids which
CC displace either the anti-CD34 monoclonal antibody designated 561, the
CC anti-CD34 mouse monoclonal antibody produced by the hybridoma ATCC HB-
CC 11646 (designated 9069), the anti-CD34 antibody produced by hybridoma
CC ATCC HB-11885 (9079), or the anti-human breast cancer antibody produced
CC by hybridoma ATCC HB-11884 (9187), from a cell surface antigen on a
CC target cell. The peptides are useful for displacing antibodies bound to
CC cell surfaces to release cells that have been positively selected by
CC antibody-mediated binding to beads or other solid support. AAY55107 to
CC AAY55319 represent peptides used in the exemplification of the present
CC invention
XX
SQ Sequence 6 AA;

Query Match 100.0%; Score 15; DB 2; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
||| |
Db 1 RER 3

RESULT 33
AAY86997
ID AAY86997 standard; peptide; 6 AA.
XX
AC AAY86997;
XX
DT 09-MAY-2000 (first entry)
XX
DE Human haematopoietic CD34+ cell binding peptide SEQ ID #145.
XX
KW Human; haematopoietic CD34+ cell; binding peptide; monoclonal antibody;
KW non-enzymatic cell selection method; haematopoietic stem cell;
KW haematopoietic progenitor cell; antibody 561; breast cancer cell;
KW antibody 9187; cell surface determinant; diagnostic cell based assay.
XX
OS Homo sapiens.
XX
PN US6017719-A.
XX
PD 25-JAN-2000.
XX
PF 07-JUN-1995; 95US-00482528.
XX
PR 14-JUN-1994; 94US-00259427.
XX
PA (NEXE-) NEXELL THERAPEUTICS INC.
XX
PI Guillermo R, Helgerson SL, Deans RJ, Tseng-Law J, Kobori JA;
PI Al-Abdaly FA;
XX
DR WPI; 2000-136676/12.
XX
PT Non-enzymatic method for the positive selection of target cells from a
PT heterogeneous cell suspension, useful for selecting human breast cancer
PT cells from a patient's blood or bone marrow.
XX
PS Example 9; Col 36; 82pp; English.
XX
CC This sequence represents a human haematopoietic CD34+ cell binding
CC peptide, and was used to test the method of the invention. The method is
CC a non-enzymatic method for the positive selection of one or more target
CC cells from a heterogeneous cell suspension, by using specific peptides
CC which effect the displacement and release of a specific target cell from
CC a specific monoclonal antibody. The method is useful for positive
CC selection and specific release of target human haematopoietic
CC stem/progenitor cells bound by the monoclonal anti-CD34 antibodies and
CC the antibody 561. The method is also useful for positive selection and
CC specific release of target human breast cancer cells, bound by the
CC monoclonal anti-breast cancer antibody 9187, from a patient's blood or
CC bone marrow. Identification of peptide epitopes for antibodies which
CC recognise cell surface determinants also allows construction of
CC diagnostic cell based assays. The peptide mediated release is enzyme free
CC and thus leaves the cell surface proteins intact. Moreover, peptide
CC mediated release leaves the target cell free of bound antibody or
CC antibody fragments. The method also produces a high yield of functional
CC target cells and is relatively inexpensive to carry out
XX
SQ Sequence 6 AA;

Query Match 100.0%; Score 15; DB 3; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
||| |
Db 1 RER 3

RESULT 34
AAB36760
ID AAB36760 standard; peptide; 6 AA.
XX
AC AAB36760;
XX
DT 16-FEB-2001 (first entry)
XX
DE HRG-beta1 library B variant 12.
XX
KW Heregulin; ErbB receptor; transplantation; cancer;
KW nervous system disease; musculature; epithelium.
XX
OS Unidentified.
XX
PN US6136558-A.
XX
PD 24-OCT-2000.
XX
PF 09-FEB-1998; 98US-00020880.
XX

PR 10-FEB-1997; 97US-0037581P.
XX
PA (GETH) GENENTECH INC.
XX
PI Jones JT, Fairbrother WJ, Ballinger MD, Wells JA, Sliwkowski MX;
XX
DR WPI; 2000-678767/66.
XX
PT New variants of heregulin, useful e.g. for treating cancer, comprises
PT specific amino acid alterations that increase affinity for ErbB
PT receptors.
XX
PS Example 3; Col 73; 58pp; English.
XX
CC The present invention relates to variants of heregulin that can bind to
CC an ErbB receptor and include a portion of the 175-230 region of native
CC human heregulin-betal. The variants may be used to promote ex vivo
CC survival, proliferation and differentiation of cells, particularly when
CC intended for transplantation. They may also be used to treat a wide range
CC of cancers and diseases of the nervous system, musculature and epithelium
XX
SQ Sequence 6 AA;

Query Match 100.0%; Score 15; DB 3; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
|||
Db 2 RER 4

RESULT 35
AAY94683
ID AAY94683 standard; protein; 6 AA.
XX
AC AAY94683;
XX
DT 01-DEC-2000 (first entry)
XX
DE Human zsig83 hydrophilic region peptide.
XX
KW Alpha-helical protein; zsig83; cell growth; differentiation; cancer;
KW proliferation; chromosome 22q13.1-q13.2; cytostatic; vulneray;
KW degenerative condition; metastasis; wound healing.
XX
OS Homo sapiens.
XX
PN WO200050594-A2.
XX
PD 31-AUG-2000.
XX
PF 25-FEB-2000; 2000WO-US004816.
XX
PR 26-FEB-1999; 99US-00259131.
XX
PA (ZYMO) ZYMOGENETICS INC.
XX
PI Presnell SR;
XX
DR WPI; 2000-572091/53.
XX
PT Alpha-helical protein zsig83, its antibodies and the polynucleotide
PT encoding the protein useful for treating disorders associated with
PT abnormal cell growth e.g. cancer and agonists useful for treating wounds.
XX
PS Disclosure; Page 77; 83pp; English.
XX
CC This invention relates to a novel human alpha-helical protein designated
CC zsig83. Zsig83 plays a role in the process of cell growth,
CC differentiation, or proliferation. The zsig83 gene is located on
CC chromosome 22 at position 22q13.1-q13.2. Included in the invention are
CC polynucleotide sequences encoding the zsig83 protein, expression vectors
CC containing the zsig83 DNA sequence, a cultured cell containing the
CC expression vector, and antibodies specific to the zsig83 protein. The
CC zsig83 protein contains 5 alpha helix regions (represented by sequences
CC AAY94677-Y94681) and also contains epitope bearing regions (represented
CC by sequences AAY94688-Y94698) to which the antibodies are directed. The
CC protein exhibits cytostatic and vulneray activity. The zsig83 protein and
CC nucleotide sequences and antibodies are used for treating disorders
CC associated with abnormal cell growth e.g. cancer, degenerative conditions
CC and metastasis. The zsig83 protein and its agonists or antagonists are
CC useful for promoting wound healing. The zsig83 DNA sequence can be used
CC to identify defective zsig83 genes and may therefore be used as a
CC diagnostic indicator of cancer. The present sequence represents a
CC hydrophilic region of the human zsig83 protein
XX
SQ Sequence 6 AA;

Query Match 100.0%; Score 15; DB 3; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
|||
Db 4 RER 6

RESULT 36
AAB97624
ID AAB97624 standard; peptide; 6 AA.
XX
AC AAB97624;
XX
DT 21-SEP-2001 (first entry)
XX
DE Neuropeptide Y (NPY) modulator, Ac-Ile-Trp-Arg-Glu-Arg-Tyr-NH2.
XX
KW Neuropeptide Y; NPY modulator; agonist; antagonist; appetite; obesity;
KW eating disorder; blood pressure; cardiovascular response; hypertension;
KW libido; sexual dysfunction; circadian rhythm; sleep disorder;
KW gastrointestinal disorder; gallbladder disorder;
KW central nervous system disorder; insulin-related disorder;
KW type II diabetes; pain; anorectic; hypertensive; hypotensive; cardiant;
KW vasotropic; analgesic.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 1
FT /note= "N-terminal acetyl"
FT Modified-site 6
FT /note= "C-terminal amide"
XX
PN US6235718-B1.
XX
PD 22-MAY-2001.
XX
PF 02-DEC-1999; 99US-00449914.
XX
PR 09-AUG-1996; 96US-0023588P.
PR 07-AUG-1997; 97US-00907408.
XX
PA (UYCI-) UNIV CINCINNATI.
XX
PI Balasubramanium A, Chance WT;
XX
DR WPI; 2001-440207/47.
XX
PT New tripeptide derivatives are neuropeptide Y modulators useful for
PT controlling appetite, blood pressure, cardiovascular response, libido and
PT circadian rhythm.
XX
PS Disclosure; Col 19; 13pp; English.
XX
CC The invention relates to neuropeptide Y (NPY) agonist and antagonist

CC peptides. The peptides comprise a unit of 3 amino acids (N-terminally
CC designated A1, A2 and A3, where A1 is joined to two chemical groups,
CC designated R1 and R2, and A3 is linked to a chemical moiety designated W.
CC These are defined as follows: A1 is Trp (or a derivative thereof, e.g.,
CC Tcc), Gln (or a derivative thereof), a tethered amino acid with an indole
CC ring (e.g., NMe-Trp), Phe, Hyp, Pyr, Bth, Nal, Tcc, Asn, Nva, Abu, Tyr,
CC Tic-OH, Phe, Tip or Dip; A2 is Arg, N-Me-Arg, C-alpha-Me-Arg, Orn, Cit,
CC hArg(R)2 (where R is selected from the group consisting of H, alkyl,
CC aralkyl, or alkylaryl), or Lys-epsilon-NHR; A3 is N-Me-Tyr, C-alpha-Me-
CC Tyr, Tic-OH, Tic, Dip, Trp, Phe, des-carboxylic-Tyr or Tyr-R' (where R'
CC is H or a lipophilic group) R1 and R2 are independently H, 1-12C alkyl, 6
CC -18C aryl, 1-18C acyl, 7-18C aralkyl, 7-18C alkaryl or
CC dihydrotrigonellinate; and W is OH, NR3R4 or OR5 (where R3, R4 and R5 are
CC independently H, 1-12C alkyl, 6-18C aryl, 1-12C acyl, 7-18C aralkyl or 7-
CC 18C aralkyl. The peptide bonds may be replaced by pseudo-peptide bonds.
CC In certain embodiments of the invention, A1 or A3 are absent, in which
CC case the N-terminal residue is joined to groups R1 and R2, and the C-
CC terminal residue is joined to group W. The invention also encompasses
CC peptide dimers, in which peptides of the invention are dimerised with
CC cystine, dicarboxylic acids, or diaminodicarboxylic acids. The invention
CC further encompasses peptides of the formula Ac-[A1-A2-A3]n-NH2, where n
CC is 1,2, or 3, or a cyclic peptide of formula cyclo-[A1-A2-A3], cyclo-[A1-
CC A2-A3]2, or cyclo-[A1-A2-A3-A3-A2-A1]. The neuropeptide Y agonists and
CC antagonists of the invention are useful for regulating appetite, blood
CC pressure, cardiovascular response, libido and circadian rhythm, and may
CC therefore be used in the treatment of obesity, eating disorders,
CC hypertension, alterations in sexual function, and sleep disorders. They
CC may also be used in the treatment of gastrointestinal disorders
CC (including gallbladder disorders), central nervous system disorders,
CC insulin-related disorders (e.g., type II diabetes), and pain. The present
CC sequence represents a neuropeptide Y modulator peptide of the invention
XX
SQ Sequence 6 AA;

Query Match 100.0%; Score 15; DB 4; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
|||
Db 3 RER 5

RESULT 37
AAB82171
ID AAB82171 standard; peptide; 6 AA.
XX
AC AAB82171;
XX
DT 20-JUL-2001 (first entry)
XX
DE Peptide #22 used in a method for inducing TH1 immune response.
XX
KW Antibacterial; antiallergic; cytostatic; TH1 immune response inducer;
KW vaccine; infectious disease; allergy; cancer.
XX
OS Synthetic.
XX
PN WO200126682-A2.
XX
PD 19-APR-2001.
XX
PF 13-OCT-2000; 2000WO-US028443.
XX
PR 14-OCT-1999; 99GB-00024351.
XX
PA (DOWC) DOW CHEM CO.
XX
PI Brennan F;
XX
DR WPI; 2001-281838/29.
XX
PT Increasing the level of TH1-type responses to molecules, used to treat
PT infectious diseases, allergies and cancer, comprises conjugating the
PT molecule to a plant virus.
XX
PS Example 11; Page 70; 89pp; English.
XX
CC The present invention relates to a method for increasing the level of a
CC TH1-type immune response to a molecule. The method comprising conjugating
CC the molecule to a heterologous peptide expressed by a plant virus, and
CC administering the conjugate to an animal. The present sequence is one
CC such heterologous peptide, which may be used in the method of the present
CC invention. The method is useful for treating infectious diseases,
CC allergies and cancer, by administering appropriate antigens conjugated to
CC a plant virus
XX
SQ Sequence 6 AA;

Query Match 100.0%; Score 15; DB 4; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
|||
Db 1 RER 3

RESULT 38
ABB99622
ID ABB99622 standard; peptide; 6 AA.
XX
AC ABB99622;
XX
DT 28-MAR-2003 (first entry)
XX
DE Peptide derived from human amyloid precursor protein (APP).
XX
KW Amyloid precursor protein; APP; protein derivative;
KW neurodegenerative disease; Alzheimer's disease; cognitive enhancer.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO200283729-A2.
XX
PD 24-OCT-2002.
XX
PF 17-APR-2002; 2002WO-GB001769.
XX
PR 18-APR-2001; 2001GB-00009558.
PR 17-AUG-2001; 2001GB-00020084.
PR 30-NOV-2001; 2001US-00998491.
PR 28-MAR-2002; 2002GB-00007387.
XX
PA (UYOP-) UNIV OPEN.
XX
PI Mileusnic R, Rose SPR;
XX
DR WPI; 2003-111814/10.
XX
PT Derivatives of polypeptides, useful for treating neurodegenerative
PT disease e.g. Alzheimer's disease, comprises one functional amino acid
PT residue or derivative protected by a protective group.
XX
PS Disclosure; Page 9; 85pp; English.
XX
CC The present sequence is derived from amyloid precursor protein (APP).
CC Derivatives of the invention are based on APP sequences. The
CC specification describes a derivative of a polypeptide in which at least
CC one functional group of at least one amino acid residue or derivative is
CC protected by a protective group. This derivative is of the formula given
CC in ABB99625. The derivative is useful in medicine and in the preparation
CC of a medicament for use in the treatment of a neurodegenerative disease
CC e.g. Alzheimer's disease. It is also useful as a cognitive enhancer
XX

SQ Sequence 6 AA;

Query Match 100.0%; Score 15; DB 6; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
||||
Db 2 RER 4

RESULT 39
ADE65222
ID ADE65222 standard; peptide; 6 AA.
XX
AC ADE65222;
XX
DT 29-JAN-2004 (first entry)
XX
DE Corticotropin-releasing factor-2 polypeptide, SEQ ID No 525.
XX
KW corticotropin-releasing factor-2; CRF2; myopathic; osteopathic;
KW hypotensive; cardiant; vasotropic; antimigraine; cerebroprotective;
KW nootropic; neuroprotective; anorectic; antidiabetic; analgesic;
KW antiallergic; tranquilizer; anxiolytic; antidepressant; antiarthritic;
KW gene therapy.
XX
OS Unidentified.
XX
PN WO2003062277-A1.
XX
PD 31-JUL-2003.
XX
PF 16-JAN-2003; 2003WO-US001454.
XX
PR 16-JAN-2002; 2002US-0349117P.
PR 29-APR-2002; 2002US-0376337P.
PR 14-JUN-2002; 2002US-0388895P.
PR 19-SEP-2002; 2002US-0411988P.
XX
PA (PROC) PROCTER & GAMBLE CO.
XX
PI Isfort RJ, Mazur WA;
XX
DR WPI; 2003-787975/74.
XX
PT New non-native peptide derived from corticotropin-releasing factor-2,
PT useful for treatment and prevention of e.g. muscular atrophy, also
PT related nucleic acid and antibodies.
XX
PS Example 2; SEQ ID NO 525; 304pp; English.
XX
CC The invention relates to a novel non-native peptide derived from
CC corticotropin-releasing factor-2 (CRF2). The CRF2 peptides have the
CC following activities: myopathic, osteopathic, hypotensive, cardiant,
CC vasotropic, antimigraine, cerebroprotective, nootropic, neuroprotective,
CC anorectic, antidiabetic, analgesic, antiallergic, tranquilizer,
CC anxiolytic, antidepressant, and antiarthritic. The CRF2 peptides, and
CC related compounds derived from other proteins, are used to prevent or
CC treat disorders modulated by the CRF2 receptor, e.g. skeletal muscle
CC atrophy or wasting, and bone disorders, however caused; heart/circulatory
CC diseases (e.g. hypertension, congestive heart failure, heart attack,
CC reperfusion injury, migraine, stroke, memory loss, Alzheimer's disease,
CC dementia); joint disorders (osteoarthritis or rheumatoid arthritis);
CC metabolic disease (obesity or diabetes); pain; allergy; stress; anxiety;
CC low levels of adrenocorticotrophic hormone; anorexia nervosa; depression;
CC also to reduce body temperature and to control appetite or cognitive
CC function. Nucleic acids, optionally labelled, that encode the CRF2
CC peptides are used as primers and probes for amplification, also for gene
CC synthesis and for recombinant production of CRF2 peptides, including use
CC in gene therapy. Antibodies specific for the CRF2 peptides are used to
CC evaluate expression of the CRF2 peptides after gene therapy. This
CC sequence represents a novel native CRF polypeptide of the invention.

XX
SQ Sequence 6 AA;

Query Match 100.0%; Score 15; DB 7; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
||||
Db 3 RER 5

RESULT 40
ADE65221
ID ADE65221 standard; peptide; 6 AA.
XX
AC ADE65221;
XX
DT 29-JAN-2004 (first entry)
XX
DE Corticotropin-releasing factor-2 polypeptide, SEQ ID No 524.
XX
KW corticotropin-releasing factor-2; CRF2; myopathic; osteopathic;
KW hypotensive; cardiant; vasotropic; antimigraine; cerebroprotective;
KW nootropic; neuroprotective; anorectic; antidiabetic; analgesic;
KW antiallergic; tranquilizer; anxiolytic; antidepressant; antiarthritic;
KW gene therapy.
XX
OS Unidentified.
XX
PN WO2003062277-A1.
XX
PD 31-JUL-2003.
XX
PF 16-JAN-2003; 2003WO-US001454.
XX
PR 16-JAN-2002; 2002US-0349117P.
PR 29-APR-2002; 2002US-0376337P.
PR 14-JUN-2002; 2002US-0388895P.
PR 19-SEP-2002; 2002US-0411988P.
XX
PA (PROC) PROCTER & GAMBLE CO.
XX
PI Isfort RJ, Mazur WA;
XX
DR WPI; 2003-787975/74.
XX
PT New non-native peptide derived from corticotropin-releasing factor-2,
PT useful for treatment and prevention of e.g. muscular atrophy, also
PT related nucleic acid and antibodies.
XX
PS Example 2; SEQ ID NO 524; 304pp; English.
XX
CC The invention relates to a novel non-native peptide derived from
CC corticotropin-releasing factor-2 (CRF2). The CRF2 peptides have the
CC following activities: myopathic, osteopathic, hypotensive, cardiant,
CC vasotropic, antimigraine, cerebroprotective, nootropic, neuroprotective,
CC anorectic, antidiabetic, analgesic, antiallergic, tranquilizer,
CC anxiolytic, antidepressant, and antiarthritic. The CRF2 peptides, and
CC related compounds derived from other proteins, are used to prevent or
CC treat disorders modulated by the CRF2 receptor, e.g. skeletal muscle
CC atrophy or wasting, and bone disorders, however caused; heart/circulatory
CC diseases (e.g. hypertension, congestive heart failure, heart attack,
CC reperfusion injury, migraine, stroke, memory loss, Alzheimer's disease,
CC dementia); joint disorders (osteoarthritis or rheumatoid arthritis);
CC metabolic disease (obesity or diabetes); pain; allergy; stress; anxiety;
CC low levels of adrenocorticotrophic hormone; anorexia nervosa; depression;
CC also to reduce body temperature and to control appetite or cognitive
CC function. Nucleic acids, optionally labelled, that encode the CRF2
CC peptides are used as primers and probes for amplification, also for gene
CC synthesis and for recombinant production of CRF2 peptides, including use
CC in gene therapy. Antibodies specific for the CRF2 peptides are used to
CC evaluate expression of the CRF2 peptides after gene therapy. This

CC sequence represents a novel native CRF polypeptide of the invention.
XX
SQ Sequence 6 AA;

Query Match 100.0%; Score 15; DB 7; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
||||
Db 3 RER 5

RESULT 41
ADE65159
ID ADE65159 standard; peptide; 6 AA.
XX
AC ADE65159;
XX
DT 29-JAN-2004 (first entry)
XX
DE Corticotropin-releasing factor-2 polypeptide, SEQ ID No 462.
XX
KW corticotropin-releasing factor-2; CRF2; myopathic; osteopathic;
KW hypotensive; cardiant; vasotropic; antimigraine; cerebroprotective;
KW nootropic; neuroprotective; anorectic; antidiabetic; analgesic;
KW antiallergic; tranquilizer; anxiolytic; antidepressant; antiarthritic;
KW gene therapy.
XX
OS Unidentified.
XX
PN WO2003062277-A1.
XX
PD 31-JUL-2003.
XX
PF 16-JAN-2003; 2003WO-US001454.
XX
PR 16-JAN-2002; 2002US-0349117P.
PR 29-APR-2002; 2002US-0376337P.
PR 14-JUN-2002; 2002US-0388895P.
PR 19-SEP-2002; 2002US-0411988P.
XX
PA (PROC) PROCTER & GAMBLE CO.
XX
PI Isfort RJ, Mazur WA;
XX
DR WPI; 2003-787975/74.
XX
PT New non-native peptide derived from corticotropin-releasing factor-2,
PT useful for treatment and prevention of e.g. muscular atrophy, also
PT related nucleic acid and antibodies.
XX
PS Example 2; SEQ ID NO 462; 304pp; English.
XX
CC The invention relates to a novel non-native peptide derived from
CC corticotropin-releasing factor-2 (CRF2). The CRF2 peptides have the
CC following activities: myopathic, osteopathic, hypotensive, cardiant,
CC vasotropic, antimigraine, cerebroprotective, nootropic, neuroprotective,
CC anorectic, antidiabetic, analgesic, antiallergic, tranquilizer,
CC anxiolytic, antidepressant, and antiarthritic. The CRF2 peptides, and
CC related compounds derived from other proteins, are used to prevent or
CC treat disorders modulated by the CRF2 receptor, e.g. skeletal muscle
CC atrophy or wasting, and bone disorders, however caused; heart/circulatory
CC diseases (e.g. hypertension, congestive heart failure, heart attack,
CC reperfusion injury, migraine, stroke, memory loss, Alzheimer's disease,
CC dementia); joint disorders (osteoarthritis or rheumatoid arthritis);
CC metabolic disease (obesity or diabetes); pain; allergy; stress; anxiety;
CC low levels of adrenocorticotrophic hormone; anorexia nervosa; depression;
CC also to reduce body temperature and to control appetite or cognitive
CC function. Nucleic acids, optionally labelled, that encode the CRF2
CC peptides are used as primers and probes for amplification, also for gene
CC synthesis and for recombinant production of CRF2 peptides, including use
CC in gene therapy. Antibodies specific for the CRF2 peptides are used to
CC evaluate expression of the CRF2 peptides after gene therapy. This
CC sequence represents a novel native CRF polypeptide of the invention.
XX
SQ Sequence 6 AA;

Query Match 100.0%; Score 15; DB 7; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
||||
Db 3 RER 5

RESULT 42
ADE51507
ID ADE51507 standard; peptide; 6 AA.
XX
AC ADE51507;
XX
DT 29-JAN-2004 (first entry)
XX
DE CRF2 non-native polypeptide, SEQ ID No 524.
XX
KW non-native; corticotropin-releasing factor-2; CRF2; myopathic;
KW osteopathic; hypotensive; cardiant; vasotropic; antimigraine;
KW cerebroprotective; nootropic; neuroprotective; anorectic; antidiabetic;
KW analgesic; antiallergic; tranquilizer; anxiolytic; antidepressant;
KW antiarthritic.
XX
OS Unidentified.
XX
PN WO2003062268-A2.
XX
PD 31-JUL-2003.
XX
PF 16-JAN-2003; 2003WO-US001451.
XX
PR 16-JAN-2002; 2002US-0349117P.
PR 29-APR-2002; 2002US-0376337P.
PR 14-JUN-2002; 2002US-0388895P.
PR 19-SEP-2002; 2002US-0411988P.
XX
PA (PROC) PROCTER & GAMBLE CO.
XX
PI Isfort RJ, Mazur WA;
XX
DR WPI; 2003-787974/74.
XX
PT New non-native peptide derived from corticotropin-releasing factor-2,
PT useful for treatment and prevention of e.g. muscular atrophy, also
PT related nucleic acid and antibodies.
XX
PS Example 2; SEQ ID NO 524; 300pp; English.
XX
CC The invention relates to a novel non-native peptide derived from
CC corticotropin-releasing factor-2 (CRF2). The non-native CRF2 peptides
CC have the following activities: myopathic, osteopathic, hypotensive,
CC cardiant, vasotropic, antimigraine, cerebroprotective, nootropic,
CC neuroprotective, anorectic, antidiabetic, analgesic, antiallergic,
CC tranquilizer, anxiolytic, antidepressant, and antiarthritic. The non-
CC native CRF2 peptides, and related compounds derived from other proteins,
CC are used to prevent or treat disorders modulated by the CRF2 receptor,
CC e.g. skeletal muscle atrophy or wasting, and bone disorders, however
CC caused; heart/circulatory diseases (e.g. hypertension, congestive heart
CC failure, heart attack, reperfusion injury, migraine, stroke, memory loss,
CC Alzheimer's diseases, dementia); joint disorders (osteoarthritis or
CC rheumatoid arthritis); metabolic disease (obesity or diabetes); pain;
CC allergy; stress; anxiety; low levels of adrenocorticotrophic hormone;
CC anorexia nervosa; depression; also to reduce body temperature and to
CC control appetite or cognitive function. Nucleic acids, optionally
CC labelled, that encode the non-native CRF2 peptides are used as primers
CC and probes for amplification, also for gene synthesis and for recombinant

```
CC   production of the non-native CRF2 peptides, including use in gene
CC   therapy. Antibodies specific for the non-native CRF2 peptides are used to
CC   evaluate expression of the non-native CRF2 peptides after gene therapy.
CC   This sequence represents a CRF2 non-native polypeptide of the invention.
XX
SQ   Sequence 6 AA;

  Query Match             100.0%;  Score 15;  DB 7;  Length 6;
  Best Local Similarity   100.0%;  Pred. No. 1.4e+06;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          3 RER 5


RESULT 43
ADE51445
ID   ADE51445 standard; peptide; 6 AA.
XX
AC   ADE51445;
XX
DT   29-JAN-2004  (first entry)
XX
DE   CRF2 non-native polypeptide, SEQ ID No 462.
XX
KW   non-native; corticotropin-releasing factor-2; CRF2; myopathic;
KW   osteopathic; hypotensive; cardiant; vasotropic; antimigraine;
KW   cerebroprotective; nootropic; neuroprotective; anorectic; antidiabetic;
KW   analgesic; antiallergic; tranquilizer; anxiolytic; antidepressant;
KW   antiarthritic.
XX
OS   Unidentified.
XX
PN   WO2003062268-A2.
XX
PD   31-JUL-2003.
XX
PF   16-JAN-2003; 2003WO-US001451.
XX
PR   16-JAN-2002; 2002US-0349117P.
PR   29-APR-2002; 2002US-0376337P.
PR   14-JUN-2002; 2002US-0388895P.
PR   19-SEP-2002; 2002US-0411988P.
XX
PA   (PROC ) PROCTER & GAMBLE CO.
XX
PI   Isfort RJ,  Mazur WA;
XX
DR   WPI; 2003-787974/74.
XX
PT   New non-native peptide derived from corticotropin-releasing factor-2,
PT   useful for treatment and prevention of e.g. muscular atrophy, also
PT   related nucleic acid and antibodies.
XX
PS   Example 2; SEQ ID NO 462; 300pp; English.
XX
CC   The invention relates to a novel non-native peptide derived from
CC   corticotropin-releasing factor-2 (CRF2). The non-native CRF2 peptides
CC   have the following activities: myopathic, osteopathic, hypotensive,
CC   cardiant, vasotropic, antimigraine, cerebroprotective, nootropic,
CC   neuroprotective, anorectic, antidiabetic, analgesic, antiallergic,
CC   tranquilizer, anxiolytic, antidepressant, and antiarthritic. The non-
CC   native CRF2 peptides, and related compounds derived from other proteins,
CC   are used to prevent or treat disorders modulated by the CRF2 receptor,
CC   e.g. skeletal muscle atrophy or wasting, and bone disorders, however
CC   caused; heart/circulatory diseases (e.g. hypertension, congestive heart
CC   failure, heart attack, reperfusion injury, migraine, stroke, memory loss,
CC   Alzheimer's diseases, dementia); joint disorders (osteoarthritis or
CC   rheumatoid arthritis); metabolic disease (obesity or diabetes); pain;
CC   allergy; stress; anxiety; low levels of adrenocorticotrophic hormone;
CC   anorexia nervosa; depression; also to reduce body temperature and to
CC   control appetite or cognitive function. Nucleic acids, optionally
CC   labelled, that encode the non-native CRF2 peptides are used as primers
CC   and probes for amplification, also for gene synthesis and for recombinant
CC   production of the non-native CRF2 peptides, including use in gene
CC   therapy. Antibodies specific for the non-native CRF2 peptides are used to
CC   evaluate expression of the non-native CRF2 peptides after gene therapy.
CC   This sequence represents a CRF2 non-native polypeptide of the invention.
XX
SQ   Sequence 6 AA;

  Query Match             100.0%;  Score 15;  DB 7;  Length 6;
  Best Local Similarity   100.0%;  Pred. No. 1.4e+06;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          3 RER 5


RESULT 44
ADE51508
ID   ADE51508 standard; peptide; 6 AA.
XX
AC   ADE51508;
XX
DT   29-JAN-2004  (first entry)
XX
DE   CRF2 non-native polypeptide, SEQ ID No 525.
XX
KW   non-native; corticotropin-releasing factor-2; CRF2; myopathic;
KW   osteopathic; hypotensive; cardiant; vasotropic; antimigraine;
KW   cerebroprotective; nootropic; neuroprotective; anorectic; antidiabetic;
KW   analgesic; antiallergic; tranquilizer; anxiolytic; antidepressant;
KW   antiarthritic.
XX
OS   Unidentified.
XX
PN   WO2003062268-A2.
XX
PD   31-JUL-2003.
XX
PF   16-JAN-2003; 2003WO-US001451.
XX
PR   16-JAN-2002; 2002US-0349117P.
PR   29-APR-2002; 2002US-0376337P.
PR   14-JUN-2002; 2002US-0388895P.
PR   19-SEP-2002; 2002US-0411988P.
XX
PA   (PROC ) PROCTER & GAMBLE CO.
XX
PI   Isfort RJ,  Mazur WA;
XX
DR   WPI; 2003-787974/74.
XX
PT   New non-native peptide derived from corticotropin-releasing factor-2,
PT   useful for treatment and prevention of e.g. muscular atrophy, also
PT   related nucleic acid and antibodies.
XX
PS   Example 2; SEQ ID NO 525; 300pp; English.
XX
CC   The invention relates to a novel non-native peptide derived from
CC   corticotropin-releasing factor-2 (CRF2). The non-native CRF2 peptides
CC   have the following activities: myopathic, osteopathic, hypotensive,
CC   cardiant, vasotropic, antimigraine, cerebroprotective, nootropic,
CC   neuroprotective, anorectic, antidiabetic, analgesic, antiallergic,
CC   tranquilizer, anxiolytic, antidepressant, and antiarthritic. The non-
CC   native CRF2 peptides, and related compounds derived from other proteins,
CC   are used to prevent or treat disorders modulated by the CRF2 receptor,
CC   e.g. skeletal muscle atrophy or wasting, and bone disorders, however
CC   caused; heart/circulatory diseases (e.g. hypertension, congestive heart
CC   failure, heart attack, reperfusion injury, migraine, stroke, memory loss,
CC   Alzheimer's diseases, dementia); joint disorders (osteoarthritis or
CC   rheumatoid arthritis); metabolic disease (obesity or diabetes); pain;
CC   allergy; stress; anxiety; low levels of adrenocorticotrophic hormone;
```

CC anorexia nervosa; depression; also to reduce body temperature and to
CC control appetite or cognitive function. Nucleic acids, optionally
CC labelled, that encode the non-native CRF2 peptides are used as primers
CC and probes for amplification, also for gene synthesis and for recombinant
CC production of the non-native CRF2 peptides, including use in gene
CC therapy. Antibodies specific for the non-native CRF2 peptides are used to
CC evaluate expression of the non-native CRF2 peptides after gene therapy.
CC This sequence represents a CRF2 non-native polypeptide of the invention.
XX
SQ Sequence 6 AA;

Query Match 100.0%; Score 15; DB 7; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
|||
Db 3 RER 5

RESULT 45
AAR24590
ID AAR24590 standard; peptide; 7 AA.
XX
AC AAR24590;
XX
DT 25-MAR-2003 (revised)
DT 03-DEC-1992 (first entry)
XX
DE Immunomodulatory peptide.
XX
KW Immunodeficiencies; immunosuppression; T-cell subset; immunotherapy;
KW inflammation; wounds; lymphocyte; vaccine.
XX
OS Synthetic.
XX
PN WO9209628-A1.
XX
PD 11-JUN-1992.
XX
PF 22-NOV-1991; 91WO-US008795.
XX
PR 23-NOV-1990; 90US-00617494.
XX
PA (IMMU-) IMMUNODYNAMICS INC.
XX
PI Atkin A;
XX
DR WPI; 1992-217021/26.
XX
PT New synthetic immunomodulatory peptide(s) - for treating
PT immunodeficiencies, immunosuppression and T-cell subset deviations and
PT immuno-therapy of infections, inflammation, wounds etc.
XX
PS Claim 9; Page 34; 52pp; English.
XX
CC The immunomodulatory peptide is a specific example of a peptide cpd. (or
CC an acid or base salt) constructed by combination and/or overlapping of
CC the amino acid sequences A1B1XB2A2, A3B3XA4B4, B5A5XA6B6, B7A7XB8A8,
CC A9B9, A10A11, B10A12, and B11B12 (X= Ala, Gly, Ile, Leu, Phe or Val, A1-
CC A12 each= Arg, Asn, Gln, Lys, Phe or Val; B1-B12 each= Asp, Glu, Tyr, Phe
CC or Val. The synthetic peptide may be used for immunomodulation of various
CC immunodeficiencies and immunosuppressed conditions, T-cell subset and
CC lymphocyte deviations, enhancement of a vaccines efficacy, as well as for
CC immunotherapy, including infections, local or systemic complications of
CC non- infectious diseases, postoperative inflammations, wounds and burns.
CC See also AAR24583-R24701. (Updated on 25-MAR-2003 to correct PN field.)
XX
SQ Sequence 7 AA;

Query Match 100.0%; Score 15; DB 2; Length 7;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
|||
Db 1 RER 3

RESULT 46
AAW21423
ID AAW21423 standard; peptide; 7 AA.
XX
AC AAW21423;
XX
DT 29-JUL-1997 (first entry)
XX
DE Alzheimer amyloid A4 derived signal oligopeptide #9.
XX
KW Hydrophilic; signal oligopeptide; hydrophilicity maxima; vaccine; SIV;
KW competitive inhibitor; feedback regulator; synthesis; gastrin precursor;
KW charge; polarity; farnesyl synthetase; plasminogen activator inhibitor 1;
KW hydroxymethylglutaryl coenzyme A reductase; glucagon precursor; rhesus;
KW gonadoliberin precursor; plasminogen activator inhibitor 2; prorenin;
KW Alzheimer amyloid A4; corticotropin releasing factor binding protein;
KW apolipoprotein E; herpes virus 1 glycoprotein B; HSV1; human; OMVVS;
KW herpes virus 2 glycoprotein B; HSV2; collagenase; apolipoprotein A;
KW Treponema pallidum membrane protein; TMPA; islet amyloid polypeptide;
KW fibroblast MMP1; schistosoma elastase precursor; schistosomin;
KW hepatitis delta antigen; rev protein; HIV; VILV; angiotensinogen.
XX
OS Homo sapiens.
XX
PN WO9519568-A1.
XX
PD 20-JUL-1995.
XX
PF 12-JAN-1995; 95WO-US000575.
XX
PR 14-JAN-1994; 94US-00182248.
XX
PA (RATH/) RATH M.
XX
PI Rath M;
XX
DR WPI; 1995-263953/34.
XX
PT Identifying signal oligopeptide(s) in protein sequence(s) - shown as
PT regions of max. hydrophilicity, used in modulating communication between
PT protein(s).
XX
PS Claim 5; Page 60; 88pp; English.
XX
CC The sequences given in AAW21201-560 represent hydrophilic signal oligo-
CC peptides. These signal oligopeptides are localised on the surface of the
CC protein and are represented by the hydrophilicity maxima of the protein.
CC These peptides are enriched in charged amino acids arranged with neutral
CC spacer amino acids. The specific signal character of these oligopeptides
CC is determined by a characteristic combination of conformation and charge
CC within the signal sequence. These oligopeptides may be used as vaccines
CC in the treatment of human disease, as competitive inhibitors to prevent
CC or reduce the metabolic action or interaction of a selected protein by
CC blocking its specific signal sequences, or as therapeutic agents to
CC function as feedback regulators to reduce synthesis rate of a selected
CC protein. These peptides may be modified by omitting one or more amino
CC acids at the N- and/or C-terminal, by substituting one or more amino
CC acids without consideration of charge and polarity, by substituting one
CC or more amino acids with amino acid residues with similar charge and/or
CC polarity, by omitting one or more amino acids or a combination of these
XX
SQ Sequence 7 AA;

Query Match 100.0%; Score 15; DB 2; Length 7;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 RER 3
              |||
Db          5 RER 7


RESULT 47
AAR77509
ID   AAR77509 standard; protein; 7 AA.
XX
AC   AAR77509;
XX
DT   27-AUG-2003  (revised)
DT   14-APR-1996  (first entry)
XX
DE   Basic region motif in MASH neurogenesis protein.
XX
KW   NeuroD; neurogenic differentiation; neuronal growth factor;
KW   basic helix-loop-helix secondary structure; neurogenesis;
KW   non-neuronal cell differentiation; antigen; drug screening;
KW   neurodegenerative disease; traumatic injury; gene therapy.
XX
OS   Mammalia.
XX
PN   WO9530693-A1.
XX
PD   16-NOV-1995.
XX
PF   08-MAY-1995;   95WO-US005741.
XX
PR   06-MAY-1994;   94US-00239228.
XX
PA   (HUTC-) HUTCHINSON CANCER RES CENT FRED.
PA   (WEIN/) WEINTRAUB N.
XX
PI   Weintraub HM,  Lee JE,  Hollenberg SM,  Tapscott SJ;
XX
DR   WPI; 1995-404081/51.
XX
PT   Nucleic acid molecule which hybridises with a neuroD HLH domain - is used
PT   in a method for inducing differentiation of a non-neuronal cell.
XX
PS   Example 3; Page 41; 50pp; English.
XX
CC   The basic region motif of the MASH (mammalian achaete-scute homologue)
CC   neurogenesis protein is similar to that of the Drosophila Atonal protein
CC   (see AAR77508) and to the basic region motif of murine NeuroD (AAR77504).
CC   NeuroD induces differentiation of a non-neuronal cell into a neuron. DNA
CC   encoding NeuroD may be used in the development of probes, in the
CC   construction of recombinant cell lines and transgenic animals, and in the
CC   construction of gene therapy vectors for the repair of neuronal defects
CC   resulting from traumatic injury and neurodegenerative diseases
CC   (Alzheimer's disease, Huntington's disease, Parkinson's disease).
CC   Transformed host cells are used (1) as a source of neuronal growth
CC   factors, (2) in transient and continuous cultures for anti-cancer drug
CC   screening, and (3) as sources of recombinant NeuroD for use as an antigen
CC   in diagnostic antibody production. (Updated on 27-AUG-2003 to correct OS
CC   field.)
XX
SQ   Sequence 7 AA;

  Query Match            100.0%;  Score 15;  DB 2;  Length 7;
  Best Local Similarity  100.0%;  Pred. No. 1.4e+06;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          3 RER 5


RESULT 48
AAR77508
ID   AAR77508 standard; protein; 7 AA.
XX
AC   AAR77508;
XX
DT   14-APR-1996  (first entry)
XX
DE   Basic region motif in Atonal neurogenesis protein.
XX
KW   NeuroD; neurogenic differentiation; neuronal growth factor;
KW   basic helix-loop-helix secondary structure; neurogenesis;
KW   non-neuronal cell differentiation; antigen; drug screening;
KW   neurodegenerative disease; traumatic injury; gene therapy.
XX
OS   Drosophila sp.
XX
PN   WO9530693-A1.
XX
PD   16-NOV-1995.
XX
PF   08-MAY-1995;   95WO-US005741.
XX
PR   06-MAY-1994;   94US-00239228.
XX
PA   (HUTC-) HUTCHINSON CANCER RES CENT FRED.
PA   (WEIN/) WEINTRAUB N.
XX
PI   Weintraub HM,  Lee JE,  Hollenberg SM,  Tapscott SJ;
XX
DR   WPI; 1995-404081/51.
XX
PT   Nucleic acid molecule which hybridises with a neuroD HLH domain - is used
PT   in a method for inducing differentiation of a non-neuronal cell.
XX
PS   Example 3; Page 41; 50pp; English.
XX
CC   The basic region motif of the Drosophila Atonal protein is similar to
CC   that of the MASH (mammalian achaete-scute homologue) (see AAR77509) and
CC   to the basic region motif of the murine NeuroD (see AAR77504). NeuroD
CC   induces differentiation of a non-neuronal cell into a neuron. DNA
CC   encoding NeuroD may be used in the development of probes, in the
CC   construction of recombinant cell lines and transgenic animals, and in the
CC   construction of gene therapy vectors for the repair of neuronal defects
CC   resulting from traumatic injury and neurodegenerative diseases
CC   (Alzheimer's disease, Huntington's disease, Parkinson's disease).
CC   Transformed host cells are used (1) as a source of neuronal growth
CC   factors, (2) in transient and continuous cultures for anti-cancer drug
CC   screening, and (3) as sources of recombinant NeuroD for use as an antigen
CC   in diagnostic antibody production
XX
SQ   Sequence 7 AA;

  Query Match            100.0%;  Score 15;  DB 2;  Length 7;
  Best Local Similarity  100.0%;  Pred. No. 1.4e+06;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          3 RER 5


RESULT 49
AAW22454
ID   AAW22454 standard; peptide; 7 AA.
XX
AC   AAW22454;
XX
DT   27-AUG-2003  (revised)
DT   02-OCT-1997  (first entry)
XX
DE   NARERR motif of mammalian achaete-scute homologue protein.
XX
KW   Neurogenic differentiation protein; neuroD1; neurogenesis;
KW   transcriptional activator; mammalian achaete-scute homologue; MASH.
XX
OS   Unidentified.
```

XX
PN WO9716548-A1.
XX
PD 09-MAY-1997.
XX
PF 30-OCT-1996; 96WO-US017532.
XX
PR 02-NOV-1995; 95US-00552142.
XX
PA (HUTC-) HUTCHINSON CANCER RES CENT FRED.
PA (WEIN/) WEINTRAUB N.
XX
PI Weintraub HM, Lee JE, Hollenberg SM, Tapscott SJ;
XX
DR WPI; 1997-272117/24.
XX
PT Nucleic acid encoding neurogenic differentiation polypeptide - useful
PT e.g. in regulating neuronal, endocrine and gastrointestinal development.
XX
PS Example 3; Page 23; 81pp; English.
XX
CC The NARERRR (AAW22453) and NERERNR (AAW22454) motifs are found in the
CC Drosophila Atonal and mammalian achaete-scute homologue proteins,
CC respectively, and are thought to be involved in neurogenesis. The related
CC NARER motif (AAW22449) of mouse neurogenic differentiation protein
CC neuroD1 (see also AAW22436) is shared by other basic- helix-loop-helix
CC (bHLH) proteins, and the Drosophila Daughterless and mammalian E
CC proteins. The basic region of bHLH proteins is important for DNA binding
CC site recognition, and there is homology between neuroD1 and other
CC neuroproteins in this functional region. (Updated on 27-AUG-2003 to
CC correct OS field.)
XX
SQ Sequence 7 AA;

Query Match 100.0%; Score 15; DB 2; Length 7;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
||||
Db 3 RER 5

RESULT 50
AAW22453
ID AAW22453 standard; peptide; 7 AA.
XX
AC AAW22453;
XX
DT 02-OCT-1997 (first entry)
XX
DE NARERR motif of Drosophila Atonal.
XX
KW Neurogenic differentiation protein; neuroD1; neurogenesis;
KW transcriptional activator; Atonal.
XX
OS Drosophila sp.
XX
PN WO9716548-A1.
XX
PD 09-MAY-1997.
XX
PF 30-OCT-1996; 96WO-US017532.
XX
PR 02-NOV-1995; 95US-00552142.
XX
PA (HUTC-) HUTCHINSON CANCER RES CENT FRED.
PA (WEIN/) WEINTRAUB N.
XX
PI Weintraub HM, Lee JE, Hollenberg SM, Tapscott SJ;
XX
DR WPI; 1997-272117/24.
XX
PT Nucleic acid encoding neurogenic differentiation polypeptide - useful
PT e.g. in regulating neuronal, endocrine and gastrointestinal development.
XX
PS Example 3; Page 23; 81pp; English.
XX
CC The NARERRR (AAW22453) and NERERNR (AAW22454) motifs are found in the
CC Drosophila Atonal and mammalian achaete-scute homologue proteins,
CC respectively, and are thought to be involved in neurogenesis. The related
CC NARER motif (AAW22449) of mouse neurogenic differentiation protein
CC neuroD1 (see also AAW22436) is shared by other basic- helix-loop-helix
CC (bHLH) proteins, and the Drosophila Daughterless and mammalian E
CC proteins. The basic region of bHLH proteins is important for DNA binding
CC site recognition, and there is homology between neuroD1 and other
CC neuroproteins in this functional region
XX
SQ Sequence 7 AA;

Query Match 100.0%; Score 15; DB 2; Length 7;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RER 3
||||
Db 3 RER 5

Search completed: March 5, 2004, 16:09:35
Job time : 72 secs

GenCore version 5.1.6

OM protein - protein search, using sw model

Run on: March 5, 2004, 16:08:22 ; Search time 23 Seconds
(without alignments)
6.734 Million cell updates/sec

Title: US-09-998-491-9
Perfect score: 15
Sequence: 1 RER 3

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 389414 seqs, 51625971 residues

Total number of hits satisfying chosen parameters: 234

Minimum DB seq length: 0
Maximum DB seq length: 20

Post-processing: Minimum Match 100%
Maximum Match 100%
Listing first 1000 summaries

Database : Issued_Patents_AA:*
1: /cgn2_6/ptodata/2/iaa/5A_COMB.pep:*
2: /cgn2_6/ptodata/2/iaa/5B_COMB.pep:*
3: /cgn2_6/ptodata/2/iaa/6A_COMB.pep:*
4: /cgn2_6/ptodata/2/iaa/6B_COMB.pep:*
5: /cgn2_6/ptodata/2/iaa/PCTUS_COMB.pep:*
6: /cgn2_6/ptodata/2/iaa/backfiles1.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	15	100.0	4	3	US-08-864-301-1	Sequence 1, Appli
2	15	100.0	4	3	US-09-142-078-29	Sequence 29, Appl
3	15	100.0	4	3	US-09-357-141-29	Sequence 29, Appl
4	15	100.0	4	4	US-09-533-889-29	Sequence 29, Appl
5	15	100.0	4	4	US-09-142-080-29	Sequence 29, Appl
6	15	100.0	4	5	PCT-US92-09070-14	Sequence 14, Appl
7	15	100.0	5	1	US-08-552-142A-7	Sequence 7, Appli
8	15	100.0	5	1	US-08-704-170-13	Sequence 13, Appl
9	15	100.0	5	1	US-08-704-170-14	Sequence 14, Appl
10	15	100.0	5	1	US-08-704-170-60	Sequence 60, Appl
11	15	100.0	5	1	US-08-910-973-7	Sequence 7, Appli
12	15	100.0	5	4	US-09-499-227-7	Sequence 7, Appli
13	15	100.0	5	4	US-09-638-202A-59	Sequence 59, Appl
14	15	100.0	5	4	US-09-096-749A-59	Sequence 59, Appl
15	15	100.0	5	5	PCT-US92-09070-1	Sequence 1, Appli
16	15	100.0	5	5	PCT-US94-02631-13	Sequence 13, Appl
17	15	100.0	5	5	PCT-US94-02631-14	Sequence 14, Appl
18	15	100.0	5	5	PCT-US94-02631-60	Sequence 60, Appl
19	15	100.0	5	5	PCT-US95-05741-7	Sequence 7, Appli
20	15	100.0	6	1	US-08-704-170-4	Sequence 4, Appli
21	15	100.0	6	1	US-08-704-170-97	Sequence 97, Appl
22	15	100.0	6	2	US-08-482-228-145	Sequence 145, App
23	15	100.0	6	3	US-08-482-528-145	Sequence 145, App
24	15	100.0	6	3	US-09-020-880-60	Sequence 60, Appl
25	15	100.0	6	4	US-09-101-544-60	Sequence 60, Appl
26	15	100.0	6	4	US-09-007-288E-21	Sequence 21, Appl
27	15	100.0	6	4	US-08-932-411A-29	Sequence 29, Appl
28	15	100.0	6	4	US-08-932-411A-30	Sequence 30, Appl
29	15	100.0	6	5	PCT-US92-09070-13	Sequence 13, Appl
30	15	100.0	6	5	PCT-US94-02631-4	Sequence 4, Appli
31	15	100.0	6	5	PCT-US94-02631-97	Sequence 97, Appl
32	15	100.0	7	1	US-08-552-142A-5	Sequence 5, Appli
33	15	100.0	7	1	US-08-552-142A-6	Sequence 6, Appli
34	15	100.0	7	1	US-08-910-973-5	Sequence 5, Appli
35	15	100.0	7	1	US-08-910-973-6	Sequence 6, Appli
36	15	100.0	7	3	US-08-907-403A-5	Sequence 5, Appli
37	15	100.0	7	3	US-08-907-403A-6	Sequence 6, Appli
38	15	100.0	7	4	US-09-499-227-5	Sequence 5, Appli
39	15	100.0	7	4	US-09-499-227-6	Sequence 6, Appli
40	15	100.0	7	4	US-09-007-288E-49	Sequence 49, Appl
41	15	100.0	7	5	PCT-US95-05741-5	Sequence 5, Appli
42	15	100.0	7	5	PCT-US95-05741-6	Sequence 6, Appli
43	15	100.0	8	1	US-08-259-550A-35	Sequence 35, Appl
44	15	100.0	8	2	US-08-461-216-7	Sequence 7, Appli
45	15	100.0	8	3	US-09-105-839D-25	Sequence 25, Appl
46	15	100.0	8	3	US-09-105-839D-40	Sequence 40, Appl
47	15	100.0	8	3	US-09-105-839D-57	Sequence 57, Appl
48	15	100.0	8	3	US-09-105-839D-69	Sequence 69, Appl
49	15	100.0	8	4	US-08-723-661B-7	Sequence 7, Appli
50	15	100.0	8	4	US-09-344-040C-39	Sequence 39, Appl
51	15	100.0	8	4	US-09-344-040C-64	Sequence 64, Appl
52	15	100.0	8	4	US-09-344-040C-91	Sequence 91, Appl
53	15	100.0	8	4	US-09-344-040C-111	Sequence 111, App
54	15	100.0	8	4	US-08-932-411A-28	Sequence 28, Appl
55	15	100.0	8	4	US-08-475-955-79	Sequence 79, Appl
56	15	100.0	8	4	US-08-475-955-80	Sequence 80, Appl
57	15	100.0	8	4	US-09-833-039A-39	Sequence 39, Appl
58	15	100.0	8	4	US-09-833-039A-64	Sequence 64, Appl
59	15	100.0	8	4	US-09-833-039A-91	Sequence 91, Appl
60	15	100.0	8	4	US-09-833-039A-111	Sequence 111, App
61	15	100.0	9	2	US-08-668-128B-10	Sequence 10, Appl
62	15	100.0	9	2	US-08-905-445-10	Sequence 10, Appl
63	15	100.0	9	2	US-08-718-661-6	Sequence 6, Appli
64	15	100.0	9	3	US-08-644-116A-9	Sequence 9, Appli
65	15	100.0	9	3	US-09-105-839D-27	Sequence 27, Appl
66	15	100.0	9	3	US-09-105-839D-44	Sequence 44, Appl
67	15	100.0	9	3	US-09-105-839D-51	Sequence 51, Appl
68	15	100.0	9	3	US-09-105-839D-60	Sequence 60, Appl
69	15	100.0	9	3	US-09-105-839D-70	Sequence 70, Appl
70	15	100.0	9	4	US-09-658-645A-11	Sequence 11, Appl
71	15	100.0	9	4	US-09-144-280-15	Sequence 15, Appl
72	15	100.0	9	4	US-09-344-040C-41	Sequence 41, Appl
73	15	100.0	9	4	US-09-344-040C-68	Sequence 68, Appl
74	15	100.0	9	4	US-09-344-040C-75	Sequence 75, Appl
75	15	100.0	9	4	US-09-344-040C-94	Sequence 94, Appl
76	15	100.0	9	4	US-09-344-040C-112	Sequence 112, App
77	15	100.0	9	4	US-09-833-039A-41	Sequence 41, Appl
78	15	100.0	9	4	US-09-833-039A-68	Sequence 68, Appl
79	15	100.0	9	4	US-09-833-039A-75	Sequence 75, Appl
80	15	100.0	9	4	US-09-833-039A-94	Sequence 94, Appl
81	15	100.0	9	4	US-09-833-039A-112	Sequence 112, App
82	15	100.0	10	1	US-08-253-171-2	Sequence 2, Appli
83	15	100.0	10	1	US-08-464-522-2	Sequence 2, Appli
84	15	100.0	10	1	US-08-443-352-2	Sequence 2, Appli
85	15	100.0	10	3	US-09-188-579-30	Sequence 30, Appl
86	15	100.0	10	3	US-09-315-444-30	Sequence 30, Appl
87	15	100.0	10	4	US-09-227-357-388	Sequence 388, App
88	15	100.0	10	4	US-09-721-362-30	Sequence 30, Appl
89	15	100.0	10	4	US-09-752-165-32	Sequence 32, Appl
90	15	100.0	10	4	US-09-752-165-44	Sequence 44, Appl
91	15	100.0	10	4	US-08-837-199A-28	Sequence 28, Appl
92	15	100.0	10	4	US-09-265-222-1	Sequence 1, Appli
93	15	100.0	10	4	US-09-526-193A-65	Sequence 65, Appl
94	15	100.0	10	5	PCT-US91-08328-24	Sequence 24, Appl
95	15	100.0	10	6	5168045-8	Patent No. 5168045
96	15	100.0	10	6	5177189-10	Patent No. 5177189
97	15	100.0	10	6	5182364-11	Patent No. 5182364
98	15	100.0	11	1	US-08-445-745-122	Sequence 122, App
99	15	100.0	11	3	US-08-444-818-105	Sequence 105, App
100	15	100.0	11	4	US-08-456-466-100	Sequence 100, App

101	15	100.0	11	4	US-09-410-551B-57	Sequence 57, Appl
102	15	100.0	11	4	US-08-445-638-122	Sequence 122, App
103	15	100.0	11	5	PCT-US91-08328-14	Sequence 14, Appl
104	15	100.0	11	5	PCT-US91-08328-16	Sequence 16, Appl
105	15	100.0	11	5	PCT-US91-08328-18	Sequence 18, Appl
106	15	100.0	11	5	PCT-US91-08328-20	Sequence 20, Appl
107	15	100.0	11	5	PCT-US92-09070-10	Sequence 10, Appl
108	15	100.0	12	1	US-08-704-170-2	Sequence 2, Appli
109	15	100.0	12	3	US-09-058-459-32	Sequence 32, Appl
110	15	100.0	12	3	US-09-058-459-33	Sequence 33, Appl
111	15	100.0	12	3	US-09-127-926-32	Sequence 32, Appl
112	15	100.0	12	3	US-09-127-926-33	Sequence 33, Appl
113	15	100.0	12	3	US-08-083-945C-10	Sequence 10, Appl
114	15	100.0	12	3	US-08-779-814-1	Sequence 1, Appli
115	15	100.0	12	4	US-08-961-578C-24	Sequence 24, Appl
116	15	100.0	12	4	US-09-347-926-11	Sequence 11, Appl
117	15	100.0	12	4	US-09-638-202A-118	Sequence 118, App
118	15	100.0	12	4	US-09-526-193A-63	Sequence 63, Appl
119	15	100.0	12	4	US-09-526-193A-64	Sequence 64, Appl
120	15	100.0	12	4	US-09-096-749A-118	Sequence 118, App
121	15	100.0	12	5	PCT-US94-02631-2	Sequence 2, Appli
122	15	100.0	12	5	PCT-US94-07107A-10	Sequence 10, Appl
123	15	100.0	13	3	US-08-388-353-634	Sequence 634, App
124	15	100.0	13	3	US-08-488-551B-634	Sequence 634, App
125	15	100.0	13	3	US-08-147-592A-41	Sequence 41, Appl
126	15	100.0	13	4	US-08-292-694A-41	Sequence 41, Appl
127	15	100.0	13	4	US-08-292-694A-46	Sequence 46, Appl
128	15	100.0	14	1	US-08-258-851-4	Sequence 4, Appli
129	15	100.0	14	2	US-08-484-905-55	Sequence 55, Appl
130	15	100.0	14	3	US-08-481-985B-55	Sequence 55, Appl
131	15	100.0	14	3	US-08-370-476-55	Sequence 55, Appl
132	15	100.0	14	3	US-09-248-588-99	Sequence 99, Appl
133	15	100.0	14	4	US-08-992-877-35	Sequence 35, Appl
134	15	100.0	14	4	US-09-638-202A-1	Sequence 1, Appli
135	15	100.0	14	4	US-09-096-749A-1	Sequence 1, Appli
136	15	100.0	14	5	PCT-US95-13975-10	Sequence 10, Appl
137	15	100.0	15	1	US-08-685-660A-1	Sequence 1, Appli
138	15	100.0	15	1	US-08-460-874A-26	Sequence 26, Appl
139	15	100.0	15	1	US-08-133-271-2	Sequence 2, Appli
140	15	100.0	15	1	US-08-133-271-3	Sequence 3, Appli
141	15	100.0	15	2	US-08-967-101-167	Sequence 167, App
142	15	100.0	15	2	US-08-974-196-1	Sequence 1, Appli
143	15	100.0	15	2	US-08-388-883B-26	Sequence 26, Appl
144	15	100.0	15	2	US-08-726-306A-60	Sequence 60, Appl
145	15	100.0	15	2	US-08-592-541-167	Sequence 167, App
146	15	100.0	15	3	US-09-124-698-167	Sequence 167, App
147	15	100.0	15	3	US-08-462-211A-26	Sequence 26, Appl
148	15	100.0	15	3	US-09-127-480-167	Sequence 167, App
149	15	100.0	15	3	US-08-496-841C-164	Sequence 164, App
150	15	100.0	15	3	US-09-013-896A-29	Sequence 29, Appl
151	15	100.0	15	4	US-09-124-523-167	Sequence 167, App
152	15	100.0	15	4	US-09-636-796A-167	Sequence 167, App
153	15	100.0	15	4	US-09-827-948-29	Sequence 29, Appl
154	15	100.0	15	4	US-09-409-938-8	Sequence 8, Appli
155	15	100.0	15	4	US-08-685-852-2	Sequence 2, Appli
156	15	100.0	16	1	US-08-478-312-27	Sequence 27, Appl
157	15	100.0	16	1	US-08-485-302-27	Sequence 27, Appl
158	15	100.0	16	1	US-08-476-169-23	Sequence 23, Appl
159	15	100.0	16	1	US-08-484-083-23	Sequence 23, Appl
160	15	100.0	16	2	US-08-373-190-26	Sequence 26, Appl
161	15	100.0	16	2	US-08-902-623-6	Sequence 6, Appli
162	15	100.0	16	2	US-08-438-190A-26	Sequence 26, Appl
163	15	100.0	16	3	US-08-350-215-26	Sequence 26, Appl
164	15	100.0	16	3	US-09-287-145A-26	Sequence 26, Appl
165	15	100.0	16	3	US-08-564-164A-11	Sequence 11, Appl
166	15	100.0	16	4	US-09-556-111-26	Sequence 26, Appl
167	15	100.0	16	4	US-09-336-093-1	Sequence 1, Appli
168	15	100.0	16	4	US-09-461-325-523	Sequence 523, App
169	15	100.0	16	4	US-09-557-465D-1	Sequence 1, Appli
170	15	100.0	16	4	US-10-012-542-523	Sequence 523, App
171	15	100.0	16	5	PCT-US91-09422-22	Sequence 22, Appl
172	15	100.0	17	1	US-08-168-809-21	Sequence 21, Appl
173	15	100.0	17	1	US-08-071-811A-1	Sequence 1, Appli
174	15	100.0	17	1	US-08-071-811A-3	Sequence 3, Appli
175	15	100.0	17	1	US-08-071-811A-4	Sequence 4, Appli
176	15	100.0	17	1	US-08-071-811A-5	Sequence 5, Appli
177	15	100.0	17	1	US-08-460-874A-22	Sequence 22, Appl
178	15	100.0	17	1	US-08-460-874A-27	Sequence 27, Appl
179	15	100.0	17	2	US-08-388-883B-22	Sequence 22, Appl
180	15	100.0	17	2	US-08-388-883B-27	Sequence 27, Appl
181	15	100.0	17	2	US-08-598-873-50	Sequence 50, Appl
182	15	100.0	17	3	US-07-808-452-22	Sequence 22, Appl
183	15	100.0	17	3	US-08-462-211A-22	Sequence 22, Appl
184	15	100.0	17	3	US-08-462-211A-27	Sequence 27, Appl
185	15	100.0	17	3	US-08-605-430-50	Sequence 50, Appl
186	15	100.0	17	4	US-09-227-357-349	Sequence 349, App
187	15	100.0	17	4	US-09-518-036-22	Sequence 22, Appl
188	15	100.0	17	4	US-09-079-030-189	Sequence 189, App
189	15	100.0	17	4	US-10-279-130-22	Sequence 22, Appl
190	15	100.0	17	4	US-09-564-677A-18	Sequence 18, Appl
191	15	100.0	17	5	PCT-US92-09070-8	Sequence 8, Appli
192	15	100.0	17	5	PCT-US92-09070-17	Sequence 17, Appl
193	15	100.0	17	5	PCT-US92-10770-22	Sequence 22, Appl
194	15	100.0	17	5	PCT-US94-06192-1	Sequence 1, Appli
195	15	100.0	18	1	US-08-240-514-47	Sequence 47, Appl
196	15	100.0	18	2	US-08-612-302A-47	Sequence 47, Appl
197	15	100.0	18	2	US-08-824-151-5	Sequence 5, Appli
198	15	100.0	18	2	US-08-902-623-8	Sequence 8, Appli
199	15	100.0	18	2	US-09-017-205-23	Sequence 23, Appl
200	15	100.0	18	3	US-08-943-173-4	Sequence 4, Appli
201	15	100.0	18	3	US-08-943-173-5	Sequence 5, Appli
202	15	100.0	18	4	US-09-325-601-8	Sequence 8, Appli
203	15	100.0	18	4	US-09-440-781-72	Sequence 72, Appl
204	15	100.0	18	4	US-09-079-030-182	Sequence 182, App
205	15	100.0	18	4	US-09-564-677A-17	Sequence 17, Appl
206	15	100.0	18	5	PCT-US94-01234-9	Sequence 9, Appli
207	15	100.0	18	5	PCT-US95-07543-4	Sequence 4, Appli
208	15	100.0	19	1	US-08-019-073-30	Sequence 30, Appl
209	15	100.0	19	2	US-08-442-461D-15	Sequence 15, Appl
210	15	100.0	19	4	US-09-082-358B-69	Sequence 69, Appl
211	15	100.0	19	5	PCT-US94-01768-30	Sequence 30, Appl
212	15	100.0	19	5	PCT-US95-03236-15	Sequence 15, Appl
213	15	100.0	19	5	PCT-US95-03236-58	Sequence 58, Appl
214	15	100.0	20	1	US-07-651-710A-17	Sequence 17, Appl
215	15	100.0	20	1	US-08-080-809-3	Sequence 3, Appli
216	15	100.0	20	1	US-07-956-848A-24	Sequence 24, Appl
217	15	100.0	20	1	US-07-864-475A-5	Sequence 5, Appli
218	15	100.0	20	1	US-08-460-874A-21	Sequence 21, Appl
219	15	100.0	20	1	US-08-460-874A-23	Sequence 23, Appl
220	15	100.0	20	1	US-08-460-874A-24	Sequence 24, Appl
221	15	100.0	20	1	US-08-471-956-24	Sequence 24, Appl
222	15	100.0	20	2	US-08-715-568A-13	Sequence 13, Appl
223	15	100.0	20	2	US-08-388-883B-21	Sequence 21, Appl
224	15	100.0	20	2	US-08-388-883B-23	Sequence 23, Appl
225	15	100.0	20	2	US-08-388-883B-24	Sequence 24, Appl
226	15	100.0	20	2	US-08-468-249A-5	Sequence 5, Appli
227	15	100.0	20	3	US-08-462-211A-21	Sequence 21, Appl
228	15	100.0	20	3	US-08-462-211A-23	Sequence 23, Appl
229	15	100.0	20	3	US-08-462-211A-24	Sequence 24, Appl
230	15	100.0	20	3	US-08-817-895-7	Sequence 7, Appli
231	15	100.0	20	3	US-08-817-895-8	Sequence 8, Appli
232	15	100.0	20	4	US-09-144-428-64	Sequence 64, Appl
233	15	100.0	20	4	US-09-428-082B-327	Sequence 327, App
234	15	100.0	20	4	US-09-881-710-14	Sequence 14, Appl

ALIGNMENTS

RESULT 1
US-08-864-301-1
; Sequence 1, Application US/08864301
; Patent No. 6126939
; GENERAL INFORMATION:
; APPLICANT: Eisenbach-Schwartz, M.
; APPLICANT: Beserman, P.

```
;  APPLICANT: Hirschberg, D
;  TITLE OF INVENTION: ANTI-INFLAMMATORY PEPTIDES AND USES THEREOF
;  FILE REFERENCE: 5763-021
;  CURRENT APPLICATION NUMBER: US/08/864,301
;  CURRENT FILING DATE: 1997-05-28
;  EARLIER APPLICATION NUMBER: PCT/IL97/00295
;  EARLIER FILING DATE: 1997-09-03
;  EARLIER APPLICATION NUMBER: 08/864,301
;  EARLIER FILING DATE: 1997-05-28
;  EARLIER APPLICATION NUMBER: 08/753,141
;  EARLIER FILING DATE: 1996-11-20
;  EARLIER APPLICATION NUMBER: 60/025,376
;  EARLIER FILING DATE: 1996-09-03
;  NUMBER OF SEQ ID NOS: 1
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1
;   LENGTH: 4
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: peptide
;   OTHER INFORMATION: derivative
US-08-864-301-1

  Query Match            100.0%;  Score 15;  DB 3;  Length 4;
  Best Local Similarity  100.0%;  Pred. No. 3e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          2 RER 4


RESULT 2
US-09-142-078-29
; Sequence 29, Application US/09142078
; Patent No. 6172041
;  GENERAL INFORMATION:
;    APPLICANT:  McCabe, R. Tyler
;    APPLICANT:  Zhou, Li-Ming
;    APPLICANT:  Layer, Richard T.
;    TITLE OF INVENTION:  Use of Conantokins
;    NUMBER OF SEQUENCES:  71
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Rothwell, Figg, Ernst & Kurz, p.c.
;      STREET:  555 Thirteenth Street, N.W., Suite 701-E
;      CITY:  Washington
;      STATE:  D.C.
;      COUNTRY:  USA
;      ZIP:  20004
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/142,078
;      FILING DATE:  10-FEB-1999
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  WO US97/12652
;      FILING DATE:  21-JUL-1997
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/762,377
;      FILING DATE:  06-DEC-1996
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/684,750
;      FILING DATE:  22-JUL-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Ihnen, Jeffrey L.
;      REGISTRATION NUMBER:  28,957
;      REFERENCE/DOCKET NUMBER:  2314-135.A
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  202-783-6040
;      TELEFAX:  202-783-6031
;  INFORMATION FOR SEQ ID NO:  29:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  4 amino acids
;      TYPE:  amino acid
;      STRANDEDNESS:
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
;    FRAGMENT TYPE:  internal
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  4
;      OTHER INFORMATION:  /note= "Xaa is
;      OTHER INFORMATION:  gamma-carboxyglutamic acid"
US-09-142-078-29

  Query Match            100.0%;  Score 15;  DB 3;  Length 4;
  Best Local Similarity  100.0%;  Pred. No. 3e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          1 RER 3


RESULT 3
US-09-357-141-29
; Sequence 29, Application US/09357141
; Patent No. 6277825
; GENERAL INFORMATION:
;  APPLICANT:  Olivera, Baldomero M.
;  APPLICANT:  McIntosh, J. Michael
;  APPLICANT:  McCabe, R. Tyler
;  APPLICANT:  Layer, Richard T.
;  APPLICANT:  Zhou, Li-Ming
;  TITLE OF INVENTION:  Use of Conantokins for Treating Pain
;  FILE REFERENCE:  2314-171
;  CURRENT APPLICATION NUMBER: US/09/357,141
;  CURRENT FILING DATE:  1999-07-20
;  PRIOR APPLICATION NUMBER:  US 09/283,277
;  PRIOR FILING DATE:  1999-04-01
;  PRIOR APPLICATION NUMBER:  US 09/142,078
;  PRIOR FILING DATE:  1999-02-10
;  PRIOR APPLICATION NUMBER:  WO US97/12652
;  PRIOR FILING DATE:  1997-07-21
;  PRIOR APPLICATION NUMBER:  US 08/762,377
;  PRIOR FILING DATE:  1996-12-06
;  PRIOR APPLICATION NUMBER:  US 08/684,750
;  PRIOR FILING DATE:  1996-07-22
;  NUMBER OF SEQ ID NOS:  71
;  SOFTWARE:  PatentIn Ver. 2.0
; SEQ ID NO 29
;   LENGTH: 4
;   TYPE: PRT
;   ORGANISM: Conus sulcatus
;   FEATURE:
;   NAME/KEY: PEPTIDE
;   LOCATION: (4)
;   OTHER INFORMATION: Xaa is gamma-carboxyglutamic acid.
US-09-357-141-29

  Query Match            100.0%;  Score 15;  DB 3;  Length 4;
  Best Local Similarity  100.0%;  Pred. No. 3e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          1 RER 3


RESULT 4
US-09-533-889-29
; Sequence 29, Application US/09533889
```

```
; Patent No. 6399574
;  GENERAL INFORMATION:
;    APPLICANT:  McCabe, R. Tyler
;    APPLICANT:  Zhou, Li-Ming
;    APPLICANT:  Layer, Richard T.
;    APPLICANT:  Olivera, Baldomero M.
;    APPLICANT:  McIntosh, J. Michael
;    TITLE OF INVENTION:  Use of Conantokins
;    NUMBER OF SEQUENCES:  71
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Rothwell, Figg, Ernst & Kurz, p.c.
;      STREET:  555 Thirteenth Street, N.W., Suite 701-E
;      CITY:  Washington
;      STATE:  D.C.
;      COUNTRY:  USA
;      ZIP:  20004
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/533,889
;      FILING DATE:  22 MAR-2000
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 09/142,078
;      FILING DATE:  10-FEB-1999
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  WO US97/12652
;      FILING DATE:  21-JUL-1997
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/762,377
;      FILING DATE:  06-DEC-1996
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/684,750
;      FILING DATE:  22-JUL-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Ihnen, Jeffrey L.
;      REGISTRATION NUMBER:  28,957
;      REFERENCE/DOCKET NUMBER:  2314-168.A
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  202-783-6040
;      TELEFAX:  202-783-6031
;  INFORMATION FOR SEQ ID NO:  29:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  4 amino acids
;      TYPE:  amino acid
;      STRANDEDNESS:
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
;    FRAGMENT TYPE:  internal
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  4
;      OTHER INFORMATION:  /note= "Xaa is
;      OTHER INFORMATION:  gamma-carboxyglutamic acid"
US-09-533-889-29

  Query Match             100.0%;  Score 15;  DB 4;  Length 4;
  Best Local Similarity   100.0%;  Pred. No. 3e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
               |||
Db          1 RER 3


RESULT 5
US-09-142-080-29
; Sequence 29, Application US/09142080
; Patent No. 6515103
;   GENERAL INFORMATION:
;        APPLICANT: Abogadie, Fe C.
;                   Cruz, Lourdes J.
;                   Olivera, Baldomero M.
;                   Walker, Craig
;                   Colledge, Clark
;                   Hillyard, David R.
;                   Jimenez, Elsie
;                   Layer, Richard T.
;                   Zhou, Li-Ming
;                   McCabe, R. Tyler
;        TITLE OF INVENTION: Conantokins
;        NUMBER OF SEQUENCES: 71
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Rothwell, Figg, Ernst & Manbeck, p.c.
;             STREET: 555 Thirteenth Street, N.W., Suite 701-E
;             CITY: Washington
;             STATE: D.C.
;             COUNTRY: USA
;             ZIP: 20004
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/142,080
;             FILING DATE: 11-May-2000
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: WO US97/12618
;             FILING DATE: 21-JUL-1997
;             APPLICATION NUMBER: US 08/684,742
;             FILING DATE: 22-JUL-1996
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Ihnen, Jeffrey L.
;             REGISTRATION NUMBER: 28,957
;             REFERENCE/DOCKET NUMBER: 2314-134.A
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: 202-783-6040
;             TELEFAX: 202-783-6031
;   INFORMATION FOR SEQ ID NO: 29:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 4 amino acids
;             TYPE: amino acid
;             STRANDEDNESS: <Unknown>
;             TOPOLOGY: linear
;        MOLECULE TYPE: peptide
;        FRAGMENT TYPE: internal
;        FEATURE:
;             NAME/KEY:  Modified-site
;             LOCATION:  4
;             OTHER INFORMATION:  /note= "Xaa is
;             gamma-carboxyglutamic acid"
;        SEQUENCE DESCRIPTION: SEQ ID NO: 29:
US-09-142-080-29

  Query Match             100.0%;  Score 15;  DB 4;  Length 4;
  Best Local Similarity   100.0%;  Pred. No. 3e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
               |||
Db          1 RER 3


RESULT 6
PCT-US92-09070-14
; Sequence 14, Application PC/TUS9209070
;  GENERAL INFORMATION:
;    APPLICANT:  Saitoh, Tsunao [NMI]
;    TITLE OF INVENTION:  SUBSTANCES HAVING THE GROWTH-PROMOTING
;    TITLE OF INVENTION:  EFFECT OF AMYLOID PRECURSOR PROTEIN
;    NUMBER OF SEQUENCES:  18
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Knobbe, Martens, Olson and Bear
```

```
;      STREET:  620 Newport Center Drive
;      CITY:  Newport Beach
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  92660
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US92/09070
;      FILING DATE:  19921023
;      CLASSIFICATION:  514
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Altman, Daniel E
;      REGISTRATION NUMBER:  34,115
;      REFERENCE/DOCKET NUMBER:  UC035.001A
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (714) 760-0404
;      TELEFAX:  (714) 760-9502
;  INFORMATION FOR SEQ ID NO:  14:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  4 amino acids
;      TYPE:  AMINO ACID
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
;    FRAGMENT TYPE:  internal
PCT-US92-09070-14

  Query Match             100.0%;  Score 15;  DB 5;  Length 4;
  Best Local Similarity   100.0%;  Pred. No. 3e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
               |||
Db          1 RER 3


RESULT 7
US-08-552-142A-7
; Sequence 7, Application US/08552142A
; Patent No. 5695995
;  GENERAL INFORMATION:
;    APPLICANT:  Weintraub, Harold M.
;    APPLICANT:  Lee, Jacqueline E.
;    APPLICANT:  Tapscott, Stephen J.
;    APPLICANT:  Hollenberg, Stanley M.
;    TITLE OF INVENTION:  Neurogenic Differentiation (NeuroD) Genes
;    TITLE OF INVENTION:  and Proteins
;    NUMBER OF SEQUENCES:  20
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Christensen O'Connor Johnson KindnessPLLC
;      STREET:  1420 Fifth Avenue, Suite 2800
;      CITY:  Seattle
;      STATE:  WA
;      COUNTRY:  USA
;      ZIP:  98101-2347
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/552,142A
;      FILING DATE:  02-NOV-1995
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/239,238
;      FILING DATE:  06-MAY-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  WO PCT/US95/05741
;      FILING DATE:  08-MAY-1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Broderick, Thomas F.
;      REGISTRATION NUMBER:  31,332
;      REFERENCE/DOCKET NUMBER:  FHCR-1-8933
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  206-682-8100
;      TELEFAX:  206-225-0709
;  INFORMATION FOR SEQ ID NO:  7:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  5 amino acids
;      TYPE:  amino acid
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
;    FRAGMENT TYPE:  internal
US-08-552-142A-7

  Query Match             100.0%;  Score 15;  DB 1;  Length 5;
  Best Local Similarity   100.0%;  Pred. No. 3e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
               |||
Db          3 RER 5


RESULT 8
US-08-704-170-13
; Sequence 13, Application US/08704170
; Patent No. 5707626
;  GENERAL INFORMATION:
;    APPLICANT:  Douvas, Angeline
;    APPLICANT:  Takehana, Yoshi
;    APPLICANT:  Ehresmann, Glenn
;    TITLE OF INVENTION:  THERAPEUTIC STRATEGIES FOR
;    TITLE OF INVENTION:  IMMUNOINFECTIVE CLUSTER VIRUS INFECTIONS
;    NUMBER OF SEQUENCES:  121
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Robbins, Berliner & Carson
;      STREET:  201 No. 5707626th Figueroa Street, Suite 500
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90012
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/704,170
;      FILING DATE:
;      CLASSIFICATION:  424
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/029,850
;      FILING DATE:  11-MAR-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Spitals, John P.
;      REGISTRATION NUMBER:  29,215
;      REFERENCE/DOCKET NUMBER:  1920-331
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 977-1001
;      TELEFAX:  (213) 977-1003
;  INFORMATION FOR SEQ ID NO:  13:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  5 amino acids
;      TYPE:  amino acid
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
US-08-704-170-13
```

```
  Query Match           100.0%;  Score 15;  DB 1;  Length 5;
  Best Local Similarity  100.0%;  Pred. No. 3e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          1 RER 3


RESULT 9
US-08-704-170-14
; Sequence 14, Application US/08704170
; Patent No. 5707626
;  GENERAL INFORMATION:
;    APPLICANT:  Douvas, Angeline
;    APPLICANT:  Takehana, Yoshi
;    APPLICANT:  Ehresmann, Glenn
;    TITLE OF INVENTION:  THERAPEUTIC STRATEGIES FOR
;    TITLE OF INVENTION:  IMMUNOINFECTIVE CLUSTER VIRUS INFECTIONS
;    NUMBER OF SEQUENCES:  121
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Robbins, Berliner & Carson
;      STREET:  201 No. 5707626th Figueroa Street, Suite 500
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90012
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/704,170
;      FILING DATE:
;      CLASSIFICATION:  424
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/029,850
;      FILING DATE:  11-MAR-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Spitals, John P.
;      REGISTRATION NUMBER:  29,215
;      REFERENCE/DOCKET NUMBER:  1920-331
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 977-1001
;      TELEFAX:  (213) 977-1003
;  INFORMATION FOR SEQ ID NO:  14:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  5 amino acids
;      TYPE:  amino acid
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
US-08-704-170-14

  Query Match           100.0%;  Score 15;  DB 1;  Length 5;
  Best Local Similarity  100.0%;  Pred. No. 3e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          2 RER 4


RESULT 10
US-08-704-170-60
; Sequence 60, Application US/08704170
; Patent No. 5707626
;  GENERAL INFORMATION:
;    APPLICANT:  Douvas, Angeline
;    APPLICANT:  Takehana, Yoshi
;    APPLICANT:  Ehresmann, Glenn
;    TITLE OF INVENTION:  THERAPEUTIC STRATEGIES FOR
;    TITLE OF INVENTION:  IMMUNOINFECTIVE CLUSTER VIRUS INFECTIONS
;    NUMBER OF SEQUENCES:  121
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Robbins, Berliner & Carson
;      STREET:  201 No. 5707626th Figueroa Street, Suite 500
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90012
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/704,170
;      FILING DATE:
;      CLASSIFICATION:  424
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/029,850
;      FILING DATE:  11-MAR-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Spitals, John P.
;      REGISTRATION NUMBER:  29,215
;      REFERENCE/DOCKET NUMBER:  1920-331
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 977-1001
;      TELEFAX:  (213) 977-1003
;  INFORMATION FOR SEQ ID NO:  60:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  5 amino acids
;      TYPE:  amino acid
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
US-08-704-170-60

  Query Match           100.0%;  Score 15;  DB 1;  Length 5;
  Best Local Similarity  100.0%;  Pred. No. 3e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          1 RER 3


RESULT 11
US-08-910-973-7
; Sequence 7, Application US/08910973
; Patent No. 5795723
;  GENERAL INFORMATION:
;    APPLICANT:  Tapscott, Stephen J.
;    APPLICANT:  Olson, James M.
;    TITLE OF INVENTION:  Expression of Neurogenic bHLH Genes in Primitive Neuroectoder
;    NUMBER OF SEQUENCES:  24
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Christensen O'Connor Johnson KindnessPLLC
;      STREET:  1420 Fifth Avenue, Suite 2800
;      CITY:  Seattle
;      STATE:  WA
;      COUNTRY:  USA
;      ZIP:  98101-2347
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/910,973
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/239,238
;      FILING DATE:  06-MAY-1994
;    PRIOR APPLICATION DATA:
```

```
;      APPLICATION NUMBER:  WO PCT/US95/05741
;      FILING DATE:  08-MAY-1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US96/17532
;      FILING DATE:  30-October-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sheiness, Diana K.
;      REGISTRATION NUMBER:  35,356
;      REFERENCE/DOCKET NUMBER:  FHCR-1-10958
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  206-682-8100; 206-224-0735 (direct)
;      TELEFAX:  206-225-0779
;  INFORMATION FOR SEQ ID NO:  7:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  5 amino acids
;      TYPE:  amino acid
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
;    FRAGMENT TYPE:  internal
US-08-910-973-7

  Query Match             100.0%;  Score 15;  DB 1;  Length 5;
  Best Local Similarity   100.0%;  Pred. No. 3e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          3 RER 5


RESULT 12
US-09-499-227-7
; Sequence 7, Application US/09499227
; Patent No. 6444463
;  GENERAL INFORMATION:
;    APPLICANT:  Tapscott, Stephen J.
;    APPLICANT:  Olson, James M.
;    TITLE OF INVENTION:  Expression of Neurogenic bHLH Genes in Primitive Neuroectoder
;    NUMBER OF SEQUENCES:  24
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Christensen O'Connor Johnson KindnessPLLC
;      STREET:  1420 Fifth Avenue, Suite 2800
;      CITY:  Seattle
;      STATE:  WA
;      COUNTRY:  USA
;      ZIP:  98101-2347
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/499,227
;      FILING DATE:  05-August-1998
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/239,238
;      FILING DATE:  06-May-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  WO PCT/US95/05741
;      FILING DATE:  08-May-1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US96/17532
;      FILING DATE:  30-October-1996
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/910,973
;      FILING DATE:  07-August-1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sheiness, Diana K.
;      REGISTRATION NUMBER:  35,356
;      REFERENCE/DOCKET NUMBER:  FHCR-1-12742
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  206-682-8100; 206-224-0735 (direct)
;      TELEFAX:  206-225-0779
;  INFORMATION FOR SEQ ID NO:  7:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  5 amino acids
;      TYPE:  amino acid
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
;    FRAGMENT TYPE:  internal
US-09-499-227-7

  Query Match             100.0%;  Score 15;  DB 4;  Length 5;
  Best Local Similarity   100.0%;  Pred. No. 3e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          3 RER 5


RESULT 13
US-09-638-202A-59
; Sequence 59, Application US/09638202A
; Patent No. 6462189
;  GENERAL INFORMATION:
;       APPLICANT: Koieda, Shohei
;       TITLE OF INVENTION: ARTIFICIAL ANTIBODY POLYPEPTIDES
;       NUMBER OF SEQUENCES: 118
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Schwegman, Lundberg, Woessner & Kluth P.A.
;            STREET: 121 South Eighth Street, Ste. 1600
;            CITY: Minneapolis
;            STATE: MN
;            COUNTRY: USA
;            ZIP: 55402
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Diskette
;            COMPUTER: IBM Compatible
;            OPERATING SYSTEM: DOS
;            SOFTWARE: FastSEQ Version 2.0b
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/09/638,202A
;            FILING DATE: 11-Aug-2000
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: 09/096,749
;            FILING DATE: <Unknown>
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Ann S. Viksnins
;            REGISTRATION NUMBER: 37,748
;            REFERENCE/DOCKET NUMBER: 109.034US1
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: (612) 373-6900
;            TELEFAX: (612) 339-3061
;  INFORMATION FOR SEQ ID NO: 59:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 5 amino acids
;            TYPE: amino acid
;            STRANDEDNESS: single
;            TOPOLOGY: linear
;       MOLECULE TYPE: peptide
;       HYPOTHETICAL: NO
;       ANTI-SENSE: NO
;       FRAGMENT TYPE: internal
;       ORIGINAL SOURCE:
;       SEQUENCE DESCRIPTION: SEQ ID NO: 59:
US-09-638-202A-59

  Query Match             100.0%;  Score 15;  DB 4;  Length 5;
  Best Local Similarity   100.0%;  Pred. No. 3e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          3 RER 5
```

```
RESULT 14
US-09-096-749A-59
; Sequence 59, Application US/09096749A
; Patent No. 6673901
;  GENERAL INFORMATION:
;    APPLICANT:  Koieda, Shohei
;    TITLE OF INVENTION:  ARTIFICIAL ANTIBODY POLYPEPTIDES
;    NUMBER OF SEQUENCES:  118
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Schwegman, Lundberg, Woessner & Kluth P.A.
;      STREET:  121 South Eighth Street, Ste. 1600
;      CITY:  Minneapolis
;      STATE:  MN
;      COUNTRY:  USA
;      ZIP:  55402
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  DOS
;      SOFTWARE:  FastSEQ Version 2.0b
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/096,749A
;      FILING DATE:  June 12, 1998
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Ann S. Viksnins
;      REGISTRATION NUMBER:  37,748
;      REFERENCE/DOCKET NUMBER:  109.034US1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (612) 373-6900
;      TELEFAX:  (612) 339-3061
;  INFORMATION FOR SEQ ID NO:  59:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  5 amino acids
;      TYPE:  amino acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
;    FRAGMENT TYPE:  internal
;    ORIGINAL SOURCE:
US-09-096-749A-59

  Query Match             100.0%;  Score 15;  DB 4;  Length 5;
  Best Local Similarity   100.0%;  Pred. No. 3e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          3 RER 5


RESULT 15
PCT-US92-09070-1
; Sequence 1, Application PC/TUS9209070
;  GENERAL INFORMATION:
;    APPLICANT:  Saitoh, Tsunao [NMI]
;    TITLE OF INVENTION:  SUBSTANCES HAVING THE GROWTH-PROMOTING
;    TITLE OF INVENTION:  EFFECT OF AMYLOID PRECURSOR PROTEIN
;    NUMBER OF SEQUENCES:  18
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Knobbe, Martens, Olson and Bear
;      STREET:  620 Newport Center Drive
;      CITY:  Newport Beach
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  92660
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US92/09070
;      FILING DATE:  19921023
;      CLASSIFICATION:  514
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Altman, Daniel E
;      REGISTRATION NUMBER:  34,115
;      REFERENCE/DOCKET NUMBER:  UC035.001A
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (714) 760-0404
;      TELEFAX:  (714) 760-9502
;  INFORMATION FOR SEQ ID NO:  1:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  5 amino acids
;      TYPE:  AMINO ACID
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
;    FRAGMENT TYPE:  internal
PCT-US92-09070-1

  Query Match             100.0%;  Score 15;  DB 5;  Length 5;
  Best Local Similarity   100.0%;  Pred. No. 3e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          1 RER 3


RESULT 16
PCT-US94-02631-13
; Sequence 13, Application PC/TUS9402631
;  GENERAL INFORMATION:
;    APPLICANT:  Douvas, Angeline
;    APPLICANT:  Takehana, Yoshi
;    APPLICANT:  Ehresmann, Glenn
;    TITLE OF INVENTION:  THERAPEUTIC STRATEGIES FOR
;    TITLE OF INVENTION:  IMMUNOINFECTIVE CLUSTER VIRUS INFECTIONS
;    NUMBER OF SEQUENCES:  121
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Robbins, Berliner & Carson
;      STREET:  201 North Figueroa Street, Suite 500
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90012
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US94/02631
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/029,850
;      FILING DATE:  11-MAR-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Spitals, John P.
;      REGISTRATION NUMBER:  29,215
;      REFERENCE/DOCKET NUMBER:  1920-331
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 977-1001
;      TELEFAX:  (213) 977-1003
;  INFORMATION FOR SEQ ID NO:  13:
;    SEQUENCE CHARACTERISTICS:
```

```
;      LENGTH:  5 amino acids
;      TYPE:  amino acid
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
PCT-US94-02631-13

  Query Match             100.0%;  Score 15;  DB 5;  Length 5;
  Best Local Similarity   100.0%;  Pred. No. 3e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
               |||
Db          1 RER 3


RESULT 17
PCT-US94-02631-14
; Sequence 14, Application PC/TUS9402631
;  GENERAL INFORMATION:
;    APPLICANT:  Douvas, Angeline
;    APPLICANT:  Takehana, Yoshi
;    APPLICANT:  Ehresmann, Glenn
;    TITLE OF INVENTION:  THERAPEUTIC STRATEGIES FOR
;    TITLE OF INVENTION:  IMMUNOINFECTIVE CLUSTER VIRUS INFECTIONS
;    NUMBER OF SEQUENCES:  121
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Robbins, Berliner & Carson
;      STREET:  201 North Figueroa Street, Suite 500
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90012
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US94/02631
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/029,850
;      FILING DATE:  11-MAR-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Spitals, John P.
;      REGISTRATION NUMBER:  29,215
;      REFERENCE/DOCKET NUMBER:  1920-331
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 977-1001
;      TELEFAX:  (213) 977-1003
;  INFORMATION FOR SEQ ID NO:  14:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  5 amino acids
;      TYPE:  amino acid
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
PCT-US94-02631-14

  Query Match             100.0%;  Score 15;  DB 5;  Length 5;
  Best Local Similarity   100.0%;  Pred. No. 3e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
               |||
Db          2 RER 4


RESULT 18
PCT-US94-02631-60
; Sequence 60, Application PC/TUS9402631
;  GENERAL INFORMATION:
;    APPLICANT:  Douvas, Angeline
;    APPLICANT:  Takehana, Yoshi
;    APPLICANT:  Ehresmann, Glenn
;    TITLE OF INVENTION:  THERAPEUTIC STRATEGIES FOR
;    TITLE OF INVENTION:  IMMUNOINFECTIVE CLUSTER VIRUS INFECTIONS
;    NUMBER OF SEQUENCES:  121
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Robbins, Berliner & Carson
;      STREET:  201 North Figueroa Street, Suite 500
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90012
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US94/02631
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/029,850
;      FILING DATE:  11-MAR-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Spitals, John P.
;      REGISTRATION NUMBER:  29,215
;      REFERENCE/DOCKET NUMBER:  1920-331
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 977-1001
;      TELEFAX:  (213) 977-1003
;  INFORMATION FOR SEQ ID NO:  60:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  5 amino acids
;      TYPE:  amino acid
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
PCT-US94-02631-60

  Query Match             100.0%;  Score 15;  DB 5;  Length 5;
  Best Local Similarity   100.0%;  Pred. No. 3e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
               |||
Db          1 RER 3


RESULT 19
PCT-US95-05741-7
; Sequence 7, Application PC/TUS9505741
;  GENERAL INFORMATION:
;    APPLICANT:  Weintraub, Harold
;    APPLICANT:  Lee, Jacqueline E.
;    APPLICANT:  Tapscott, Stephen J.
;    APPLICANT:  Hollenberg, Stanley M.
;    TITLE OF INVENTION:  Neurogenic Differentiation (NeuroD) Gene
;    TITLE OF INVENTION:  and Protein
;    NUMBER OF SEQUENCES:  11
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Christensen O'Connor Johnson Kindness
;      STREET:  1420 Fifth Avenue, Suite 2800
;      CITY:  Seattle
;      STATE:  WA
;      COUNTRY:  USA
;      ZIP:  98101-2347
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US95/05741
```

```
;      FILING DATE:
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Broderick, Thomas F.
;      REGISTRATION NUMBER:  31,332
;      REFERENCE/DOCKET NUMBER:  FHCR-1-8504
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  206-682-8100
;      TELEFAX:  206-225-0709
;  INFORMATION FOR SEQ ID NO:  7:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  5 amino acids
;      TYPE:  amino acid
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
;    FRAGMENT TYPE:  internal
PCT-US95-05741-7

  Query Match            100.0%;  Score 15;  DB 5;  Length 5;
  Best Local Similarity  100.0%;  Pred. No. 3e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
               |||
Db          3 RER 5


RESULT 20
US-08-704-170-4
; Sequence 4, Application US/08704170
; Patent No. 5707626
;  GENERAL INFORMATION:
;    APPLICANT:  Douvas, Angeline
;    APPLICANT:  Takehana, Yoshi
;    APPLICANT:  Ehresmann, Glenn
;    TITLE OF INVENTION:  THERAPEUTIC STRATEGIES FOR
;    TITLE OF INVENTION:  IMMUNOINFECTIVE CLUSTER VIRUS INFECTIONS
;    NUMBER OF SEQUENCES:  121
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Robbins, Berliner & Carson
;      STREET:  201 No. 5707626th Figueroa Street, Suite 500
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90012
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/704,170
;      FILING DATE:
;      CLASSIFICATION:  424
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/029,850
;      FILING DATE:  11-MAR-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Spitals, John P.
;      REGISTRATION NUMBER:  29,215
;      REFERENCE/DOCKET NUMBER:  1920-331
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 977-1001
;      TELEFAX:  (213) 977-1003
;  INFORMATION FOR SEQ ID NO:  4:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  6 amino acids
;      TYPE:  amino acid
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
US-08-704-170-4

  Query Match            100.0%;  Score 15;  DB 1;  Length 6;
  Best Local Similarity  100.0%;  Pred. No. 3e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
               |||
Db          2 RER 4


RESULT 21
US-08-704-170-97
; Sequence 97, Application US/08704170
; Patent No. 5707626
;  GENERAL INFORMATION:
;    APPLICANT:  Douvas, Angeline
;    APPLICANT:  Takehana, Yoshi
;    APPLICANT:  Ehresmann, Glenn
;    TITLE OF INVENTION:  THERAPEUTIC STRATEGIES FOR
;    TITLE OF INVENTION:  IMMUNOINFECTIVE CLUSTER VIRUS INFECTIONS
;    NUMBER OF SEQUENCES:  121
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Robbins, Berliner & Carson
;      STREET:  201 No. 5707626th Figueroa Street, Suite 500
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90012
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/704,170
;      FILING DATE:
;      CLASSIFICATION:  424
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/029,850
;      FILING DATE:  11-MAR-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Spitals, John P.
;      REGISTRATION NUMBER:  29,215
;      REFERENCE/DOCKET NUMBER:  1920-331
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 977-1001
;      TELEFAX:  (213) 977-1003
;  INFORMATION FOR SEQ ID NO:  97:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  6 amino acids
;      TYPE:  amino acid
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
US-08-704-170-97

  Query Match            100.0%;  Score 15;  DB 1;  Length 6;
  Best Local Similarity  100.0%;  Pred. No. 3e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
               |||
Db          2 RER 4


RESULT 22
US-08-482-228-145
; Sequence 145, Application US/08482228
; Patent No. 5968753
;  GENERAL INFORMATION:
;    APPLICANT:  Tseng-Law, Janet
;    APPLICANT:  Kobori, Joan A.
;    APPLICANT:  Al-Abdaly, Fahad A.
;    APPLICANT:  Guillermo, Roy
;    APPLICANT:  Helgerson, Sam L.
;    APPLICANT:  Deans, Robert J.
```

```
;    TITLE OF INVENTION:  POSITIVE AND POSITIVE/NEGATIVE CELL
;    TITLE OF INVENTION:  SELECTION MEDIATED BY PEPTIDE RELEASE
;    NUMBER OF SEQUENCES:  215
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Janice Guthrie, Ph.D.
;      STREET:  P.O. Box 15210
;      CITY:  Irvine
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  92713-5210
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/482,228
;      FILING DATE:  07-JUN-1995
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Guthrie, Janice
;      REGISTRATION NUMBER:  35,170
;      REFERENCE/DOCKET NUMBER:  IT-4630CIP3
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (714) 440-5353
;      TELEFAX:  (714) 553-1952
;  INFORMATION FOR SEQ ID NO:  145:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  6 amino acids
;      TYPE:  amino acid
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
US-08-482-228-145

  Query Match             100.0%;  Score 15;  DB 2;  Length 6;
  Best Local Similarity   100.0%;  Pred. No. 3e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
               |||
Db          1 RER 3


RESULT 23
US-08-482-528-145
; Sequence 145, Application US/08482528
; Patent No. 6017719
;  GENERAL INFORMATION:
;    APPLICANT:  Tseng-Law, Janet
;    APPLICANT:  Kobori, Joan A.
;    APPLICANT:  Al-Abdaly, Fahad A.
;    APPLICANT:  Guillermo, Roy
;    APPLICANT:  Helgerson, Sam L.
;    APPLICANT:  Deans, Robert J.
;    TITLE OF INVENTION:  POSITIVE AND POSITIVE/NEGATIVE CELL
;    TITLE OF INVENTION:  SELECTION MEDIATED BY PEPTIDE RELEASE
;    NUMBER OF SEQUENCES:  215
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Janice Guthrie, Ph.D.
;      STREET:  P.O. Box 15210
;      CITY:  Irvine
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  92713-5210
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/482,528
;      FILING DATE:  07-JUN-1995
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Guthrie, Janice
;      REGISTRATION NUMBER:  35,170
;      REFERENCE/DOCKET NUMBER:  IT-4630CIP4
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (714) 440-5353
;      TELEFAX:  (714) 553-1952
;  INFORMATION FOR SEQ ID NO:  145:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  6 amino acids
;      TYPE:  amino acid
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
US-08-482-528-145

  Query Match             100.0%;  Score 15;  DB 3;  Length 6;
  Best Local Similarity   100.0%;  Pred. No. 3e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
               |||
Db          1 RER 3


RESULT 24
US-09-020-880-60
; Sequence 60, Application US/09020880A
; Patent No. 6136558
; GENERAL INFORMATION:
;  APPLICANT: Genentech, Inc.
;  APPLICANT: Ballinger, Marcus D.
;  APPLICANT: Jones, Jennifer T.
;  APPLICANT: Fairbrother, Wayne J.
;  APPLICANT: Sliwkowski, Mark X.
;  APPLICANT: Wells, James A.
;  TITLE OF INVENTION: HEREGULIN VARIANTS
;  FILE REFERENCE: 14918-720CON1
;  CURRENT APPLICATION NUMBER: US/09/020,880A
;  CURRENT FILING DATE: 1998-02-09
;  EARLIER APPLICATION NUMBER: US 60/037,581
;  EARLIER FILING DATE: 1997-02-10
;  NUMBER OF SEQ ID NOS: 116
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 60
;   LENGTH: 6
;   TYPE: PRT
;   ORGANISM: No. 6136558 relevant (recombinant)
US-09-020-880-60

  Query Match             100.0%;  Score 15;  DB 3;  Length 6;
  Best Local Similarity   100.0%;  Pred. No. 3e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
               |||
Db          2 RER 4


RESULT 25
US-09-101-544-60
; Sequence 60, Application US/09101544
; Patent No. 6387638
; GENERAL INFORMATION:
;  APPLICANT:  Genentech, Inc.
;  APPLICANT:  Ballinger, Marcus D.
;  APPLICANT:  Jones, Jennifer T.
;  APPLICANT:  Fairbrother, Wayne J.
;  APPLICANT:  Sliwkowski, Mark X.
;  APPLICANT:  Wells, James A.
;  TITLE OF INVENTION:  HEREGULIN VARIANTS
;  FILE REFERENCE:  14918-720CON2
;  CURRENT APPLICATION NUMBER: US/09/101,544
;  CURRENT FILING DATE:  1998-07-17
```

```
;  PRIOR APPLICATION NUMBER:  US 09/020,880
;  PRIOR FILING DATE:  1998-02-09
;  PRIOR APPLICATION NUMBER:  US 60/037,581
;  PRIOR FILING DATE:  1997-02-10
;  NUMBER OF SEQ ID NOS:  116
;  SOFTWARE:  FastSEQ for Windows Version 4.0
; SEQ ID NO 60
;   LENGTH: 6
;   TYPE: PRT
;   ORGANISM: No. 6387638 relevant (recombinant)
US-09-101-544-60

  Query Match            100.0%;  Score 15;  DB 4;  Length 6;
  Best Local Similarity  100.0%;  Pred. No. 3e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
               |||
Db          2 RER 4


RESULT 26
US-09-007-288E-21
; Sequence 21, Application US/09007288E
; Patent No. 6495357
; GENERAL INFORMATION:
;  APPLICANT: Fuglsang, Claus
;  APPLICANT:  Okkels, Jens
;  APPLICANT:  Petersen, Dorte
;  APPLICANT:  Patkar, Shamkant
;  APPLICANT:  Thellersen, Marianne
;  APPLICANT:  Svenden, Allan
;  APPLICANT:  Borch, Kim
;  APPLICANT:  Royer, John
;  APPLICANT:  Kretzschmar, Titus
;  APPLICANT:  Halkier, Torben
;  APPLICANT:  Vind, Jesper
;  APPLICANT:  Jorgensen, Steen
;  TITLE OF INVENTION: No. 6495357el Lipolytic Enzymes
;  FILE REFERENCE: 4455.404-US
;  CURRENT APPLICATION NUMBER: US/09/007,288E
;  CURRENT FILING DATE:  2000-01-14
;  NUMBER OF SEQ ID NOS: 162
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 21
;   LENGTH: 6
;   TYPE: PRT
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Peptide addition
US-09-007-288E-21

  Query Match            100.0%;  Score 15;  DB 4;  Length 6;
  Best Local Similarity  100.0%;  Pred. No. 3e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
               |||
Db          4 RER 6


RESULT 27
US-08-932-411A-29
; Sequence 29, Application US/08932411A
; Patent No. 6566496
;  GENERAL INFORMATION:
;    APPLICANT:  Anderson, David J.
;    APPLICANT:  Ma, Qiufu
;    TITLE OF INVENTION:  NEUROGENIN
;    NUMBER OF SEQUENCES:  31
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Flehr Hohbach Test Albritton & Herbert LLP
;      STREET:  Four Embarcadero Center, Suite 3400
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States
;      ZIP:  94111-4187
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/932,411A
;      FILING DATE:  15-SEP-1997
;      CLASSIFICATION:  536
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/772,009
;      FILING DATE:  19-DEC-1996
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/722,570
;      FILING DATE:  19-DEC-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Silva, Robin M.
;      REGISTRATION NUMBER:  38,304
;      REFERENCE/DOCKET NUMBER:  A-63902-3/RFT/RMS
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 781-1989
;      TELEFAX:  (415) 398-3249
;      TELEX:  910 277299
;  INFORMATION FOR SEQ ID NO:  29:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  6 amino acids
;      TYPE:  amino acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  protein
US-08-932-411A-29

  Query Match            100.0%;  Score 15;  DB 4;  Length 6;
  Best Local Similarity  100.0%;  Pred. No. 3e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
               |||
Db          4 RER 6


RESULT 28
US-08-932-411A-30
; Sequence 30, Application US/08932411A
; Patent No. 6566496
;  GENERAL INFORMATION:
;    APPLICANT:  Anderson, David J.
;    APPLICANT:  Ma, Qiufu
;    TITLE OF INVENTION:  NEUROGENIN
;    NUMBER OF SEQUENCES:  31
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Flehr Hohbach Test Albritton & Herbert LLP
;      STREET:  Four Embarcadero Center, Suite 3400
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States
;      ZIP:  94111-4187
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/932,411A
;      FILING DATE:  15-SEP-1997
;      CLASSIFICATION:  536
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/772,009
;      FILING DATE:  19-DEC-1996
```

```
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/722,570
;      FILING DATE:  19-DEC-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Silva, Robin M.
;      REGISTRATION NUMBER:  38,304
;      REFERENCE/DOCKET NUMBER:  A-63902-3/RFT/RMS
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 781-1989
;      TELEFAX:  (415) 398-3249
;      TELEX:  910 277299
;  INFORMATION FOR SEQ ID NO:  30:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  6 amino acids
;      TYPE:  amino acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  protein
US-08-932-411A-30

  Query Match           100.0%;  Score 15;  DB 4;  Length 6;
  Best Local Similarity  100.0%;  Pred. No. 3e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          4 RER 6


RESULT 29
PCT-US92-09070-13
; Sequence 13, Application PC/TUS9209070
;  GENERAL INFORMATION:
;    APPLICANT:  Saitoh, Tsunao [NMI]
;    TITLE OF INVENTION:  SUBSTANCES HAVING THE GROWTH-PROMOTING
;    TITLE OF INVENTION:  EFFECT OF AMYLOID PRECURSOR PROTEIN
;    NUMBER OF SEQUENCES:  18
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Knobbe, Martens, Olson and Bear
;      STREET:  620 Newport Center Drive
;      CITY:  Newport Beach
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  92660
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US92/09070
;      FILING DATE:  19921023
;      CLASSIFICATION:  514
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Altman, Daniel E
;      REGISTRATION NUMBER:  34,115
;      REFERENCE/DOCKET NUMBER:  UC035.001A
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (714) 760-0404
;      TELEFAX:  (714) 760-9502
;  INFORMATION FOR SEQ ID NO:  13:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  6 amino acids
;      TYPE:  AMINO ACID
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
;    FRAGMENT TYPE:  internal
PCT-US92-09070-13

  Query Match           100.0%;  Score 15;  DB 5;  Length 6;
  Best Local Similarity  100.0%;  Pred. No. 3e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          2 RER 4


RESULT 30
PCT-US94-02631-4
; Sequence 4, Application PC/TUS9402631
;  GENERAL INFORMATION:
;    APPLICANT:  Douvas, Angeline
;    APPLICANT:  Takehana, Yoshi
;    APPLICANT:  Ehresmann, Glenn
;    TITLE OF INVENTION:  THERAPEUTIC STRATEGIES FOR
;    TITLE OF INVENTION:  IMMUNOINFECTIVE CLUSTER VIRUS INFECTIONS
;    NUMBER OF SEQUENCES:  121
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Robbins, Berliner & Carson
;      STREET:  201 North Figueroa Street, Suite 500
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90012
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US94/02631
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/029,850
;      FILING DATE:  11-MAR-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Spitals, John P.
;      REGISTRATION NUMBER:  29,215
;      REFERENCE/DOCKET NUMBER:  1920-331
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 977-1001
;      TELEFAX:  (213) 977-1003
;  INFORMATION FOR SEQ ID NO:  4:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  6 amino acids
;      TYPE:  amino acid
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
PCT-US94-02631-4

  Query Match           100.0%;  Score 15;  DB 5;  Length 6;
  Best Local Similarity  100.0%;  Pred. No. 3e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          2 RER 4


RESULT 31
PCT-US94-02631-97
; Sequence 97, Application PC/TUS9402631
;  GENERAL INFORMATION:
;    APPLICANT:  Douvas, Angeline
;    APPLICANT:  Takehana, Yoshi
;    APPLICANT:  Ehresmann, Glenn
;    TITLE OF INVENTION:  THERAPEUTIC STRATEGIES FOR
;    TITLE OF INVENTION:  IMMUNOINFECTIVE CLUSTER VIRUS INFECTIONS
;    NUMBER OF SEQUENCES:  121
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Robbins, Berliner & Carson
```

```
;      STREET:  201 North Figueroa Street, Suite 500
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90012
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US94/02631
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/029,850
;      FILING DATE:  11-MAR-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Spitals, John P.
;      REGISTRATION NUMBER:  29,215
;      REFERENCE/DOCKET NUMBER:  1920-331
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 977-1001
;      TELEFAX:  (213) 977-1003
;  INFORMATION FOR SEQ ID NO:  97:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  6 amino acids
;      TYPE:  amino acid
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
PCT-US94-02631-97

  Query Match            100.0%;  Score 15;  DB 5;  Length 6;
  Best Local Similarity  100.0%;  Pred. No. 3e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
               |||
Db          2 RER 4


RESULT 32
US-08-552-142A-5
; Sequence 5, Application US/08552142A
; Patent No. 5695995
;  GENERAL INFORMATION:
;    APPLICANT:  Weintraub, Harold M.
;    APPLICANT:  Lee, Jacqueline E.
;    APPLICANT:  Tapscott, Stephen J.
;    APPLICANT:  Hollenberg, Stanley M.
;    TITLE OF INVENTION:  Neurogenic Differentiation (NeuroD) Genes
;    TITLE OF INVENTION:  and Proteins
;    NUMBER OF SEQUENCES:  20
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Christensen O'Connor Johnson KindnessPLLC
;      STREET:  1420 Fifth Avenue, Suite 2800
;      CITY:  Seattle
;      STATE:  WA
;      COUNTRY:  USA
;      ZIP:  98101-2347
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/552,142A
;      FILING DATE:  02-NOV-1995
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/239,238
;      FILING DATE:  06-MAY-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  WO PCT/US95/05741
;      FILING DATE:  08-MAY-1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Broderick, Thomas F.
;      REGISTRATION NUMBER:  31,332
;      REFERENCE/DOCKET NUMBER:  FHCR-1-8933
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  206-682-8100
;      TELEFAX:  206-225-0709
;  INFORMATION FOR SEQ ID NO:  5:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  7 amino acids
;      TYPE:  amino acid
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
;    FRAGMENT TYPE:  internal
US-08-552-142A-5

  Query Match            100.0%;  Score 15;  DB 1;  Length 7;
  Best Local Similarity  100.0%;  Pred. No. 3e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
               |||
Db          3 RER 5


RESULT 33
US-08-552-142A-6
; Sequence 6, Application US/08552142A
; Patent No. 5695995
;  GENERAL INFORMATION:
;    APPLICANT:  Weintraub, Harold M.
;    APPLICANT:  Lee, Jacqueline E.
;    APPLICANT:  Tapscott, Stephen J.
;    APPLICANT:  Hollenberg, Stanley M.
;    TITLE OF INVENTION:  Neurogenic Differentiation (NeuroD) Genes
;    TITLE OF INVENTION:  and Proteins
;    NUMBER OF SEQUENCES:  20
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Christensen O'Connor Johnson KindnessPLLC
;      STREET:  1420 Fifth Avenue, Suite 2800
;      CITY:  Seattle
;      STATE:  WA
;      COUNTRY:  USA
;      ZIP:  98101-2347
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/552,142A
;      FILING DATE:  02-NOV-1995
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/239,238
;      FILING DATE:  06-MAY-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  WO PCT/US95/05741
;      FILING DATE:  08-MAY-1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Broderick, Thomas F.
;      REGISTRATION NUMBER:  31,332
;      REFERENCE/DOCKET NUMBER:  FHCR-1-8933
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  206-682-8100
;      TELEFAX:  206-225-0709
;  INFORMATION FOR SEQ ID NO:  6:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  7 amino acids
;      TYPE:  amino acid
;      TOPOLOGY:  linear
```

```
;    MOLECULE TYPE:  peptide
;    FRAGMENT TYPE:  internal
US-08-552-142A-6

  Query Match            100.0%;  Score 15;  DB 1;  Length 7;
  Best Local Similarity  100.0%;  Pred. No. 3e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
               |||
Db          3 RER 5


RESULT 34
US-08-910-973-5
; Sequence 5, Application US/08910973
; Patent No. 5795723
;  GENERAL INFORMATION:
;    APPLICANT:  Tapscott, Stephen J.
;    APPLICANT:  Olson, James M.
;    TITLE OF INVENTION:  Expression of Neurogenic bHLH Genes in Primitive Neuroectoder
;    NUMBER OF SEQUENCES:  24
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Christensen O'Connor Johnson KindnessPLLC
;      STREET:  1420 Fifth Avenue, Suite 2800
;      CITY:  Seattle
;      STATE:  WA
;      COUNTRY:  USA
;      ZIP:  98101-2347
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/910,973
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/239,238
;      FILING DATE:  06-MAY-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  WO PCT/US95/05741
;      FILING DATE:  08-MAY-1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US96/17532
;      FILING DATE:  30-October-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sheiness, Diana K.
;      REGISTRATION NUMBER:  35,356
;      REFERENCE/DOCKET NUMBER:  FHCR-1-10958
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  206-682-8100; 206-224-0735 (direct)
;      TELEFAX:  206-225-0779
;  INFORMATION FOR SEQ ID NO:  5:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  7 amino acids
;      TYPE:  amino acid
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
;    FRAGMENT TYPE:  internal
US-08-910-973-5

  Query Match            100.0%;  Score 15;  DB 1;  Length 7;
  Best Local Similarity  100.0%;  Pred. No. 3e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
               |||
Db          3 RER 5


RESULT 35
US-08-910-973-6
; Sequence 6, Application US/08910973
; Patent No. 5795723
;  GENERAL INFORMATION:
;    APPLICANT:  Tapscott, Stephen J.
;    APPLICANT:  Olson, James M.
;    TITLE OF INVENTION:  Expression of Neurogenic bHLH Genes in Primitive Neuroectoder
;    NUMBER OF SEQUENCES:  24
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Christensen O'Connor Johnson KindnessPLLC
;      STREET:  1420 Fifth Avenue, Suite 2800
;      CITY:  Seattle
;      STATE:  WA
;      COUNTRY:  USA
;      ZIP:  98101-2347
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/910,973
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/239,238
;      FILING DATE:  06-MAY-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  WO PCT/US95/05741
;      FILING DATE:  08-MAY-1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US96/17532
;      FILING DATE:  30-October-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sheiness, Diana K.
;      REGISTRATION NUMBER:  35,356
;      REFERENCE/DOCKET NUMBER:  FHCR-1-10958
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  206-682-8100; 206-224-0735 (direct)
;      TELEFAX:  206-225-0779
;  INFORMATION FOR SEQ ID NO:  6:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  7 amino acids
;      TYPE:  amino acid
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
;    FRAGMENT TYPE:  internal
US-08-910-973-6

  Query Match            100.0%;  Score 15;  DB 1;  Length 7;
  Best Local Similarity  100.0%;  Pred. No. 3e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
               |||
Db          3 RER 5


RESULT 36
US-08-907-403A-5
; Sequence 5, Application US/08907403A
; Patent No. 6013633
;  GENERAL INFORMATION:
;    APPLICANT:  Balasubramanium, Ambikaipakan
;    APPLICANT:  Chance, William T.
;    TITLE OF INVENTION:  Compounds For Control
;    TITLE OF INVENTION:  Of Appetite, Blood Pressure, Cardiovascular
;    TITLE OF INVENTION:  Response, Libido, And Circadian Rhythm
;    NUMBER OF SEQUENCES:  8
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Wood, Herron & Evans, L.L.P.
;      STREET:  441 Vine Street
;      CITY:  Cincinnati
```

```
;       STATE:  Ohio
;       COUNTRY:  USA
;       ZIP:  45202-2917
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Diskette, 3.50 inch,
;       MEDIUM TYPE:  1.44 MB storage
;       COMPUTER:  IBM Compatible
;       OPERATING SYSTEM:  Windows 95
;       SOFTWARE:  Microsoft Word
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/907,403A
;       FILING DATE:  07-AUG-1997
;       CLASSIFICATION:  514
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  60/023,588
;       FILING DATE:  09-AUG-1996
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Albainy-Jenei, Stephen R.
;       REGISTRATION NUMBER:  41,487
;       REFERENCE/DOCKET NUMBER:  UOC-113A-111
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (513) 241-2324
;       TELEFAX:  (513) 421-7269
;   INFORMATION FOR SEQ ID NO:  5:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  7
;       TYPE:  amino acid
;       STRANDEDNESS:
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  peptide
;     HYPOTHETICAL:  no
;     ANTI-SENSE:  no
;     FEATURE:
;       LOCATION:  1
;       OTHER INFORMATION:  Xaa represents Dap
US-08-907-403A-5

  Query Match             100.0%;  Score 15;  DB 3;  Length 7;
  Best Local Similarity   100.0%;  Pred. No. 3e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          4 RER 6


RESULT 37
US-08-907-403A-6
; Sequence 6, Application US/08907403A
; Patent No. 6013633
;  GENERAL INFORMATION:
;    APPLICANT:  Balasubramanium, Ambikaipakan
;    APPLICANT:  Chance, William T.
;    TITLE OF INVENTION:  Compounds For Control
;    TITLE OF INVENTION:  Of Appetite, Blood Pressure, Cardiovascular
;    TITLE OF INVENTION:  Response, Libido, And Circadian Rhythm
;    NUMBER OF SEQUENCES:  8
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Wood, Herron & Evans, L.L.P.
;      STREET:  441 Vine Street
;      CITY:  Cincinnati
;      STATE:  Ohio
;      COUNTRY:  USA
;      ZIP:  45202-2917
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.50 inch,
;      MEDIUM TYPE:  1.44 MB storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  Windows 95
;      SOFTWARE:  Microsoft Word
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/907,403A
;      FILING DATE:  07-AUG-1997
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/023,588
;      FILING DATE:  09-AUG-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Albainy-Jenei, Stephen R.
;      REGISTRATION NUMBER:  41,487
;      REFERENCE/DOCKET NUMBER:  UOC-113A-111
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (513) 241-2324
;      TELEFAX:  (513) 421-7269
;  INFORMATION FOR SEQ ID NO:  6:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  7
;      TYPE:  amino acid
;      STRANDEDNESS:
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
;    HYPOTHETICAL:  no
;    ANTI-SENSE:  no
US-08-907-403A-6

  Query Match             100.0%;  Score 15;  DB 3;  Length 7;
  Best Local Similarity   100.0%;  Pred. No. 3e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          4 RER 6


RESULT 38
US-09-499-227-5
; Sequence 5, Application US/09499227
; Patent No. 6444463
;  GENERAL INFORMATION:
;    APPLICANT:  Tapscott, Stephen J.
;    APPLICANT:  Olson, James M.
;    TITLE OF INVENTION:  Expression of Neurogenic bHLH Genes in Primitive Neuroectoder
;    NUMBER OF SEQUENCES:  24
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Christensen O'Connor Johnson KindnessPLLC
;      STREET:  1420 Fifth Avenue, Suite 2800
;      CITY:  Seattle
;      STATE:  WA
;      COUNTRY:  USA
;      ZIP:  98101-2347
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/499,227
;      FILING DATE:  05-August-1998
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/239,238
;      FILING DATE:  06-May-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  WO PCT/US95/05741
;      FILING DATE:  08-May-1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US96/17532
;      FILING DATE:  30-October-1996
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/910,973
;      FILING DATE:  07-August-1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sheiness, Diana K.
;      REGISTRATION NUMBER:  35,356
;      REFERENCE/DOCKET NUMBER:  FHCR-1-12742
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  206-682-8100; 206-224-0735 (direct)
```

```
;      TELEFAX:  206-225-0779
;  INFORMATION FOR SEQ ID NO:  5:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  7 amino acids
;      TYPE:  amino acid
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
;    FRAGMENT TYPE:  internal
US-09-499-227-5

  Query Match           100.0%;  Score 15;  DB 4;  Length 7;
  Best Local Similarity  100.0%;  Pred. No. 3e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          3 RER 5


RESULT 39
US-09-499-227-6
; Sequence 6, Application US/09499227
; Patent No. 6444463
;  GENERAL INFORMATION:
;    APPLICANT:  Tapscott, Stephen J.
;    APPLICANT:  Olson, James M.
;    TITLE OF INVENTION:  Expression of Neurogenic bHLH Genes in Primitive Neuroectoder
;    NUMBER OF SEQUENCES:  24
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Christensen O'Connor Johnson KindnessPLLC
;      STREET:  1420 Fifth Avenue, Suite 2800
;      CITY:  Seattle
;      STATE:  WA
;      COUNTRY:  USA
;      ZIP:  98101-2347
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/499,227
;      FILING DATE:  05-August-1998
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/239,238
;      FILING DATE:  06-May-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  WO PCT/US95/05741
;      FILING DATE:  08-May-1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US96/17532
;      FILING DATE:  30-October-1996
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/910,973
;      FILING DATE:  07-August-1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sheiness, Diana K.
;      REGISTRATION NUMBER:  35,356
;      REFERENCE/DOCKET NUMBER:  FHCR-1-12742
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  206-682-8100; 206-224-0735 (direct)
;      TELEFAX:  206-225-0779
;  INFORMATION FOR SEQ ID NO:  6:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  7 amino acids
;      TYPE:  amino acid
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
;    FRAGMENT TYPE:  internal
US-09-499-227-6

  Query Match           100.0%;  Score 15;  DB 4;  Length 7;
  Best Local Similarity  100.0%;  Pred. No. 3e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          3 RER 5


RESULT 40
US-09-007-288E-49
; Sequence 49, Application US/09007288E
; Patent No. 6495357
; GENERAL INFORMATION:
;  APPLICANT: Fuglsang, Claus
;  APPLICANT:  Okkels, Jens
;  APPLICANT:  Petersen, Dorte
;  APPLICANT:  Patkar, Shamkant
;  APPLICANT:  Thellersen, Marianne
;  APPLICANT:  Svenden, Allan
;  APPLICANT:  Borch, Kim
;  APPLICANT:  Royer, John
;  APPLICANT:  Kretzschmar, Titus
;  APPLICANT:  Halkier, Torben
;  APPLICANT:  Vind, Jesper
;  APPLICANT:  Jorgensen, Steen
;  TITLE OF INVENTION: No. 6495357el Lipolytic Enzymes
;  FILE REFERENCE: 4455.404-US
;  CURRENT APPLICATION NUMBER: US/09/007,288E
;  CURRENT FILING DATE:  2000-01-14
;  NUMBER OF SEQ ID NOS: 162
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 49
;   LENGTH: 7
;   TYPE: PRT
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Peptide addition
US-09-007-288E-49

  Query Match           100.0%;  Score 15;  DB 4;  Length 7;
  Best Local Similarity  100.0%;  Pred. No. 3e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          4 RER 6


RESULT 41
PCT-US95-05741-5
; Sequence 5, Application PC/TUS9505741
;  GENERAL INFORMATION:
;    APPLICANT:  Weintraub, Harold
;    APPLICANT:  Lee, Jacqueline E.
;    APPLICANT:  Tapscott, Stephen J.
;    APPLICANT:  Hollenberg, Stanley M.
;    TITLE OF INVENTION:  Neurogenic Differentiation (NeuroD) Gene
;    TITLE OF INVENTION:  and Protein
;    NUMBER OF SEQUENCES:  11
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Christensen O'Connor Johnson Kindness
;      STREET:  1420 Fifth Avenue, Suite 2800
;      CITY:  Seattle
;      STATE:  WA
;      COUNTRY:  USA
;      ZIP:  98101-2347
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US95/05741
;      FILING DATE:
```

```
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Broderick, Thomas F.
;      REGISTRATION NUMBER:  31,332
;      REFERENCE/DOCKET NUMBER:  FHCR-1-8504
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  206-682-8100
;      TELEFAX:  206-225-0709
;  INFORMATION FOR SEQ ID NO:  5:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  7 amino acids
;      TYPE:  amino acid
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
;    FRAGMENT TYPE:  internal
PCT-US95-05741-5

  Query Match           100.0%;  Score 15;  DB 5;  Length 7;
  Best Local Similarity  100.0%;  Pred. No. 3e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          3 RER 5


RESULT 42
PCT-US95-05741-6
; Sequence 6, Application PC/TUS9505741
;  GENERAL INFORMATION:
;    APPLICANT:  Weintraub, Harold
;    APPLICANT:  Lee, Jacqueline E.
;    APPLICANT:  Tapscott, Stephen J.
;    APPLICANT:  Hollenberg, Stanley M.
;    TITLE OF INVENTION:  Neurogenic Differentiation (NeuroD) Gene
;    TITLE OF INVENTION:  and Protein
;    NUMBER OF SEQUENCES:  11
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Christensen O'Connor Johnson Kindness
;      STREET:  1420 Fifth Avenue, Suite 2800
;      CITY:  Seattle
;      STATE:  WA
;      COUNTRY:  USA
;      ZIP:  98101-2347
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US95/05741
;      FILING DATE:
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Broderick, Thomas F.
;      REGISTRATION NUMBER:  31,332
;      REFERENCE/DOCKET NUMBER:  FHCR-1-8504
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  206-682-8100
;      TELEFAX:  206-225-0709
;  INFORMATION FOR SEQ ID NO:  6:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  7 amino acids
;      TYPE:  amino acid
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
;    FRAGMENT TYPE:  internal
PCT-US95-05741-6

  Query Match           100.0%;  Score 15;  DB 5;  Length 7;
  Best Local Similarity  100.0%;  Pred. No. 3e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          3 RER 5


RESULT 43
US-08-259-550A-35
; Sequence 35, Application US/08259550A
; Patent No. 5776892
;  GENERAL INFORMATION:
;    APPLICANT:  Counts, David F.
;    APPLICANT:  Duff, Ronald G.
;    TITLE OF INVENTION:  Anti-Inflammatory Peptides
;    NUMBER OF SEQUENCES:  91
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  PENNIE & EDMONDS
;      STREET:  1155 Avenue of the Americas
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  U.S.A.
;      ZIP:  10036-2711
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/259,550A
;      FILING DATE:  16-JUN-1994
;      CLASSIFICATION:  514
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Misrock, S. Leslie
;      REGISTRATION NUMBER:  18,872
;      REFERENCE/DOCKET NUMBER:  7142-011
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (212) 790-9090
;      TELEFAX:  (212) 869-8864/9741
;      TELEX:  66141 PENNIE
;  INFORMATION FOR SEQ ID NO:  35:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  8 amino acids
;      TYPE:  amino acid
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  peptide
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
US-08-259-550A-35

  Query Match           100.0%;  Score 15;  DB 1;  Length 8;
  Best Local Similarity  100.0%;  Pred. No. 3e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          6 RER 8


RESULT 44
US-08-461-216-7
; Sequence 7, Application US/08461216
; Patent No. 5958883
;  GENERAL INFORMATION:
;    APPLICANT:  Snow, A.D.
;    TITLE OF INVENTION:  ANIMAL MODELS OF HUMAN AMYLOIDOSES
;    NUMBER OF SEQUENCES:  8
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Christensen, O'Connor, Johnson and Kindness
;      STREET:  1420 Fifth Avenue, Suite 2800
;      CITY:  Seattle
;      STATE:  Washington
;      COUNTRY:  USA
;      ZIP:  98101-2347
;    COMPUTER READABLE FORM:
```

```
;      MEDIUM TYPE:  Diskette-5.25 inch, 1.2Mb storage
;      COMPUTER:  IBM PC/386 Compatible
;      OPERATING SYSTEM:  MS-DOS 4.01
;      SOFTWARE:  Word for Windows-t
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/461,216
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/969,734
;      FILING DATE:  October 23, 1992
;      APPLICATION NUMBER:  07/950,417
;      FILING DATE:  September 23, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Broderick, Thomas F.
;      REGISTRATION NUMBER:  31,332
;      REFERENCE/DOCKET NUMBER:  UOFW-1-6707
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  1-206-682-8100; 1-206-224-0709 (direct)
;      TELEFAX:  1-206-224-0779
;      TELEX:  4938023
;  INFORMATION FOR SEQ ID NO:  7:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  8 amino acids
;      TYPE:  amino acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
;      DESCRIPTION:  APP(324-331); page 84, lines 8-13
US-08-461-216-7

  Query Match             100.0%;  Score 15;  DB 2;  Length 8;
  Best Local Similarity   100.0%;  Pred. No. 3e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          5 RER 7


RESULT 45
US-09-105-839D-25
; Sequence 25, Application US/09105839D
; Patent No. 6287756
; GENERAL INFORMATION:
;  APPLICANT: Tureci, Ozlem
;  APPLICANT:  Chen, Yao-Tseng
;  APPLICANT:  Sahin, Ugur
;  APPLICANT:  Gure, Ali
;  APPLICANT:  Old, Lloyd J
;  APPLICANT:  Pfreundschuh, Michael
;  TITLE OF INVENTION: Method for Determining Presence of Cancer In A Sample By Determin
;  TITLE OF INVENTION:  Expression of an SSX gene
;  FILE REFERENCE: LUD 5556
;  CURRENT APPLICATION NUMBER: US/09/105,839D
;  CURRENT FILING DATE:  1998-06-26
;  PRIOR APPLICATION NUMBER: US 08/851,130
;  PRIOR FILING DATE: 1997-05-05
;  NUMBER OF SEQ ID NOS: 72
; SEQ ID NO 25
;   LENGTH: 8
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-09-105-839D-25

  Query Match             100.0%;  Score 15;  DB 3;  Length 8;
  Best Local Similarity   100.0%;  Pred. No. 3e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          3 RER 5


RESULT 46
US-09-105-839D-40
; Sequence 40, Application US/09105839D
; Patent No. 6287756
; GENERAL INFORMATION:
;  APPLICANT: Tureci, Ozlem
;  APPLICANT:  Chen, Yao-Tseng
;  APPLICANT:  Sahin, Ugur
;  APPLICANT:  Gure, Ali
;  APPLICANT:  Old, Lloyd J
;  APPLICANT:  Pfreundschuh, Michael
;  TITLE OF INVENTION: Method for Determining Presence of Cancer In A Sample By Determin
;  TITLE OF INVENTION:  Expression of an SSX gene
;  FILE REFERENCE: LUD 5556
;  CURRENT APPLICATION NUMBER: US/09/105,839D
;  CURRENT FILING DATE:  1998-06-26
;  PRIOR APPLICATION NUMBER: US 08/851,130
;  PRIOR FILING DATE: 1997-05-05
;  NUMBER OF SEQ ID NOS: 72
; SEQ ID NO 40
;   LENGTH: 8
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-09-105-839D-40

  Query Match             100.0%;  Score 15;  DB 3;  Length 8;
  Best Local Similarity   100.0%;  Pred. No. 3e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          3 RER 5


RESULT 47
US-09-105-839D-57
; Sequence 57, Application US/09105839D
; Patent No. 6287756
; GENERAL INFORMATION:
;  APPLICANT: Tureci, Ozlem
;  APPLICANT:  Chen, Yao-Tseng
;  APPLICANT:  Sahin, Ugur
;  APPLICANT:  Gure, Ali
;  APPLICANT:  Old, Lloyd J
;  APPLICANT:  Pfreundschuh, Michael
;  TITLE OF INVENTION: Method for Determining Presence of Cancer In A Sample By Determin
;  TITLE OF INVENTION:  Expression of an SSX gene
;  FILE REFERENCE: LUD 5556
;  CURRENT APPLICATION NUMBER: US/09/105,839D
;  CURRENT FILING DATE:  1998-06-26
;  PRIOR APPLICATION NUMBER: US 08/851,130
;  PRIOR FILING DATE: 1997-05-05
;  NUMBER OF SEQ ID NOS: 72
; SEQ ID NO 57
;   LENGTH: 8
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-09-105-839D-57

  Query Match             100.0%;  Score 15;  DB 3;  Length 8;
  Best Local Similarity   100.0%;  Pred. No. 3e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          3 RER 5


RESULT 48
US-09-105-839D-69
; Sequence 69, Application US/09105839D
; Patent No. 6287756
```

```
; GENERAL INFORMATION:
;  APPLICANT: Tureci, Ozlem
;  APPLICANT:  Chen, Yao-Tseng
;  APPLICANT:  Sahin, Ugur
;  APPLICANT:  Gure, Ali
;  APPLICANT:  Old, Lloyd J
;  APPLICANT:  Pfreundschuh, Michael
;  TITLE OF INVENTION: Method for Determining Presence of Cancer In A Sample By Determin
;  TITLE OF INVENTION:  Expression of an SSX gene
;  FILE REFERENCE: LUD 5556
;  CURRENT APPLICATION NUMBER: US/09/105,839D
;  CURRENT FILING DATE:  1998-06-26
;  PRIOR APPLICATION NUMBER: US 08/851,130
;  PRIOR FILING DATE: 1997-05-05
;  NUMBER OF SEQ ID NOS: 72
; SEQ ID NO 69
;   LENGTH: 8
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-09-105-839D-69

  Query Match            100.0%;  Score 15;  DB 3;  Length 8;
  Best Local Similarity  100.0%;  Pred. No. 3e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          3 RER 5


RESULT 49
US-08-723-661B-7
; Sequence 7, Application US/08723661B
; Patent No. 6340783
;   GENERAL INFORMATION:
;        APPLICANT: Alan D Snow
;        TITLE OF INVENTION: Animal Models of Human Amyloidoses
;        NUMBER OF SEQUENCES: 7
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Patrick M. Dwyer
;             STREET: 1818 Westlake Avenue N, Suite 114
;             CITY: Seattle
;             STATE: WA (Washington)
;             COUNTRY: United States of America
;             ZIP: 98109
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Diskette - 3.50 inch, 1.44 Mb storage
;             COMPUTER: IBM PC
;             OPERATING SYSTEM: PC-DOS (Windows 98)
;             SOFTWARE: WordPerfect 5.2
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/08/723,661B
;             FILING DATE: 31-Oct-1996
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 08/461,216
;             FILING DATE: 05-Jun-1995
;             APPLICATION NUMBER: 07/969,734
;             FILING DATE: 23-Oct-1992
;             APPLICATION NUMBER: 07/950,417
;             FILING DATE: 23-Sep-1992
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Dwyer, Patrick M.
;             REGISTRATION NUMBER: 32,411
;             REFERENCE/DOCKET NUMBER: PROTEO.P00C1
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (206) 343-7074
;             TELEFAX: (206) 343-7085
;   INFORMATION FOR SEQ ID NO: 7:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 8 AMINO ACIDS
;             TYPE: AMINO ACID
;             STRANDEDNESS: SINGLE
;             TOPOLOGY: LINEAR
;        MOLECULE TYPE: PEPTIDE
;             DESCRIPTION: APP (324-331); page 84, lines 8-13
;        SEQUENCE DESCRIPTION: SEQ ID NO: 7:
US-08-723-661B-7

  Query Match            100.0%;  Score 15;  DB 4;  Length 8;
  Best Local Similarity  100.0%;  Pred. No. 3e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          5 RER 7


RESULT 50
US-09-344-040C-39
; Sequence 39, Application US/09344040C
; Patent No. 6548064
; GENERAL INFORMATION:
;  APPLICANT: Tureci, Ozlem
;  APPLICANT:  Sahin, Ugur
;  APPLICANT:  Pfreundschuh, Michael
;  APPLICANT:  Ramensee, Hans Georg
;  APPLICANT:  Stevanovic, Stefan
;  TITLE OF INVENTION: Method for Determining Presence of Cancer In a Sample By Determini
;  TITLE OF INVENTION:  Expression of an SSX Gene, Peptides Derived From Said SSX Gene ar
;  TITLE OF INVENTION:  Gene, and Uses Thereof
;  FILE REFERENCE: LUD 5556.1
;  CURRENT APPLICATION NUMBER: US/09/344,040C
;  CURRENT FILING DATE:  1999-06-25
;  PRIOR APPLICATION NUMBER: US 09/105,839
;  PRIOR FILING DATE: 1998-06-26
;  PRIOR APPLICATION NUMBER: US 08/851,130
;  PRIOR FILING DATE: 1997-05-05
;  NUMBER OF SEQ ID NOS: 132
; SEQ ID NO 39
;   LENGTH: 8
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-09-344-040C-39

  Query Match            100.0%;  Score 15;  DB 4;  Length 8;
  Best Local Similarity  100.0%;  Pred. No. 3e+05;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 RER 3
              |||
Db          3 RER 5


Search completed: March  5, 2004, 16:11:42
Job time : 25 secs
```

```
=> fil reg; d stat que l5
FILE 'REGISTRY' ENTERED AT 12:04:31 ON 08 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:     7 MAR 2004  HIGHEST RN 659718-58-8
DICTIONARY FILE UPDATES:    7 MAR 2004  HIGHEST RN 659718-58-8

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html


L1                  STR
```




```
NODE ATTRIBUTES:
CONNECT IS E2  RC AT  10
CONNECT IS E2  RC AT  15
CONNECT IS E2  RC AT  18
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  23

STEREO ATTRIBUTES: NONE
L5             2 SEA FILE=REGISTRY SSS FUL L1

100.0% PROCESSED  66592 ITERATIONS                          2 ANSWERS
SEARCH TIME: 00.00.17


=> d sqide l5 1-2
```

L5 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2004 ACS on STN
RN 148914-10-7 REGISTRY Use Registry # to match structure to citation
CN L-Arginine, L-arginyl-L-.alpha.-glutamyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN L-Arginine, N2-(N-L-arginyl-L-.alpha.-glutamyl)-
OTHER NAMES:
CN 9: PN: WO02083729 SEQID: 9 claimed sequence
FS STEREOSEARCH
MF C17 H33 N9 O6
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2004 ACS on STN
RN 106326-11-8 REGISTRY
CN L-Arginine, N2-(N-L-arginyl-L-.alpha.-aspartyl)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C16 H31 N9 O6
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

Searched by Barb O'Bryen, STIC 571-272-2518

```
=> fil capl uspatf toxcenter; s l5
FILE 'CAPLUS' ENTERED AT 12:05:28 ON 08 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 12:05:28 ON 08 MAR 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'TOXCENTER' ENTERED AT 12:05:28 ON 08 MAR 2004
COPYRIGHT (C) 2004 ACS

L6          10 L5
```

cross Registry answer set into CAPLUS, USPATFULL, TOXcenter to get references

```
=> dup rem l6
PROCESSING COMPLETED FOR L6
L7          10 DUP REM L6 (0 DUPLICATES REMOVED)
               ANSWERS '1-6' FROM FILE CAPLUS
               ANSWER '7' FROM FILE USPATFULL
               ANSWERS '8-10' FROM FILE TOXCENTER

=> d ibib ed abs hitstr 1-6; d ibib abs hitstr 7; d iall 8-10; fil hom

L7   ANSWER 1 OF 10  CAPLUS  COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER:         2003:818235  CAPLUS
DOCUMENT NUMBER:          139:322283
TITLE:                    Methods for production and use of mammalian
                          complementarity determining region mimetibodies for
                          diagnosis and therapy of human diseases
INVENTOR(S):              Heavner, George A.; Knight, David M.; Scallon, Bernard
                          J.; Ghrayeb, John
PATENT ASSIGNEE(S):       Centocor, Inc., USA
SOURCE:                   PCT Int. Appl., 97 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.        KIND  DATE           APPLICATION NO.   DATE
     ----------------  ----  --------       ----------------  --------
     WO 2003084477      A2   20031016       WO 2003-US9139    20030324
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
             PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
             TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD,
             RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
             CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
             NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
             GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.:                    US 2002-368791P  P  20020329
ED   Entered STN:  17 Oct 2003
AB   This invention pertains to methods for prodn. and use of mammalian
     complementarity detg. region (CDR) mimetibodies for diagnosis and therapy
     of human diseases.  Genetic engineering, expression, and purifn. of human
     mimetibodies contg. Ig fragments (CDR, variable, framework and/or const.
     region) as well as a ligand binding domain are disclosed in this
     invention.  Peptides that mimic the activity of EPO, TPO, growth hormones,
     G-CSF, GM-CSF, IL-1ra, leptin, CTLA4, TRAIL, TGF-.alpha. and TGF-.beta.
```

are the focus of this genetic engineering. The aim of the invention is use of the purified recombinant proteins for diagnosis or treatment of anemia, immune or autoimmune disease, cancer, or infectious diseases. At the time of publication, claimed sequence nos. 997 to 1109 were missing, and claimed sequence nos. 984 to 996 were not clearly identified.

IT **148914-10-7**
RL: DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(macrophage/T cell-inhibiting peptide; methods for prodn. and use of mammalian CDR mimetibodies for diagnosis and therapy of human diseases)

RN 148914-10-7 CAPLUS
CN L-Arginine, L-arginyl-L-.alpha.-glutamyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:814182 CAPLUS
DOCUMENT NUMBER: 137:329414
TITLE: Polypeptides for treatment of Alzheimer's disease or use as cognition enhancers
INVENTOR(S): Mileusnic, Radmila; Rose, Steven Peter Russell
PATENT ASSIGNEE(S): The Open University, UK
SOURCE: PCT Int. Appl., 85 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083729	A2	20021024	WO 2002-GB1769	20020417
WO 2002083729	A3	20030731		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003166529	A1	20030904	US 2001-998491	20011130
EP 1381627	A2	20040121	EP 2002-720228	20020417
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
GB 2391548	A1	20040211	GB 2003-26855	20020417

PRIORITY APPLN. INFO.: GB 2001-9558 A 20010418

GB	2001-20084	A	20010817
US	2001-998491	A1	20011130
GB	2002-7387	A	20020328
WO	2002-GB1769	W	20020417

OTHER SOURCE(S): MARPAT 137:329414
ED Entered STN: 25 Oct 2002
AB The invention provides a compd. having formula X1-Arg-Xaa-Arg-X2 in which X1 and X2 are up to 30 amino acid residues and Xaa is an amino acid residue. A preferred compd. is the tripeptide Arg-Glu-Arg which corresponds to amino acid residues 328 to 330 of human amyloid precursor protein. The invention further provides a deriv. of a polypeptide having the formula: X1-Arg-Xaa-Arg-X2 wherein X1 and X2, which may be the same or different, each represents from zero to 30 natural or synthetic amino acid residues or derivs. thereof and Xaa represents a natural or synthetic amino acid residue or deriv. thereof, at least one functional group of at least one said amino acid residue or deriv. thereof being protected by a protective group. The compds. of the invention are believed to be useful in the treatment of Alzheimer's disease and as cognitive enhancers.
IT **148914-10-7**
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polypeptides for treatment of Alzheimer's disease or use as cognition enhancers)
RN 148914-10-7 CAPLUS
CN L-Arginine, L-arginyl-L-.alpha.-glutamyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1998:175943 CAPLUS
DOCUMENT NUMBER: 128:226237
TITLE: Anti-inflammatory peptides and therapeutic uses thereof
INVENTOR(S): Eisenbach-Schwartz, Michal; Beserman, Pierre; Hirschberg, David L.
PATENT ASSIGNEE(S): Yeda Research and Development Co. Ltd., Israel; Eisenbach-Schwartz, Michal; Beserman, Pierre; Hirschberg, David L.
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9809985	A2	19980312	WO 1997-IL295	19970903
WO 9809985	A3	19980507		

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

US 6126939	A	20001003	US 1997-864301	19970528
AU 9740301	A1	19980326	AU 1997-40301	19970903
EP 927191	A2	19990707	EP 1997-937794	19970903
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2001500492	T2	20010116	JP 1998-512435	19970903

PRIORITY APPLN. INFO.:

US 1996-25376P	P	19960903
US 1996-753141	A	19961120
US 1997-864301	A	19970528
US 1996-31191P	P	19961120
WO 1997-IL295	W	19970903

OTHER SOURCE(S): MARPAT 128:226237

ED Entered STN: 25 Mar 1998

AB The invention is directed to peptides of the formulas (i) Xaa-Yaa-Arg (either Xaa is any amino acid residue and Yaa is Glu or Xaa is absent and Yaa is any amino acid residue with the exception of Pro), (ii) Arg-Yaa-Xaa (either Xaa is any amino acid residue and Yaa is Glu or Xaa is absent and Yaa is any amino acid residue with the exception of Asn), (iii) Xaa-Arg-Yaa (Xaa is any amino acid residue and Yaa is Glu), and (i.v.) Yaa-Arg-Xaa (Xaa is any amino acid residue and Yaa is Glu), and to derivs. thereof, which exert an inhibitory effect on macrophage migration and/or macrophage phagocytic activity. In addn., the peptides and derivs. thereof exert an inhibitory effect on the ability of macrophages and T cells to adhere to extracellular matrix and/or fibronectin. The peptides and derivs. thereof exert an inhibitory effect on a humoral and/or cellular immune response. The invention is also directed to methods for use of the peptides and derivs. thereof and compns. contg. them for the inhibition of inflammation, including but not limited to, inflammation at a joint, in the central nervous system generally, at specific lesions in the central nervous system, and other immune privileged sites. Immune privilege factor was purified from brain conditioned medium and shown to have a similar migration pattern to Glu-Arg.

IT **148914-10-7**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-inflammatory peptides and therapeutic uses)

RN 148914-10-7 CAPLUS

CN L-Arginine, L-arginyl-L-.alpha.-glutamyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Searched by Barb O'Bryen, STIC 571-272-2518

L7 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1994:570570 CAPLUS
DOCUMENT NUMBER: 121:170570
TITLE: Substances having the growth-promoting effect of amyloid precursor protein
INVENTOR(S): Saitoh, Tsunao
PATENT ASSIGNEE(S): University of California, USA
SOURCE: PCT Int. Appl., 115 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9409808	A1	19940511	WO 1992-US9070	19921023
W: AU, CA, JP, KZ, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE				
AU 9228951	A1	19940524	AU 1992-28951	19921023

PRIORITY APPLN. INFO.: WO 1992-US9070 19921023
ED Entered STN: 15 Oct 1994
AB Peptides derived from amyloid precursor protein (APP) that retain at least some neuronal growth promoting effect of APP are described. The peptides include at least five consecutive amino acid residues with side-chain polarities corresponding to the side-chain polarities of the sequence RERMS. Non-peptide compds. with the same activity and methods of prepg. them are described. The peptides and nonpeptides are for use in treatment of neurol. conditions (no data). A series of peptides covering amino acids 296-335 of APP were synthesized and their growth stimulating effects tested on fibroblast cell lines; full-length APP and an analog with a deletion of amino acids 306-335 were prepd. by expression of the cloned gene for use as controls. Only peptides with the RERMS sequence showed growth stimulation and some of the peptides adjacent to the RERMS peptide antagonized its action at high concns. The growth stimulating activity was not due to heparin binding. Studies on the role of APP in neurite outgrowth and sprouting and its interaction with GAP-43 are described. Use of RERMS peptides in the treatment of exptl. spinal ischemia significantly improved the neurol. outcome over the first three days.
IT **148914-10-7**
RL: BIOL (Biological study)
(peptide of human amyloid precursor protein, growth-promoting properties of)
RN 148914-10-7 CAPLUS
CN L-Arginine, L-arginyl-L-.alpha.-glutamyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1993:492151 CAPLUS
DOCUMENT NUMBER: 119:92151
TITLE: Amino acid sequence RERMS represents the active domain of amyloid .beta./A4 protein precursor that promotes fibroblast growth
AUTHOR(S): Ninomiya, Haruaki; Roch, Jean Marc; Sundsmo, Mary P.; Otero, Deborah A. C.; Saitoh, Tsunao
CORPORATE SOURCE: Dep. Neurosci., Univ. California, San Diego, La Jolla, CA, 92093, USA
SOURCE: Journal of Cell Biology (1993), 121(4), 879-86
CODEN: JCLBA3; ISSN: 0021-9525
DOCUMENT TYPE: Journal
LANGUAGE: English
ED Entered STN: 04 Sep 1993
AB The growth of A-1 fibroblasts depends on exogenous amyloid .beta./A4 protein precursor (APP), providing a simple bioassay to study the function of APP. To further characterize the growth-promoting activity of the secreted form of APP-695 (sAPP-695) on fibroblasts, the authors applied a battery of synthetic peptides and found that: (1) the sequence of 5 amino acids, RERMS (APP328-332), was uniquely required for the growth-promoting activity of sAPP-695; (2) the activity was sequence specific because the reverse-sequence peptide of the active domain had no activity; and (3) the 4-amino-acid peptide RMSQ (APP330-333), which partially overlaps the C-terminal side of the active sequence RERMS, could antagonize the activity of sAPP-695. Furthermore, a recombinant protein which lacks this active domain (APP20-591 without 306-335) did not promote fibroblast cell growth, suggesting that this domain is the only site of sAPP-695 involved in the growth stimulation. The availability of these biol. active, short peptides and their antagonists should prove to be an essential step for the elucidation of APP involvement in regulation of cellular homeostasis.
IT **148914-10-7**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(fibroblast growth stimulation by, amyloid .beta./A4 protein precursor structure in relation to)
RN 148914-10-7 CAPLUS
CN L-Arginine, L-arginyl-L-.alpha.-glutamyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1987:61216 CAPLUS
DOCUMENT NUMBER: 106:61216
TITLE: Immunoregulatory peptides
INVENTOR(S): Hahn, Gary Scott
PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Fed. Rep. Ger.
SOURCE: PCT Int. Appl., 109 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 8604334	A1	19860731	WO 1986-EP12	19860115
W: AU, JP				
RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
AU 8653198	A1	19860813	AU 1986-53198	19860115
AU 602483	B2	19901018		
EP 215805	A1	19870401	EP 1986-900764	19860115
R: AT, BE, CH, DE, FR, GB, IT, LI, NL, SE				
JP 62501502	T2	19870618	JP 1986-500766	19860115

PRIORITY APPLN. INFO.: US 1985-692711 19850118
US 1985-803452 19851129
US 1985-805504 19851129
WO 1986-EP12 19860115

ED Entered STN: 07 Mar 1987
AB Immunoregulatory peptides AX(BY)nC (X and Y = amino acid residue with pos. charged side chains; A and C = substituents that preserve or augment the immunoregulatory activity of the peptide; B = amino acid residue that preserves or augments the immunoregulatory activity of the peptide; n = 0, 1) are prepd. for use as medicaments for immune system response control. Thus, the bis-trifluoroacetate salt of L-Lys-L-Ser-OH was prepd. by reacting L-serine with N,N'-bis-tert-butyloxycarbonyl-L-lysine N-hydroxysuccinimide ester in THF, deprotection, and reaction with anhyd. trifluoroacetic acid.
IT **106326-11-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, or immunoregulator)
RN 106326-11-8 CAPLUS
CN L-Arginine, N2-(N-L-arginyl-L-.alpha.-aspartyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 7 OF 10 USPATFULL on STN
ACCESSION NUMBER: 2003:238371 USPATFULL
TITLE: Polypeptides and their uses
INVENTOR(S): Mileusnic, Radmila, Milton Keynes, UNITED KINGDOM
Russell Rose, Steven Peter, Milton Keynes, UNITED KINGDOM

NUMBER	KIND	DATE

Searched by Barb O'Bryen, STIC 571-272-2518

PATENT INFORMATION:	US 2003166529	A1	20030904
APPLICATION INFO.:	US 2001-998491	A1	20011130 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2001-9558	20010418
	GB 2001-20084	20010817

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: DRINKER BIDDLE & REATH, ONE LOGAN SQUARE, 18TH AND CHERRY STREETS, PHILADELPHIA, PA, 19103-6996
NUMBER OF CLAIMS: 35
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 1091
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides compounds having formulae comprising

X.sub.1-Ser-Met-Arg-Glu-Arg-X.sub.2

in which X.sub.1 and X.sub.2 are up to 30 amino acid residues and the formula represents a reverse-order sequence corresponding to amino acid residues 332 to 328 of human APP and from zero to 30 successive amino acid residues of human APP extending in each direction therefrom, The invention also provides the pentapeptide Ser-Met-Arg-Glu-Arg, corresponding to residues 332 to 328 of human amyloid precursor protein in reverse order, and the tripeptide Arg-Glu-Arg which corresponds residues 328 to 330 of human amyloid precursor protein, the tripeptide and pentapeptide being provided as pharmaceutical compositions. The invention further provides conjugates of the foregoing compounds which can cross the blood-brain barrier and pharmaceutical compositions containing such conjugates. The compounds and compositions of the invention are believed to be useful in the treatment of Alzheimer's disease and as cognitive enhancers and appropriate methods of medical treatment are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **148914-10-7**
(polypeptides for treatment of Alzheimer's disease or use as cognition enhancers)
RN 148914-10-7 USPATFULL
CN L-Arginine, L-arginyl-L-.alpha.-glutamyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 8 OF 10 TOXCENTER COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:119433 TOXCENTER
COPYRIGHT: Copyright 2004 ACS
DOCUMENT NUMBER: CA12819226237F
TITLE: Anti-inflammatory peptides and therapeutic uses thereof
AUTHOR(S): Eisenbach-Schwartz, Michal; Beserman, Pierre; Hirschberg, David L.
CORPORATE SOURCE: ASSIGNEE: Hirschberg, David L.
PATENT INFORMATION: WO 989985 A2 12 Mar 1998
SOURCE: (1998) PCT Int. Appl., 44 pp.
CODEN: PIXXD2.
COUNTRY: ISRAEL
DOCUMENT TYPE: Patent
FILE SEGMENT: CAPLUS
OTHER SOURCE: CAPLUS 1998:175943
LANGUAGE: English
ENTRY DATE: Entered STN: 20020528
Last Updated on STN: 20020605

ABSTRACT:
The invention is directed to peptides of the formulas (i) Xaa-Yaa-Arg (either Xaa is any amino acid residue and Yaa is Glu or Xaa is absent and Yaa is any amino acid residue with the exception of Pro), (ii) Arg-Yaa-Xaa (either Xaa is any amino acid residue and Yaa is Glu or Xaa is absent and Yaa is any amino acid residue with the exception of Asn), (iii) Xaa-Arg-Yaa (Xaa is any amino acid residue and Yaa is Glu), and (i.v.) Yaa-Arg-Xaa (Xaa is any amino acid residue and Yaa is Glu), and to derivs. thereof, which exert an inhibitory effect on macrophage migration and/or macrophage phagocytic activity. In addn., the peptides and derivs. thereof exert an inhibitory effect on the ability of macrophages and T cells to adhere to extracellular matrix and/or fibronectin. The peptides and derivs. thereof exert an inhibitory effect on a humoral and/or cellular immune response. The invention is also directed to methods for use of the peptides and derivs. thereof and compns. contg. them for the inhibition of inflammation, including but not limited to, inflammation at a joint, in the central nervous system generally, at specific lesions in the central nervous system, and other immune privileged sites. Immune privilege factor was purified from brain conditioned medium and shown to have a similar migration pattern to Glu-Arg.

CLASSIFICATION CODE: 1-7
SUPPLEMENTARY TERMS: Miscellaneous Descriptors
immunosuppressant antiinflammatory peptide; immune privilege factor isolation
REGISTRY NUMBER: 1238-09-1Q (derivs.)
2418-74-8Q (Prolylarginine, derivs.)
2478-01-5Q (derivs.)
2640-07-5Q (derivs.)
7219-59-2Q (derivs.)
13261-11-5Q (Serylarginine, derivs.)
13448-26-5Q (derivs.)
15483-27-9Q (Arginylarginine, derivs.)
16709-12-9Q (derivs.)
18635-55-7Q (Glycylarginine, derivs.)
26607-15-8Q (derivs.)
29586-66-1Q (derivs.)
37682-75-0Q (Valylarginine, derivs.)
55715-01-0Q (derivs.)
60461-10-1Q (derivs.)
68040-95-9Q (derivs.)
70904-56-2Q (derivs.)
77369-21-2Q (derivs.)
88831-09-8Q (derivs.)
126590-89-4Q (derivs.)
186761-64-8Q (derivs.)
204644-00-8Q (derivs.)
204866-55-7 (Immune Privilege Factor)

REGISTRY NUMBER: 1188-24-5; 2047-13-4; 2418-67-9; 2418-69-1; 2483-17-2; 2639-45-4; 2896-20-0; 6418-86-6; 15706-88-4; 15706-89-5; 25615-38-7; 40968-45-4; 40968-46-5; 45243-23-0; 61192-07-2; 62632-70-6; 70921-62-9; 74863-12-0; 82261-72-1; 105425-96-5; 106326-78-7; 115945-15-8; 116685-16-6; 116854-12-7; 125557-81-5; 128500-64-1; 131837-03-1; 132105-44-3; 137427-66-8; 140360-47-0; 140716-02-5; 140716-03-6; 140716-04-7; 140716-05-8; 140716-06-9; 140716-07-0; **148914-10-7**; 155114-05-9; 172684-37-6; 175175-18-5; 175175-24-3; 175175-25-4; 175175-40-3; 175175-41-4; 175175-42-5; 175175-43-6; 175175-44-7; 175175-45-8; 175175-46-9; 175175-47-0; 175175-48-1; 175175-65-2; 175175-91-4; 175176-43-9; 175176-92-8; 175177-31-8; 175177-64-7; 175276-10-5; 182295-52-9; 201463-77-6; 201463-84-5; 204644-01-9; 204644-02-0; 204644-03-1; 204644-04-2; 204644-05-3; 204644-06-4; 204644-07-5; 204644-08-6; 204644-09-7; 204644-10-0; 204644-11-1; 204644-12-2; 204644-13-3; 204644-14-4; 204644-15-5; 204644-16-6; 204644-17-7; 204644-18-8; 204644-19-9; 204644-20-2; 204644-21-3; 204644-22-4; 204644-23-5; 204644-24-6; 204644-25-7; 204644-26-8; 204644-27-9; 204644-28-0; 204644-29-1; 204644-30-4; 204644-31-5; 204644-32-6; 204644-33-7; 204644-34-8

L7 ANSWER 9 OF 10 TOXCENTER COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1994:171025 TOXCENTER
COPYRIGHT: Copyright 2004 ACS
DOCUMENT NUMBER: CA12115170570V
TITLE: Substances having the growth-promoting effect of amyloid precursor protein
AUTHOR(S): Saitoh, Tsunao
CORPORATE SOURCE: ASSIGNEE: University of California
PATENT INFORMATION: WO 949808 A1 11 May 1994
SOURCE: (1994) PCT Int. Appl., 115 pp.
CODEN: PIXXD2.
COUNTRY: UNITED STATES
DOCUMENT TYPE: Patent
FILE SEGMENT: CAPLUS
OTHER SOURCE: CAPLUS 1994:570570
LANGUAGE: English
ENTRY DATE: Entered STN: 20011116
Last Updated on STN: 20020910

ABSTRACT:
Peptides derived from amyloid precursor protein (APP) that retain at least some neuronal growth promoting effect of APP are described. The peptides include at least five consecutive amino acid residues with side-chain polarities corresponding to the side-chain polarities of the sequence RERMS. Non-peptide compds. with the same activity and methods of prepg. them are described. The peptides and nonpeptides are for use in treatment of neurol. conditions (no data). A series of peptides covering amino acids 296-335 of APP were synthesized and their growth stimulating effects tested on fibroblast cell lines; full-length APP and an analog with a deletion of amino acids 306-335 were prepd. by expression of the cloned gene for use as controls. Only peptides with the RERMS sequence showed growth stimulation and some of the peptides adjacent to the RERMS peptide antagonized its action at high concns. The growth stimulating activity was not due to heparin binding. Studies on the role of APP in neurite outgrowth and sprouting and its interaction with GAP-43 are described. Use of RERMS peptides in the treatment of exptl. spinal ischemia significantly improved the neurol. outcome over the first three days.
CLASSIFICATION CODE: 1-11
SUPPLEMENTARY TERMS: Miscellaneous Descriptors
amyloid precursor growth promoting peptide; neurite

outgrowth amyloid precursor peptide
REGISTRY NUMBER: 148914-08-3Q (peptide and non-peptide analogs)
117-89-5 (Trifluoperazine)
77086-22-7 (MK801)
78990-62-2 (Calpain)
REGISTRY NUMBER: 148914-13-0; 148914-08-3; 157622-71-4; 50-53-3;
148913-99-9; 148914-00-5; 148914-01-6; 148914-02-7;
148914-03-8; 148914-04-9; 148914-05-0; 148914-06-1;
148914-07-2; 148914-09-4; **148914-10-7**;
148914-11-8; 148914-12-9; 149146-19-0

L7 ANSWER 10 OF 10 TOXCENTER COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1987:110406 TOXCENTER
COPYRIGHT: Copyright 2004 ACS
DOCUMENT NUMBER: CA10609061216D
TITLE: Immunoregulatory peptides
AUTHOR(S): Hahn, Gary Scott
CORPORATE SOURCE: ASSIGNEE: Merck Patent G.m.b.H.
PATENT INFORMATION: WO 864334 A1 31 Jul 1986
SOURCE: (1986) PCT Int. Appl., 109 pp.
CODEN: PIXXD2.
COUNTRY: FED. REP. GER.
DOCUMENT TYPE: Patent
FILE SEGMENT: CAPLUS
OTHER SOURCE: CAPLUS 1987:61216
LANGUAGE: English
ENTRY DATE: Entered STN: 20011116
Last Updated on STN: 20021105

ABSTRACT:
Immunoregulatory peptides AX(BY)nC (X and Y = amino acid residue with pos. charged side chains; A and C = substituents that preserve or augment the immunoregulatory activity of the peptide; B = amino acid residue that preserves or augments the immunoregulatory activity of the peptide; n = 0, 1) are prepd. for use as medicaments for immune system response control. Thus, the bis-trifluoroacetate salt of L-Lys-L-Ser-OH was prepd. by reacting L-serine with N,N'-bis-tert-butyloxycarbonyl-L-lysine N-hydroxysuccinimide ester in THF, deprotection, and reaction with anhyd. trifluoroacetic acid.
CLASSIFICATION CODE: 1-6
SUPPLEMENTARY TERMS: Miscellaneous Descriptors
immunoregulation peptide prepn; antitumor peptide prepn
immunoregulation
REGISTRY NUMBER: 6235-35-4 (Lys-Phe)
2130-96-3Q (resin-bound)
2389-45-9Q (resin-bound)
4530-20-5Q (resin-bound)
7764-95-6Q (resin-bound)
13734-34-4Q (resin-bound)
13836-37-8Q (resin-bound)
15761-39-4Q (resin-bound)
23680-31-1Q (resin-bound)
35899-43-5Q (resin-bound)
47173-80-8Q (resin-bound)
55592-81-9Q (benzhydrylamine resin-bound)
78331-03-0Q (benzhydrylamine resin-bound)
106326-22-1Q (benzhydrylamine resin-bound)
106326-23-2Q (resin-bound)
106326-24-3Q (resin-bound)
REGISTRY NUMBER: 56-45-1; 21160-83-8; 30189-36-7; 106326-27-6; 77235-89-3;
106326-26-5; 106326-29-8; 106326-34-5; 106326-36-7;
77236-16-9; 106326-28-7; 106326-31-2; 32388-19-5;
106400-37-7; 6403-11-8; 7369-79-1; 27780-85-4; 92352-82-4;
100385-49-7; 106325-90-0; 106325-94-4; 106326-15-2;
106326-30-1; 106326-32-3; 106326-33-4; 106326-35-6;

106326-37-8; 106326-38-9; 106326-39-0; 106326-40-3;
106326-41-4; 106326-42-5; 106326-43-6; 106326-44-7;
106326-45-8; 106326-46-9; 106326-47-0; 106326-48-1;
106326-49-2; 106326-50-5; 106326-51-6; 106326-52-7;
106326-53-8; 106326-54-9; 106326-55-0; 106326-56-1;
106326-57-2; 106326-58-3; 106326-59-4; 106326-60-7;
106326-61-8; 106326-62-9; 106326-63-0; 106326-64-1;
106326-65-2; 106326-66-3; 106326-67-4; 106326-68-5;
106326-69-6; 106326-70-9; 106326-71-0; 106326-72-1;
106326-73-2; 106326-74-3; 106326-75-4; 106326-76-5;
106326-77-6; 106326-78-7; 106326-79-8; 106326-80-1;
106326-81-2; 106326-82-3; 106326-83-4; 106326-84-5;
106326-85-6; 106326-86-7; 106326-87-8; 106339-43-9;
106339-44-0; 6665-19-6; 20556-18-7; 21438-60-8;
52766-27-5; 55024-09-4; 66138-71-4; 72815-17-9;
74838-86-1; 106325-88-6; 106325-89-7; 106325-91-1;
106325-92-2; 106325-93-3; 106325-95-5; 106325-96-6;
106325-97-7; 106325-98-8; 106325-99-9; 106326-00-5;
106326-01-6; 106326-02-7; 106326-03-8; 106326-04-9;
106326-05-0; 106326-06-1; 106326-07-2; 106326-08-3;
106326-09-4; 106326-10-7; **106326-11-8**;
106326-12-9; 106326-13-0; 106326-14-1; 106326-16-3;
106326-17-4; 106326-18-5; 106326-19-6; 106326-20-9;
106326-21-0; 106339-42-8; 2389-45-9; 2480-93-5; 4530-20-5;
6404-29-1; 7536-58-5; 13139-15-6; 13139-16-7; 13574-13-5;
13734-34-4; 13734-41-3; 13836-37-8; 15260-10-3;
15761-38-3; 15761-39-4; 22838-58-0; 35899-43-5;
55878-47-2; 106326-25-4

FILE 'HOME' ENTERED AT 12:06:14 ON 08 MAR 2004